Mutagenesis Studies of the Varicella-Zoster Virus Thymidylate Synthase by Harrison, Patrick Thomas
 
 
 
 
 
 
 
https://theses.gla.ac.uk/ 
 
 
 
 
Theses Digitisation: 
https://www.gla.ac.uk/myglasgow/research/enlighten/theses/digitisation/ 
This is a digitised version of the original print thesis. 
 
 
 
 
 
 
 
 
Copyright and moral rights for this work are retained by the author 
 
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge 
 
This work cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the author 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the author 
 
When referring to this work, full bibliographic details including the author, 
title, awarding institution and date of the thesis must be given 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten: Theses 
https://theses.gla.ac.uk/ 
research-enlighten@glasgow.ac.uk 
MUTAGENESIS STUDIES OF THE 
VARICELLA-ZOSTER VIRUS 
THYMIDYLATE SYNTHASE
by
PATRICK THOMAS HARRISON®
A Thesis Presented for the Degree of 
Doctor of Philosophy
in
The Faculty of Science, 
University of Glasgow
Institute of Virology, 
Church Street,
Glasgow Gil 5JR
January 1992
ProQuest Number: 11011431
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 11011431
Published by ProQuest LLC(2018). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLC.
ProQuest LLC.
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106- 1346
ACKNOWLEDGEMENTS
SUMMARY
ABBREVIATIONS
1. INTRODUCTION
TABLE OF CONTENTS
Page No
1 .1
1.2
1 . 3
1 . 4
Herpesviruses
1.1.1 Virion structure
1.1.2 Genome structure
1.1.3 Molecular and biological properties
1.1.4 Herpesvirus taxonomy
1.1. 4.1 Alphaherpesvirinae
1.1. 4.2 Betaherpesvirinae 
1.1.4. 3 Gammaherpesvirinae
Molecular biology of varicella-zoster virus
1.2.1 Genome structure and organization
1.2.2 Transcriptional analysis
1.2.3 VZV gene products involved in DNA 
precursor synthesis
1.2.4 Regulation of gene expression
1.2.5 VZV DNA replication
Biology of varicella-zoster virus
1.3.1 Varicella: disease
1.3.2 Varicella: pathogenesis
1.3.3 Zoster: disease
1.3.4 Zoster: pathogenesis
1.3.5 Latency
Control of infection
1.4.1 VZV immune serum globulin and 
zoster immune plasma
1.4.2 Vaccination
1.4.3 Antiviral compounds
1.4.4 Antiviral resistance
14
21
1.5 Thymidylate synthase: an introduction 26
1.5.1 The thymidylate cycle
1.5.2 TS from different sources
1.5.2.1 Bacteri a
1.5.2.2 Bacteriophage 
1 . 5.2.3 Mammals
1.5.2.4 Herpesviruses 
1 . 5 . 2.5 Protozoa 
1.5.2.6 Yeast 
1 . 5 . 2.7 Plants
1.5.3 Amino acid sequence homology
1.6 Catalytic mechanism of TS 35
1.6.1 Identification of catalytic residues
1.6.2 Ordered binding of substrate and 
cofactor
1.6.3 Conformational changes associated with 
catalysis: ternary complex formation
1.6.4 Stereospecific reaction mechanism
1.6.5 Reaction mechanism based on X-ray 
crystallographic data
1.6.5.1 Model of Matthews and 
co-workers
1.6.5.2 Model of Stroud and 
co-workers
1.6.5.3 Summary
1.7 Structural features of TS
1.7.1 X-Ray crystallography
1.7.2 General structural features
1.7.3 Specific features of the large domain
1.7.3.1 6-kink of strands i, ii and i
1.7.3.2 Dimer-interface
1.7.3.3 The J-helix
1.7.3.4 Active site cavity
1.8 Conformational changes during ligand 
binding: segmental accomodation
1.9 Structural plasticity and covariant 
accomodation
1.10 Models of VZV TS
1.11 Mutational analysis of TS
1.11.1 Site-directed mutagenesis
1.11.2 Saturation site-directed mutagenesis
1.12 TS inhibitors
1.12.1 Nucleoside analogues requiring 
activation
1.12.2 Cofactor analogues
1.12.3 Bisubstrate analogues
1.12.4 Nucleoside analogues not requiring 
activation
1.12.5 In vivo regulators
1.12.6 Anti-sense oligonucleotides
1.12.7 Oligopeptide inhibition of TS
1.13 Nucleoside and nucleoside analogue metabolism
1.13.1 Mammalian systems
1.13.2 Bacterial systems
1.14 Resistance to TS inhibitors
1.14.1 Mammalian systems
1.14.2 Bacterial systems
1.15 Aims of the project 
MATERIALS AND METHODS
2.1 Bacteria and bacteriophage
2.1.1 Bacterial strains
2.1.2 Bacteriophage
2.2 Plasmids
2.2.1 Plasmids provided
2.2.2 Plasmid constructs
2.3 Bacterial growth media 76
2.3.1 Liquid media
2.3.2 Solid media
2.4 Chemicals, drugs, radiochemicals and enzymes 76
2.4.1 Chemicals
2.4.2 Drugs
2.4.3 Radiochemicals
2.4.4 Enzymes
2.5 Commonly used buffers 78
2.6 Growth and maintenance of bacteria and 78
bacteriophage
2.6.1 Bacteria
2.6.1.1 Laboratory stocks of E.coli
2.6.1.2 New strains of E.coli
2.6.1.3 Overnight cultures
2.6.1.4 Glycerol stocks
2.6.1.5 Antibiotics
2.6.2 Bacteriophage
2.6.2.1 Titration of helper phage
2.6.2.2 Growth of helper phage
2.7 Bacterial manipulation 80
2.7.1 Transformation
2.7.1.1 Calcium chloride
2.7.1.2 DMSO-PEG4000
2.7.2 Generation of thyA strains of E.coli
2.8 DNA Isolation 81
2.8.1 Mini-prep plasmid DNA preparation
2.8.2 Midi-Prep Plasmid DNA preparation
2.8.3 Maxi-prep plasmid DNA preparation
2.8.4 ssDNA preparation from phageraid 
vectors
2.8.4.1 Midi-scale ssDNA preparation
2.8.4.2 Maxi-scale ssDNA preparation
2.8.5 Plasmid DNA sequencing preparations
2.9. DNA Manipulations 85
2.9.1 Restriction enzyme digests
2.9.2 Removal of 5*-phosphate groups
2.9.3 Isolation of DNA fragments from 
agarose gels
2.9.3.1 Electroelution
2.9.3.2 Low melting point agarose
2.9.3.3 Use of NA45 ion-exchange 
membrane
2.9.4 Conversion of 5 ’-overhangs to 
blunt ends
2.9.5 DNA ligation
2.9.6 Gapped duplex DNA (gdDNA) synthesis
2.10 Oligonucleotides 88
2.10.1 Synthesis and purification
2.10.2 Synthesis of spiked oligonucleotides
2.10.3 Radioactive 5 ’-end labelling of 
oligonucleotides
2.10.4 Oligonucleotide sequences
2.10.4.1 Sequencing oligos
2.10.4.2 Site-directed mutagenesis 
oligos
2.10.4.3 Spiked oligos
2.11 Mutagenesis 92
2.11.1 Chemical mutagenesis
2.11.1.1 Ethyl methanesulphonate
2.11.1.2 Hydroxylamine
2.11.1.3 Sodium bisulphite
2.11.2 Growth in a mutator strain
2.11.3 Oligonucleotide directed mutagenesis
2.11.4 Misincorporation mutagenesis
2.12 Mutant screening 96
2.12.1 Growth complementation assays
2.12.1.1 Thymidylate synthase
2.12.1.2 Thymidine kinase
2.12.2 Drug resistance screening protocols
2.12.2.1 Method 1
2.12.2.2 Method 2
2.12.2.3 Method 3
2.12.2.4 Method 4
2.12.2.5 Method 5
2.12.3 Slot blot hybridization
2.13 Mutant characterization 99
2.13.1 DNA Sequencing
2.13.1.1 Sequencing solutions
2.13.1.2 Sequencing reactions
2.13.1.3 Polyacrylamide gel 
electrophoresis
2.13.2 TS Extracts
2.13.2.1 Extract preparation
2.13.2.2 Protein concentration 
determination
2.13.3 TS Assays
2.13.3.1 Tritium release assay
2.13.3.2 Debromination assay
2.13.4 Characterization of FUdR 
resistant TS variants
2.13.5 TK extracts
2.13.6 TK assays
2.14 Computing and molecular modelling 106
3. RESULTS AND DISCUSSION 107
3.1 Drug resistance studies
3.1.1 Initial experiments 107
3.1.2 New drug screening protocols
3. 1.2.1 The use of FUdR rather than FU
3.1.2.2 A thyA derivative of the 
E.coli strain S0928
3.1.2.3 Co-expression of VZV TK 
in S092SthyA
3.1.2.4 Drug evaluation
3.1.3 New Mutagenesis Protocols
3.1.3.1 ssDNA and plasmid constructs
3.1.3.2 Strand selection procedure
3.1.4 Misincorporation mutagenesis
3.1.4.1 Use of the Klenow fragment 
of DNA polymerase I
3.1.4.2 Use of reverse transcriptase
3.1.5 Spiked oligonucleotide mutagenesis
3.1.6 Screening clones for drug resistance 
generated by misincorporation 
mutagenesis
3.1.6.1 Success of drug selection 
scheme
3.1.6.2 Wide scale screening using 
methods 4 and 5
3.1.6.3 Summary and statistical 
analysis
3.1.7 Screening clones generated by 
spiked oligo mutagenesis
3.1.7.1 Statistical analysis
3.1.7.2 Summary
3.1.8 Site-directed mutagenesis studies
3.1.8.1 Mutant construction and 
enzyme activities
3.1.8.2 Molecular modelling
3.1.8.3 Summary
3.2 Mutants created by random mutagenesis 133
3.2.1 Mutant enzyme activities
3.2.2 Modelling studies
3.2.2.1 141 L
3.2.2.2 N54K
3 . 2 . 2 . 3 I96M
3.2.2.4 S102F
3.2.2.5 D174A/174H175
3 . 2 . 2 . 6 V179E
3.2.2.7 Cl83/Q188K
3.2.2.8 C187G
3.2.2.9 F189L
3.2.2.10 SI97T/C198R
3.2.3 Summary
3.3 Studies of Key Structural Regions of TS 141
3.3.1 13-Strand i
3.3.1.1 Mutant construction and 
enzyme activities
3.3.1.2 Predicted role of G31 in 
E.coli TS
3.3.1.3 A glycine residue at 
postition 48 is not 
essential for VZV TS activity
3.3.1.4 The additional residue in 
(3-strand i of yeast TS and 
a VZV TS mutant is accomo­
dated by a (3-bulge
3.3.1.5 Identification of a covariant 
insertion adjacent to the 
(3-bulge in (3-strand i
3.3.1.6 Summary
3.3.2 Carboxy terminus
3.3.2.1 Mutant construction and
enzyme activities
3.3.2.2 The C-terminal interactions 
of L.casei and E.coli TS are 
essentially identical
3. 3.2.3 The C-terminal interactions 
of VZV and L.casei are 
significantly different
3.3.2.4 Comparison of the C-terminal 
interactions of VZV and 
L.casei at a molecular level
3.3.2.5 Differences in activity of 
the VZV and L.casei TS 
C-terminal deletion mutants 
explained in molecular terms
3.3.2.6 The C-terminal interactions 
in VZV TS are unique
3.3.2.7 TS activity and modelling of 
the mutant A300E/L301A
3.3.2.8 Summary
3.4 Thymidine Kinase
3.4.1 Site-directed mutagenesis of VZV TK
3.4. 1.1 Mutant construction and 
enzyme activities
3.4.1.2 Summary
3.4.2 Evolution of the herpesvirus 
thymidine kinase
3.4.2.1 Herpesvirus TKs are genetic­
ally and biochemically 
distinct from their 
cellular counterparts
3.4.2.2 Channel catfish virus T K : 
the most divergent herpes­
virus TK sequence known?
3.4.2.3 Evolutionary source of 
herpesvirus TK is the cell­
ular deoxycytidine kinase
4. FINAL DISCUSSION
4.1 Drug resistance studies
4.1.1 Original aims and rationale
4.1.2 A drug resistant variant of VZV TS 
requires more than one 
nucleotides substituition
4.1.3 Possibilities for future study
4.2 VZV TS as a possible target for antiviral 
chemotherpy: identification of an exploitable 
difference for rational drug design
4.3 Plastic and covariant accomodation: the 
ability of a protein to tolerate amino 
acid substitutions
4.3.1 Globins, lac and lambda repressor, 
and T4 lysozyme
4.3.2 Relationship of our studies of VZV TS 
to previous studies in other proteins
155
163
163
166
167
4.4 Conservation of the TS primary structure
4.4.1 The primary structure of TS is 
highly conserved
4.4.2 Wh\ is the primary strueture of TS 
so highly conserved
5. APPENDIX
A reappraisal of the thyl gene product of 
Dictyostelium discoideum
172
175
REFERENCES
ACKNOWLEDGEMENTS
I thank Professor John H. Subak-Sharpe for providing me 
with opportunity to work and make use of the facilities at 
the Institute of Virology.
I am indebted to Dr. Russell Thompson for his 
supervision over the past four years and for giving me the 
opportunity to explore some of my more unorthodox ideas. I 
am also grateful for his assistance with photography and 
tireless proof-reading of my thesis.
I would like to thank Dr. Graham Darby for allowing me 
to conduct part of my studies at the Wellcome Research 
Laboratories and Dr. Peter Collins and Dr. Denise Lowe for 
the support, encouragement and supervision during this 
period.
I am grateful to Professor Neil Isaacs for allowing me 
access to the computer facilities in the Chemistry 
Department of Glasgow University, and to Dr. Robert Stroud 
and Dr. Celia Schiffer for generating the model structures 
of VZV TS and providing the co-ordinates of Escherichia 
coli TS.
I thank Dr. Andrew Davison for access to unpublished 
sequencing data, Dr. John McLauchlan for synthesizing the 
large number of oligonucleotides used in this project and 
Simon Cook for assistance and patience with computing.
Special thanks to Jim Scott for invaluable help, 
assistance and patience over the past few years, without 
which this project would have been infinitely more 
difficult..
I would like to acknowledge the friendship and am 
grateful for the encouragement I have received from other 
members of Lab 201, past and present.
I am also thankful to all those people who have shared
the good bits, and endured the not-so-good bits, and put up 
with my moans when most other folk wouldn’t. These include 
Valgerdur, Martina, Janice, Ruth, Gordon, John M., John E., 
.Toe. and Jane. Apologies, but no l oss t h a n k s  to those I ’ ve 
missed.
The 'Hungry Hairy Hippos’ of the Wellcome rugby XV also 
deserve a mention as they’ll probably never get mentioned 
anywhere else.
This thesis is dedicated to my parents. I would like to 
acknowledge their considerable sacrifices, constant support 
and financial assistance over many years. Without this, my 
studies would have been as near to impossible, as I believe 
exists.
The author was the recipient of a C.A.S.E. research 
studentship from the Science and Engineering Research 
Council, and the Wellcome Research Laboratories. Unless 
otherwise stated, all the results described in this thesis 
were obtained by the author’s own efforts.
SUMMARY
Varicella-zoster virus (VZV), the causative agent of 
chickenpox and shingles, encodes approximately 70 different 
proteins including the enzyme thymidylate synthase (TS). 
TS catalyses the reductive methylation of deoxyuridylate to 
form thymidylate using N5 ,N10-methylene-tetrahydrofolate as 
a cofactor. The enzyme plays a pivotal role in the 
provision of an essential precursor for DNA synthesis. As 
such it has been used as a target for antimetabolites which 
are effective against a variety of infectious and 
proliferative diseases.
The work presented in this thesis describes the 
establishment of two random mutagenesis protocols suitable 
for the generation of complete mutant DNA libraries of the 
VZV TS gene. Use of these libraries, in conjunction with a 
novel screening protocol, has shown that a single 
nucleotide change is not sufficient to give rise to a VZV 
TS variant resistant to the potent inhibitors 5-fluoro-2’- 
deoxyuridine-monophosphate (FdUMP) and 5-ethynyl-2’-deoxy- 
uri d ine-monophosphate (EYdUMP). This is in contrast to a 
variant of human TS which contains a single nucleotide 
substitution that has been proposed to confer resistance to 
FdUMP. The introduction of the equivalent nucleotide 
substitution into the VZV TS gene by site-directed 
mutagenesis (which resulted in the equivalent amino acid 
change) did not result in a drug resistant viral enzyme.
The mutant library was used to isolate variants of VZV 
Tc that lack catalytic activity. Molecular modelling of 
the effects of the amino acid substitutions that gave rise 
to these inactive variants, extended our understanding of 
the plasticity of protein structure.
As a complementary approach to investigating the 
structure and function of T S , site-directed mutagenesis was 
used to study the effects of amino acid changes in two 
specific regions of the protein; one buried and one exposed 
to solvent. In the buried region it was shown that the 
enzyme is more flexible to amino acid substitutions than 
previously expected, and the mechanism of accomodation of 
at least one of the changes was identified.
A study of the solvent exposed C-terminal region 
identified structural and functional differences between 
VZV TS and Lactobacillus casei T S . The two enzymes 
responded differently to amino acid changes, and the VZV 
enzyme relied more heavily on hydrophobic contacts to 
maintain a functional conformation. Phylogenetic 
comparisons and molecular modelling suggested that the VZV 
TS may be unique in this regard. Exploitation of the 
difference between the VZV TS and the human enzyme may 
allow the rational design of VZV-specific inhibitors and 
such compounds may have a role as anti-varicella drugs.
It was shown that the expression of the active VZV 
thymidine kinase (T K ) was necessary for the phosphorylation 
of 5-ethynyl-2’-deoxyuridine to a form that would inhibit 
T S . This led to the identification of an amino acid 
essential for VZV TK activity in a region of the enzyme not 
previously thought to play a role in catalysis.
The evolutionary source of the herpesvirus TKs has been 
hitherto obscure. A comparison of the conserved amino acid 
regions of herpesvirus TKs with cellular deoxycytidine 
kinase revealed a significant degree of homology. In 
addition, the herpesvirus TKs and deoxycytidine kinase 
share common biochemical properties. Taken together, this 
led to the proposal that the evolutionary source of the 
herpesvirus TKs was the cellular deoxycytidine kinase.
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11. INTRODUCTION
This introduction will review aspects of the biology and 
molecular biology of herpesviruses, with special reference 
to varicella-zoster virus. In addition, it will provide 
some background information on the enzyme thymidylate 
synthase.
1.1 Herpesviruses
Membership in the family Herpesviridae is based 
primarily, though not exclusively, on virion architecture 
(Roizman, 1990). Indeed, herpesviruses have been defined 
as viruses of eukaryotes, having single, linear, double­
stranded DNA genomes of greater than, or equal to, lOOkb. 
They are replicated and packaged into icosahedral nucleo- 
capsids of lOOnm diameter, with 162 prismatic capsomers 
within the nuclei of infected cells. These are then 
enclosed in protein teguments and glycoprotein and lipid 
envelopes to give their infectious extracellular forms 
(Honess & Watson, 1977; Roizman, 1982; Honess, 1984). 
Nearly 100 herpesviruses have been characterized, including 
seven human herpesviruses (Roizman, 1990; Frenkel et al,t 
1990 ) .
1.1.1 Virion structure
The herpesvirus virion is 120 to 200nm in diameter and 
consists of four structural components, the core, capsid, 
tegument and envelope (reviewed in Dargan, 1986). The 
precise number of viral polypeptides in herpesvirus virions 
is not known but estimates generally vary from 18 to 33. 
The core, which lies at the centre of the virion, consists 
of the viral genome. The widely accepted proposal that the 
DNA was wound around a cylindrical or toroidal protein- 
aceous plug (Furlong et al. , 1972; Nazerian, 1974; Nii &
Yasuda, 1975; Irmiere & Gibson, 1983) has recently been 
challenged by Booy and co-workers (1991). They analysed 
the organization of DNA within the herpes simplex virus 
type 1 (HSV-1) capsid by cryoelectron microscopy and image
2reconstruction and demonstrated the presence of a uniformly 
dense ball of DNA. This ball of DNA extends radially as 
far as the inner surface of the icosahedral shell, thus 
negating the presence of a protein plug. The absence of a 
candidate protein to form this plug, as reflected by the 
identical protein profiles of A- and C-capsids (Booy et 
al. , 1991), the similarity to the observed DNA organisation 
of several large dsDNA bacteriophages (Lepault et al. , 
1987; Black, 1989) and biophysical studies of DNA packaging 
(Rau et al. , 1984; Richter & Dubochet, 1990) give further
weight to this proposal. The suggestion by Friedman and 
co-workers (1975) that the toroid/cylinder morphology may 
represent a developmental intermediate in mature capsid 
formation, with a uniformly staining species of particle 
representing the mature capsid, seems to reconcile the two 
sets of observations.
Capsid morphology is a characteristic feature of the 
Herpesviridae. The capsid exhibits 2-, 3- and 5-fold
symmetry and comprises 162 capsomers. There are 150 
hexameric prisms and 12 pentameric prisms that are arranged 
in the form of an icosahedron (Wildy et al., 1960). Recent 
studies using the techniques of cryoelectron microscopy and 
image reconstruction have significantly increased our 
knowledge of herpesvirus capsid structure (Schrag et al. , 
1989; Baker et al., 1990; Booy et al., 1991).
In 1974, Roizman and Furlong used the term tegument to 
describe the structures between the capsid and the 
envelope. This region has no distinct features in thin 
section but appears fibrous on negative staining (Morgan et 
al., 1968). The tegument is frequently distributed 
assymetrically and its overall bulk seems to be virus 
rather than host determined (McCombs et al., 1971).
When visualised by electron micoscopy, the virus 
envelope has a trilaminar appearance (Epstein, 1962). It 
appears to be derived from the infected cell nuclear 
membrane and contains a variety of virus specific glyco­
proteins (Stannard et al., 1987).
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31.1.2 Genome structure
The complete DNA sequence of at least six herpesviruses 
have been determined. These are, Epstein Barr virus (EBV; 
Baer et al., 1984), varicella-zoster virus (VZV; Davison &
Scott, 1986), herpes simplex virus type 1 (HSV-1; McGeoch
et al . , 1988 ), human cytomegalovirus (HCMV; Chee et al, ,
1990), channel catfish virus (CCV; Davison, 1992) and 
equine herpesvirus type 1 (EHV-1; E. Telford, personal
communication). Moreover the genome layout of many more 
herpesviruses is known. When analysed in terms of the 
presence and location of reiterations in excess of lOObp, 
they can be arranged into five groups (Roizman et al. , 
1981; Dargan, 1986; McGeoch, 1989; Chee & Barrell, 1990; 
see Fig. 1.1).
1.1.3 Molecular and biological properties
Many molecular and biological properties are common to 
all herpesviruses. Viral replication commences with the 
attachment of the viral envelope to receptors on the plasma 
membrane of the host cell, followed by fusion with the 
membrane and subsequent release of the capsid.
Virus DNA is replicated in the 
nucleus and unit length DNA is cleaved from concatemers and
spooled into preformed, immature capsids which mature by 
the acquisition or processing of proteins that bind to the 
surface of the capsid. Virus DNA is also transcribed in the 
nucleus and the mRNA is translated in the cytoplasm
(Roi zman, 1991).
The virus develops the ability to become infectious when 
the capsids are enveloped by budding through the inner
lamella of the nuclear membrane. The virus accumulates in 
the perinuclear space and cisternae of the endoplasmic 
reticulum, prior to the release of virus particles via 
transport to the cell surface through modified endoplasmic 
reticulum structures bounded by cytoplasmic membranes.
In terms of common biological properties, each herpes­
virus has its own natural and experimental host range, with 
both warm and cold-blooded vertebrates and invertebrates
4being hosts for herpesviruses. Some herpesviruses can 
induce neoplasias in both their natural hosts and 
experimental animals.
Herpesvirus transmission is usually by contact between 
moist mucosal surfaces. Some herpesviruses can be trans­
mitted transplacentally, via breast milk or by trans­
fusions. Herpesviruses can remain latent in their primary 
hosts for the lifetime of these hosts, the cells harbouring 
the latent virus vary depending upon the virus (Honess, 
1984; Clements, 1990; Roizman, 1990. 1991).
1.1.4 Herpesvirus taxonomy
The similarities, and the differences, in the molecular 
and biological properties of the herpesviruses, have been 
exploited for the purpose of classification, with the 
result that the members of the Herpesviridae are divided 
into three subfamilies (Roizman, 1982, 1991; Matthews,
1982 ) .
1.1 . 4 . 1 Alphaherpesvirinae
The host range of the Alphaherpesvirinae is variable in 
that some viruses have a very narrow host range, whereas 
others can have a very wide host range. For example HSV-1, 
naturally infects only one organism, namely humans, whereas 
other members, such as pseudorabies virus (P R V ), can infect 
a wide range of organisms (Trainer &. Karstad, 1963; Kirk­
patrick et al ., 1980; Gustafson, 1981). Alpha herpes­
viruses have a relatively rapid growth cycle (less than 
24h), their rapid spread in tissue culture is associated 
with a high level of cell destruction. In addition, latent 
infections are frequently, though not exclusively, 
established in sensory and autonomic ganglia. The DNA 
genome ranges in length from 120 to 180kb, with sequences 
from the termini present in an inverted form internally. 
The genome packaged in virions may consist of two or four 
isomeric forms. This subfamily includes the type species 
HSV-1, as well as HSV-2, VZV, EHV-1 and PRV (Roizman, 
1991 ) .
51 .1 .4 .2 Betaherpesvirinae
The Betaherpesvirinae have a restricted host range. In 
vivo the host range is restricted to the species or genus 
to which the host belongs; in vitro replication is usually 
restricted to a specific cell type, although exceptions do 
exist. The Betaherpesvirinae are also distinguished by a 
relatively slow reproductive cycle (longer than 24h), with 
siowly progressing lytic foci observed in tissue culture. 
This subfamily includes the type species human (HCMV) and 
murine (MCMV) cytomegaloviruses which take their name from 
the observation that infected cells frequently become 
enlarged (cytomegalia). Other members include the more 
recently characterized human herpesviruses 6 (HHV-6;
Lawrence et al., 1990) and 7 (HHV-7; Frenkel et al., 1990). 
Latent infections are predominantly established in the 
secretory glands, lymphoreticular cells and the kidneys. 
The DNA genome ranges in size from 180 to 250kb and 
sequences from either or both termini may be present in an 
inverted form internally.
1 .1 .4.3 Gammaherpesvirinae
The members of this subfamily only infect their natural 
host and cannot infect experimental animals outside the 
family or order. The length of the replication cycle is 
variable. These viruses are specific for B- or T-lympho- 
cytes, and infection is frequently arrested at a prelytic 
stage, with persistence and minimal expression of the viral 
genome (Jatent infection), or at a lytic stage, causing 
cell death without the production of infectious virus 
progeny. In vitro they replicate in lymphoblastoid cells. 
The DNA genome varies in length from 100 to 170kb with both 
ends of the molecule containing reiterated sequences that 
are not reiterated internally (Roizman, 1991). Members of 
the Gammaherpesvirinae include the type species EBV, 
herpesvirus saimiri (HVS) and herpesvirus ateles (HVA).
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Fig 1.2. Genome layout of VZV.
VZV gene arrangement as deduced from the DNA sequence. ATG- 
initiated open reading frames (ORFs) predicted to encode proteins are 
shown as open arrows. ORFs 42 and 45 are shown in black and are 
predicted to form a spliced message. Vertical arrows indicate potential 
polyadenylation sites in the appropriate strand. The origins of viral DNA 
replication are indicated by open boxes; the reiterations are shown by 
filled boxes (see text for details). The scale in kb is also shown (adapted 
from Davison, 1991).
61.2 Molecular biology of varicella-zoster virus
VZV is an extremely cell-associated virus that grows 
relatively rapidly in tissue culture cells. However, a 
method for preparing high titre cell-free virus is 
unavailable, nearly 40 years after VZV was first isolated 
(Weller, 1953). This, together with the lack of a suitable 
animal model, has, until recently, resulted in a very 
limited understanding of VZV genetics and gene expression. 
A major step to bringing the understanding of the molecular 
biology of VZV into line with that of HSV, was the deter­
mination of the complete genome sequence by Davison and 
Scott (1986).
1.2.1 Genome structure and organization
The genome of the Dumas strain of the VZV (Dumas et al., 
1981) consists of 124,884bp (Davison & Scott, 1986). Of 
the 71 predicted ATG-initiated open reading frames (ORFs), 
three are duplicated and two (ORFs 42 and 45) are probably 
expressed as a spliced mRNA. Thus, there are potentially 
67 unique genes, containing from 71 to 2,763 codons, that 
are arranged compactly on both strands of the DNA and do 
not extensively overlap (Davison & Scott, 1986). The 
locations of 48 predicted polyadenylation signals are shown 
in Fig. 1.2. These were identified by the presence of the 
polyadenylation signal sequence, AATAAA (or ATTAAA), which 
in most cases, was located upstream of the consensus 
sequence, YGTGTTYY, a conserved element located 25 to 40bp 
downstream from the polyadenylation signal sequence 
(McLauchlan et al . , 1985 ). This particular analysis
suggested that whilst some polyadenylation signals serve a 
unique gene, others may serve up to four genes in so-called 
3* co-terminal families. This type of gene arrangement has 
also been recorded for HSV (reviewed in Wagner, 1985).
The genome of VZV possesses five regions, R1 to R 5 , 
which comprise tandem direct reiterations of fairly short 
sequences with a partial copy at the 3 ’ end (Davison,
1991). The reiterations comprise individual
elements that are made up from multiples of 3bp, thus the
7reading frame of the ORFs within which R1 , R2 and R3 lie, 
is not disrupted. Reiteration R1 has the most complex 
arrangement of its individual elements and varies in 
different strains of VZV (Kinoshita et al. , 1988).
Reiterations R 2 , R3 and R4 have less complex patterns, but 
also vary in size in different virus isolates (Straus et 
al., 1983; Hondo et al. , 1987 ). R 5 , which exists as only
one single and one partial copy of the reiterated element 
in the Dumas strain of VZV (Davison & Scott, 1986) has been 
shown to exist in the form of multiple copies in other 
strains (Hondo & Yogo, 1988). These observations suggest 
that the genome of VZV is not of a unique size, and may 
vary in length between the approximate limits of 124,000 to 
126,000bp (Davison, 1991). The role of the reiterated 
regions is unknown at present. The fact that R 1 , R2 and R3 
lie within protein coding regions, and the reiterations do 
not introduce alterations in the reading frame, suggests 
that the virus possesses the potential to encode repeated 
amino acid sequences within proteins, the functional
significance of this unknown.
1.2.2 Transcriptional analysis
Maps of VZV transcription units have come from just two 
groups (Ostrove et al ., 1985; Maguire et al ., 1986;
Reinhoid et al., 1988). Both groups used specific VZV DNA 
fragments to map transcripts in VZV infected cells by
Northern blot hybridization, and in the most recent 
investigation ssDNA probes were used to determine the 
location and orientation of the mRNAs (Reinhold et al., 
1988). The results are in accordance with the gene layout 
predicted from the DNA sequence (Davison & Scott, 1986). 
In addition to general transcript analysis, the precise 5 ’ 
and 3 ’ ends of the mRNAs corresponding to genes 36 and 61 
(Davison & Scott, 1986; Stevenson et al., 1992) and the 5 ’ 
end of the mRNA corresponding to gene 62 (McKee et al.,
1990) have been determined. More recently, several
transcripts have been mapped to genes 12 to 15, including a 
l.lkb transcript that maps to gene 13 (Ling et al., 1991),
Gene Codons Function or Properties Gene Codons Function or Properties
1 108 35 258
2 238 36 341 Thymidine kinase
3 179 37 841 Glycoprotein (gplll)
4 452 Transcriptional activator 38 541
5 340 Poss. membrane protein 39 240 Multiply hydrophobic 
protein
6 1083 Component of DNA 
helicase-primase complex
40 1396 Major capsid protein
7 259 41 316 Capsid protein
8 396 dUTPase 42+45 747
9 302 43 676
10 410 Poss. tegument protein 44 363
11 819 46 199
12 661 47 510 Probable protein kinase
13 301 Thymidylate synthase 48 551 DNase
14 560 Glycoprotein (gpV) 49 81 Myristylated virion 
protein
15 406 Multiply hydrophobic 
protein
50 435 Multiply hydrophobic 
protein
16 408 Associated with DNA 51 835 or/s-binding protein
polymerase
17 455 Host shutoff virion 
protein
52 771 Component of DNA
helicase-primase
complex
18 306 Ribonucleotide reductase 
small sub-unit
53 331
19 775 Ribonucleotide reductase 54 769 Virion protein
large sub-unit
20 483 Capsid protein 55 881 Component of helicase- 
primase complex
21 1038 56 244
22 2763 Tegument protein 57 71
23 235 58 221
24 269 Poss. virion protein 59 305 Uracil-N glycosylase
25 156 60 159
26 585 Prob. virion protein 61 467 Poss. transcriptional 
repressor
27 333 62/71 1310 Transcriptional activator
28 1194 DNA polymerase 63/70 278 Homologue of HSV-1 
IE gene
29 1204 ssDNA-binding protein 64/69 180 Virion protein
30 770 Prob. virion protein 65 102 Tegument protein
31 868 Glycoprotein (gpll) 66 393 Protein kinase
32 143 67 254 Glycoprotein (gpIV)
33 605 Required for DNA 
packaging
68 623 Glycoprotein (gpl)
34 579 Virion protein
Table 1.1. VZV gene products.
Functions or properties of VZV proteins (see text for further details). 
(Adapted from Davison, 1991).
8the gene that encodes TS (Thompson et al., 1987 ). The 5 ’ 
and 3* ends of the mRNA for gene 14 have been determined. 
In addition, the transcripts of genes 12 and 13 are 3* co­
terminal (Ling et al., 1991) in agreement with the 
prediction of Davison and Scott (1986).
1.2.3 VZV gene products involved in DNA precursor 
synthesis
Prior to the genomic sequencing of VZV relatively few 
virus-induced proteins had been described and no 
localization of a protein to a specific gene had been 
reported. Of the 67 unique genes encoded by VZV, functions 
and/or properties have been assigned to at least 44 as 
shown in Table 1.1. Functions were initially assigned by 
identifying homologies to other herpesvirus proteins and/or 
those of other organisms. Several of these gene products 
are directly involved in the synthesis of DNA precursors.
The thymidine kinase (TK) expressed by VZV produces 
thymidylate (dTMP) by the salvage pathway, and like most 
herpesvirus TKs has a broad substrate specificity (Kit, 
1985). In addition to catalysing the phosphorylation of 
thymidine (T d R ) it can also catalyse the phosphorylation of 
deoxycytidine (C d R ) , thymidylate (dTMP) and a variety of 
nucleoside analogues (Fyfe et al. , 1978; Cheng et al.,
1981; Larder et al., 1983; Chen et al . , 1979; Kit et al.,
1974). VZV is unique amongst the human herpesviruses as it 
encodes T S , the enzyme that catalyses the de novo 
synthesis of thymidylate (Thompson et al., 1987; see 
Section 1.5). Ribonucleotide reductase (R R ), which 
catalyses the conversion of ribonucleoside diphosphates to 
their corresponding deoxyribonucleotides is encoded by VZV 
genes 18 and 19 (Davison & Scott, 1986). In the case of 
HSV-1, this enzyme is essential for growth in non-dividing 
cells or at elevated temperatures (39.5*C; Goldstein A 
Weller, 1988). In addition, it has been shown to be a 
successful target enzyme for antiviral chemotherapy in both 
VZV and HSV (Cameron et al. , 1988; Spector et al., 1989).
VZV also specifies deoxyuridine triphosphatase (dUTPase)
9(Davison & Scott, 1986), an enzyme that catalyses the 
conversion of deoxyuridine triphosphate (dUTP) to its
corresponding monophosphate (dUMP) with the concomitant
release of pyrophosphate. Whether dUTPase plays a role in 
providing dUMP as a substrate for TS and/or helps to lower 
the levels of dUTP pools to prevent the incorporation of 
uracil into viral DNA remains unresolved.
1.2.4 Regulation of gene expression
The understanding of the regulation of gene expression 
during VZV replication is still rudimentary, partly due to 
the difficulty of inducing co-ordinate infections. It is 
still not clear whether VZV follows a distinct cascade 
pattern during which three classes of genes, immediate 
early, early and late, are sequentially expressed, as found 
in other herpesviruses such as HSV-1. Immediate early (IE) 
genes in HSV have been defined as those which are 
transcribed by the unmodified host RNA polyflvLtTv^ e. in the 
absence of de novo protein synthesis (Honess & Roizman, 
1974; Clements et al., 1977; Jones & Roizman, 1979).
Functional IE gene products are absolutely required for the 
expression of HSV-1 early and late genes (Preston, 1979; 
Watson & Clements, 1980). Early genes are expressed after 
protein synthesis but are not dependent on DNA replication. 
The expression of both immediate early and early genes is a 
prerequisite for late gene expression, which requires DNA 
replication for maximum efficiency (Jones & Roizman, 1979; 
Pedersden et al ., 1981).
From studies of HSV-1 infected cells, it has been shown 
that immediate early gene transcription is stimulated by 
the virion protein Vmw65, a protein that is important for 
virus replication after infection at low multiplicities or 
in vivo (Ace et al., 1989). Five immediate early genes are 
transcribed upon initial infection, and at least three of 
the immediate early proteins are important transactivators 
required for maximal expression of early and late genes 
(Everett, 1984a; O ’Hare & Hayward, 1985; Sacks et al., 
1985). Two of these proteins, Vmw175 (IE175 gene product)
10
and Vmw63 (UL54 gene product) appear to be essential for 
virus growth in tissue culture (Deluca et al, , 1985; Dixon
& Schaffer, 1980; Preston, 1979b). The third trans­
criptional activator, VmwIIO (IE110 gene product) is not 
essential for virus replication in tissue culture (Stow & 
Stow, 1986; Sacks & Schaffer, 1987).
Sequencing of the VZV genome revealed the presence of 
potential homologues to four of the five HSV-1 IE genes 
(Davison & Scott, 1986). In addition, four polypeptides 
have been identified as immediate early proteins by the 
classic inhibitor approach (Lopetegui et al., 1985; Shiraki 
& Hyman, 1987), suggesting that the control of gene 
expression between the two viruses may be similar. A 
number of recent studies by several groups have confirmed 
some functional similarities between the control of gene 
expression in both viruses, but also discovered significant 
di f ferences.
The protein encoded by VZV gene 62 shares amino acid 
homology to functionally important regions of Vmw175 of 
HSV-1 (McGeoch et al., 1986), and, like Vmw175, can
function as a transcriptional transactivator (Everett, 
1984a; Inchauspe et a l ., 1989). The protein can complement 
the growth of HSV-1 mutants with temperature sensitive 
lesions in, or deletions of the IE175 gene, that normally 
can only be propagated on cell lines that const itutively 
express Vmw175 (Felser et al,, 1988). When both copies of 
the IE175 gene from HSV-1 were replaced by the VZV gene 62, 
under the control of the IE175 promoter, the resulting 
recombinant virus could be propagated on normal cell lines 
(Disney & Everett, 1990). The gene product of VZV gene 62 
can autoregulate expression from its own promoter (Disney 
et al ., 1990) but not the IE175 promoter (Disney & Everett, 
1990). This is similar to Vmw175 and suggests that the two 
proteins play very similar roles in the control of virus 
gene expression.
The product of VZV gene 4 and Vmv63 of HSV-1 share 29% 
amino acid identity (McGeoch et al,, 1988). Vnw63 is 
essential for HSV-1 replication (Sacks et al,, 1985) and
11
functions as a trans-regulatory protein (Everett, 1986; 
Rice & Knipe, 1988; Sekulovich et al. , 1988 ). The VZV
gene 4 protein product can transactivate at least one early 
and one late gene in a synergistic manner with the gene 
product of VZV gene 62 (Inchauspe et al., 1989). However,
it has also been shown that the gene products of the two 
VZV immediate early genes, 4 and 62 can transactivate the 
thymidine kinase promoters of both the VZV and HSV, but 
that their HSV-1 homologues, Vmw175 and Vmw63, can only 
transactivate the HSV-1 thymidine kinase promoter 
(Inchauspe & Ostrove, 1989). Thus, despite the functional 
simlilarities of these transcriptional activator proteins, 
their precise mechani sms of action differ. Thi s i s 
probably caused by a combination of differences in the cis 
acting sequences of the genes upon which they act 
(Inchauspe & Ostrove, 1989) and differences in the 
architecture of the individual proteins.
The gene product of VZV gene 63 displays a short region 
of amino acid sequence homology to the HSV-1 IE protein 
Vm w 68 (Davison & McGeoch, 1986). No function has been 
assigned to either protein, but an HSV-1 mutant lacking 
the carboxy-terminal third of Vmw 6 8  exhibits poor growth 
in tissue culture, shows reduced expression of at least one 
late gene and is non-neurovirulent in mice (Post & Roizman, 
1981; Sears et a l ., 1985). Expression of gene 63 has been
detected in human trigeminal ganglia (Vafai et al., 1988), 
but no further studies of the function of its gene product 
ha\e been reported.
VZV gene 61 is located at the position equivalent to 
HSV-1 IE110 which encodes the transactivating protein 
VmwIIO (McGeoch et al., 1988). Despite the fact that the
VZV protein is just over half the size of VmwIIO and bears 
only local amino acid homology, at a region that has been 
proposed as a putative zinc-finger DNA binding motif, this 
lead to the tentative proposition that the two proteins 
could have similar functions (Perry et al ., 1986). This
particular zinc-finger motif has since been found in 
several non-herpesvirus proteins (Freemont et al., 1991).
12
The VZV gene 61 product can function as trans-repressor 
(Inchauspe et al ., 1989; Nagpal & Ostrove, 1991) and
possesses no trans-activational activity (Cabriac et al. , 
1990). The IE110 gene possesses several upstream elements 
essential for immediate early gene expression, such as the 
so-called "TAATGARAT" sequence (Mackem & Roizman, 1982). 
However, analysis of the upstream region of the VZV gene 61 
revealed no convincing examples of such elements (Stevenson 
et a 1 . , 1992 ). In addition, it is not clear from studies
of VZV immediate early gene expression (Lopetegui et al. , 
1985; Shiraki & Hyman, 1987) if any of the proteins 
identified correspond to the gene 61 protein. Indeed, the 
counterpart of gene 61 in another alphaherpesvirus, PRV, is 
an early gene (Cheung, 1991), and the transcription of the 
gene 61 homologue in EHV-1 has not been detected under 
immediate early conditions (Gray et al. , 1987; E. Telford
and A. J. Davison, personal communication). These data 
suggest that Vm w IIO and the VZV gene 61 protein are not 
functional homologues.
The discovery that Vmw 65, the product of UL48 gene of 
HSV-1, could transactivate the VZV7 gene 62 promoter (McKee, 
1990; McKee et al. , 1990), in an analogous manner to the
way in which it transactivates HSV-1 immediate early genes, 
led to obvious interest in VZV gene 10, which lies at the 
equivalent position to the HSV-1 gene UL48 (McGeoch et al.,
1988). The predicted gene product of gene 10 shows 35% 
homology with Vmw65 (Dalrymple et al. , 1985 ), but recent
analysis has shown that, in contrast to Vmw65, it cannot 
stimulate transcription from the gene 62 promoter (McKee, 
1990). Neither can it form a complex analogous to the 
immediate early complex that is formed when Vmw65 interacts 
with oligonucleotides representative of promoter elements 
of HSV-1 immediate early genes or VZV gene 62 (McKee et 
al., 1990).
In summary, there are certain similarities between the 
control of gene expression in VZV and HSV-1, but also 
significant differences. These differences between the two 
viruses may, in part, explain some of their major
Fig. 1.3. VZV DNA replication.
Step A represents the circularization of one of the four possible genome 
arrangements and step B indicates the period during which limited 
replication occurs and segment inversion may take place. At step C, 
DNA replication occurs by a rolling circle mechanism, and in the final 
step D, concatemers are cleaved to produce unit length genomes for 
encapsidation (adapted from Davison, 1984).
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biological differences. The view is now emerging that 
HSV-1 may not be the best model on which to base studies of 
the control of VZV gene expression, and other alphaherpes- 
viruses such as PRV and EHV-1, may serve as better models 
for future studies (Stevenson et al ., 1992).
1.2.5 VZV DNA replication
A model for VZV DNA replication, based on several 
structural features of the viral genome and experimentally 
supported views of PRV and HSV-1 DNA Replication, has been 
proposed by Davison (1984). Linear DNA, in one of its four 
isomeric forms, circularises, probably by the direct 
ligation of the termini to produce a novel L-S joint 
identical to the normal L-S joint in the linear genome. 
After circularisation, limited DNA replication occurs and 
the short segment can be inverted by intramolecular
recombination between inverted repeats. DNA replication 
proceeds by the generally accepted rolling-circle method to 
produce head-to-tail concatemers, as has been shown for PRV 
and HSV-1 (Ben-Porat & Rixon, 1979; Jacob et al,, 1979). 
The final stage involves the specific cleavage of
concatemers to generate unit length genomes for 
encapsidation. Cleavage usually occurs at the novel L-S 
junction, but occasionally at the normal L-S junction 
generating the major and minor genome arrangements
(Davison, 1984; see Fig. 1.3).
Two copies of a putative origin of DNA replication were 
detected in TRs/IRs (Davison & Scott, 1985), on the basis 
of homology to the HSV-1 oris sequence (Stow & McMonagle,
1983). A 259bp fragment containing the putative 
palindromic origin of replication showed activity in 
plasmid replication assays, originally used to identify the 
HSV-1 origin of DNA replication, strongly suggesting that 
this was the real origin of VZV DNA replication (Stow, 
1982; Stow & Davison, 1986). Deletions made in the 
palindromic region of the putative origin sequence 
dramatically reduced replicative ability, confirming that 
this sequence was the origin of replication (Stow &
14
Davi son, 1986).
A set of seven HSV-1 genes which encode proteins 
necessary and sufficient for viral DNA synthesis have 
recently been identified (McGeoch et al., 1988; Wu et al. t
1988; Challberg & Kelly, 1989). VZV possesses seven genes 
whose predicted gene products show homology to those of 
HSV-1 (McGeoch et al. , 1988), only one of which, the gene
product of gene 51, has been characterized in any detail. 
This protein, which has extensive amino acid homology with 
its HSV-1 counterpart, the gene product of the UL9 gene, 
has been shown to bind to the VZV origin of DNA replication 
(Stow et a l ., 1990).
1.3 Biology of varicella-zoster virus
Varicella-zoster virus is the causative agent of two 
distinct clinical syndromes, chickenpox and shingles. 
Chickenpox, or varicella, is a relatively benign disease in 
children, but can be severe, and in some cases life 
threatening. in infected adults or immunocompromised 
individuals.
1.3.1 Varicella: disease
After an incubat ion period of 10 to 20 days f oil owing 
initial infection a characteristic rash, the most typical 
feature of varicella, starts to erupt. Succesive crops of 
new lesions erupt over the next two to four days, appearing 
first on the scalp and trunk and then spreading to the 
extremities. The crusts from these lesions are shed 
between one and three weeks later. Vesicles also appear on 
all mucosal surfaces, which rupture and are thought to be 
responsible for the spread of virus by the respiratory 
route (Gelb, 1990).
The illness is generally benign with only mild fever 
whilst new lesions are erupting, and pruritis which 
persists throughout the vesicular stage (Broughton, 1966). 
The most frequent complication is bacterial superinfection 
of skin lesions (Bullowa & Wishik, 1935) but administration
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of appropriate antibiotic treatment is usually successful. 
Varicella pneumonia is the commonest serious complication 
in adults with a mortality rate of 10% to 40% (Guess,
1986). A recent study of pregnant women with primary 
varicella reported an incidence of symptomatic pneumonia of 
almost 10% with one fatality (Paryani & Arvin, 1986). 
Neonatal varicella is seen in infants infected in utero or 
shortly after birth and have insufficent maternal antibody 
to combat the disease and has a fatality rate exceeding 80% 
(Brunell, 1983; Preblud et al., 1985). Varicella infect­
ions in the mother during the first trimester of pregnancy 
can occasionally result in congenital defects (Brunell, 
1983; Paryani & Arvin, 1986; Batik & Stevens, 1989).
Immunocompromised patients, whether leukaemic, suffering 
other malignacies, receiving immunosuppressive chemotherapy 
or suffering from the acquired immunodeficiency syndrome 
(AIDS), have significantly increased complications and 
severe infections of varicella (Krugman, 1977; Jura et al.,
1989). In addition, a variety of neurological defects are 
associated with varicella, not least Reye syndrome. Little 
is known about this association but varicella preceeds 20% 
to 30% of Reye syndrome cases and salicylate (aspirin) use 
has been linked to an increased risk of the disease 
(Hurwitz et al., 1982; Remington et al. , 1986 ).
1.3.2 Varicella: pathogenesis
Infection is initiated when the virus invades the mucosa 
of the upper respiratory tract and oropharynx, or 
alternatively via the conjunctiva. Viral replication 
commences at the primary site of inoculation and virus 
dissemination, termed primary viremia, is via the 
bloodstream and the lymphatic system. When taken up by the 
cells of the reticuloendothelial system, the virus
undergoes multiple cycles of replication and extensive 
secondary viremia develops. These events take place during 
the prodromal or incubation period of the disease (Gelb,
1990). Three to five days prior to the onset of clinical 
varicella, simultaneous increases in cellular and viral TK
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activity are seen in serum samples (Kallander et al. ,
1989) .
Secondary viremia is followed by vesicle eruption with 
fresh lesions appearing in successive crops, due to the 
process of cyclic viremia (Feldman & Epp, 1979). Viremia 
is usually terminated after three days by specific humoral 
and cell mediated responses, after which no fresh lesions 
erupt (Gelb, 1990).
1.3.3 Zoster: disease
Shingles, or zoster, is the clinical syndrome associated 
with the reactivation of VZV from its site of latency (see 
Section 1.3.5). The rash associated with zoster is usually 
preceeded by pain and paresthesia in the involved dermatome 
which ranges from mild itching, or tingling, to severe 
pain. The term 'zoster sine herpete’ has been applied to 
describe those prodromal symptoms where there is no 
subsequent vesicle eruption, but a typical antibody 
response is observed (Lewis, 1958).
When vesicle eruption does occur, it is character­
istically unilateral, does not cross the mid-line and is 
limited to the cutaneous innervation of a single sensory 
ganglion. Lesions are typically varicelli-form, but evolve 
less rapidly and appear more often as grouped vesicles 
rather than the discrete lesions seen with varicella. The 
areas supplied by the trigeminal nerve and thoracic ganglia 
are most commonly involved in zoster (Burgoon et al. , 
1957). New lesions erupt over a period of several days, 
and crusts, taking as long as a week to form, may persist 
for two to three weeks. The severity and duration of the 
cutaneous eruptions are roughly proportional to patient age 
(Brown, 1976). When zoster involves the opthalmic division 
of the trigeminal nerve, a variety of eye lesions can occur 
(Guess, 1986). The Ramsev-Hunt syndrome, characterised by 
facial palsy and zoster of the external ear, results from 
the involvement of the geniculate ganglia (Denny-Brown et 
al., 1944).
The commonest complication of zoster is post-herpetic
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neuralgia, occuring in 50% of infected individuals over 60 
years of age. This is especially common with opthalmic 
zoster and, although difficult to treat, often resolves 
spontaneously (de Moragas & Kierland, 1957). True post­
herpetic neuralgia, where pain persists for more than one 
month, has an estimated incidence of approximately 10% 
(Watson & Evans, 1986). In approximately half of these 
patients pain resolves within two months, but in 20% to 30% 
of those affected it can persist for over a year, and in a 
minority of cases for over a decade (de Moragas & Kierland, 
1957 ) .
As with varicella, herpes zoster is more severe in 
immunocompromised individuals or those with malignancies. 
Chronic zoster and persistent infection of the central 
nervous system are common complications in these 
individuals (Gallagher & Merigan, 1979; Horten et al . , 
1981; Ryder et al., 1986).
1.3.4 Zoster: pathogenesis
Although the pathogenesis of herpes zoster is poorly 
understood, the relationship between the distribution of 
skin lesions and the anatomy of the nervous system was
first appreciated by Bright in 1831. The current model of 
zoster pathogenesis is based on clinical and epidemiol­
ogical data, and analogy to HSV infections (Hope-Simpson, 
1965). Reactivation of VZV is sporadic and infrequent, and 
although the mechanism of reactivation is unclear, many of 
the conditions correlated to reactivation are associated 
wjth immunosuppression (Gelb, 1990). This led to the
proposal that it is the deterioration of host defences, 
below the level of containment, that allows VZV to begin 
active replication in the sensory ganglia (Hope-Simpson, 
1965). The resultant virus produced is almost immediately 
contained by either antibody or cell mediated immunity. 
However, the release of antigen boosts antibody levels 
sufficiently to mark the event (Gershon et al., 1982; Luby
et al., 1977). Similar boosts in VZV-specific antibody are
seen following exposure to varicella and reinfection has
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been suggested in the partially immune host (Arvin et al. , 
1983; Gershon et al. , 1986; Oxman 1981; Weigle & Grose, 
1984). When host defences deteriorate below the point 
where VZV replication can be fully contained, extensive 
viral multiplication occurs in ganglia, resulting in 
neuronal necrosis and intense inflammation. The infectious 
virus then spreads down the sensory nerve, infects the skin 
and produces the characteristic clustered vesicles of 
herpes zoster. Zoster vesicles, like those of varicella, 
contain cell-free VZV that may be shed to the environment.
Occasionally, the immune system can curtail the 
formation of cutaneous lesions but not the necrosis and 
inflammatory response in the ganglia, resulting in pain 
without associated skin lesions, (zoster sine herpete) 
(Lewis, 1958; Easton, 1970; Juel-Jenson, 1972; Luby et al., 
1 977 ) .
Formal proof that herpes zoster is caused by the same 
virus that caused the initial varicella infection only came 
in the last decade. Straus and co-workers (1984) used DNA 
restriction enzyme analysis to show that a single VZV 
isolate caused both varicella and subsequent zoster 
infections in a child with Wiskott-Aldrich syndrome.
Recent invesigations have suggested that more than one 
strain of VZV can be present during the course of a VZV 
infection. This was shown in a study of VZV isolated from 
zoster lesions from a boy previously inoculated with the 
vaccine strain of VZV. Although zoster may be caused by 
the reactivation of the vaccine strain (see Section 1.4.2), 
Gelb and co-workers (1987) were able to show that the virus 
recovered from the zoster lesions was wild type VZV as it 
differed from the DNA restriction enzyme profile of the 
vaccine strains of VZV. In a second study, Hondo and co- 
workers (1987) reported different strains of virus isolated 
from zoster lesions and the corresponding spinal ganglia. 
However, the strains described by Hondo and co-workers 
(1987) vary predominately in the regions of reiteration. 
Although these regions are relatively stable, even after 
extensive passaging in tissue culture, variants do arise
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(Straus et a l . 1981; Ecker et a l . 1984; Zweerink et a l .
1984). In addition, the occasional loss of restriction 
sites in this case (Hondo et al., 1987) could be the result 
of a single point mutation or small deletion. This is 
indicative of only minor differences that could theoretic­
ally arise during viral DNA replication and therefore not 
reflect strain differences.
1.3.5 Latency
The processes and mechanisms of herpesviral latency are 
now becoming reasonably well understood, especially for HSV 
and EBV (Stevens, 1989; Kosz-Vnenchak et al,, 1990). 
Despite this, the understanding of the latent infection of 
VZV is still at an early stage. However, it is now clear 
that although there are some similarities between the 
latent infections of VZV and H S V , there are al so some 
distinct differences.
In HSV latent infections, it is universally accepted 
that the virus resides in sensory neurons (Kennedy et al,,
1 983; McLennon et al. , 1980; Cook et al. , 1974 ).
Detectable transcription only occurs in a single region of 
the HSV genome to produce abundant copies of the so-called 
latency associated transcripts (LATs) which are anti-sense, 
relative to the VmwIIO mRNA (Stevens et a l ., 1987).
Stevens and co-workers (1987) postulated that the retention 
of VmwIIO mRNA within the nucleus could effectively block 
translation of a viral protein important in initiating 
productive infection, and thereby play a role on the 
maintenance of the latent state.
The HSV-1 IE protein Vmw175 has been implicated in the 
establishment and maintenance of the latent state (Stevens 
et al,, 1987; Green et al . , 1981; Puga & Notkins, 1987).
Its role in latency is not yet fully understood, however, 
it can serve as a transcriptional activator both in vivo 
and in vitro (Beard et al., 1986). In addition, V m w 175 is 
essential for the reactivation of HSV in an in vitro model 
system (Russell & Preston, 1986; Russell et al,, 1987). A 
second HSV-1 IE protein, VmwIIO, which is dispensable for
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growth in tissue culture, has also been shown to be
essential for the reactivation of HSV-1 in the in vitro 
model system (Russell & Preston, 1986; Russell et al. ,
1987). In addition, Vm w IIO can act synergistically with
Vm w 175 in the process of transactivation (Everett, 1984a).
It is now clear that sensory ganglia harbour latent VZV 
as has been demonstrated by in situ and Southern blot 
analysis (Croen et al. , 1988; Gilden et a l . , 1983, 1986;
Hyman et al . , 1983). This has been confirmed by
explantation and in vitro cultivation experiments of such 
ganglia which have demonstrated the production of VZV 
encoded IE mRNAs and proteins (Vafai et a l . , 1988). In
contrast to HSV, infectious VZV could not be detected in 
the ganglia by this procedure (Vafai et a l ., 1988).
A detailed analysis of ganglia latently infected with 
VZV has shown that transcription occurs from five separate 
regions of the viral genome (Croen et a l ., 1988). By using 
strand specific probes, Croen and co-workers (1988) were 
able to demonstrate the transcription of VZV genes 4 
( transcript ’ '~nal activator), 29 (major DNA binding), 31
(gpll), and 6 2  (transcriptional activator), whilst showing 
that genes 10 (tegument protein), 14 (g p V ) and 67 (gpIV)
were not transcribed during latent infection. In addition, 
explantation and in vitro cultivation experiments have 
detected a transcript from VZV gene 6 3  (homologue of HSV-1 
IE68 gene), and seven major protein species from ganglia 
latently infected with VZV (Vafai et al . , 1988). Moreover,
VZV lacks a homologue of VmwIIO (see Section 1.2.4) and 
transcripts covering a region of the VZV genome equivalent 
to the region of HSV-1 where the LATs have been mapped do 
not appear to have been detected (Vafai et al., 1988; Croen
et al., 1988; Croen & Straus, 1991). Clearly, this
situation is different to the HSV latent infection.
Further differences between the latent infections of VZV 
and HSV have been reported. VZV replicates efficiently in 
both neuronal and non-neuronal cells (Nagaskima et a l ., 
1975; Croen et a l . , 1988). The virus remains latent, and
subsequently reactivates from non-neuronal cells that
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support its replication. This facilitates its spread to 
neuronal and non-neuronal cells, resulting in the destruct­
ion of large parts of the ganglion (Head k Campbell, 1900; 
Esiri & Tomlinson, 1972). During this process, multiple 
sensory nerves become infected and convey the virus to all 
quadrants of the cutaneous dermatome, the resulting 
inflammation and necrosis inciting severe and chronic 
neuropathy.
In contrast, HSV reactivates within a neuronal cell and 
spreads readily to the skin. However, spread within the 
ganglion is inefficient, as the surrounding satellite cells 
are less permissive for productive HSV replication (than 
VZV), so that cutaneous involvement: and neuropathy are
limited.
The relative infrequency of VZV reactivation compared to 
that of HSV may reflect its non-neuronal site of latency, 
thus rendering it less subject to the neural triggers that 
provoke HSV reactivation. There may also be a variety of 
physical, metabolic or immune obstacles to the spread of 
VZV from its latent site to the neural conduit through 
which it is transported to the skin.
In summary, VZV latent infections, do not produce LATs, 
but at least five regions of the genome are transcription­
ally active. The virus also lacks a functional homologue 
of the HSV-1 Vm w IIO protein. VZV resides at many sites in 
ganglia and reactivates infrequently, possibly from non­
neuronal cells. In HSV-1 latent infections, the only 
detectable transcripts are the LATs, the virus resides 
almost exclusively in neuronal cells, and it reactivates 
frequently from single neurons. These observed differences 
may, in part, explain the differences in HSV-1 and VZV 
reactivation from latency.
1.4 Control of infection
As stated above, varicella is usually a benign and 
ubiquitous disease in normal children that requires no 
specific therapy, itching being controlled locally by
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calamine lotion or systemically by antihistamines. However, 
in immunocompromised individuals, healthy adults, pregnant 
women and cases of zoster, treatment, either preventative 
or prophylactic, is desirable and several approaches exist.
1.4.1 VZV i u u n e  serum globulin and zoster immune 
plasma
The administration of either VZV immune serum globulin, 
a high-titre VZV antibody preparation, of VZV convalescent 
plasma, within three days of exposure to VZV, has been 
shown to be effective in preventing or attenuating sub­
sequent varicella in normal (Brunell et a l . , 1969) and
immunocompromised children (Gershon et a l . , 1974; Zaia et
al., 1983; Geiser et al. , 1975; Balfour et al ., 1977 ).
However, VZV immune serumglobulin (and probably zoster 
immune plasma) has no role to play in the treatment of 
established disease (Brunell, 1981; Brunell et al ., 1969;
Gershon et al., 1974).
1.4.2 Vaccination
The Oka vaccine strain of VZV was produced by 
attenuating the virus in tissue culture (Takahashi et a l . , 
1974, 1975). The virus has been tested extensively in
Japan and appears safe and effective, even in immuno­
compromised children. It is currently licenced in Japan 
and several European countries. In healthy children its 
efficacy approaches 100% (Arbeter et al . , 1986a; Asano et
a l ., 1 985; Weibel et a l . , 1 984 ), with the immune response
lasting for several years (Arbeter, 1986a). In adults 
lower rates of seroconversion and break-through infections 
are seen (Gershon et al . , 1986).
Although efficacious the vaccine is not without its 
problems. Zoster may be caused by reactivation of the 
latent vaccine strain (Gelb et a1 ., 1987; Hayakawa et a l ., 
1984; Williams et al., 1985) or wild-type virus. The true 
longevity of protection is still to be determined, with 
waning protection in adults, after childhood immunization, 
possibly resulting in increases of morbidity and mortality.
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However, the Oka vaccine strain is responsive to at least 
one antiviral compound, acyclovir (Preblud et a l . , 1984a).
The effectiveness of the vaccine strain in high risk 
children is sufficient to warrant vaccination of these 
individuals (Gershon et al., 1986). A good immune response 
is seen when the Oka vaccine strain is combined with the 
vaccine against mumps, measles and rubella. In addition, 
both universal vaccination with the combined vaccine, and 
the Oka vaccine strain alone, has been proposed (Brunell, 
1977; Arbeter et al. , 1986). However, for reasons stated
above, this still remains a controversial proposition.
1.4.3 Antiviral compounds
Antiviral therapies are probably inappropriate or un­
necessary in routine varicella of immunocompetent children, 
but should be considered when complications occur. They 
should also be a consideration in persons with acquired or 
congenital cellular immune deficiences, or in pregnant 
women (Straus, 1987; Straus et a l ., 1988).
Human leukocyte, or alpha-interferon, has successfully 
been used to treat children infected with varicella who 
have cancer (Arvin et al. , 1982). However, it must be
given parent^o-UU^ and has several associated toxicities. 
As a consequence, most therapies are currenly based on two 
nucleoside analogues. Vidarabine (araA; 1-B-D-arabino-
furanosyladenosine; adenosine arabinoside) has proved 
efficacious for both varicella and zoster despite some 
toxicity ( Johnson et a l 1 975; Whitley et a l . , 1981,
1982a, b). However, it has been largely superceded for
most applications by acyclovir (ACV, 9-(2-hydroxyethoxy- 
methyl)guanine). Although originally identified as a 
potent inhibitor of HSV-1 (Elion et al. 1977; Schaeffer et
al. , 1978), ACV is also effective against VZV and seems to 
be superior to araA for most applications (Shepp et a l . , 
1986). ACV, along with many other nucleoside analogues 
that are active against herpesviruses, must first be 
phosphorylated by the virus encoded thymidine kinase (see 
Sections 3.1 and 3.4).
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Many other compounds have been shown to have anti­
varicella activity. These include 5-bromovinyl-2’-deoxy- 
uridine (BVdU), the 5-bromo-, 5-chloro- and 5-iodo-vinyl- 
derivatives of B-D-arabinofuranosyldeoxyuridine (BVaraU, 
CVaraU, IVaraU respectively), 1-(2-deoxy-2-fluoro-B-D- 
arabinofuranosyl)-5-methyluracil (FMAU) and 1-(2-deoxy-2- 
fluoro-B-D-arabinofuranosyl)-5-iodocytosine (FIAC; Machida, 
1986; Machida et a l ., 1982). The therapeutic index, the
ratio between the ICso for tissue culture cells and the 
concentration of drug to give 50% plaque reduction for VZV, 
of BVaraU is >3xl06 whilst ACV has a therapeutic index of 
520, an approximate 10,000 fold difference (Machida et al., 
1986 ) .
Additional compounds, which have been shown to possess 
anti-varicella activity include 5-ethynyl-2’-deoxyuridine 
(EYUdR) and 5-propynyl-2 *-deoxyuridine (PYUdR) and their 
corresponding B-D-arabinofuranosyl-derivatives EYaraU and 
PYaraU (Lacey et al. , 1991). Interestingly, several of
these compounds can inhibit VZV T S , when converted to the 
monophosphate form, including EYUdR (Simon Lacey, personal 
communication). Whether their antiviral activities are
mediated through this enzyme remains unresolved. One of 
these recently described compounds, BVaraU, is currently
under-going clinical trials as a potential anti-varicella 
drug (Lacey et al., 1991).
A number of highly potent antiviral compounds that do 
not require activation by the the viral TK have recently 
been described, including (S )-9-(3-hydroxy-2-phosphonyl- 
methoxypropyl)adenine ((S)-HPMPA) which is highly active 
against both wild-type and TK* strains of VZV (DeClercq et 
al. , 1986). In this system, it has a therapeutic index in
excess of 25,000, compared with ACV (>400) and BVdU 
(>15,000) (DeClercq et al., 1986). Similar values were
obtained in a separate study for ACV (520) and BVdU
(18,000) (Machida et al. , 1986). In an analysis of twenty
different VZV isolates, the mean ICso value for (S)-HPMPA 
was 0.0018pM, giving a mean therapeutic index of 29,000 
(Baba et al. , 1987). Another compound that is active
i
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against VZV, and is not activated by TK (at least for 
HSV-1), is cyclopentenylcytosine (Marquez et al. , 1990).
Recently the mechanism of action of (S)-HPMPA has been 
elucidated. The enzyme 5-phosphoribosyl-l-pyrophosphate 
synthetase catalyses the formation of the diphosphate 
derivative (Balzarini & DeClercq, 1991) and the 
triphosphate derivative is presumably formed by cellular 
kinases (see Larder & Darby, 1984). The triphosphate form, 
which may be thought of as an ATP analogue, is predicted to 
interfere with the viral DNA polymerase (Balzarini & 
DeClercq, 1991).
Another drug that is active against VZV is 9-[4-hydroxy- 
2-(hydroxymethyl)butyl] guanine, which inhibits the VZV DNA 
polymerase (Abele et al. , 1988). Improved prodrug forms of
this compound have also been described (Lake-Bakaar et al.,
1989). In addition, the 9-(3-hydroxypropoxy)- and 9-[3-
hydroxy-2-(hydroxymethyl)propoxy]-guanine analogues have 
been shown to be more active in vitro against VZV than ACV 
(Harnden et al. , 1990).
1.4.4 Antiviral resistance
Strains of VZV resistant to one or more of a broad range 
of antivirals have been isolated in vitro. These include 
strains resistant to ACV (Biron et al, , 1982; Shiraki et
al. , 1986; Sawyer et al., 1988), BVaraU and araA (Sakuma,
1984), BVaraU (Sakuma et al., 1985), BUdR and IUdR (Shigeta 
et al. , 1986) and BVaraU and PYaraU (Lacey et al., 1991).
Recently, ACV resistant clinical isolates have been 
observed, but to date have been confined to individuals 
with AIDS (Jacobson et al., 1990; Linnemann et al., 1990).
In the cases where the mode of resistance has been 
characterized at a molecular level, lesions in the virus 
encoded TK have been shown to confer drug resistance. 
These lesions take the form of single point mutations in 
the TK gene. In many cases, resistance is associated with 
the expression of a form of VZV TK with no detectable
enzyme activity; in some cases the expressed TK has
modified activity. Mutations in the VZV DNA polymerase
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have been shown to confer resistance to ACV (Gaillard et 
al., 1990), a mode of resistance which is also seen in 
HSV-1 (Larder & Darby, 1984).
The variety of methods for attacking the diseases caused 
by VZV hold promise for control of the virus in the future. 
This is particularly so because of the availability of the 
broad array of antiviral compounds and the fact that wide­
spread resistance has not been seen to the same levels as 
with ACV treatment of HSV infections.
1.5 Thymidylate synthase: an introduction
Efficient DNA synthesis requires the presence of
adequate pools of the four 2 1-deoxyribonucleotides, dATP, 
dCTP, dGTP and dTTP. The first three of these are
synthesized by direct reduction of their corresponding 
ribonucleotides in a reaction catalysed by ribonucleotide 
reductase. In eukaryotes and certain prokaryotes,
reduction occurs at the diphosphate level and is followed 
by phosphorylation of the dNDPs to dNTPs by the enzyme 
nucleoside diphosphate kinase. In other prokaryotic organ­
isms reduction of ribonucleotides occurs at the triphos­
phate level. Ribonucleotide reductase also mediates the 
synthesis of a fourth 2 ’-deoxyribonucleotide, namely dUTP.
As dTTP has no ribonucleotide counterpart, it cannot be 
synthesized in this way. Instead, it is synthesized de 
novo, commencing with the formation of thymidylate (dTMP) 
from deoxyuridylate (dUMP) in a reaction catalysed by the 
enzyme thymidylate synthase (T S ) . dUMP is provided by the 
hydrolysis of dUTP, catalysed by deoxyuridylate triphos­
phate dephosphohydrolase (dUTPase), or by the deamination 
of deoxvcytidylate (dCMP). dTMP can also be formed by a 
salvage pathway where thymidine kinase (TK) catalyses the 
phosphorylation of thymidine. The phosphorylation of dTMP 
to dTDP is catalysed by thymidylate kinase and nucleoside 
diphosphate kinase catalyses the phosphorylation of dTDP to 
form dTTP (Neuhard & Nygaard, 1987; O ’Donovan & Neuhard, 
1970) .
R ib o n u c leo t id e
r e d u c ta s e
ADP dA DP ► dATP
COP *- dCDP dCTP
DNA
GDP ► dGDP dGTP
dTDP dTTP
T h y m id y la te
s y n t h a s e
dUMP dTMP
CH H Folate H F olate
^ • K - o - Ur»w u 7
Serine
trans-hydroxy
methylase
Dihydrofolate
r e d u c ta s e
H F o la te
Fig. 1.4. Thymidylate cycle.
The role of TS in the formation of DNA precursors. The following 
abbreviations are used: H2folate - dihydrofolate; F^folate - tetrahydro- 
folate; CH2H4folate - N5Nl°methylenetetrahydrofolate. Standard abbrev­
iations are used for nucleotides (adapted from Lewis & Dunlap, 1981).
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1.5.1 The Thymidylate Cycle
The thymidylate cycle involves three enzymes, 
thymidylate synthase, dihydrofolate reductase and serine 
trans-hydroxymethylase (Fig. 1.4; Lewis &. Dunlap, 1981). 
Thymidylate synthase (methylenetetrahydrofolate: deoxy-
uridine-5’-monophosphate C-methyltransferase: EC 2.1.1.45)
catalyses the de novo synthesis of thymidylate via the 
reductive methylation of deoxyuridylate with the 
concomitant conversion of the cofactor, N5 , N10-methylene­
tetrahydrof ol ate to dihydrofolate. This reaction is the 
only one in Nature that results in the production of 
dihydrofolate, an oxidised form of folate that cannot be 
used in any biological process. To regenerate the reduced 
folate pools, dihydrofolate is converted to tetrahydro- 
folate by dihydrofolate reductase (DHFR), a reaction 
essential for the maintenance of these pools and thus cell 
viability. The enzyme serine trans-hydroxymethylase 
completes the thymidylate cycle by catalysing the formation 
of N5 ,N10-methylenetetrahydrofolate. The pivotal roles 
played by both TS and DHFR in the synthesis of DNA
precursors has lead to their recognition as target enzymes 
for the treatment of both infectious diseases and cancer 
(see Sections 1.4.3 and 1.12)
1.5.2 TS from different sources
TS is a ubiquitous enzyme found in all cellular 
organisms and some large DNA viruses. The characterization 
of T S , its relationship with DHFR and its interaction with 
other proteins is discussed below for a variety of
different organisms.
1 .5.2.1 Bacteria
The first studies of TS were performed on the enzyme 
isolated from Lactobacillus casei (Friedkin et al . , 1962;
Blakley, 1963). The isolation of a methotrexate resistant 
L.casei strain, that over-produced TS and DHFR, meant that 
large amounts of highly purified enzyme were available for
study (Crusberg et al. , 1970) and has resulted in the
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L.casei enzyme becoming the most intensively studied TS 
from all sources (Santi & Danenberg, 1984). The over­
production of both TS and DHFR suggests that the genes 
encoding these two enzymes are closely linked.
The genes encoding TS and DHFR are also closely linked 
in Bacillus subtilis and Staphylococcus aureus. B.subtilis 
has two TS loci, thyA and thyB (Piggot & Hoch, 1985). The 
thyB gene encodes a heat-sensitive form of TS (Neuhard et 
al. , 1978 ) and can complement the growth of both an
Escherichia coli thyA strain (Rubin et al . , 1978 ) and a
B. subtilis thyA thyB strain (Iwakura et al. , 1988). This
gene is located within the same operon as dfrA> the gene 
encoding DHFR, with the termination codon of thyB 
overlapping the initiation codon of dfrA (Iwakura et a l . ,
1988) .
The nucleotide sequence of the gene for DHFR and the 
partial sequence of the gene for TS of S.aureus (Burdeska 
et al., 1990) are identical to the complete nucleotide
sequences of the genes for TS and DHFR in 7724003 , a 
transposon that confers resistance to trimethoprim (a DHFR 
inhibitor) in S.aureus (Rouch et a l . , 1989). In both
cases, the two genes are separated by only 44 nucleotides 
on the same strand, suggesting they form part of the same 
operon.
By way of contrast the genes for TS {thyA) and DHFR 
( frd) are widely separated on the E.coli chromosome 
(Bachmann, 1983). However, the two enzymes have been 
proposed to form part of a multienzyme complex that is 
responsible for channelling newly synthesized dNTPs into 
replicating DNA (Mathews et al., 1978; 1988).
The gene coding for TS in Lactococcus 1 act is can 
complement the growth of an E.coli thyA strain, and its 
predicted amino acid sequence is the most widely diverged 
TS sequence known (Ross et al. , 1990a; see Section 1.5.3
and Appendix). This gene has also been proposed as a safe 
selectable marker for use in the generation of strains 
whose ultimate fate will be in food systems or for release 
into the environment (Ross et a l ., 1990b).
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1 .5 .2 .2 Bacteriophage
TS and DHFR from bacteriophage T4 have been extensively 
characterized by Mathews and co-workers (1978, 1988). The
two enzymes form part of a multi-enzyme aggregate, 
comprising both T4 and E.coli proteins and termed the dNTP 
synthetase complex (Moen et al., 1988). This complex
produces dNTPs in a manner tightly co-ordinated with DNA 
replication (Allen et al., 1980; Chiu et al ., 1982; Mathews 
et al. , 1988; Moen et al. , 1988). In addition to their
catalytic roles, the two enzymes act as structural 
components of the T4 virion base plate (Capco et al.,
1973), an example of enzymes with a stable protein fold 
being recruited into a structural role.
Analysis of mutants that lack both TS and DHFR genes has 
confirmed their role as structural components of the T4 
virion, and also shows that the products of these two genes 
are not essential for bacteriophage T4 viability (Wang & 
Mathews, 1989).
1 .5 .2 .3 Mammals
In mammalian cells, TS gene expression is tightly 
regulated with respect to the proliferative state of the 
cell (Conrad, 1971; Navalgund et a l ., 1980). In human,
mouse and Chinese hamster, TS enzyme and mRNA levels are 
low in quiescent cells but increase approximately 20-fold 
on stimulation to re-enter the cell cycle (Ayusawa et al., 
1986; Jenh et al., 1985; Conrad & Ruddle, 1972). In human 
and mouse cells, the increase in mRNA levels alone is not 
sufficient to explain the increase seen in TS activity, 
thus implying some form of post-transcriptional control 
mechanism, possibly at the level of mRNA stability (Ayusawa 
et al. , 1986; Jenh et al . , 1985). In mouse cells, this
control mechanism, at least in part, is at the level of 
polyadenylation (DeWille et al . , 1989 ). The mouse TS mRNA
completely lacks a 3 ’ untranslated region with poly- 
adenylation commencing at the termination codon (Jenh et 
al. , 1986), whereas the human TS mRNA has a 3* untranslated 
region of approximately 500 nucleotides (Kaneda et al.,
Herpesvirus % G+C content
total unique
regions
repeat
regions
VZV (1) 46.0 44.3 59.9
HVS(2) 45.5 35.8 70.6
HVA (2) 47.0 37.5 74.5
Herpesvirus aotus -40.0 -49.0 -69.0
Table 1.2. A+T rich herpesviruses.
The G+C% content of the four herpesviruses known to encode TS. 
Genome compostion data taken from; 1 Davison & Scott, 1986; 2 
Fleckenstein et al., 1978; 3 Riiger et al., 1980).
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1990). It is still unkown whether these differences in 
mRNA primary sequence play a role in post-transcriptional 
regulation.
The TS genes from both mice and humans are 12kb and 
16kb in length respectively (Deng et a l 1986; Kaneda et 
al., 1990). Both genes lack TATAA and CCAAT elements, but
contain potential binding sites for other transcription 
factors such as Spl (Jolliff et al. , 1991; Kaneda et a l . ,
1990), features that are characteristic of 'house-keeping’ 
gene promoters (Bird, 1986).
The use of vectors that contain the TS gene, constructed 
such that its intron sequences have been removed, so-called 
'mini-genes’, has shown that the inclusion of introns 1 and 
2, or 5 and 6, in a mouse TS mini-gene leads to increased 
levels of transcription compared to one that contains no 
introns (Deng et al. , 1989). In human TS mini-genes,
intron 1 may play a role in post-transcriptional regulation 
(Kadena et a 1 . , 1990). Similar stimulatory effects have
been previously described in other genes (Buchman & Berg, 
1988; Chung & Perry, 1989; Hamer & Leder, 1979 ). TS is 
also thought to be a component of a so-called 'metabolon’ 
multi-enzyme complex, that catalyses the synthesis of dNTPs 
(reviewed in Mathews et al ., 1988).
1 . 5 . 2.4 Herpesviruses
TS has so far been found in four herpesviruses, HVS 
(Hone ss et al., 1986), VZV (Thompson et al . , 1987 ), HVA
(Richter et al., 1988) and herpesvirus aotus 2 (Bob Honess, 
personal communication), all of which have A+T-rich genomes 
(see Table 1.2; Davison & Scott, 1986; Fleckenstein et al., 
1978; Riiger et a l . , 1 980). This observation, coupled with
the fact that TS has not been found in any of the G + C-rich 
viruses studied to date, led to speculation that TS may 
form part of a virus specific replication complex. This 
could influence the supply of thymidylate directed towards 
DNA replication and contribute to the nonselected bias in 
base substitutions that have produced the A+T-rich coding 
sequences of some subgroups of herpesviruses (Honess, 1984;
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Fig. 1.5. TS sequence alignment.
Alignment of the 21 TS sequences to illustrate the hypervunerable site of 
the protozoan enzymes. These are Crithidium fasciculata, Leishmania 
am azon en sis , L.major, L.tropica, Plasmodium falciparum  and P. 
chadaudi. For full details see text. The location of helix G is shown with 
numbers referring to VZV TS. For full organism names and the 
convention for lower case, upper case and bold, see legend to Fig. 1.6.
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Honess et al . , 1986). However, a virally encoded TS gene
is not a prerequisite for an A+T-rich genome, as several 
other herpesviruses with such a genome composition lack TS 
(Lawrence et al. , 1990; Neipel et al . , 1991; Bob Honess,
personal communication).
No studies to formally investigate the requirement for 
the virally encoded TS in virus DNA replication have been 
reported but, the pattern of TS gene expression in HVS and 
HVA has been linked to their ability to induce tumours in 
marmosets and other New World primates (Fleckenstein & 
Desrosiers, 1982). It has been proposed that the continuous 
unregulated expression of a herpesvirus TS enzyme in 
persistantly infected lymphoid cells could interfere with 
the activity of cellular T S , disrupt nucleotide pools, 
induce mutations and thus contribute to the neoplastic 
phenotype (Bodemer et a l ., 1986).
1 . 5 . 2.5 Protozoa
In protozoa, TS exists on the same polypeptide as DHFR. 
The DHFR domain forms the amino terminus, TS the carboxy 
terminus and a junction peptide links the two domains to 
form a single protein, whose size is species dependent, 
usually falling in the range of 110 to 140 kDa (Ivanetich & 
Santi, 1990). One immediately apparent biological 
advantage of a bifunctional DHFR/TS is metabolic channell­
ing of dihydrofolate as is seen with the Leishmania tropica 
enzyme. Dihydrofolate produced by the TS component of the 
bifunctional enzyme is channeled to DHFR faster than it is 
released into the medium, thus the net rate of the 
sequential reactions is governed by the rate of TS (Meek et 
al . , 1985). This arrangement also results in both
activities being co-ordinately regulated, resulting in 
optimal dTMP synthesis when required.
Another novel feature of protozoan DHFR/TS is the 
proposition that enzyme activity may be regulated in vivo 
by proteolysis at a ’hypervulnerable’ site (Grumont et al., 
1986; Garvey & Santi, 1985). Determination of the sequence 
of the amino-terminal region of a 20 kDa fragment released
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upon proteolysis of DHFR/TS from L.tropica suggests 
cleavage immediately before residue 334 (117 in VZV).
Cleavage at this site does not completely disrupt the 
enzymes tertiary structure and, although TS activity is 
lost, DHFR activity is preserved (Garvey & Santi, 1985). 
Interestingly, protozoan DHFR/TS sequences have either the 
amino acid methionine or asparagine at this position, 
whilst in TS sequences from all other sources a glycine 
residue is seen (see Fig. 1.5). This is the only amino 
acid change in this region that differentiates the 
protozoan TS-DHFR sequences from those of TS from other 
sources.
The TS activity in Scenedesmus obiiquus, is inseparable 
from that of DHFR. The two activities co-purify as a dimer 
of relative molecular mass of 100 kDa suggesting that they 
exist as a bifunctional enzyme as seen in other protozoa 
(Bachmann & Follmann, 1987).
1 . 5.2.6 Yeast
TS specific mRNA production peaks in Saccharomyces 
cerevisiae at the time during the cell cycle when TS levels 
are at their highest, a point that immediately preceeds 
maximal rates of DNA synthesis during S-phase (Storms et 
al. , 1984). Yeast cells lack thymidine kinase and are
impermeable to thymine, thymidine and thymidylate, thus 
their only source of thymine nucleotides is from 
thymidylate produced de novo by TS (Bisson & Thorner, 
1977). The S.cerevisiae temperature sensitive mutant, 
cdc-21, becomes quiescent when shifted to the non- 
permissive temperature due to the rapid cessation of both 
nuclear and mitochondrial DNA synthesis (Hartwell, 1973; 
Newlon & Fangman, 1975). The availability of S.cerevisiae 
strains permeable to dTMP (Wickner, 1975), has permitted 
the isolation of a dTMP auxotrophic mutant, tmp-1, that 
rapidly loses viability in the absence of exogenous 
thymidylate (Bisson & Thorner, 1977; Brendel & Langjahr,
1974). Recent sequence analysis has confirmed that both 
tmp-1 and cdc-21 mutants of S .cerevisiae contain lesions
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in the same gene, that encoding TS (Taylor et a l ., 1987).
TS is thought to be a component of a multi-enzyme 
complex found in yeast, similar to those involved in dNTP 
synthesis seen in other organisms, although only some of 
its components have been identified (Jazwinski & Edelman, 
1984; Mathews et al., 1988). However, the introduction of
a large insertion into the TS gene of S.cerevisiae has no 
effect on viability, other than to create a thymidylate 
auxotrophic phenotype, implying that S.cerevisiae TS plays 
no significant structural role in the complex of 
replication enzymes (Taylor et al . , 1987 ).
1.5.2.7 Plants
Early analysis of TS and DHFR in higher plants was 
limited to a handful of investigations that described the 
preliminary measurements of TS activity (Ohyama, 1976; 
Vandiver & Fites, 1979) and the purification of DHFR from 
carrot and soybean cells (Albani et al ., 1985; Reddy & R a o , 
1976). More recently, two groups have produced conflicting 
reports concerning the nature of TS and DHFR expressed in 
carrot cells. Nielson and Celia (1988) reported that, in 
contrast to other eukaryotic cells, the levels of TS did 
not vary significantly, in the carrot cells growth cycle, 
except for a slight decrease in the late stationary phase. 
The same authors described the purification of TS activity 
and found it inseparable from that of DHFR activity. The 
fact that both activities were ascribed to a protein 
complex of 185 kDa and that DHFR levels vary in 
concentration with TS during the growth cycle (Albani et 
al. , 1985 ), led to the proposal that TS and DHFR from
carrot cells may exist as a bifunctional enzyme, similar 
to, albeit larger than, those found in protozoa (Ivantiech 
& Santi, 1990). In contrast, Goodman and co-workers 
described a 285 kDa complex comprised of five polypeptides. 
TS activity has been assigned in this case to a 70 kDa 
polypeptide whilst DHFR has been located to a 45 kDa 
polypeptide within the complex (Toth et al. , 1987).
Further characterization of these activities by workers in
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Fig. 1.6. TS sequence alignment.
Alignment of the 21 TS sequences reported to date. B O L D  
UPPERCASE letters indicate completely conserved residues in all 21 
TS sequences. UPPERCASE letters indicate a residue in one of the 
groups (I/L/M/V) (D/E) (S/T) (F/Y/W) (F/L) (KIR) in all 21 TS 
sequences. The numbering scheme refers to VZV TS. The secondary
structure elements (AAAAA = p-sheet; = a-helix) are based on TS from
L.casei (see Hardy et al., 1987; Perry et al., 1990). TS sequences shown 
include those for VZV (Thompson et al., 1987); HVS (Honess et al., 
1986); HVA (Richter et al., 1988); human (Takeishi et al., 1985); mouse 
(Perryman et al., 1986); Candida albicans  (Singer et al., 1989); 
Pneumocystis carinii (Edman et al., 1989); Saccharomyces cerevisiae 
(Taylor et al., 1987); Crithidia fasiculata  (Hughes et al., 1989); 
Leishmania amazonensis (Nelson et al., 1990); Leishmania major 
(Beverley et al., 1986); Leishmania tropica (Grumont et al., 1986); 
Plasmodium chabaudi (Cowman & Lew, 1989); Escherichia coli (Belfort 
et al., 1983b); Bacillus subtilis (Iwakura et al., 1988); Lactococcus lactis 
(Ross et al., 1990a); Lactobacillus casei (Maley et al., 1979b); 
Staphylococcus aureus transposon 7n4003 (Rouch et al., 1989); coliphage 
T4 (Chu et al., 1984); B.subtilis phage phi3T (Kenny et al., 1985). Only 
the TS portion of the DHFR/TS sequences of Leishm ania  spp., 
C.fasiculata and Plasmodium spp. are shown (see Perry et al., 1990). An 
additional, larger scale, loose copy of this figure is also provided for easy 
reference.
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the same group has shown that the two enzymes are co- 
ordinately regulated (Lazar et al. , 1989). These studies
have been performed in overproducer cell lines and the
elevated levels of specific mRNAs should facilitate cloning 
and sequencing of the TS and DHFR from carrot cells, which 
may resolve some of the discrepancies reported by these two 
groups.
1.5.3 Amino acid sequence homology
The amino acid sequence of TS from Lactobacillus casei 
was determined in 1979 by Maley and co-workers (Bellisario 
et al. , 1979; Maley et a l . , 1979a,b). Since then, the
complete nucleotide sequence of this gene has been
determined (Andrews et al ., 1985; Pinter et a l., 1988) and
shown to be identical to that found by amino acid sequenc­
ing techniques (Maley et a l ., 1979b). Moreover, the TS
gene from twenty other organisms has been cloned, sequenced 
and the amino acid sequence predicted (see legend from 
Fig. 1.6 for references). A striking feature of the TS 
sequences is the very high degree of amino acid con­
servation, approximately 11% (27 out of a core of "250
residues) of the residues are absolutely conserved in the 
21 known complete sequences (see Fig. 1.6). If the two 
most divergent TS sequences, those of bacteriophage 03T and 
L. lactis are excluded, the degree of conservation rises to 
approximately 24% (61 out of a core of ~ 250 residues).
This is equivalent of one in every four residues being 
completely conserved in 19 TS sequences (but see Appendix). 
Such a degree of amino acid sequence conservation places TS 
amongst the most highly conserved enzymes, a group that 
includes proteins such as the cytochromes (Dickerson 1971). 
The cytochromes however, are much smaller than TS (less 
than half the number of amino acids) and much of their 
surface is involved in interactions with oxidase and 
reductase. It has been suggested that some reasons why TS 
is so highly conserved are related to the chemical reaction 
catalysed and the conformational dynamics that occur during 
catalysis (Finer-Moore et al., 1990). Conservation may
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Fig. 1.7. Catalytic mechanism of TS.
The proposed mechanism for methyl transfer to dUMP by TS, showing 
the numbering scheme for CH2FH4. The formation of a covalent bond 
between the catalytic thiol of C l98 of VZV TS and C-6 of dUMP 
activates C-5 of dUMP for condensation with the one-carbon unit of 
CH2FH4 (intermediate 1). Elimination and hydride transfer from C-6 of 
the cofactor result in the generation of dTMP and FH2 (taken from Finer- 
Moore et al., 1990).
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also be due to the need to maintain interactions with other
enzymes such as DHFR.
The probability of structural homology at such levels of 
primary sequence conservation is very high. The value for 
the minimum amino acid sequence homology between a pair of 
proteins likely to reflect significant structural 
similarity has been estimated to be 26% (Sander & 
Schneider, 1991). The likelihood of structural homology, 
based on the high level of amino acid identity between 
E.coli and L.casei TS (60%), has facilitated the interpret­
ation of the X-ray data obtained from E.coli TS by 
molecular replacement, by using the co-ordinates of the 
L.casei TS structure (Hardy et al., 1987; Perry et al .,
1990). In addition, the high degree of amino acid sequence 
identity between VZV and E.coli TS (48%), has allowed 
models of the VZV TS to be constructed with a high degree 
of confidence, from the known structures of unliganded, and 
ligand bound forms of E.coli TS (see Section 1.10; Celia 
Schiffer and Robert Stroud, personal communication).
1.6 Catalytic mechanism of TS
It has been recognized for over 30 years that N5 ,N10- 
methylene tetrahydrofolate serves the dual function of both 
one carbon donor and reductant in the reaction catalysed by 
TS (Humpreys & Greenberg, 1958; Friedkin, 1959). Friedkin 
first proposed in 1959 that the reaction involved the 
condensation of N5 ,N10-CH2FH4 with dUMP to produce a 5- 
thymidylyl-tetrahydrofolate intermediate. This would then 
undergo a 1,3-hydride shift to produce dTMP and FH2 . The 
first step represents an electrophi1ic substitution 
reaction in which the one-carbon unit of N5 ,N10-CH2FH4 
replaces the hydrogen at the 5-position of dUMP without a 
change in the oxidation level. The second step involves 
hydride transfer to the exocyclic methylene group of dUMP, 
by the hydrogen originating from the 6-position of the co­
factor, to produce free dTMP and FH2 (see Fig. 1.7).
Since then, numerous groups have conducted exhaustive
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investigations into the reaction mechanism of T S . This 
includes a fully detailed stereospecific reaction mechanism 
that was described after the determination of the crystal 
structure of the covalent inhibitory ternary complex of TS 
from E.coli (Finer-Moore et al . , 1990; Matthews et al. ,
1990b). However, a brief summary of the early data, is 
necessary for a complete understanding of the reaction 
mechani sm .
1.6.1 Identification of catalytic residues
Studies of the inhibitory ternary complex, comprised of 
FdUMP and N5 ,N10-CH2FH4 covalently bound to T S , have 
identified cysteine 198 (C183 in VZV) of L.casei TS as
forming a covalent bond to FdUMP (Bellisario et a l ., 1979). 
Further studies proved the existence of a covalent bond 
linking C-5 of FdUMP to the methylene group and N-5 of the 
co-factor (Pellino & Danenberg, 1985). Moore and co­
workers (1986) proved the existence of a stable binary 
complex, consisting of dUMP (or dTMP) covalently bound to 
T S . Both findings are as predicted by the proposed 
reaction mechanism (Friedkin, 1959). Moore and co-workers 
(1986) also revealed that FdUMP and dUMP (and also dTMP) 
were linked to the same residue, cysteine 198, thus 
augmenting the use of the FdUMP based covalent ternary 
complex for studies of the catalytic mechanism of T S .
In additon to the active-site cysteine residue, arginine 
and tyrosine residues have been proposed to play a role in 
catalysis, on the basis of chemical modification 
experiments (Lewis & Dunlap, 1981; Rosson et a l . , 1980).
Structural studies have implicated four highly conserved 
arginine residues in the coordination of the 5 ’-phosphate 
of dUMP and two conserved tyrosine residues are also 
predicted to form part of the active site (Finer-Moore et 
al. , 1990; Matthews et al ., 1990b).
1.6.2 Ordered binding of substrate and cofactor
Kinetic investigations by Daron and Aull (1978) 
suggested that the process of substrate addition and
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product release is an ordered sequential mechanism. dUMP 
binds first, followed by cofactor to form the covalent 
ternary complex. Catalysis takes place, and the oxidised 
cofactor is released followed by the product, dTMP. 
However, polyglutamate derivatives of N5 ,N10-CH2FH4 serve 
as more efficient cofactors, and indeed are the normal form 
of folates found in vivo (Kisliuk & Gaumont, 1974; Galivan
et al. , 1976a; Dolnick & Cheng, 1978; Eto & Krumdieck,
1981; Foo & Shane, 1982). When Galivan and co-workers 
(1976a) demonstrated that the pentaglutamate form of the 
cofactor could form a binary complex with TS in the absence 
of dUMP, this suggested that the ordered sequential 
reaction seen in vitro with the monoglutamate form of the 
co-factor (Daron & Aull, 1978 ), may not follow in vivo. 
Indeed, Lu and co-workers (1984) showed that for the 
tetraglutamate form of N5 ,N10-CH2FH4 , the order of 
substrate binding and product release was reversed in vivo.
1.6.3 Conformational changes associated with 
catalysis: ternary complex formation
A series of conformational changes have been associated 
with the catalytic process performed by T S . The binding of 
dUMP or FdUMP causes a change in the fluorescence and
ultra-violet (lTV ) spectra, indicating changes in the
environment of tyrosine and tryptophan residues (Donato et 
al. , 1976; Galivan et al . , 1975; Leary et al . , 1975 ).
However, no change was seen in the circular dichromic (CD) 
spectrum upon the binding of FdUMP or cofactor independ­
ently to L.casei TS (Manavalan et al ., 1986). It has been
suggested that, because of the ordered sequential mechanism 
of binding seen in vitro, these spectral changes are
associated with the creation of a binding site for N5 ,N10- 
CH2FH4 (Santi & Danenberg, 1984).
The UV and CD spectra a)ter considerably upon the
addition of N5 ,N10-CH2FH4 to the binary complex, due to 
subsequent ternary complex formation (Donato et al . , 1976;
Danenberg et al., 1974; Santi et a l ., 1974; Manavalan et
al. , 1986). Formation of the ternary complex results in a
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considerably more compact structure for the protein, 
corresponding to an apparent decrease of 3.5% in the Stokes 
radius (Lockshin & Danenberg, 1980) and correlating well 
with the fluorescence quenching observed upon ternary 
complex formation (Bellisario et a l ., 1976). These factors
provide evidence that changes in the protein conformation, 
as opposed to changes in the environment of the ligand, 
contribute to the majority of the observed variation in the 
fluorescence spectrum (Santi & Danenberg, 1984).
TS from all sources is thought to be an obligate 
homodimer with residues from both subunits forming two 
active sites (Hardy et al., 1987). In the presence of co­
factor, FdUMP binds with a stoichiometry of approximately 
2 mols FdUMP per mol of enzyme forming a FdUMP. N5 , N1 0 - 
CH2 FH4 .TS ternary complex (the 2:2:1 complex; Danenberg et 
al. , 1974; Danenberg & Danenberg, 1979; Plese & Dunlap,
1977; Santi & Danenberg, 1984). However, the 2:2:1 ternary 
complex decays within 24h to a significantly more stable 
complex with only 1 mol FdUMP bound per mol of enzyme, 
(Aull et al. , 1974; Santi &, Danenberg, 1984), suggesting
that the two binding sites are not equivalent. 
Furthermore, in the presence of triglutamated forms of 
N5 ,N10-CH2FH4 , the two binding sites show a twenty-fold 
difference in affinity for dUMP (Lockshin and Danenberg, 
1979 ) .
In the absence of co-factor, only a single molecule of 
dUMP or FdUMP is bound per mol of enzyme (Galivan et al. , 
1976a; Beaudette & Kisliuk, 1980; Langenbach, 1976), 
although Plese and Dunlap (1978) report that approximately
1.5 nucleotides were bound per enzyme molecule.
These observations have been proposed to reflect a 
sequential action of the catalytic sites, where the binding 
of one molecule of dUMP at either site results in minor 
conformational changes, and renders the second site 
inaccessible. This corresponds to the observed changes 
in the fluorescence and UV spectra (Donato et al ., 1976;
Galivan et al., 1975; Leary et al., 1975). Binding of co­
factor causes a much greater conformational change, thus
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providing access to the second site (Donato et al.y 1976; 
Danenberg et al. , 1974; Santi et a l . , 1974; Manavalan et
al. , 1986). A second dUMP molecule is then bound and the
interaction of a second cofactor molecule completes the 
formation of the ternary complex (Santi & Danenberg, 1984).
1.6.4 Stereospecific reaction mechanism
The current, widely accepted chemical basis of the 
reaction catalysed by TS was described by Santi and
Danenberg (1984 ) and is shown in Fig. 1.7 (Pogolotti & 
Santi, 1977; Heidelberger et a l ., 1983; Santi & Danenberg,
1984; Finer-Moore et al . , 1990 ). The covalent bond formed
between the active site cysteine residue and C-6 of dUMP 
serves to activate C-5 of dUMP for condensation with the 
one-carbon unit of N5 ,N10-CH2FH4. An activated form of the 
cofactor, the iminium ion 5-CH2=FH4, has been postulated to 
act as an electophilic species in the condensation reaction 
(Kallen & Jencks, 1966; Benkovic &. Bullard, 1973). An
acidic group on the enzyme has been suggested to catalyse 
opening of the imidazoline ring of N5 ,N10-CH2FH4 by 
protonation at N-10. A basic group of the enzyme was
postulated to abstract a proton from C-5 of dUMP (Benkovic, 
1980; Fife & Pellino, 1981). Subsequent B-elimination and 
hydride transfer from C-6 of the cofactor would then 
generate dTMP and dihydrofolate.
In addition, the TS catalysed reaction proceeds under 
tight stereochemical control. A detailed experimental 
analysis led to the proposal that dUMP would bind in the 
syn-conformation, to account for the observed stereo­
chemical nature of the reaction (Slieker & Benkovic, 1984). 
CD and 19 FNMR studies suggested that dUMP is bound in a
syn-conformation in the non-covalent TS.dUMP binary complex 
(Leary et al . , 1975; Lewis & Dunlap, 1981). In contrast,
molecular modelling of dUMP, based upon the crystal 
structure of L. casei TS with bound phosphate suggests that 
dUMP would bind with 0-2 anti to the ribose ring (Hardy et 
al., 1987). In studies of the covalent ternary complex,
dUMP has indeed been shown to be bound in the anti-
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conformation by 19FNMR studies of the L.casei TS.FdUMP. 
N5 f n1 o -CH2 FH4 complex (Byrd et al. , 1978) and by X-ray
crystallographic studies of the E.coli T S .dUMP.CB3717 
complex (Montfort et a l . , 1990). FdUMP, a close analogue
of the substrate dUMP, adopts the same conformation in both 
the E.coli T S .FdUMP.CB3717 (Matthews et al. , 1990a) and
T S .FdUMP.N5 ,N l0-CH2FH4 complexes (Matthews et al ., 1990b).
1.6.5 Reaction mechanism based upon X-ray 
crystallographic data
Recently, two groups have independantly published 
detailed schemes for a stereospecific mechanism for the TS 
catalysed reaction. Both groups have reported essentially 
identical structures for the ternary complexes, but have 
described different mechanisms for the reaction. For this 
reason, the reports by the two groups are discussed 
separately, followed by a brief summary of the differences.
1 . 6.5.1 Model of Matthews and co-workers
Matthews and co-workers (1990b) determined the structure 
of the T S .FdUMP.N5 ,N10-CH2FH4 covalent ternary complex from 
E.coli, which was thought to accurately represent the 
catalytic intermediate of the TS catalysed reaction
(Danenberg, 1977). They have shown that FdUMP and CH2FH4 
are precisely bound by a number of highly conserved 
residues. FdUMP is found in the anti-conformation. The 
bond between Cysl46 and C6 of FdUMP, and the C5-C11 bond 
are in a trans-diaxial arrangement. The tetrahydrozine
ring of the co-factor has its C6-C9 bond axial, C6-H 
equatorial. The methylene bridge of the nucleotide
orients the C5-H such that it is also equatorial. These
observations concur with 19FNMR studies of the L.casei 
T S .FdUMP.N5 ,N1 0-CH2FH4 ternary complex (Byrd et al . , 1978).
To assess the validity of the covalent ternary complex
as a model for the catalytic intermediate, Matthews and co­
workers (1990b) attempted to predict the stereochemical
course of the reaction, from the E.coli ternary complex
structure, and compare this with experimental results of
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Fig. 1.8. Catalytic mechanism of TS.
The proposed conformational isomerization of the catalytic intermediate 
that preceeds p-elimination (see text for details). R' represents deoxy- 
ribose, CNHR represents the remainder of the cofactor molecule, and 
Enz-S indicates the catalytic thiol, C198 in VZV TS (taken from 
Matthews et al., 1990b).
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Sleiker and Benkovic (1984). They argued that if this 
complex was an accurate representation of the catalytic 
intermediate, then the ensuing elimination reaction should 
result in the formation of a methyl group at C5 of dUMP 
with the S conf igurat ion. However, the first step in the 
reaction is the elimination across the C5-C6 bond, which is 
in a syn-conformation (this is henceforth referred to as 
svii-el i mination ) . This would result in the formation of an 
exocyclic methylene derivative of dUMP having a Z 
configuration. Since the C6 hydrogen of N5 ,N 10-CH2 FH4 
approaches from above the si face of CH2=dUMP the resultant 
methyl group would have the configuration R.
An alternative is to consider the possibility of anti­
elimination across the C5-C6 bond. Indeed, anti­
eliminations are more favoured than syn-eliminations, and 
the fact that thiols are better leaving groups than 
tertiary amines, adds weight to this notion. However, 
anti-elimination would result in the bizoff e situation
where the substrate and cofactor are regenerated. Clearly 
these contradictory observations suggest that the structure 
of the T S .FdUMP.N5 ,N10-CH2FH4 ternary complex does not
accurately represent the catalytic intermediate (Matthews 
et al., 1990b).
To rationalize these observations, Matthews and co­
workers (1990b) proposed that if the pyrimidine ring 
adopted the opposite pucker (C5 below the plane, with 
C5-C11 bond equatorial, and the C6 bond to Cys 146 lying 
above the plane), then a reaction mechanism that agrees 
with the observed stereochemistry (Sleiker & Benkovic,
1984), could be readily formulated (see Fig. 1.8). The 
pyrimidine ring of dihydrouridine, a nucleoside which has a 
similarly substituted pyrimidine ring to that of 
deoxyuridine (the unphosphorylated precursor of dUMP), can 
adopt both the above forms of puckering with equal energies 
(Suck et al., 1972 ). This premis lead Matthews and co-
workers (1990b) to suggest that the uracil ring of dUMP may 
also be capable of adopting either of the puckering
conformations.
Pterin ring
H N
NH,
ribose
P A 8 A  r in g
NH
«N
ribose
Fig. 1.9. Catalytic mechanism of TS.
The proposed structure for the TS.dUMP.CF^FFU complex (intermediate 
II in Fig. 1.7) which is consistent with the dUMP conformation seen in 
the crystal structure of the TS.dUMP.CB3717 complex. Rotation about 
the N 1-ribose bond must occur prior to hydride transfer (see text for 
details; taken from Finer-Moore et al., 1990),
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Molecular modelling has shown that a pyrimidine ring of 
opposite pucker to that observed in the T S .FdUMP.N5 ,N10 - 
CH2 FH4 ternary complex could readily be accommodated at the 
TS active site, with only minor perturbations in the 
relative juxtapositions of the folate and nucleotide to 
each other, and the overall relationship to the protein 
(Matthews et al., 1990b). Such an intermediate could
undergo anti-periplanar elimination across C5-C11 to give 
an exocyclic methylene, having the configuration required 
to yield a methyl group with the correct chirality, 
following hydride transfer from N5 ,N10-CH2FH4 .
1. 6.5.2 Model of Stroud and co-workers
Workers from Robert Stroud’s laboratory have recently 
determined the structure of the E.coli TS with bound 
phosphate and the T S .dUMP.CB3717 complex (Perry et a l . , 
1990; Montfort et al., 1990). They have shown that dUMP is 
bound in the anti-conformation, as is also seen in the 
T S .FdUMP.CH2FH4 and T S .FdUMP.CB3717 structures of Matthews 
and co-workers (1990a,b). Workers in Stroud’s group have 
used molecular modelling techniques (Singh et al., 1986; 
Weiner et al., 1984, 1986) to generate a description of the 
catalytic intermediate which is consistent with the stereo- 
specific reaction mechanism. They described several 
alternatives for the catalytic mechanism, but their 
favoured model is described here. The Cysl46 sulphydryl 
group and methylene bridge are covalently bound in a trans- 
diaxial manner to C6 and C5 of dUMP respectively. The 
para-aminobenzoic acid ring of N5 , N10-CH2 FH4 and the 
phosphate moiety of dUMP are close to the positions of the 
same groups in the crystal structure of the T S .dUMP.CB3717 
ternary complex and no major conformational changes are 
made to the protein (see Fig. 1.9; Finer-Moore et al., 
1990). dUMP is bound with its pyrimidine ring in the anti­
conformation, with respect to its ribose moiety, and has S 
absolute configuration at C6. This leaves the pyrimidine 
ring of dUMP and the pteridine ring of the cofactor rotated 
only slightly from their positions observed in the crystal
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structure.
Stroud and co-workers propose that syn-elimination 
occurs across the C5—C6 bond to forni the exocyclic 
methylene derivative of dUMP. However, if this inter­
mediate were then to undergo hydride transfer, it would 
result in the formation of dTMP with R absolute 
configuration for the methyl group. As mentioned 
previously, the R configuration is incompatible with the 
experimental data (Sleiker & Benkovic, 1984).
To overcome this, Stroud and co-workers have proposed 
that the pyrimidine ring of dUMP undergoes a 180* rotation 
about the Nl-ribose ring bond, after the process of syn- 
elimination. This now leaves the C6-hydrogen of the co­
factor orientated for hydride transfer to the re face of
the exocyclic methylene group (see Fig. 1.9), which would 
result in the formation of a methyl group with the absolute 
configuration S, consistent with the experimental data 
(Sleiker & Benkovic, 1984).
1 . 6.5.3 Summary
These studies have confirmed the conformation of the
bound ligands in the TS ternary complex first studied by 
19FNMR (Byrd et a l . , 1978). In addition, they have
demonstrated that this complex does not represent the true 
catalytic intermediate.
The reaction mechanisms postulated by both groups, 
although based partly on crystal structures of different 
ternary complexes, share many common features, suggesting 
that the schemes are essentially correct. The major 
discrepancy is that workers from Stroud’s group (Finer- 
Moore et al., 1990) infer that reorientation of the
pyrimidine ring is necessary for the proposed stereo- 
specificitv of the TS catalysed reaction (Slieker & 
Benkovic, 1984), whereas Matthew’s group (1990b) propose 
that alternate ring puckering of the pyrimidine ring 
occurs. Further work will be required to rationalize these 
alternate observations and reveal the precise nature of the 
reaction mechanism.
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1 . 7 Structural features of TS
Prior to X-ray crystallographic studies of T S , Manavalan 
and co-workers (1986) used the techniques of circular 
dichroism (CD) and four different empirical methods to 
predict elements of secondary structure in TS. The CD 
spectrum was analysed for the various secondary structure 
elements and suggested 33% a-helix, 25% 13-strand, 20% turns 
and 16% other structures. Four algorithms which were used 
to predict the elements of secondary structure in -TS 
(Burgess et al., 1974; Chou & Fasman, 1974; Garnier et al., 
1978; Lim, 1974). The average values for the a-helical 
(32%) and fl-sheet (23%) content were comparable to the CD 
data. In addition, the value for a-helical content 
compares favourably with the observed value of 36.4% seen 
in the crystal structure of the native L.casei T S . 
However, their predicted locations in the primary sequence 
showed little relationship to the sites of helices in the 
native enzyme structure and the values for the (3-sheets 
show little correlation with the observed figure of 15.5% 
(Hardy et a l ., 1987).
1.7.1 X-Ray crystallography
The understanding of many facets of TS function and 
dynamic behaviour during catalysis has been significantly 
enhanced by X-ray crystallographic studies. In the past 
four years, the 3-D structures of TS from various sources 
in several forms have been solved. These include the 
structures of the native unliganded enzymes of both L.casei 
(Hardy et al. , 1987 ) and E.coli (Perry et al . , 1990;
Matthews et al., 1990b). These structures reveal that T S , 
although not bound to any ligands, does have a phosphate 
ion bound at the dUMP phosphate site. The structure of the 
ternary complex of the E.coli enzyme with different 
combinations of substrate and cofactor analogues has also 
been reported (Montfort et al. , 1990; Matthews et al.,
1990a,b). Human TS has also been crystallized (Schiffer et 
al., 1991), the first example of TS crystallization from 
phosphate and/or substrate free medium, thus representing a
Fig. 1.10. E.coli TS.
The complete TS.dUMP.CB3717 ternary complex of E.coli TS is shown 
here, with one monomer in purple and the second coloured in blue. The 
five p-strands of each monomer are number i through v, and the 
a-helices from A through C, and G through K. Note that helix 
designations are from the L. casei TS and that helices D, E and F are 
absent in many other TSs. The active site residue of E.coli TS, C l98 
(C l83 in VZV TS), is located at the N-terminal end of p-strand iv and is 
coloured in yellow. dUMP is shown in white, with the C-5 position 
juxtaposed to C l98. The cofactor analogue, CB3717, is coloured in red, 
with the quinazoline ring lying on top of the pyrimidine ring of dUMP. 
The ligands are illustrated for both active sites (taken from Finer-Moore 
et al., 1990).
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true native enzyme. Indeed, the addition of phosphate to 
the suspension cracks the crystals, suggesting that a 
possible phosphate induced conformational change takes 
place (Schiffer et a l . , 1991). The crystal structures of
human TS and bacteriophage T4 TS have been solved (Robert 
Stroud, personal communication).
1.7.2 General structural features
Comparison of the L.casei and E.coli primary structures 
reveals only one major difference, namely a 50 amino acid 
insertion around the middle of the L.casei enzyme (Hardy et 
al., 1987; see Fig. 1.6). Comparison of the native enzyme
structures reveals that, apart from the aforementioned 
insertion, the structures are very similar. Use of a 
difference distance matrix has identified a common core of
95 a-carbon atoms, from a total of 528 common to TS of both
species, per dimer, as bearing a constant relationship of 
±0.5 Angstoms (A) to each other (Perry et al. , 1990). A
difference of this magnitude is comparable to the 
difference observed between two crystal structures of the 
same protein solved in different space groups (Chothia & 
Lesk, 1986).
The insertion in L.casei TS represents a small domain of 
74 amino acids arranged as three short a-helices. The 
larger domain, common to all species of T S , is comprised of 
three layers of secondary structure. The first layer has 
five B-strands that form the dimer interface. The central
layer is made up exclusively of helices, a feature not
normally seen in a/B domains (Richardson, 1981), whilst the 
third layer consists of several other helices and the 
carboxy-terminal region (see Fig. 1.10).
1.7.3 Specific features of the large domain
1.7.3.1 fi-kink of strands i, ii and iii
Hardy and co-workers (1987) described an aligned
discontinuity in B-strands i through iii of the L.casei
native enzyme at residues G33, A258 and Q217 twisting the 
bottom left corner of the B-sheet outwards. Matthews and
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Fig. 1.11. p-interface of TS.
Face to face packing geometry of two aligned p-sheets. For the top sheet, 
U and D indicate up-pointing and down-pointing regions respectively. 
Corresponding portions of the bottom sheet are labelled UU and DD. (a) 
represents the anti-clockwise rotation of the bottom sheet relative to the 
top. (b) represents the clockwise rotation of the bottom sheet relative to 
the top, causing D to closely approach UU which would produce an 
unfavourable cavity (see text for details), (c) shows the stacked p-kinks 
in TS which "turn" the corner A of the top sheet upward and the corner 
B of the bottom sheet downward, thereby facilitating favourable packing 
of side chains across the entire dimer interface (adapted from Matthews et 
al., 1989a).
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co-workers (1989) looked at the corresponding structure 
from the ternary complex of E.colif and noted that the 
discontinuity corresponds to the amino acids G31, G204 and 
R166. These residues correspond to G33, G256 and R218 in 
the L.casei TS. However, it is immediately apparent that 
these residues are not those involved in the discontinuity 
of the 13-strands in native L.casei TS. Assuming that both 
structures are correct, and that the L.casei amino acids 
involved adopt the same secondary structural element as 
those corresponding to the E.coli residues in the ternary 
complex, then this suggests that significant movement of 
13-strand ii relative to 13-strands i and iii occurs upon 
ternary complex formation (see Sections 1.6.3 and 1.8).
1.7.3.2 Dimer-interface
The dimer interface of TS comprises two 13-sheets of five 
or six strands that stack face to face, and are related by 
a unique right-handed twist (Hardy et a l . , 1987; Matthews
et al. , 1989). This is in marked contrast to other
proteins where the packing of 13-sheet interfaces has 
previously been observed only with a left-handed twist 
(Chothia et al ., 1977; Cohen et a l ., 1981; Chothia & Janin, 
1981). These studies suggest that the commonly observed, 
left-handed rotation in two such aligned sheets, is the 
result of the natural twist between individual strands in a 
single sheet. This left-handed rotation creates a deformed 
rectangular surface such that diagonally opposed corners 
both point either up or down. When brought together, two 
such surfaces would adopt a left-handed rotation relative 
to each other. This conformation is favoured by the down- 
pointing corners of the top sheet folding over the edge of 
the lower sheet, and the up-pointing corners of the lower 
sheet folding over the edge of the top sheet. A right- 
handed rotation would force interior regions of the sheet 
to separate, creating an unfavourable cavity in the 
interface (Chothia et al. , 1977; Cohen et a l . , 1981; see
Fig. 1.11).
As the two 13-sheets of TS are related by a right-handed
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twist, such a cavity could be expected to exist between the 
sheets. However, at the point where a down-pointing corner 
of the top sheet would be predicted to interfere with an 
up-pointing corner of the bottom face, the B-kink, which is 
comprised of the stacked (3-bulges, acts to reorientate a 
portion of the bottom sheet so that it bends in the same 
direction as the top sheet. This favours a close 
association between the top and bottom sheets,and also 
maintains optimal side-chain packing in the central region 
of the interface. The two-fold symmetry of TS means that a 
similar conformation occurs on the top sheet (Matthews et 
al., 1989). This data suggests that efficient side-chain
packing of residues from opposing 13-sheets can occur at the 
centre of a (3-sheet interface, either as a result of left- 
handed or right-handed rotation between the sheets, 
provided that in the latter case, the unfavourable edge 
interactions can be relieved by bulging (Matthews et al . , 
1989 ) .
1.7.3.3 The J-helix
A core structural element around which the large domain 
is folded, is the J-helix. This six-turn 3-10 helix is 
unusually hydrophobic, more so than some membrane spanning 
helices, and is almost completely buried from solvent. It 
sits on top of the (3-sheet, is flanked by the amphipathic 
helices A and H, and is capped by helix B (Hardy et a l .,
1987).
1.7.3.4 Active site cavity
The active site is a shallow cavity in the large domain. 
The left hand wall is formed by residues in the (3-kink of 
strands ii and iii, and the loop connecting helix A and 
(3-strand i. The ceiling is composed of the solvent exposed 
accessible residues of the N-terminus of the J-helix, and 
the right hand wall by the N-terminus of strand iv, 
including the catalytic cysteine residue. The rear of the 
cavity is comprised of four residues from the 13-sheet of 
the second subunit (Hardy et al ., 1987). Of the 25
Fig. 1.12. TS monomer.
A single monomer of E.coli TS, presented in the same orientation as in 
Fig. 1.10, is shown to illustrate the residues involved in the 
conformational changes associated with ligand binding. Residues shown 
in yellow deviate from their original position by a RMS value of less than 
0.5A upon ligand binding, whereas residues shown in blue undergo 
substantial movement (see text for details). (Taken from Finer-Moore et 
al., 1990).
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residues that line the active site cavity, 12 are 
completely conserved in the 21 TS sequences reported to 
date. These include R163’ and R164 (VZV numbering; amino 
acids from the second subunit are distinguished by a prime 
(’) following the residue number of on monomer).
1.8 Conformational changes during ligand binding:
segmental accomodation
In an attempt to understand the conformational changes 
that occur during the binding of substrate and co-factor, 
two groups have analysed the differences between the 
structures of the unliganded and ligand bound forms of 
E.coli TS (Matthews et a l . , 1990a,b; Monfort et al. , 1990;
Finer-Moore et a l ., 1990; Perry et al ., 1990). To quantify 
the movement, a core of 155 alpha-carbon (Ca ) atoms whose 
mutual disposition is unchanged, +/- 0.5 Angstroms, between 
the liganded and unliganded forms, was identified (Monfort 
et al., 1990). Most non-core residues had shifted between 
0.5 to 1.25 Angstroms, the largest shift being associated 
with the C-terminus (see Fig. 1.12). In contrast to the 
domain shifts, seen in proteins such as hexokinase 
(Anderson et al., 1978) or citrate synthase (Remington et
al. , 1982) ,  the changes seen in TS are due to segmental
tvccofwcctat ion, where a-helices, 13-strands and connecting 
loops undergo concerted movement towards the active centre 
(Matthews et al., 1990b; Monfort et al., 1990).
The central J-helix pivots around a central point such 
that the N-terminal end moves '0.5 Angstroms towards the 
active centre, causing the region of 13-strands i, ii and 
iii below the 13-kink to move towards the same location (see 
Section 1.6.5). Indeed, the 13-kink acts as one of several 
hinge points in the structure, about which other segments 
of secondary structure move. The region containing the 
active site residue, C146 (C183 in VZV numbering), moves
inward, whilst the loop containing the two arginine 
residues 126’ (164’; primed numbers indicate residues from
the other subunit of the dimer) and 127* (163’) also moves
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inwards. The two largest shifts involve the loop 
containing R21 (38) and T22 (39) that moves up to interact
with the C-terminus, and the movement of the four 
C-terminal residues, P261 (E298) to 1264 (L301). In the
unliganded structure, these four residues point out into 
the solvent, suggesting they are disordered (Matthews et 
al. , 1990a). However, on the binding of ligands, this
region moves "4.0 Angstroms, sequestering several water 
molecules, to anchor the co-factor in place. This directs 
the exact alignment of substrate and co-factor to allow the 
formation of the observed H-bonds between the carboxylate 
group of 1264 and residues R21 , T22 and W83 (via a water
molecule), and between R21 , A263, a water molecule and the 
cofactor (see Fig. 1.10; Matthews et al. , 1990a,b; Monfort
et al., 1990; Finer-Moore et al., 1990).
1.9 Structural plasticity and covariant accomodation
The introduction of amino acid substitutions by site- 
directed mutagenesis affects protein function in an, as
yet, poorly understood manner. The variations are often 
tolerated by adjustment of neighbouring residues and can 
result in unexpected properties. The accomodation of 
substitutions is due to the structural plasticity of the 
protein, the ability of a protein to adapt to changes in
its primary structure, whilst maintaining the integrity of 
its tertiary fold. To quantitatively describe the capacity 
for structural plasticity, in response to substitutions, 
two approaches could be envisaged. The first involves the 
comparison of the structures of many site-directed variants 
of a single protein. The second would be a comparison of 
two structures that differ at many positions, with an
attempt to generalize the effects of substitutions.
A detailed comparison of the structures of unliganded TS 
from L.casei and E.coli has shown that they are 89% 
conserved in terms of atom sites (sharing 3824 common atoms 
out of 4300 from E.coli). This comparison has provided an 
ideal opportunity to investigate the plastic adaptations
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seen in proteins by the second method (Perry et al ., 1990).
A detailed study of the buried region of TS from both 
structures revealed three different mechanisms by which 
substitutions could be accomodated (Perry et el., 1990). 
The first is the occurrence of local changes, whereby large 
effects observed close to the site of mutation dissipate as 
a function of distance. This is usually achieved by a 
mechanism that involves local rearrangements, often the 
repacking of adjacent residues, with only minimal effeots 
on the overall architecture of the protein (Perry et al. , 
1990 ) .
A second mechanism is covariant accomodation where 
multiple sequence changes combine to minimize the 
distortion of the main chain atoms and simultaneously 
preserve the volume of the packed side-chains. A 
representative example of this is found in the /3-sheet, 
structurally the most conserved region of the TS protein. 
F255 at the centre of /3-strand ii of L.casei is substituted 
by glycine in E.coli (see Fig. 1.6). The space ’vacated’ 
by the glycine residue is 'filled’ by the side-chains of
W253 and T^38 (L.casei numbering), whereas the residues
H253 and A258 surround F255 in L.casei. This corresponds 
to a net difference of only a single atom in these three 
residues (Perry et al., 1990). An example of a covariant
pair across the dimer interface is seen where T200 and L201
of L.casei TS are replaced by A200 and F201 (L.casei
numbering) in E.coli T S , thus preserving a similar side 
chain volume (Perry et al., 1990). In both examples, the
positions of the main chain Ca atoms are essentially 
unchanged. In general, it has been found that when a
substitution introduces three or more heavy atoms (carbon, 
oxygen, sulphur or nitrogen), this nearly always results in 
a second site, or covariant change nearby (Perry et al., 
1990 ) .
These observations correlate with experimental data 
obtained from mutagenesis studies of the hydrophobic core 
of the bacteriophage lambda repressor protein, where a net 
change of > + 2 or <-3 methylene groups has been shown to
51
inactivate the protein (Lim & Sauer, 1989). Moreover, 
where a mutation increases the volume of the core in excess 
of the permitted levels, second site mutations that reduce 
the net volume, can restore activity (Lim k Sauer, 1991).
A final mechanism by which plastic adaptation can occur 
is by the concerted movement of individual elements of 
secondary structure. Several of the helical regions of T S , 
which contain the largest structural differences between 
the enzyme from L.casei and E.coli, have been accomodated 
in this fashion. The 'ensemble’ movement of helices B, C 
and G is the most prominent example of this process, where 
these structures have shifted together as a unit in the 
L.casei structure, relative to E.coli. This movement has 
occurred to accomodate the interactions between the 3-helix 
unit and the helix D of L.casei, a helix that is absent 
from E.coli TS (Perry et al., 1990). It is interesting to
note the preservation of the side-chain packing 
interactions between these three helices during the course 
of evolution.
1.10 Models of VZV TS
Two models of the VZV TS, one of the ternary complex and 
the other of the native enzyme with bound phosphate, have 
been constructed by Celia Schiffer and Robert Stroud 
(personal communication). The models are based upon the 
coordinates of the ternary complex of E.coli TS with CB3717 
and dUMP (Montfort et al ., 1990) and the coordinates of the 
E.coli TS structure with bound phosphate respectively 
(Perry et al., 1990). All residues from the E.coli
sequence that differed from the equivalent residue of the 
VZV sequence were substituted by the latter using the 
graphics program INSIGHT (Dayringer et al., 1986). The
substituted residues were positioned in a conformation 
which overlapped as much as possible with that of the 
residue existing in the E.coli structure. Where a VZV 
residue was larger than the one it replaced, it was placed 
in a conformation which corresponds to that most frequently
Bacteriophage T4 (LaPat-Polasko et al., 1990; Frasca et al., 1988).
Mutant TS activity Mutant TS activity
K48R 6.5% P155A 87.0%
K48M <1.0% C156S 0.07%
K49R 56.0% C156R NDA
R137G <1.0% H157V 23.0%
R137K 32.0%
R176K <1.0%
R
K48 (K65); K49 (K66); P155 (P182); C156 (C183); H157 (H184). 
E.coli (Dev et al., 1988, 1989).
Mutant
C146S
C146G
C146T
TS activity 
0.02% 
NDA 
NDA
Mutant
H147V/L/Q/N/G
H147E/D
H147R/K
TS activity 
6.5-10.4% 
0.047-0.052% 
0.007-0.008%
C146 (C183); H147 (H184).
L.casei (Climie & Santi, 1990; Climie et al., 1990)
Mutant TS activity Mutant TS activity
R179A 31% H199L/K/R/M non-complementing
R179E 24% H199/N/W/Y/E non-complementing
R179T 24% H199P/S/G complementing
R179K 26% H199A/T/V complementing
R179 (R164); H199 (184).
Mouse (Zhang et al., 1990).
Mutant TS activity
R44V <1.0% R44 (R38).
Table 1.3. Site-directed mutagenesis of TS.
Summary of all the site-directed mutagenesis data of TS from different 
sources. TS activity was measured by the tritium release assay, except 
for the H199 mutants o f L . c a s e i  which were assayed for 
complementation. NDA indicates no detectable activity. / indicates 
alternative substitutions. Numbers in parentheses refer to equivalent 
amino acid from VZV TS. The convention K48R indicates that the wild 
type amino acid lysine at position 48 has been replaced by arginine.
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found for that amino acid in protein structures. The model 
lacks the first 19 amino acids from the VZV sequence, and 
the two short insertion sequences common to all eukaryotic 
TSs (residues 105-116 and 134-141; VZV numbering), that are 
not found in the E.coli enzyme. At the time the model was 
generated, these regions of the human TS being studied by 
this group (Schiffer et al ., 1991), were unresolved. The
model of the VZV native TS was refined by 200 cycles of 
conjugate gradient minimization with the refinement package 
of XPLOR (Briinger et al. , 1987), clearing up the bad
contacts generated by the amino acid substitutions. The 
minimization resulted in a root mean square (RMS) shift of 
0.38 Angstroms of the alpha-carbons (Ca ). The model of the 
VZV ternary complex was refined with 150 cycles of XPLOR. 
Due to difficulties in the initial stages of energy 
minimization, the Ca atoms were constrained to stay fixed, 
thus allowing only the movement of side chains to remove 
any energetically unfavourable contacts.
1.11 Mutational analysis of TS
In recent years, several groups have studied the role 
that individual amino acids play in the structure and 
function of TS from various sources. In particular, two 
groups have used different methods of saturation site- 
directed mutagenesis on TS from L.casei and E.coli. Some 
of their findings are summarised in this section.
1.11.1 Site-directed mutagenesis
Several groups have analysed a small subset of residues, 
thought to play key roles in the catalytic mechanism of TS, 
by site-directed mutagenesis. The results are summarised 
in Table 1.3.
These studies have served to highlight several 
interesting features of some of the residues predicted to 
play important roles in catalysis and substrate recognition 
(Finer-Moore et al . , 1990; Matthews et al . , 1990b). The
substitution of the totally conserved active site cysteine
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in E.coli TS with Gly or Thr inactivated the enzyme. 
Substitution with Ser yielded an enzyme with very low but 
detectable activity. The serine hydroxyl group to some 
extent replacing the thiol of cysteine. This confirms the 
crucial role of this amino acid in catalysis {Dev et a l .,
1988). More interestingly, several other highly conserved 
residues thought to play essential roles in activity were 
found to be dispensable, in that certain substitutions had 
little effect on enzyme activity. When proline 155 of 
bacteriopage T4 (P182 in VZV), which is totally conserved 
in all 21 TS sequences reported, was replaced by alanine, 
only a small drop in kcat was observed compared with that 
of the WT enzyme (LaPat-Polasko et al., 1990).
The mutability of three of the four highly conserved 
argini ne residues thought to play a role in the co­
ordination of the phosphate group of dUMP was also studied. 
Replacement of R44 (R38) by valine, in mouse T S , resulted
in a greater than 100-fold decrease in enzyme activity 
(Zhang et al. , 1990). Substitution of lysine for the
invariant R137 (R164) in T4 or R179 (R164) in L.casei only 
reduced k c a t  b y  3- to 4-fold (LaPat-Polasko et al. , 1990;
Santi et al . , 1990). Several other amino acid substitu­
tions, including a glutamine, were tolerated at position 
179 in L.casei TS (Santi et al., 1990). Substitution of
arginine b y  glycine inactivated T4 TS (LaPat-Polasko et 
al. , 1990). In contrast to R137 of T4 TS, the completely
conserved R176 (R203) cannot be replaced by lysine (LaPat-
Polasko et al ., 1990).
Analysis of the folate-binding region of T4 TS revealed 
that substitution of arginine for the highly conserved 
residue K48 (K65), significantly diminished TS activity,
whilst replacement of the neighbouring highly conserved 
amino acid K49 (K66) decreased activity by less than 2-fold 
(LaPat-Polasko et a l ., 1990).
The role of the histidine residue, adjacent to the 
active site cysteine, has been studied by several groups. 
This histidine is conserved in all TS sequences except 
bacteriophage phi3T (replaced by valine; Kenny et al . ,
M
ou
se Su
bs
tit
ut
ed
 
am
ino
 
ac
id
s
>
O
ri
gi
na
l 
am
ino
 
ac
id
R
44
Ph
ag
e 
T4
Su
bs
tit
ut
ed
 
am
ino
 
ac
id
s
0  <  m >  M
O
ri
gi
na
l 
am
ino
 
ac
id
r- in ''•o t"- vd co in r-i < 1 t“H
Oh u  X &
E
.c
ol
i
Su
bs
tit
ut
ed
 
am
ino
 
ac
id
s
L
H SP
L
FE
K
G
A
E
K
SG
A
P
L
F
Y
E
R
G
A
SP
L
Y
E
R
K
G
H
K
A
Y
FL
S
A
C
Q
L
Y
O
ri
gi
na
l 
am
ino
 
ac
id
R
21
R
12
6
R
12
7
C
14
6
H
14
7
R
16
6
N
17
7
L
ca
se
i
Su
bs
tit
ut
ed
 
am
ino
 
ac
id
s
L
H
V
SP
L
FE
K
A
E
K
A SG
A
P
L
F
Y
E
R
G
A
SP
L
Y
E
R
K
V
G
H
K
A
Y
FL
SH
E
K
A
C
Q
L
Y
O
ri
gi
na
l 
am
in
o 
ac
id
OO 0\ r-. OO O n oo o\ 
CN »“H 1-H H ’-H ’-H CN CN
D^D^C^CcU X 'Z.
A
Z
A
O
ri
gi
na
l 
am
ino
 
ac
id
CO tJ- CN CO Tf CO 
0 0 'O 'O 0 0 0 0 0 0 O rH 
CO i— i i-h 1 r"1 CN CN
c/i
H
Cm
O
(/>
*33a>
C
a>
04)
C3■M
3
£
£
o
T3
C
3
025
T3:
Sc3
H Th
is 
tab
le 
di
sp
la
ys
 
all
 t
he 
ra
nd
om
 
m
ut
ag
en
es
is 
da
ta 
re
po
rte
d 
to 
da
te 
wh
er
e 
ap
pl
ica
bl
e 
to 
TS
 
fro
m 
mo
re
 
tha
n 
on
e 
so
ur
ce
. 
Am
in
o 
ac
id
s 
sh
ow
n 
in 
bo
ld
 
co
m
pl
em
en
t 
the
 
gr
ow
th
 
of 
E.
co
li 
thy
A 
st
ra
in
s. 
Am
in
o 
ac
id
s 
sh
ow
n 
in 
ou
tli
ne
 
fa
il 
to
 
co
m
pl
em
en
t 
the
 
gr
ow
th
 
of 
E.
co
li 
thy
A 
str
ai
ns
. 
No
te 
th
at 
am
in
o 
aci
d 
on 
the
 
sa
me
 
lin
e 
oc
cu
py
 
eq
ui
va
le
nt
 p
os
iti
on
s 
in 
th
e 
va
rio
us
 T
S 
sp
ec
ie
s.
54
1985) and L.lactis (replaced by alanine; Ross et al., 
1990). Substitution of histidine by valine in TS from 
L.casei (H199), E.coli (H147) and bacteriophage T4 (H157) 
produced active enzyme (Climie & Santi, 1990; Dev et al., 
1989; LaPat-Polasko et al., 1990). Interestingly, 
substitution of alanine in place of histidine 199 in the 
L.casei TS also produced active enzyme (Climie & Santi, 
1990).
In summary, these initial experiments have shown that 
whilst some invariant residues cannot tolerate amino acid 
substitutions, others can be mutated freely with little 
deleterious effect on activity. Moreover, the effect of 
the substitution of one amino acid for another may, or may 
not, have an analogous effect on TS activity when the same 
substitution is made to TS from an alternate source.
1.11.2 Saturation site-directed mutagenesis
Two groups have recently described different methods for 
the large scale random mutagenesis of targeted residues of 
TS from L.casei and E.coli (Climie et al., 1990; Michaels 
et al., 1990). Some of the results from these experiments 
are shown in Table 1.4.
Workers in Dan Santi’s group constructed a synthetic 
L.casei TS gene that possessed over 30 unique restriction 
sites in the TS coding sequence and was shown to express TS 
to a level of 10% of the total soluble protein in E.coli 
(Climie & Santi, 1990). A technique of mutagenesis (Wells 
et al., 1985), using synthetic DNA cassettes containing a 
mixture of 32 possible codons (represented by NNG/C) that 
encode all 20 amino acids and the amber stop codon (TAG), 
in conjunction with a growth complementation assay was 
developed. Climie and Santi (1990) demonstrated the 
feasibility of this method for creating the majority of the 
single amino acid substitutions of a targeted residue. 
Using this technique, they went on to identify 125 mutants, 
which they grouped into three different phenotypic classes 
(active, sick and dead/inactive) at 12 different amino acid 
positions (Climie et al., 1990). These residues had all
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previously been predicted to play roles in the direct 
binding of, or lie in close proximity to dUMP (Hardy et 
al. , 1987). Eight of the 12 residues are invariant, whilst 
the other four are conserved in 15 to 19 of the 21 TS 
sequences reported to date.
All the sequenced substitutions of R23, C198, and R218 
resulted in enzyme inactivation, whilst a fourth residue, 
Y261 , only retained activity when substituted by 
methionine. The remaining eight residues, five of which 
are invariant, could be readily substituted by at least 
two, and in some cases as many as twelve, different amino 
acids without inactivating the enzyme. Although none of 
the subtitutions of R23 retained activity, the mutant R23G, 
which would mimic the only naturally occurring substitution 
mutant of this residue was not isolated. To assess the 
level of activity necessary to facilitate complementation, 
the kcat value of several mutants was determined. Mutants 
with greater than 1% activity gave full complementation, 
although some had levels comparable to WT L.casei T S , 
whereas mutants with less than 0.1% activity could not 
complement the growth of an E.coli thyA strain (Climie et 
al., 1990).
Workers from Jeffrey Miller’s group, in collaboration 
with David Matthews, adopted a different approach for the 
saturation mutagenesis of E.coli TS (Michaels et a l ., 
1990). They replaced a normal codon with the amber 
nonsense stop codon (TAG) at 20 different sites in the 
E.coli TS gene on a low-copy number plasmid. By trans­
forming these 20 thyA plasmids into 13 different E.coli 
strains, each of which harboured a different amber
suppressor tRNA, nearly 250 mutants were generated. These 
were analysed by growth complementation and enzyme assays 
were performed on a selected set of mutants (Michaels et 
al., 1990). This technique has been used to generate over 
1)600 amino acid substitutions of the E.coli lac repressor
(Miller et al., 1979; Kleina & Miller, 1990).
Seven of the 20 residues studied were totally conserved, 
eight were highly conserved (invariant in >15 TS sequences)
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and the remaining five were non-conserved (residue found in 
<7 TS sequences). This latter group (E14, R35, D105, N121, 
E223) complemented the growth of all 13 strains showing 
that all the amino acid substitutions gave at least some 
level of activity (Michaels et a l . , 1990). The highly
conserved residues show varied tolerance to substitution. 
Some could only tolerate conserved changes, such as F30 (L 
or Y) or G204 (A or S), whilst others such as Q33 could be 
replaced by any of the amino acids provided by the 
suppressor strains (Michaels et al., 1990). Surprisingly, 
even the invariant residues could tolerate substitutions. 
C146S retained some activity, in agreement with a previous 
report (Dev et al. , 1988), as did D169C, although no other
substitutions of these residues facilitated growth comp­
lementation. Growth complementaton was seen in the 
remaining conserved residues by substitutions of two to 
seven residues (Michaels et al . , 1990). Growth comple­
mentation was shown to correlate with an enzyme activity of 
less than 1.0%, whereas mutants that did not complement 
growth were shown to have specific activities of <0.32% the 
wild type level (Michaels et al ., 1990).
The efficiency of suppression can vary from 5% to 100% 
depending upon the sequence context of the amber codon 
(Kleina et al., 1990). To investigate the effects of
varying levels of suppression a comparison of the pheno­
types of four suppression mutants and four missense mutants 
was made (Michaels et a l . , 1990). Two of the missense
mutants had the same phenotype as the corresponding 
suppressor mutant (H147A and D169H). However, the other 
two missense mutants complemented the growth of E.coli 
thyA, whilst their corresponding suppressor mutants did not 
(H147E and D169E). On this basis, it was proposed that 
overproduction of mutant forms of TS can sometimes lead to 
growth complementation (Michaels et al., 1990). The growth 
complementation ability of several of the suppressor 
mutants from this study (Michaels et al., 1990) can also be 
compared to the enzyme activities of the purified missense 
mutant enzymes of E.coli TS generated by Dev and co-workers
57
(1989). H147G complements the growth of E.coli thyA and
has an enzyme activity 10% of the wt E.coli T S , whilst 
H147K has only 0.008% the activity of the wt enzyme and 
fails to complement growth. However, the mutant H147R, has 
only 0.007% activity of the wild type T S , almost identical 
to that of H147K, but can successfully complement the 
growth of E.coli thyA. Interestingly, the missense mutant 
H147E, which has 0.05% the activity of the wild type 
enzyme can complement the growth of E.coli thyA, although 
its corresponding suppressor mutant cannot (Dev et al ., 
1989; Michaels et al ., 1990). This comparison shows that
complementation of E.coli thyA strains does not always 
correlate with enzyme activity.
Where the same substitution has been made to equivalent 
residues in TS from both E.coli and L.casei, the ability to 
complement the growth of E.coli thyA strains is not always
the same. As seen in Table 1.4, of 45 such mutants,
25 (56%) are inactive in both enzymes, nine (20%) are 
active in both, nine (20%) are active in E.coli TS but not 
L.casei TS, and the remaining two mutants (4%) are active 
in L.casei TS but not E.coli T S . In a comparison of the 
limited data available for equivalent residues from phage 
T4, of five mutants, one is active in all three TS species,
two are active in T4 and L.casei, and one each are inactive
in T4 but active in E.coli or L.casei (LaPat-Polasko et 
al., 1 990). The only mutant reported for the murine TS 
(Zhang et al., 1990) has similar levels of enzyme activity
to the equivalent mutant in TS of L.casei.
When the results of these groups are compared, they show 
that many of the invariant residues of TS studied, may be 
substituted by at least one amino acid and still retain at 
least some catalytic activity. This poses the paradoxical 
question; why are so many of the residues of TS completely 
conserved in all the TS sequences reported to date, yet 
they can be substituted by other amino acids and still 
retain activity?
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1.12 TS inhibitors
Since the discovery that 5-fluorouracil (FU) is a potent 
TS inhibitor by Heidelberger and colleagues in 1957, the 
growth in the number and diversity of TS inhibitors has 
been explosive. There are currently too many compounds to 
list individually, and their mechanisms of action are also 
too diverse to cover completely. However, a number of 
representative compounds, that fall broadly into seven 
different groups, will be discussed and, where known, their 
mechanisms of action described.
1.12.1 Nucleoside analogues requiring activation
All of the nucleoside analogues discussed in this 
section, predominantly 5-substituted-2’-deoxyuridine
analogues, exert their inhibitory effects at the level of 
the corresponding 5 ’-monophosphate. For these analogues to 
be active in vivo, they must first be enzymically activated 
(see Sections 3.1 and 3.4). For studies of purified 
enzyme, the 5 ’-monophosphate derivative must be used. The 
necessity for the phosphate group was shown by the fact 
that deoxyuridine (U d R ) is not a substrate for the purified 
enzyme (Reyes & Heidelberger, 1965), with an estimated Ki 
of 0.2mM for human TS (Lockshin & Danenberg, 1981), which 
corresponds to a 500-fold drop in binding activity compared 
to dUMP. In addition, inorganic phosphate is a competitive 
inhibitor of nucleotide binding, with a Ki of lOmM 
(Lockshin & Danenberg, 1981). In in vivo studies, the 
necessity for the 5 *-monophosphate group has been 
demonstrated by the fact that mutations in the activation 
step lead to resistance to these analogues (see Section 
1.14).
A study of the quantitative structure-activity 
relationships of different TS inhibitors of L,casei TS has 
shown that analogues with a 5-substituent that increases 
electron withdrawal from the heterocyclic ring of uracil, 
increase the affinity of the analogue for the enzyme, 
whilst bulky groups at the C-5 position are usually
FUdR CF3UdR EYUdR
5-fluoro-2’- 5-(trifluoro-methyl)- 5-ethynyl-2'-
deoxyuridine 2,-deoxyuridine deoxyuridine
Fig. 1.13a. TS inhibitors:
5-substituted deoxyuridine analogues.
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CB3717 N 10-propargyl-5,8-dideazafolate 
Fig. 1.13b. TS inhibitors: folate analogues.
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detrimental to binding for steric reasons (Wayata & Santi, 
1977). Consistent with these findings is the observation 
that the 5 ’-monophosphate derivatives of 5-fluoro-2’- 
deoxyuridine (FUdR), 5-(trifluoro-methyl)-2*-deoxyuridine 
(CF3UdR; trifluorothymidine TFT), 5-nitro-2*-deoxyuridine 
(N02-UdR) and 5-ethynyl-2*-deoxyuridine (EYUdR) have 
consitently emerged as the most potent TS inhibitors in 
both in vitro and in vivo experiments with nucleoside 
analogues (see Fig. 1.13a; Balzarini et a l ., 1982; Lewis &
Dunlap, 1981).
The mode of action of these compounds is now reasonably 
well understood. FdUMP, the active form of FUdR, forms a 
covalent ternary complex with TS in the presence of the
cofactor, N5 ,N10-CH2FH4 , which is similar to the covalent
catalytic intermediate (see Section 1.6; Lewis & Dunlap, 
1981). This complex is stable and terminates the reaction 
because the fluorine atom cannot be abstracted, as occurs 
with the C-5 hydrogen in the course of the normal TS 
reaction, presumably due to the strength of the C-5-F bond 
(Santi & Danenberg, 1984).
In contrast to FdUMP, CF3dUMP and NO2dUMP can inhibit TS 
in the absence of N5 ,N10-CH2FH4 , but still interact with 
the active site cysteine residue forming a 5,6-dihydro- 
pyrimidine derivative. Their ability to interact with TS 
in the absence of the cofactor is thought to be the basis 
of their tight-binding to, and inhibition of, TS (Danenberg 
& Heidelberger, 1974; Wayata et a l ., 1980).
EYUdR is a potent inhibitor of S-49 murine lymphoma
cells with an IC50 value of 12pM, and inhibits TS only in 
the presence of the cofactor, by forming an inhibitory 
ternary complex (Barr et al., 1981).
Danenberg and co-workers (1981) confirmed that a ternary 
complex between EYdUMP, N5 ,N10-CH2 FH4 and TS was formed but 
it was much weaker than that formed by FdUMP. Furthermore, 
the EYdUMP-based complex was disrupted upon denaturation of 
the enzyme, in contrast to the FdUMP-based complex, which 
remains stable upon denaturation (Danenberg et al., 1981).
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1.12.2 Cofactor analogues
2-amino-4-hydroquinazolines (Bird et al ., 1970) and
folylpolyglutamates (Kisliuk et al. , 1974) were the first
folate analogues shown to inhibit TS. A major discovery 
that stimulated the rapid expansion of research into the 
use of anti-folates directed at T S , was the demonstration 
that pteroyl-hexaglutamate could inhibit bacteriophage T2 
TS at a concentration 100-fold lower than that required to 
inhibit E.coli TS (Maley et al., 1979c). This was a 
feature that none of the potent substrate based TS 
inhibitors had exhibited. Folate analogues have several 
other advantages over nucleoside analogues for chemothera­
peutic use, including a decreased susceptiblity to 
metabolic degradation, and they pose no significant risk of 
mutagenicity or carcinogenicty (Keyomarsi & Moran, 1990). 
Moreover, the high levels of dUMP found in many tumours 
(that would reduce the effects of nucleotide analogues such 
as FdUMP) would potentiate binding of folate analogues 
(Danenberg & Lockshin, 1982; Myers et al ., 1974; Keyomari & 
Moran, 1988, 1990; Pogolotti et al., 1986). Conversely,
the existance of low levels of N5N10-CH2FH4 in many tumours 
(which reduces the cytotoxicity of FdUMP by preventing 
maximal formation of the TS covalent ternary complex) would 
result in little competition for exogenous anti-folate 
analogues binding to TS (Houghton et al., 1981; Evans et 
al., 1981; Jackson et al ., 1983; Sikora et al., 1988).
Several other folate analogues have been shown to 
inhibit TS. One of the first, and subsequently most 
studied, compounds to emerge from these investigations was 
N10-propargyl-5,8-dideazafolate (CB3717; see Fig. 1.13b) 
which has a Ki value of 1x10"9M for TS isolated from murine 
leukemia L1210 cells (Jones et al. , 1981). Phase I and II 
clinical trials have shown that CB3717 has demonstrable 
clinical activity against ovarian, breast and liver 
cancers, but the occurrence of renal toxicity in a 
sporadic, unpredictable and life-threatening manner, has 
precluded its further development as an anti-cancer drug
OH
N 5dUM P-8-deazatetrahydrofolate 
Fig. 1.14. TS inhibitors: Bisubstrate analogues.
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(Harrap et al., 1989). However, workers in this group have 
used this compound as a parent compound to identify equally 
effective, but less toxic derivatives (Harrap et al ., 1989; 
Jones et a l . , 1989; Hughes et al. , 1990), which have met
with signif»cci/vV success (Jackman et al., 1990; Marsham et 
al., 1990).
CB3717 inhibits TS from murine L1210 cells by the
formation of a complex with dUMP, that still allows FdUMP 
to bind. This suggests that the covalent inhibitory
complex formed is similar to the 1:1:1 ternary complex of 
TS.dUMP.N5N10-CH2FH4 (see Section 1.6; Keyomarsi & Moran,
1990). TS inhibition mediated by the binding of CB3717 
also results in increased levels of the enzyme, presumably 
by protecting the enzyme against proteolysis (Keyomarsi & 
Moran, 1990 ) .
In addition to its role in the treatment of disease, 
CB3717 has been used to probe the mechanism of action of TS
by virtue of its use in structural studies of the E.coli TS
(Matthews et a l . , 1989, 1990a; Finer-Moore et al., 1990;
Montfort et al., 1990).
I^Mjirof olate, which accumulates at high levels when DHFR 
is inhibited, can directly inhibit TS (Bunni et al ., 1988;
Seither et al ., 1991). Chu and co-workers (1990) point out 
that whilst the direct inhibition of TS due to a build up 
of FH2 is indeed a major cause of growth inhibition, 
depletion of FH4 also plays a role. This lead them to 
suggest that inhibition of de novo thymidylate synthesis is 
a multi-factorial process, a proposal backed by the 
comprehensive mathematical model of folate cycle kinetics 
(Morrison & Allegra, 1989).
1.12.3 Bisubstrate analogues
Several co-called bisubstrate analogues, comprised of a 
folate molecule, covalently linked to a nucleotide analogue 
and designed to mimic the non-enzymic portion of the 
catalytic intermediate of the TS reaction, have been shown 
to inhibit TS (Park et al., 1979; Amarnath et al. , 1984).
Two such compounds, N5-dUMP-N10-propargyl-8-deazatetra-
o 
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BAT
5,-bromoacetamido-2’-deoxythymidine
Fig. 1.15a. TS inhibitors: 5 !-haloacetamido-2'-deoxythymidine 
analogues.
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Fig. 1.15b. TS inhibitors: in vivo regulators.
This figure illustrates the proposed interaction of PLP (right) with 
TS in comparison to the interaction between TS and thymidylate 
(taken from Chen et al., 1989).
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hydrofolate and N5-dUMP-8-deazatetrahydrofolate (see 
Fig. 1.14) inhibit purified TS from murine leukemic L1210 
cells in a competitive manner, with respect to dUMP, with a 
Ki value of 0.09pM for both compounds (Veda et al. , 1986).
This study has also shown that rather than entering into 
the active site of the enzyme to produce an inhibitory 
ternary complex, these compounds inhibit TS by blocking the 
nucleotide and folate binding sites. They should 
therefore, be referred to as 'substrate-product’ rather 
than *bi-substrate * analogues, as the folate analogue is 
already attached to the 5-position of dUMP.
1.12.4 Nucleoside analogues not requiring activation
A novel group of compounds, the 5 ’-haloacetamido-2’- 
deoxythymidines, do not require phosphorylation or the co­
factor to inhibit TS (see Fig. 1.15a; Sani et al. , 1986).
The three compounds 5*-bromo-, 5 ’-chloro- and 5 ’-iodo- 
acetamido-21-deoxythymidines (BAT, CAT and IAT respect­
ively) inhibit TS from L1210 cells with IC50 values 
revealing their relative potencies as BAT (1.2pM) > IAT
(6.OpM) > CAT (62.O p M ) (Sani et al . , 1986). More detailed 
kinetic studies with BAT suggest that it acted as a 
competitive inhibitor with respect to dUMP. It had a AT 
value of 5.4pM and complete and irreversible inactivation 
can be achieved by pre-incubation of TS in the presence of 
50pM BAT for 30min (Sani et al. , 1986). Replacement of the 
5*-methyl group of BAT with H, F, Br, I or an ethyl group 
reduced the IC50 by approximately 50% (Elliott et al. , 
1987). However, none of these compounds has proved more 
inhibitory to the growth of murine L1210 or P388 cells than 
BAT (Brockman et a l ., 1984; Elliott et a l . t 1987).
1.12.5 In vivo regulators
Recent studies have revealed that pyridoxal phosphate 
(PLP) reversibly inhibits TS from L.casei with a Ki value 
of 0.6-0.9pM. They also showed that inhibition is 
competitive with respect to dUMP (Chen et a l ., 1988, 1989). 
The observed changes in the absorption spectra of PLP
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resulting from the addition of TS (Chen et al., 1989 ) were 
consistent with the formation of a thiohemiacetal by 
addition of a sulphydryl group to the carbonyl group of PLP 
(Matsuo, 1957 ; Buell &, Hansen, 1960). This suggests an 
interaction between the catalytic cysteine residue and the 
carbonyl group of PLP, similar to that formed
between TS and dUMP during catalysis (Moore et a l . , 1986;
Chen et al ., 1989; see Fig. 1.15b).
In addition, the common metabolite, glyceraldehyde-3- 
phosphate (G-3-P), was shown to act as a competitve 
inhibitor with respect to dUMP, with a Ki value of 12 to 
13pM (Bures et al., 1991). Although no evidence for the 
formation of a thiohemiacetal between the sulphydryl group 
of TS and the carbonyl group of G-3-P was given by Bures 
and co-workers (1991), such an intermediate is known to 
exist in the reaction catalysed by G-3-P dehydrogenase 
(Harris & Waters, 1976). They proposed that the mechanism 
of interaction with both enzymes is similar (Bures et al.,
1991).
The most intriguing feature of these studies is the 
possible role of PLP and G-3-P in regulating DNA synthesis 
by modulating TS activity in both eukaryotic (Rode et al., 
1980; Chen et al., 1989; Matherly et al., 1989) and 
prokaryotic cells (Tolleson et al . , 1990). The observation 
that low levels of PLP are found in various rapidly 
proliferating cancer cells, and that the administration of 
pyridoxine or pyridoxal (precursors of PLP) inhibits the 
proliferation of these cells both in vitro and in vivo 
(Thanassi et al . , 1985, and references therein), augments
this idea.
1.12.6 Anti-sense oligonucleotides
An alternative approach to the inhibition of enzyme 
function other than the use of drugs is to specifically 
inhibit enzyme synthesis. The use of anti-sense 
oligodeoxynucleotides (oligos) to arrest translation of 
specific mRNA molecules (Helene & Toulm£, 1990) has 
recently been directed at the DHFR-TS mRNA of Plasmodium
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falciparum. A 49-mer targeted at the conserved region of 
TS gave 50% inhibition at 6pM and 90% inhibition at 45pM 
(Sartorius & Franklin, 1991a). Such an oligo is very 
specific to the DHFR-TS mRNA of P . falciparum. It also 
differs considerably from the human TS mRNA, sharing 29/49 
(59%) nucleotide sequence identity (Ayusawa et a l . , 1986).
However, the fact that certain useful modifications such as 
the use of methylphosphonates or poly(L-lysine) conjugates 
cannot be used for long oligos, may delay their development 
as anti-malarial drugs (Sartorius & Franklin, 1991b).
1.12.7 Oligopeptide inhibition of TS
Recently, oligopeptides have been shown to inhibit VZV 
TS activity. A linear pentadecapeptide corresponding to 
the amino acid sequence of 13-strand i (LPPCHTLCQFYVANG) 
inhibits TS in vitro (IC50 = 50pM). N- and C-terminal 
deletions of this oligopeptide have defined the active core 
as CHTLCQFY, which corresponds precisely to those amino 
acids at the interface of the two monomers (H. S. Marsden 
and R. Tbompson, personal communication). These
oligopeptides are thought to disrupt activity by preventing 
the correct formation of the dimer.
1. 13 Nucleoside and nucleoside analogue metabolism
To understand the mechanisms controlling the activation 
of nucleoside analogues, and thus potential modes of 
resistance, a thorough knowledge of nucleoside metabolism 
is necessary. The aim of this section is to describe the 
different pathways by which analogues are activated and to 
provide evidence that different pathways are followed in 
different tissues, and in different organisms. The 
pathways described below are for FU and its derivatives. 
Ft metabolism resembles that of uracil, but some differ­
ences are apparent. The metabolism of other nucleoside 
analogues is largely unexplored, but thought to resemble 
that of FU and uracil.
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Fig. 1.16. Nucleotide Metabolism.
The pathways of nucleotide metabolism in E.coli. The structural and 
biochemical similarity of uracil and FU means that most pathways for 
their metabolism are the same (see text for details). Dotted lines indicate 
minor pathways
The following abbreviations are used for the various nucleotides described in this 
sch em e : U - uracil; UR, UMP, UDP and UTP - uridine and its mono-, di- and 
triphosphate derivatives. UdR, dUMP, dUDP and dUTP - deoxyuridine and its mono-, 
di- and triphosphate derivatives. dTM P, dTDP and dTTP - the m ono-, di- and 
triphosphate derivatives of thymidine. The following abbreviations are used for the 
genes of various proteins: uraA , nupC , nupG  and tsx - genes for proteins involved in 
nucleobase and nucleoside uptake, udp  - uridine phosphorylase; deoA  - thymidine 
phosphorylase; upp  - uracil phosphoribosyl transferase; udk - uridine kinase; tdk- 
thym idine kinase; tmk - thymidylate kinase; thyA - thym idylate synthase; nrd-  
ribonucleotide reductase; dut - dUTPase; ndk - nucleoside diphosphate kinase.
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1.13.1 Mammalian Systems
There are at least two methods by which FU can inhibit 
the growth of cells. One is the inhibition of TS by FdUMP, 
a metabolite of FU, whilst the other involves the incorp­
oration of FU into RNA via the formation of FUTP.
When examining the cytotoxic effects of FU mediated via 
T S , the two routes for conversion of FU to FdUMP must be 
considered (Cory et al. , 1977 ). The most direct route
requires the formation of FUdR from FU, catalysed by 
thymidine phosphorylase (TdRPase) (and to a minor extent by 
uridine phosphorylase (URPase), followed by the 
phosphorylation of FUdR to FdUMP, a reaction catalysed by 
TK (Cory et al. , 1977 ) .
The second route commences with the formation of FUMP, 
which may be synthesized from FU by two separate pathways. 
The first pathway involves the conversion of FU to FUR, 
catalysed by URPase, and the subsequent phosphorylation of 
FUR by uridine kinase (Cory et al., 1977). The alternate 
pathway involves the direct formation of FUMP from FU in a 
reaction catalysed by uracil phosphoribosyl transferase 
(Cory et al. , 1977 ). To form FdUMP, FUMP must then be
phosphorylated to FUDP by nucleotide kinases, reduced to 
FdUDP by ribonucleotide reductase, phosphorylated again to 
FdUTP and then converted to FdUMP by dUTPase (see 
Fig. 1.16; Cory et al ., 1977).
The formation of FdUMP alone is not necessarily 
sufficient for the inhibition of T S , as suitable levels of 
cofactor are also required for formation of the inhibitory 
ternary complex. In a human colon adenocarcinoma xeno­
graft, the concentrations of CH2FH4(Glu)n have been shown 
to be too low to form stable inhibitory complexes with TS 
and FdUMP which may explain, in part, why certain tumours 
are insensitive to FU (Radparvar et al., 1989a,b).
FU is also ineffective in the treatment of certain 
tumours where there is little or no dependence on de novo 
thymidylate synthesis. Mutants of a human carcinoma cell- 
line, selected for a deficiency in TS activity, were shown
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to have a 32- and 750-fold increase in resistance to FU and 
FUdR respectively, compared to wild type parental cells. 
They also formed drug insensitive tumours in athymic nude 
mice (Houghton et al. , 1989), suggesting that such tumours
can scavenge thymine in vivo to facilitate normal tumour 
growth, in the absence of de novo thymidylate synthesis.
Studies have shown that levels of enzymes involved in 
the activation of FU such as TdRPase vary tremendously in 
human tissues: high levels are seen in T- and B-lymphocytic 
malignant lymphomas and in normal liver and lung tissues, 
but are low in lymphoblastic and myelogenous leukaemic 
cells. This again could explain why some tumours respond 
to FU whilst others are insensitive (Yoshimura et al. , 
1990). Moreover, the finding that TdRPase levels are high 
in human spleen yet remain undetectable in rat spleen, 
could explain the observed differences in response to FU 
between tumours from the same tissue of different organisms 
(Zimmerman & Seidenberg, 1964).
A block in the supply of thymidylate (thymidylate 
stress) is known to induce nucleotide pool imbalances and 
lead to rapid thymineless death of mammalian cells (Koyama
et al., 1982; Ayusawa et al., 1988). Double-stranded DNA
breaks (Ayuasawa et a l . , 1988; Seno et a l . , 1985 ),
chromosomal damage, especially in regions of active DNA 
replication (Hori et a l ., 1984a,b), and increased
recombination (Ayusawa et al . , 1986; Barclay et al., 1982;
Kunz & Haynes, 1982), have all been shown to be a
consequence of thymidylate stress.
More recently, an almost identical form of cell death 
has been observed in FUdR treated mouse cells, direct 
evidence that FUdR can induce thymineless death (Yoshioka 
et al., 1987; Ayusawa et al., 1988). In contrast, the use 
of cytotoxic drugs such as FUdR to induce thymidylate 
stress in androgen-independent rat prostatic adenocarcinoma 
AT-3 cells, results in the activation of programmed cell 
death. A characteristic feature of this process is the 
fragmentation of genomic DNA into discrete multiples of a 
nucleosomal unit of 180bp (Searle et al., 1982; Kyprianou &
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Isaacs, 1989 ) .
FU can be toxic to cells due to the incorporation of FU, 
via FUTP, into RNA and can lead to cell death solely by the 
disruption of RNA processing (Akazawa et al. t 1986; 
Greenhalgh & Parish, 1990). These aberrant processing 
events include a dose-dependent increase in the mammalian 
DHFR mRNA intron V levels (Will & Dolnick, 1986), erroneous 
processing of rRNA precursors (Greenhalgh & Parish, 1989) 
and maturation of tRNA molecules (Santi & Hardy, 1987).
1.13.2 Bacterial systems
Although FU was originally developed as an anti-cancer 
drug (Duschinsky et al., 1957), it was also shown to
inhibit the growth of several species of micro-organisms, 
including E.coli (Heidelberger et a l . , 1957 ). Studies
investigating the mode of FU toxicity have suggested three 
different mechanisms of action; inhibition of T S , incorp­
oration of FU into RNA and the disruption of cell-wall 
synthesis. To understand how FU kills the bacteria in these 
different ways, a description of the metabolism of FU is 
necessary. Comprehensive studies of these pathways have 
given an insight into the mechanisms of resistance (Neuhard 
& Nygaard, 1987; O ’Donovan & Neuhard, 1970).
Before FU can be metabolised, it must enter the cell by 
one of three mechanisms, the first being by a passive 
diff usion process (Munch-Pet.erson & Mygind, 1983; Neuhard & 
Nygaard, 1987). The gene product of uraA is responsible
for a specific transport system that brings FU into the 
cell (Burton, 1977, 1983), whilst phosphoribosyl-
transferase, encoded by upp, catalyses the uptake and
concomitant conversion of FU to the respective mono­
phosphate derivative by the addition of a ribose-5*-
phosphate group (Neuhard & Nygaard, 1987).
FU is predominantly converted to FUMP (if it was not 
already as part of the uptake process) by uracil phospho- 
ribosyltransferase (Neuhard & Nygaard, 1987). Mutant 
strains of E.coli that lack this enzyme are resistant to 
FU. FU may also be converted to FUMP by the concerted
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action of URPase and UK, but this route only operates in 
the presence of high intracellular levels of FU or ribose- 
5 ’-phosphate donors. In contrast to E.coli mutants in upp 
that confer resistance to FU, an E.coli udp udk double 
mutant is sensitive to FU (Neuhard & Nygaard, 1987). The 
formation of FUdR from FU, catalysed by TdRPase is minimal, 
as this enzyme functions in a predominantly catabolic 
fashion (Neuhard & Nygaard, 1987; see Fig. 1.16).
FUMP is readily converted to FUDP whereupon it has two 
fates. When further phoshorylated to form FUTP it can 
become incorporated into RNA (Heidelberger, 1957; Horowitz
& Chargaff, 1959; Brockman et al ., 1960; Brockman &
Anderson, 1963). When FUTP is incorporated into mRNA, the 
result is the synthesis of enzymes with altered activities 
(Horowitz & Chargaff, 1959; Horowitz et al. , 1960; Bussard 
et al. , 1960). This was shown to occur due to aberrant
amino acid incorporation into proteins (Gros, 1960; Naona & 
Gros, 1960a,b), although a second group failed to find 
evidence for such a phenomenon (Aronson, 1961).
The alternate fate for FUDP is conversion to FdUMP which 
follows the same pathway as the conversion of UDP to dUMP, 
via ribonucleotide reductase (Neuhard & Nygaard, 1987). 
FdUMP can then inhibit TS as described (see Section 
1.12.1). FUdR can also be used to inhibit the growth of 
E.coli. It enters the cell via one of three specific 
nucleoside uptake systems, encoded by the nupC, nupG or tsx 
loci (Munch-Peterson & Mygind, 1983; Hantke, 1976; McKeown 
et al., 1976). Once inside the cell, FUdR is 
phosphorylated by T K , to form FdUMP (Neuhard & Nygaard,
1987). A strain of E.coli with mutations in the udp 
(URPase) and deoA (TdRPase) genes cannot degrade FUdR and 
is more sensitive to FUdR than wild type. However, if such 
a strain is simultaneously deficient in TK activity, it 
will be resistant to FUdR (Neuhard & Nygaard, 1987). The 
inhibition of TS activity results in the so-called 
'thymineless death’ of E.coli.
In bacteria, FU can exert its toxicity by an additional 
method (Tomasz & Borek, 1959), inhibiting the incorporation
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of aG-diaminopimelic acid into the cell walls, leading to 
the formation of osmotically sensitive 1spheroplast’-1 ike 
bodies (Rogers & Perkins, 1960; Tomasz & Borek, 1962).
1.14 Resistance to TS inhibitors
As discussed above, the arrest of cell or tumour growth 
by TS inhibitors, is only accomplished under certain 
conditions. However, in some circumstances tumours and 
cells can develop or induce mechanisms that allow both to 
overcome the toxic effects of these drugs, thus conferring 
resistance. Examples of drug resistance, and the molecular 
basis of this phenomenon, will be described for both 
mammalian and bacterial systems.
1.14.1 Mammalian systems
Shortly after the introduction of FU reports of drug 
resistance began to emerge (Reichard et al., 1959; 
Heidelberger et al., 1960a,b). Three possible mechanisms 
have been identified; the prevention of activation, TS 
overproduction and structural alterations to T S .
Characterization of a variety of FU and FUdR resistant 
cell lines has shown that a significant decrease in any of 
a number of enzymes that prevent the formation of FdUMP or 
FUTP, thereby preventing inhibiton of TS (Reichard et al., 
1959; Anderson & Law, 1960; Umeda & Heidelberger, 1968; 
Slack et al. , 1 976; Kessel & Wodinskv, 1970; Mulkins &
Heidelberger, 1982) or disruption of RNA processsing 
(Brockman & Law, 1960), can be responsible for the drug 
resistant phenotype.
The cause of resistance to FUdR in at least two murine 
cell lines has been shown to be due to a 6- to 10-fold 
overproduction of TS (Baskin & Rosenberg, 1975; Priest et 
al., 1980). This form of resistance has also been observed 
for mouse FM3A mammary adenocarcinoma cells resistant to 
the folate analogue CB3717 (Danenberg & Danenberg, 1989). 
TS was overproduced by up to 200-fold in the presence of 
CB3717, but the levels of TS decayed, with a half-life of
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about 4 weeks, upon removal of the drug. The cause of 
overproduction was specific amplification of the TS gene 
(Danenberg & Danenberg, 1989).
TS analysed from crude extracts of a fluorouracil 
resistant cell line (Heidelberger et al., 1960b), was
insensitive to FdUMP inhibition (Heidelberger et al . , 
1960a). This suggests that the structure of the active 
site is altered in the mutant enzyme in such a way that it 
can descriminate between dUMP and FdUMP, in a manner that 
the wt enzyme cannot. Unfortunately, the resistant cell 
line was lost before the enzyme could be purified and 
studied in more detail (Hartmann & Heidelberger, 1961).
Heidelberger and colleagues proposed that the enzyme is 
unlikely to distinguish between the dUMP and FdUMP on the 
basis of the size of the fluorine and hydrogen atoms as 
their Van der Waals radii are very similar (Pauling, 1944; 
Heidelberger et al., 1960a). Instead, they proposed that
the fluorine substituent, which would increase the acidity 
of the pyrimidine carbonyls, which may permit the enzyme to 
distinguish between dUMP and FdUMP (Heidelberger et al., 
1960a). The determination of the structure of the E.coli 
ternary complex has recently shown that the pyrimidine ring 
C4 carbonyl group is directly involved in hydrogen-bonding, 
with a completely conserved residue in the active site, 
thus giving some support for this mechanism (Matthews et 
al., 1990b; Montfort et al. , 1990; Finer-Moore et al.,
1990 ) .
Jastreboff and co-workers (1983) isolated a different 
cell line resistant to FUdR. A comparison of TS purified 
from both the FUdR resistant cell line, and the wild type 
cell line from which it was derived, revealed that TS from 
the FUdR resistant cell line had a higher turnover number 
(91 min~1 versus 31 min"1 ) and increased Ki value for FdUMP 
(3 9nM versus 1 . 9nM) compared to the enzyme from the wild 
type cell line (Jastreboff et al. , 1983 ). Although this
altered form of TS might be expected to account for the 
drug resistant phenotype of these cells, it may not be the 
sole determinant. This is because the levels the TS are
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twice those seen in the wild type cell line, and a 
deficiency in TK could not be ruled out (Jastreboff et al., 
1983). No further reports concerning the further 
characterization of TS from this cell line have been 
published.
A cell line derived from a human colorectal tumour that 
expressed two forms of TS differing in electrophoretic 
mobility, showed resistance to FUdR (Berger & Berger,
1988). When cell lines expressing either the variant or-wt 
form of TS were isolated, drug resistance was shown to be 
linked to expression of the variant form of TS (Berger et 
al. , 1988). The variant form of TS has a more basic pi
and exhibits a three-fold reduction in affinity for both 
FdUMP and N5 ,N10-CH2 FH4 (Berger et a l . , 1988). The
isolation and sequence determination of a cDNA clone, 
specific to this form of T S , has shown it differs from wild 
type TS only by substitution of histidine for the highly 
conserved tyrosine at position 33 (Y21 in VZV T S , see Fig. 
1.6; Barbour et al. , 1990). It is possible that mutations
at other loci such as TK may contribute to the drug
resistant phenotype of cells expressing the TS variant 
(Berger et al.t 1988; Barbour et a l ., 1990), and a
detailed s t u d y  of the kinetic parameters of the purified 
enzyme would resolve the situation. This is the only
recorded instance of a variant of TS where the amino acid 
changes, possibly responsible for resistance to FdUMP, have 
been determined.
1.14.2 Bacterial systems
In bacteria resistance to fluoropvrimidines has been
investigated during the course of experiments designed to 
elucidate the pathways of nucleotide metabolism (Neuhard & 
Nygaard, 1987; O ’Donovan & Neuhard, 1970). In contrast to 
mammalian systems, only one mechanism of drug resistance 
has been described, namely the prevention of activation.
Mutant strains of E.coli that lack uracilphosphoribosyl- 
transferase activity are resitant to FU. Strains with an 
additional deficiency in uridine kinase, are also resistant
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to FUR, but remain sensitive to FUdR (Neuhard & Nygaard, 
1987). Strains that lack TK are not resistant to FUdR 
(O’Donovan & Neuhard, 1970), but mutants that lack TdRPase 
and URPase activity in addition to a deficiency in TK 
activity, are resistant to FUdR (Neuhard & Nygaard, 1987). 
Some strains of E.coli and Streptococcus faecalis resistant 
to FU have been shown to lack URPase activity and show 
decreased incorporation of FU into RNA respectively 
(Brockman et al., 1960; Brockman & Law, 1960).
The overproduction of TS leading to resistance to FU has 
not been studied in bacteria. However, at least two 
strains of L.casei have been isolated that are resistant to 
the DHFR inhibitors MTX and dichloromethotrexate. These 
overproduce both DHFR and TS 100-fold, by the process of 
gene amplification (Crusberg et a l ., 1970). Extracts of
S .faecalis resistant to MTX also show increased levels of 
DHFR and TS (Suolinna et al., 1967). Such strains would be 
expected to show resistance to FU when compared with the 
parental strains from which they were derived.
More importantly, the Lactobacillus strains were 
instrumental in many of the studies of T S , because they 
provided high levels of enzyme at a time preceeding the 
modern techniques that allow the high-level expression of 
proteins (see Sections 1.6 and 1.7).
1.15 Aims of the project
The aim of the project was to develop a system, 
employing random mutagenesis techniques, to allow the 
isolation of variants of VZV TS that were resistant to one 
or more of a range of nucleoside analogues. The identif­
ication of the amino acid changes in these variants would 
yield information as to which residues were involved in 
substrate recognition and binding.
As a complementary approach, we chose site-directed 
mutagenesis to explore the roles of secondary structure 
elements which early investigations had suggested could be 
functionally important.
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2. MATERIALS AND METHODS
2.1 Bacteria and bacteriophage
2.1.1 Bacterial strains
Strain Genotype, source and reference
BW313 relAl, spoTl, dut-1, ung-1, thi-1, Hfr
KL16(P04 5 )
R.Hayward, University of Edinburgh; Kunkel 
(1985)
0600 F" , thil, thrl, leuB6, lacYl, tonA21, supE44,
( tdk) Laboratory Stock; Appleyard, 1954
tdk variant; Kaehler (1984).
CB158 mutD
Laboratory stock; Degnen & Cox (1974).
CJ236 dutl, ungl, thil, relAl / pCJ105
P.O.Huang, John Hopkins University; Kunkel 
(1984); Joyce & Grindley (1984)
DH5a supE44, A  ( argF-lacZYA) U169, hsdRIT, recAl,
endAl, gyrA96, thi-1, relAl, (0&Ola.cZ Ml 5,)
BRL; Hanahan (1983).
JM101 supE44, thi, A(lac-proAB) / F ’[traD36, proAB* ,
lacI9,lacZ Ml 5}
Laboratory stock; Messing (1983)
JM109 recAl, supE44, endAl, hsdR17, gyrA96, relAl,
thi, (lac-proAB) / F ’[traD36, proAB+, lacl**, 
lacZ M15]
Laboratory stock 
MCI 061* hsdR, mcrAB, araDl39, & (araABC-leu) 7679,
lac X74, galU, galK, rpsL, thil 
Laboratory stock; Meissner et a l . (1987)
RZ1032 relAl, spoTl, dutl, ungl, thil, supE44,
zbd-2 79::Tnl0, Hfr KL16(P045)
R.Hayward, University of Edinburgh;
Kunkel (1985)
S0928* Adeo-11 ( = A  deoA,B,C,D), lac, thil, uppl, udpl,
tonA,
B.Mygind, University of Kobenhavn;
Valentin-Hansen et al. (1978)
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TGI supE44, hsd 5, thil, A( lac-proAB) / F*[traD36,
proAB*, lacl*, lacZ M15]
Amersham; Gibson, (1984)
W3110 lacI*Ls
Laboratory stock; Brent & Ptashne (1981)
XL-1* supE44, hsdR17, recAl, endAl, gyrA96, thil,
relAl, lac- / F ’[ proAB* , lacl* , lacZ M15 TnlO ] 
Stratagene; Bullock et a l .. (1987)
#2913 thyA 752
E.coli Genetic Stock Centre;
R. Curtiss (personal communication)
Note: thyA derivatives were made of strains marked *
as described (see Section 2.7.2).
2.1.2 Bacteriophage
Bacteriophage M13R408 (Russel et al ., 1986) was provided 
by J. Mottram, University of Glasgow. Bacteriophage M13K07 
(Vieira & Messing, 1987) was a laboratory stock.
2.2 Plasmids
2.2.1 Plasmids provided
PIasmid Source & Reference
pBS+/pBS- Stratagene
Fernandez et al. 1987 
pCB105 D. Sherratt, University of Glasgow;
Boyd & Sherratt (1986) 
pGEM3Zf+/- Promega
Dotto et al . (1984 )
PGL271 A/coI-Z/indll I fragment from VZV E’coRI m
cloned into pKK240-ll;
R. Thompson, University of Glasgow; 
Thompson et al. (1987)
PTMORF36.1 1043bp fragment containing VZV orf36 (TK) 
cloned into pKK233-2;
T. McKee, University of Glasgow;
McKee (1990)
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pUCl9-HTS Human TS cloned under the control of an 
L.casei promoter;
P. J. Greene and D. V. Santi, University of 
California, San Francisco (personal 
communication)
2 .2 . 2  
Plasmid 
pADl13
pAD203
pAD301
PAD403
PAD507
PAD601 
PAD768 
pAD87 6
PAD901 
(pCBTK3
Plasmid constructs
Details
TS containing PcoRI fragment of pGL271 
cloned into pBS+ (contains a C787T 
nucleotide substitution in the pBS+ 
backbone (numbering of pBS+)
TS containing EcoRI/Xbal fragment of pAD113 
cloned into pGEM-3Zf(+) previously digested 
with EcoRI/Xbal
rrnB containing HincII/PstI fragment of 
pGL271 cloned into pAD203 previously 
digested with Pindlll and PstI, the Hindlll 
overhanging end converted to a blunt end 
TS containing BanMI/Hindlll fragment of 
pAD113 cloned into BanMI/Hindlll digested 
pBS- (contains the mutations A-48G, A-47T; 
see pAD768)
TK containing EcoRI/Hindlll fragment of 
pTMORF36.1 was cloned into pBS+ previously 
digested with EcoRI/Hindi 11 
Constructed exactly as pAD507 except that 
pBS- was used
Oligo 68 was used to change the promoter of 
pAD403 by site-directed mutagenesis 
The human TS containing Sacl/Hindlll 
fragment of pHTS-pUC19 was cloned into pBS- 
previously digested with Sacl/Hindlll 
The BanMI/Hindlll fragment of pVZVTK+5 
1 (pAD507/52 - see Section 3.4.i) was cloned
into pCB105 previously digested with 
BanMI/Hindlll
76
2.3 Bacterial growth media
2.3.1 Liquid media
Luria-Bertani Medium (LB)
Per litre: 
lOg NaCl
lOg Bactopeptone 
5g yeast extract 
Adjusted to pH7.0 
prior to sterilization
Per litre:
Adjusted to pH7.0 
prior to sterilization
2xYT Medium (2 Y T )
16g Bactotryptone 
lOg yeast extract
5g NaCl
Minimal Medium (M9) 
Per 400ml:
300ml H2O
M9fx51 salts 
Per litre:
64g Na2 HPO4 . 7H2 0
80ml M9[x5] salts (see below) 15g KH2PO4
20ml 15% casamino acids 
4ml 20% glucose
5g NH4C1 
2 . 5g NaCl
500pl 1M MgCl2
lOOyl 0.8mg/ml thiamine
2.3.2 Solid nedia
LB
As above except supplemented with 15g Bacto-agar
As above except 300ml H20 replaced by 300ml 
2% Bacto-agar 
Top Agar (T A )
Per Litre:
7g Bacto-agar
2.4 Chemicals, drugs, radiochemicals and enzymes
2.4.1 Chemicals
All chemicals were purchased from BDH or Sigma Chemical 
Company except where stated below. Dimethyl-sulphoxide 
(DMSO) (spectophotometric grade) was from Fluka and was 
stored at -70 C in 1ml aliquots. N, N, N 9, AT '-tetramethyl- 
ethylenediamine (TEMED) and ammonium persulphate (APS) were 
from Bio-Rad. Bactopeptone, casamino acids and yeast
M9
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extract were from Difco. SeaPlaque and NuSeive agarose
were from FMC BioProducts. Organic solvents and acids were 
from May and Baker. Ecoscint A was from National 
Diagnostics. a-thio-dNTPs, dNTPs and ddNTPs were from 
Pharmacia. Glycogen was from Boehringer-Mannheim. Ethyl 
methanesulphonate (EMS) was from Koch-Light laboratories. 
Ampicillin was from Beecham research. Wacker silane GF38 
was purchased from Wacker Chemicals.
2.4.2 Drugs
All drugs not purchased from BDH or Sigma Chemical 
Company were the kind gift of Wellcome P L C . These included 
PYaraU, PYUdR, EYaraU, EYUdR, BVdU, FI AC and ACV, and were 
supplied as 40mM solutions in DMSO.
2.4.3 Radiochemicals
Radiochemicals were purchased from 
England Nuclear/DuPont as follows:
[a32P]dATP ~3,OOOmCi/mmol
[ a3 5 S ] dATP 
[tf32 P]dATP 
5-f 3 H ]dUMP 
[methyl-3 H ]TdR
[35S]Sequetide™
>1,OOOmCi/mmol 
>5,OOOmCi/mmol 
20mCi/mmol 
25mCi/mmol 
400pCi
Amersham and New
(PB10204 )
(SJ1304 ) 
(PB10218)
(TRK287) 
(TRK120) 
(NEG-034N)
2.4.4 Enzymes
T4 DNA ligase and restriction enzymes were from 
Boehringer-Mannheim and the manufacturers SuRE/cut buffer 
system was employed. T7 DNA polymerase and T4 gene 32 
protein were from Pharmacia. RNase A and lysozyme were 
from Sigma. T4 DNA polymerase and T4 polynucleotide kinase 
were from New England Biolabs. Reverse transcriptase was
from Life Sciences Incorporated. Sequenase™ from United
States Biochemicals (including sequencing solutions) and 
the large fragment of DNA polymerase I (Klenow) was from
Northumbria Biologicals Limited.
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2.5 Commonly used buffers
TBE 90mM Tris, 90mM boric acid, ImM EDTA
TE lOmM Tris-Cl pH8.0, ImM EDTA
0/CHC13 phenol/chloroform 1:1 (v /v)
0/TE phenol equilibrated with TE
5xRTB 250mM Tris-Cl p H 8 .3, 30mM MgCl2, 300mM K C 1 ,
5mM DTT, 450pg/mL BSA 
lOxKB 1M Tris-Cl pH8.0, lOOmM MgCl2 , 70mM DTT 
1 Ox 660mM Tris-Cl pH7.5, lOOmM MgCl2 , lOmM ATP,
ligase 1OmM DTT 
buffer
lOxNTB 500mM Tris-Cl pH7.2, lOOmM MgS04 , ImM DTT, 
500mg/ml BSA
20xSSC 175.3g/l NaCl, 88.2g/l Trisodium citrate, pH7.0 
50xDHB 10g/l Ficoll, 10g/l polyvinylpyrrolidone,
10g/l BSA (filtered through Whatman paper).
2.6 Growth and maintenance of bacteria and
bacteriophage
2.6.1 Bacteria
2.6. 1.1 Laboratory stocks of E.coli
25pl of a glycerol stock of each laboratory strain of 
strain of E.coli was used to inoculate 5ml LB, 
supplemented with antibiotics as appropriate, and 
incubated overnight at 37°C, A 10pl loopful of the culture 
was streaked for single colonies on selective plates and 
incubated overnight at 37'C. A well isolated single colony 
was used to make a fresh glycerol stock.
2. 6.1.2 New strains of E.coli
New strains provided by the E.coli Genetic Stock Centre 
on filter discs were placed on LB plates and moistened with 
a few drops of sterile H2O and streaked for single colonies 
and incubated overnight at 37°C. Isolated single colonies 
were streaked onto selective media, incubated overnight at 
37°C and well isolated single colonies used to make a 
glycerol stock. New strains, provided as glycerol stocks,
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were treated as above.
2. 6.1.3 Overnight cultures
A well isolated single colony, or 25pl of a glycerol 
stock was used to inoculate 5 or 10ml LB, supplemented with 
the appropriate antibiotics. The culture was incubated, 
with vigorous shaking, at 37*C overnight.
2 . 6.1.4 Glycerol stocks
A 10ml overnight culture of the appropriate clone was 
set up in a 15ml Falcon tube. Cells were pelleted by 
centrifugation at 3000rpm for lOmin in a Beckman GPR 
benchtop centrifuge. The cell pellet was resuspended in 
5ml 2% bactopeptone. 5ml 80% glycerol and 50pl lOOpg/ml 
TdR were added, mixed by repeated inversion and stored at 
-20° C.
2. 6.1.5 Antibiotics
Antibiotics were used at the following final 
concentrations, unless otherwise stated. Ampicillin (Amp) 
lOOpg/ml; Chloramphenicol (Cm) lOpg/ml; Tetracyclin (Tet) 
3 Opg/ml ) .
2.6.2 Bacteriophage
2.6.2.1 Titration of helper phage
10ml 2YT was inoculated with 1ml of an overnight culture 
(grown in 2YT) of E.coli TGI and incubated, with vigorous 
shaking, at 37 C for lh. 3mL aliquots of molten top agar 
were equilibrated to 45 “C in a waterbath. A series of 1:10 
dilutions of the helper phage were made in 2YT. 200pl
E.coli TGI and lOOpl of diluted helper phage (10-fold 
dilutions in the range 106 to 109 ) were mixed together,
added to the molten TA and immediately poured onto LB 
plates. Once the top agar 1 ayer solidified the plates were
incubated at 37*C overnight. Plaques were counted the
following day and the phage titre calculated.
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2 . 6.2.2 Growth of helper phage
100ml 2YT was inoculated with a single plaque of helper 
phage and incubated at 37*C, with vigorous shaking, 
overnight. The culture was cleared by centrifugation at 
9,000rpm at 4*C for lOmin. The supernatant was decanted to 
a fresh tube and recleared by centrifugation. This super­
natant was transferred to a 300ml bottle, heated at 55°C 
for 30min, allowed to cool to room temperature and stored 
at 4°C. The titre of the virus was determined as described 
above.
2.7 Bacterial manipulations
2.7.1 Transformation
Two methods were routinely used for the preparation of 
competent cells and transformation.
2. 7.1.1 Calcium chloride (Humphreys et a l . , 1979 ).
100ml LB was inoculated with 3ml of an appropriate 
standing overnight culture and incubated at 37'C, with 
vigorous shaking, until A6oo reached "0.3. Cells were 
pelleted by centrifugation at 9000rpm in a Sorvall SS34 for 
5min at 4°C prior to resuspension in 50ml ice-cold lOmM 
CaCl2 (supplemented with 50pg/ml TdR for thyA strains). 
The cells were re-pelleted as before and resuspended in 
50ml ice-cold 75mM CaCl2 . Cells were incubated for 30min 
on ice, repelleted and resuspended in 3ml 75mM CaCl2.
10 to lOOng DNA, in a small volume of H2 0 (<5pL), was 
added to 200pl competent cells and incubated on ice for 
30min prior to heat shock at 4 2 ’C for 2min. Cells were 
used to inoculate 3ml LB and incubated at 37*C, with 
vigorous shaking for lh. lOOpl was spread onto LB plates 
containing the appropriate antibiotic, and incubated at 
37 0 C overni ght.
2. 7.1.2 DMSO-PEG4000 (Chung and Miller, 1988).
20ml LB was inoculated with 1ml of an appropriate, 
standing overnight culture and incubated at 37*C, with 
vigorous shaking, until A600 reached -0.3. Cells were
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pelleted as above and resuspended in freshly prepared, ice- 
cold transformation and storage buffer (T S B ). TSB consists 
of 7.25ml LB, 2.0ml 50% PEG-4000, 500pl DMSO, lOOpl 1M
MgCl2 , lOOpl 1M MgS04 and 50pl T d R . Cells were incubated 
on ice for 15 to 30min prior to use.
10 to lOOng DNA, in a small volume of H2 O (<5pl), was 
added to 50pl competent cells and incubated on ice for 5 to 
30min. 450pl of TSB was added to the cells and 
incubated at 37#C for 30min to 2h. 100 to 200pl was spread
onto LB plates supplemented with the appropriate anti­
biotics and incubated at 37°C overnight.
For both methods a positive control ("10ng supercoiled 
plasmid DNA) and a negative control (no DNA) were included.
2.7.2 Generation of thyA strains of E.coli
2ml minimal media supplemented with TdR (lOOpg/ml) and 
trimethoprim (20pg/ml) was inoculated with 40pl of an 
appropriate overnight culture and incubated, with vigorous 
shaking, at 37°C overnight. 40pl of this culture was used 
to inoculate 2ml of fresh media and incubated as before. A 
single loopful of this culture was used to streak for 
single colonies on minimal media plates supplemented with 
TdR (1OOpg/ml) and incubated at 37eC overnight. Individual 
single colonies were patched onto minimal media plates and 
minimal media plates supplemented with TdR (lOOpg/ml) and 
incubated at 37‘C overnight. Colonies growing only on 
minimal media plate supplemented with TdR were classified 
as Thy" strains (Stacey & Simpson, 1965).
2.8 DNA isolation
2.8.1 Mini-prep plasmid DNA preparation
Mini-prep DNA was prepared from E.coli using the method 
of Maniatis et al., (1982). 1ml of an overnight culture 
was pelleted by centrifugation at ll,000rpm for 15s in a 
bench-top mini-centrifuge. The supernatant was discarded 
and the pellet resuspended in lOOpl fresh lysozyme solution 
(4mg/ml lysozyme, 50mM glucose, 25mM Tris-Cl p H 8 .0, lOmM
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EDTA pH8.0) and incubated at room temperature for 5min. 
200pl 0.2M NaOH, 1% SDS was added and incubated on ice for 
5min. 150pl potassium acetate solution (5.OM KOAc 60ml, 
glacial acetic acid 11.5ml, H2 O 28.5ml) was added, 
vortexed for 10s and incubated on ice for 5min. After 
centrifugation for 5min, the supernatant was removed and 
phenol extracted prior to ethanol precipitation. The 
lyophilised pellet was resuspended in 50pl H2O. 1 to 5pl 
was used for transformation or restriction enzyme analysis.
2.8.2 Midi-prep plasmid DNA preparation
This method was routinely used for the isolation of up 
to lOOpg DNA of purity comparable to caesium chloride 
banded DNA. The method utilizes the Q i a g e n ™  pack-100 
gravity flow DNA purification columns (Diagen). 100ml of 
LB, supplemented with the appropriate antibiotic, was 
inoculated with 1ml of an overnight culture and incubated 
at 37°C, with vigorous shaking, until A6 00 reached “0.6. 
Cells were harvested by centrifugation at 7,000rpm at 4*C 
for lOmin n a Sorvall GS3 rotor. The supernatant was 
discarded. The bacterial pellet was resuspended in 4ml 
buffer PI (25mM Tris-Cl p H 8 .0, lOmM EDTA p H 8 .0, 100pg/ml 
RNase A) and transferred into a disposable 30ml tube 
suitable for the Sorvall SS34 rotor. 4ml buffer P2 (200mM 
NaOH, 1% SDS) was added, mixed gently and incubated at RT 
for 5mi n . 4ml buffer P3 (2.55M KOAc p H 4 .8) was added, 
mixed gentJy and the sample immediately centrifuged at 
9,000rpm in a Sorvall SS34 at 4 0 C for 30min. A Q i a g e n ™  
pack-100 column was equilibrated with 2ml buffer QBT (750mM 
NaCl, 50mM 3-( AT-morphol i no )-propanesulphoni c acid (MOPS), 
15% EtOH, 0.15% Triton X-100 pH7.0). The supernatant was
applied directly to the pre-equi1ibrated column and left to 
flow through. The column was washed twice with 4mL 
aliquots of buffer QCT (l,500mM, 50mM MOPS, 15% EtOH, 0.15% 
Triton X-100 pH7.0). DNA was eluted with 2ml of buffer QFT 
(1500mM NaCl, 50mM MOPS, 15% EtOH, 0.15% Triton X-100 
PH8.0). DNA was precipitated with 0.8vol isopropanol, by 
centrifugation at 9,000rpm at 4*C for 30min in a Sorvall
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SS34 rotor. The lyophilised DNA pellet was resuspended in 
H20, and the concentration determined spectrophotometric- 
cally (1 A26O unit = 50pg/mL plasmid DNA).
2.8.3 Maxi-prep DNA plasmid preparation
350ml LB, supplemented with the appropriate antibiotic, 
was inoculated with 10ml of overnight culture and incubated 
at 37’C, with vigorous shaking, until A6 oo reached "0.6. 
175pl chloramphenicol (200mg/ml in EtOH) was added and the 
incubation continued overnight. Cells were harvested by 
centrifugation at 9,000rpm at 4'C for lOmin in a Sorvall 
GS3 rotor and the supernatant discarded.
Plasmid DNA was extracted by an adaptation of the 'maxi­
boiling technique’ of Holmes and Quigley (1981). The 
bacterial cell pellet was resuspended in 10ml STET (0.1M 
NaCl, lOmM Tris-Cl pH8.0, ImM EDTA pH8.0, 5.0% Triton X-
100). This was transferred to a 100ml flask containing 
15ml STET. 3ml of freshly prepared lysozyme solution 
(lOmg/ml) was added. The flask was heated over the flame 
of a Bunsen burner until Just boiling and transferred to a 
boiling water bath for 40s. The contents were transferred 
to tubes suitable for the Sorvall SS34 rotor and 
centrifuged at 18,000rpm at 4'C for 20min. The super­
natant was decanted into a 50ml Falcon tube. An equal 
volume of isopropanol was mixed with the supernatant and 
incubated at RT for 15min. After centrifugation, at 
3,000rpm for 15min, in a Beckman GPR tabletop centrifuge, 
the supernatant was discarded and the pellet dried well 
prior to being resuspended in 10.5ml H2O. CsCl was added 
to give a final density of 1.55g/mL. Ethidium bromide 
(EtBr) was added to a final concentration of 0.5mg/ml. The 
mixture was incubated on ice for lOmin and then cleared by 
centrifugation at 3,000rpm at 4 0 C for lOmin. The cleared 
supernatant was decanted to a quick-seal tube and the DNA 
was banded by ultra-centrifugation at 40,000rpm at 15‘C 
for 48h in an angled Ti50 rotor. DNA was visualized by 
long-wave UV illumination and the lower, supercoiled 
plasmid DNA band, was removed with a large gauge needle and
84
syringe. DNA was extracted twice with water saturated 
butan-l-ol and dialysed against water for 5h at RT. After 
ethanol precipitation, the pellet was washed, dried and 
resuspeded in H 2 O. The DNA concentration was determined 
spectrophotometrically.
2.8.4 ssDNA preparation from phagemid vectors
2.8.4.1 Midi-scale ssDNA preparation
ssDNA was prepared essentially as described (Dente et 
al. , 1985). 20ml 2YT in a 50ml Falcon tube, was inoculated 
with 660pl overnight culture (grown in 2YT) and incubated
with vigorous shaking at 37°C, until A6 00 reached ~0.28- 
0.30. The helper phage M13R408 was added at a 
multiplicity of infection (moi) of 20:1 (assuming a 
bacterial cell density of '2.5x10s cells/ml at A600 '0.28- 
0.30) and the culture was incubated for a further 8h. The 
culture was cleared by two centrifugation steps at 9,000rpm
at 4 * C for lOmin in a Sorvall SS34 rotor. The bacterial
cell pellet was discarded. The cleared supernatant was 
stored at 4'C or processed immediately.
A quarter volume of 3.75M NH4OAc/20%PEG-6000 was added 
to the supernatant, vortexed briefly and the solution 
incubated on ice for 30min. The ssDNA and phage were 
pelleted by centrifugation at 9,000rpm at 4 ‘C for 20min. 
The supernatant was discarded and the walls of the tube 
dried thoroughly with a tissue. The pellet was resuspended 
in 200 to 400pl T E , and CHCI3 extracted twice. The DNA was 
repeatedly extracted with O/CHCI3 until there was no
material visible at the interface. A final CHCI3 
extraction was performed prior to NH4 0Ac/Et0H precipit­
ation. The lyophilised DNA pellet was resuspended in H20, 
and the concentration determined spectrophotometrically 
(1 A260 unit = 40pg/ml ssDNA).
2.8.4.2 Maxi-scale ssDNA preparation
This method is essentially the same as the midi-scale 
method except as follows. 200ml of 2YT, in a 21 baffled 
flask, was inoculated with 6.6ml overnight culture and
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incubated and infected with helper phage as before. The
supernatant was cleared by two centrifugation steps using a 
Sorvall GS3 rotor. The ssDNA was purified as described in 
above.
2.8.5 Plasmid DNA sequencing preparations
The following method of DNA preparation is that of
Ha"tori and Sakaki (1986). 1ml of overnight culture was 
treated exactly the same as in 2.8.1, except that the final 
DNA pellet was resuspended in 50pl T E . RNaseA was added to 
a final concentration of lOpg/ml and incubated at 37°C for 
30min, 30pl 20% PEG-6000/2. 5M NaCl was added, mixed
thoroughly by vortexing and incubated on ice for lh. After 
a lOmin spin, the DNA pellet was washed, lyophilised and 
resuspended in 18pl T E . To denature the DNA, 2pl 2M NaOH
was added and incubated for 5min at R T . 1 OOpl 100% EtOH
and 8p] 5M NH4 OAc were added and incubated in a dry ice 
bath for lOmin, followed by lOmin centrifugation. The DNA 
pellet was washed with 75% EtOH, lyophilized and 
resuspended in 20p] H2O. 2 to 4pl was used directly for
sequencing or stored at -20°C.
2.9 DNA manipulations
2.9.1 Restriction enzyme digests
Restriction enzyme digests were usually performed in 10 
or 20pl reaction volumes. Restriction enzymes were added 
at a concent rat ion of 1 to 10 units (U)/pg DNA and
incubations performed at 37 eC for 1 to 4h or overnight.
Commercial restriction enzyme buffers were usually provided 
as 10x solutions and were diluted appropriately. When 
mini-prep DNA was digested, RNase A was added at a final 
concentration of 50pg/ml. For cloning experiments, DNA was 
always 0 /CHCI3 extracted and ethanol precipitated prior to 
use.
2.9.2 Removal of 5*-phosphate groups
1U of calf intestinal phosphatase (CIP) was added to the
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restriction digest reactions when digestion was complete. 
After incubation at 37'C for 30min, CIP was inactivated by 
incubation at 70*C for 15min. DNA was extracted with 
0/CHC13 and ethanol precipitation.
2.9.3 Isolation of DNA fragments from agarose gels
2.9.3.1 Electroelution
The DNA fragment to be isolated was visualised by long­
wave UV illumination, excised using a scalpel and trans­
ferred to a piece of dialysis tubing containing approx­
imately 1ml of 0.5xTBE. The dialysis tubing was placed
in a BRL gel electrophoresis kit perpendicular to the 
current flow. Electrophoresis was performed at 200V in
0.5xTBE for lh. Successful elution was determined
visually by long-wave UV illumination. Electrophoresis at
200V for 20 to 30s with reverse polarity was performed to
release DNA from the side of the dialysis tubing. DNA was 
removed from the dialysis tubing and mixed with 0.05 vol 
1.0M MOPS (pH7.0) and 0.1 vol 5. 0M NaCl. DNA was purified 
using a QIAGEN-tip 5 (Diagen). The QIAGEN-tip 5 was 
equilibrated by repeatedly pipetting 300j.il buffer A (400mM 
NaCl, 50mM MOPS, 15% EtOH pHT.O) in and out. A syringe was 
used to force the DNA sample through at a flow rate of 
~ 250j.il/min the QIAGEN-tip 5 was washed by pipetting 750pl 
buffer B (750mM NaCl, 50mM MOPS, 15% EtOH pH7.0) in and out 
five times using fresh buffer each time. The DNA was 
finally eluted by pipetting 200jil. buffer F (1500mM NaCl, 
50mM MOPS, 15% EtOH pH? . 5 ) in and out three times. This 
process was repeated twice and the eluat.es pooled. DNA was 
precipitated using O.fi vols isopropanol.
2. 9.3.2 Low melting point agarose
DNA was excised as described above from a 1% agarose gel 
made from SeaPlaque low melting point agarose. The gel 
piece was transferred to a 1.5ml eppendorf tube, covered 
with TE and incubated at 65*C for lOmin. 0/TE, prewarmed 
to 65*C, was used to extract the DNA twice. A third 
extraction was performed using 0/TE equilibrated to R T .
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After 0/CHC13 extraction, DNA was ethanol precipitated
using glycogen (final concentration - 20pg/ml) as a carrier.
2.9.3.3 Use of NA45 ion-exchange Membrane
One half of an NA45 ion-exchange membrane (Schleicher 
and Schuelk, N ‘ 417006) was pre-treated in accordance with 
the method of Dretzen et a l . (1981). After a brief wash in
H2O, the filter was washed once in TEN (TE with NaCl at a
final concentration of 1M), then four times in T E . A small
slit was made in the gel with a single edged razor blade 
just in front of the band to be eluted. The pretreated 
filter was inserted into the slit and electrophoresis
continued for 10 to 20min. The filter was removed and the 
presence of DNA bound to the filter was confirmed by brief 
long-wave UV illumination. DNA was eluted by incubation at 
37#C for lh in 250pl TEN. Buffer was removed to a fresh 
tube and a further 150pl TEN added to the membrane for 
incubation at 37#C for lh. The two aliquots of TEN 
containing the DNA were pooled and successful elution 
confirmed by visualization with long-wave UV. The pooled 
DNA sample was passed through glass wool packed in a Gilson 
P1000 tip. To maximise recovery, the tip was placed into a 
15m] disposable tube and centrifuged at l,000rpm for 2min 
in a Beckman GPR tabletop centrifuge. The DNA was ethanol 
precipitated using glycogen as a carrier.
2.9.4 Conversion of 5*-overhangs to blunt ends
Protruding 5 ’ overhangs, generated by restriction 
endonuclease treatment of plasmid DNA, were converted to 
blunt ends using the method described by Maniatis et al. 
(1982). 500 to lOOOng of completely digested DNA was
0/CHCI3 extracted, ethanol precipitated and resuspended in 
10pl H2O. To this was added lpl 2mM dNTPs, 2.5pl lOxNTB, 
2U of the Klenow fragment of DNA polymerase I and the 
volume adjusted to 25pl with H2O. After incubation at 22*C 
for 30min, the enzyme was inactivated by incubation at 70*C 
for 5min. DNA was 0 /CHCI3 extracted and excess dNTPs 
removed by two ethanol precipitations.
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2.9.5 DNA ligation
Ligations were usually performed in a total volume of 
lOpl. lOOng vector and lOOng DNA fragment to be insert 
were mixed with lpl lOxLB (Boehringer-Mannheim) or 2pl 5xLB 
(BRL), 1 . OyL (1U) T4 DNA ligase and the volume adjusted to 
lOpl with H2O. The ligation reaction was incubated at 16‘C 
overnight. 1 to 3pl was used for transformation of E.coli.
2.9.6 Gapped duplex DNA (gdDNA) synthesis
gdDNA was synthesized essentially as described (Kramer & 
Fritz, 1987). pAD113 was digested with HindXII and Ncol 
and the largest DNA fragment isolated from a 1% agarose gel 
(see Section 2.9.3). Uracil enriched, single-stranded 
(U-ss) pAD113 was separated from M13R408 helper phage in 
the same way. The concentration of the purified fragments 
was estimated by running them against samples of known 
concentration on a 1% agarose gel. gdDNA was formed by 
mixing 500ng U-ssDNA with l,250ng Hiri<\l II/Ncol fragment in 
30jj1 buffer containing 187. 5mM K C 1 , 12. 5mM Tris-Cl pH7.4
The mixture was boiled at 100*C for 3min, incubated at 6 5 *C 
for 8min and allowed to cool to room temperature over a 
period of 20 to 3 0min.
2.10 Oligonucleotides
2.10.1 Synthesis and purification
Oligonucleotides synthesized on the Biosearch 8600 DNA 
synthesizer were provided in 1 ml of ammoniacal solution. 
This was heated at 55°C for 5h and subsequently lyophilized 
overnight. The pellet was resuspended in 50pl H2O and 30pl 
was stored at -20°C. The remaining 20pl was mixed with 
20pl loading buffer without dyes (lxTBE, 90X formamide). 
The sample was boiled for 2 to 3min prior to gel electro­
phoresis through a 15% polyacrylamide gel (acrylamide: 
bisacrylamide 29:1) containing 8M urea. 4pl stop solution 
(see Section 2.13.1.1) was loaded in a separate well to 
provide tracking dyes. Electrophoresis was performed at 
250V. For ol igonucleot ies of length 15 to 32 bases in
89
length, the BPB was allowed to migrate 2 /z of the way 
through the gel. For oligonucleotides 42-57 bases in 
length the BPB was allowed to migrate to the end of the 
gel. To isolate the oligonucleotides, the gel was removed 
from the glass plates and wrapped in cling film. DNA was 
visualized by illumination of the gel, whilst on a thin 
layer chromatography (T L C ) plate, using a shortwave UV 
lamp. The DNA appears as a dark band against a uniform 
fluorescent background on the TLC plate. The band Was 
excised from the gel and eluted in lmL H2 0 by overnight 
incubation at 37*C. The DNA solution was butan-2-ol 
extracted twice to reduce the volume prior to EtOH/NaOAc 
precipitation. The DNA pellet was resuspended in 50yl H2 0 
and the concentration determined spectrophotometrically 
(1 A260 unit = 20pg/ml oligonucleotide).
Oligonucleotides synthesized on the Applied Biosystems 
394/4 4 column DNA synthesizer were provided in 200pl of 
ammoniacal solution. This was incubated at 55°C overnight. 
After 15s centrifugation the solution was decanted to a 
fresh tube. 0.1vol 3M NaOAc and 2.5vol ethanol were added 
and incubated at -70°C for lOmin. After a 5min spin in a 
microcentrifuge, the supernatant discarded and the pellet 
was rinsed with 70% ethanol before lyophilization. The 
pellet was resuspended in 200pl T E , 160pl of which was
stored as a crude extract at -20°C. The remaining solution 
was ethanol precipitated as before. The final pellet was 
resuspended in 50pl TE and the concentration determined 
spectrophotometrical1y .
As many of the oligonucleotides were subsequently phos- 
phorlylated, ethanol precipitation was performed using 
NaOAc rather than NH4O A c , as NH4+ ions can inhibit T4 poly­
nucleotide kinase (Sambrook et al ., 1989).
2.10.2 Synthesis of spiked oligonucleotides
These oligos were synthesized on the Biosearch 8600 DNA 
synthesizer using phosphoramidite mixes containing 96% of 
the normal nucleotide and 1.33% of the other three 
nucleotides (see Section 3.1).
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2.10.3 Radioactive 5*end labelling of oligonucleotides
100 to 200ng oligonucleotide was labelled with 5pl 
[gamma-32P] dATP using 1U T4 polynucleotide kinase in lxKB 
in a final volume of 25pl at 37°C for 30min. The volume 
was adjusted to lOOpl with H2O and the oligonucleotide was 
ethanol precipitated twice, using glycogen as a carrier. 
The final pellet was resuspended in 20pl H 2 0 and was 
immediately used as a probe for hybridization.
2.10.4 01igonucleotide sequences
A complete list and sequences of the oligonucleotides 
used in this project are shown here.
2.10.4.1 Site-directed mutagenesis oligos
mber Sequence Mutation
52 TCAAACTGCTTACGAAGCATG S288L(VZV TK)
57 GAGCTTGCATTGCAAATAAAG G48A
58 GTATCGAGCTTGGGGGGGTGCAAATAAAG G4 8A/M49P/49P50
68 CCACACATTATACGAGCCG promoter
69 AATCCATTATTACTCCATTTCC L301A/A300E
70 CTTGTTTTAAGTGCTGAAGTTCGC Y21H
72 GAGCTGCAGCACCTGGGGCAG Y33H (Human T S )
AR1 a a t c c a t t a t t a a g c c a t W c c L301A
AR2 AGCCATTGGCATTTTTAGGGG E298P
67 GTTAAAAGAGGAAACGTTTCATTTCGC 58T59
~ Nucl^eo^tTdes Tn ^BoTd type^face represent substitutions, 
whilst nucleotides in bold underlined type-face represent 
insertions. The mutations refer to the amino acid changes 
the oligo was designed to introduced and apply to the VZV 
TS gene, unless otherwise stated. S288L represents the 
substitution of Ser at position 288 by Leu. 48P49 
represents the insertion of Pro between amino acids 48 and 
49.
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2.10.4.2 Sequencing oligos
Number Sequence
3 TATTCTGAAATGAGC
4 GGAATCGGAACGTTA
5 ATAGGAATGGCTTCC
6 GGATATCCCCTTAAT
7 GGGGATGCACATATT
5 3 TGGGATTGAAGACAC (VZV T K )
59 GTCTGTGTATATCAT
60 CCATTGTATGAATTA
61 TTTAATTGTATCTAT
62 CCACGACGGCCCTCC
74 CATCTCTCAGGCTGTAGCGCG (Human T S )
56 CAATGTTGAACGGTAC
These oligos were used as sequencing oligos of the VZV 
TS gene unless otherwise indicated.
2.10.4.3 Spiked oligos
Number Sequence Targeted Size
R01 109 to 165 (57)
R02 160 to 213 (54 )
R0 3 208 to 249 (42)
R0 4 241 to 297 (57)
R05 466 to 513 ( 48 )
R06 499 to 546 (48)
R0 7 535 to 579 (45 )
R08 574 to 621 (48)
R09 613 to 666 ( 54 )
RIO 655 to 708 ( 54 )
Rll 700 to 753 ( 54 )
The numbering system refers to the VZV TS gene, with 
nucleotide +1 referring to the A in the ATG codon 
specifying the first methionine residue (see also 
Fig. 3.4).
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2.11 Mutagenesis
2.11.1 Chemical mutagenesis
2.11.1.1 Ethyl methanesulphonate
30ml LB was inoculated with 1ml E.coli GL271 (^C 2913
transformed with pGL271 ) overnight culture and incubated 
at 37‘C, with vigorous shaking until A6 o o reached -0.6 
(4xl08 cells/ml). 10ml was pelleted by centrifugation at 
9,000rpm for 5min at 4°C in a Sorvall SS34 rotor and 
resuspended in 5ml M9 medium. The cells were repelleted 
and then resuspended in a fresh 5ml aliquot of M9 medium. 
50pl EMS (100%) was added, mixed by vortexing and incubated 
at 37*C for 15min. The cells were repelleted as before 
and resuspended in 5ml LB. Twelve lOOpl aliquots were used 
to inoculate twelve 10ml LB overnight cultures. Mini-prep 
DNA was prepared from each of the overnight cultures. The 
mutagenized DNA was used to transform E.coli 2913.
2.11.1.2 Hydroxylamine
3 to 5 i-i g plasmid DNA, in lOOpL buffer containing 0.4M 
hydroxylamine, 50mM sodium phosphate (pH6.0), and ImM 
EDTA, was incubated at 75 °C for 30 or 60 min. A spin-X 
tube (Costar) was loaded with 1 to 2ml of Sephadex G25 
slurry in TE containing 0.02% NaN3 to form a desalting 
column. The column was washed four times with T E . DNA was 
loaded onto the column and forced through by centrifugation 
for 20 to 30s in a microcentrifuge. DNA was ethanol 
precipitated, dried and resuspended in 10 to 20pl H2O. 
1 to 2pl was used to transform E.coli 512913 or MC1061 thyA.
2.11.1.3 Sodium bisulphite
The following method for mutagenesis was based on those 
of Pine and Huang (1987). 2.5 to 25pg ssDNA or 2 to 5pg
gdDNA were mutagenized in 1ml buffer containing 3M sodium 
bisulphite (mixture of Na2SO3/NaHS03), 0.5mM hydroquinone, 
3.75M NaCl, 0.375mM tri-sodium citrate by incubation at
37 C, in the dark, for 1 to 4h. The reaction was 
terminated by the following sequence of dialysis steps:
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1 11 5mM potassium phosphate (pH6.0), 0.5mM hydroquinone 
at 4 °C for 2h.
2 As step 1.
3 11 5mM potassium phosphate (pH6.0) at 4*C for 2h.
4 11 0.2M Tris-Cl(p H 9 .2), 50mM NaCl, 2mM EDTA at 37°C 
for 16 to 24h.
5 11 2mM Tris-Cl(pH8.0), 2mM NaCl, 2mM EDTA at 4 9C 
for 6 to 12 h .
DNA was recovered from the dialysis tubing and ethanol 
precipitated using glycogen as a carrier. 1 to 2pg gdDNA 
was made completely double stranded in lOpL IxLB (B R L ) 
containing 2U Klenow fragment of DNA polymerase I, 1U T4 
DNA ligase, 1 to 2pg T4 gene 32 protein and 0. 5mM dNTPs 
incubated at room temperature for 2h. 1 to 5jj1 was used to
transform E.coli. ssDNA was made completely double 
stranded using phosphorylated oligo 3 as a primer for 
second strand synthesis (see section 2.11.3). Alter­
natively, ssDNA was made completely double-stranded in vivo 
by being used to transform E.coli BW313, and mini-prep 
dsDNA extracted from these bacteria. 1 to 5pl dsDNA was 
used to transform E.coli XL-1thyA or S0928thyA.
2 . 1 1 . 2 Growth in a mutator strain
50pl of an overnight culture of E.coli CB158 containing 
pGL271 was used to inoculate either 10ml LB supplemented 
with ampicillin, 10ml M9 media supplemented with ampicllin 
or 10ml M9 media supplemented with ampicillin and FUdR 
( 5jjM ) , and incubated overnight at 37 °C with vigorous 
shaking, 50pl of each overnight culture was used to 
inoculate 10ml of the fresh corresponding media and were 
incubated overnight at 37 °C with vigorous shaking. The 
process was continued until 5 growth 'cycles1 had been 
completed. DNA was extracted from each of the three final 
cultures and used to transform E.coli.
2.11.3 Oligonucleotide directed mutagenesis
Oligonucleotides were used to introduce defined 
mutations at. specific sites or mutations at random across a
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short targeted region essentially as described by Mead et 
al. ( 1986), with slight modifications (Nick Davis-Poynter,
personal communication). The strand selection scheme of 
Kiinkel was employed in which a uracil-containing template 
strand is degraded in an ung* host strain (Kiinkel, 1985; 
Kiinkel et al. , 1987). lnmol oligonucleotide was phosphor-
ylated in 20pl of IxKB containing 1U T4 polynucleotide 
kinase at 37°C for 30min. T4 polynucleotide kinase was 
inactivated by incubation at 70*0 for 15min. The phosphdr- 
vlated oligonucleotide was diluted in H20 to a final 
concentration of 5pmol/pl and stored at -20‘C. lpl phos- 
phorvlated oligonucleotide was annealed to 2pl (O.lpmol) 
U-ssDNA (see below) in lOpl buffer containing lOmM Tris-Cl 
pH8.0 and lOmM MgCl2 at 37°C for 30min, or at 55°C for 
5min and cooled slowly to room temperature. To generate 
dsDNA, lpl 5mM dNTP mix (a 5mM solution of all four dNTPs), 
2pL lOxLB, 5U Klenow fragment of DNA polymerase I, 1U T4 
DNA ligase, 2. Opg T4 gene 32 protein and H2 0 to a final 
volume of 20pL. After 2h incubation at R T , a further 5U 
Klenow fragment of DNA polymerase I and 1U T4 DNA ligase 
were added and incubated at RT for another 2 h . The DNA
was stored at -20°C or 1 to 5pl used to transform E.coli.
U-ssDNA was made in exactly the same manner as ssDNA
(see Section 2.8.4) except DNA was propagated in either 
E.coli BW 313 , RZ1 032 or CJ236.
2.11.4 Misincorporation mutagenesis
The following method was based upon that of Lehtovaara 
et al. (1988) with modifications based upon the protocol of
Shiraishi and Shimura (1988). 5pmol phosphorylated 
oligonucleotide was annealed to 2.5pmol U-ssDNA in 25pl 
15mM Tris-Cl pH8.0, 7.5mM MgCl2 by incubation at 37'C for
30 min. 155pl 15mM Tris-Cl pH8.0, 7. 5mM MgCl2 was added
and the sample divided into twelve 15pl aliquots. These
wore sub-divided into four groups of three and referred to 
as A*, C~ , G" and T- (N~ col lect ively) . 3 . Opl of the
appropriate N~ reaction mix (see below) was added to each 
aliquot. 2. Op] of one of three concentrations of the
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appropriate limiting nucleotide was added (0.75, 2.0 and
3.25pM). Each reaction was initiated by the addition of 2U 
Klenow fragment of DNA polymerase I, incubated at room 
temperature for 5min, and terminated by the addition of
1. 5pl 0.25M EDTA. The three tubes from each group were
pooled, 0/CHC13 extracted and ethanol precipitated three 
times (to remove free nucleotides) in the presence of 2. 5M 
NH4OAC using glycogen as a (20pg/ml) carrier. The final
pellet was washed with 75% ethanol and lyophilized.
Two methods were used for the misincorporation of
nucleotides and subsequent complete second strand synthesis 
and ligation. The first method was based on that of 
Lehetovaara (1988). Each of the four DNA samples (A*, C " ,
G" and T~ ), was resuspended in lOpL dH20 and 6. 3pL 5xRTB,
12.4pl of the appropriate misincorporation mix (misinc N 
mix) and 10U RT were added. Samples were incubated at 37 *C 
for 1.5h. A further 10U reverse RT were added and
incubation continued for 1 . 5 h . 3 . 5pl 5mM dNTPs were
added to all four tubes and incubated at 37°C for 30min.
15pl 5x RTB, 4pl (10U) Klenow fragment of DNA polymerase I, 
14pl (14U) T4 DNA ligase, 2pl (7pg) T4 gene 32 protein and 
7 pi 5mM ATP were added to each tube. After mixing, the 
contents were divided between two tubes and incubated at 
14 °C overnight. DNA was stored at -20 0 C . 1 to 5pl DNA was
used to transform bacteria.
The N" reaction mixes used were as follows:
A' reaction mix 3.3mM dNTPs except dATP
Cr reaction mix 3.3mM dNTPs except dCTP 
G" reaction mix 3.3mM dNTPs except dGTP
T" reaction mix 3.3mM dNTPs except dTTP
The misincorporation mixes (misinc-N-mix) used were as 
f ollows:
Misinc-A-mix 75pM dCTP, 0.4pM dGTP, 200pM dTTP
Misinc-C-mix 200pM dATP, 50pM dGTP, lpM dTTP
Misinc-G-mix 50pM dATP, 250pM dCTP, 100pM dTTP
Misinc-T-mix 50pM dATP, lOOpM dCTP, 200pM dGtTP
The second method was based upon that of Shiraishi and 
Shimura ( 1988). Each of the four samples was resuspended
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in 20pl H2 0 and divided into four 5pl aliquots, one each 
for the misincorporation of the four different a-thio 
dNTPs. Misincorporation was performed in 20pl of 130mM N- 
2-hydroxyethylpiperazine-AT '-2-ethanesulphonic acid (HEPES) 
pH7.6, 0.2mM MnCl2 , 2mM B-mercaptoethanol (B-ME), O.lmg/ml 
BSA, O.lmM a-thio dNTP and Klenow fragment of DNA 
polymerase I (1U) at 25°C overnight. 6.Opl 5xLB, 2.5pl 
(5U) Klenow, 1 . Opl T4 DNA ligase, 0.5pl (2pg) T4 gene 32
protein and lpl 5mM dNTPs were added and incubated for '2h 
at RT. A further 5U Klenow fragment of DNA polymerase I 
and 1U T4 DNA ligase were added, and the incubation 
continued for a further 2h. DNA was stored at -20°C. 1 to
5pl DNA was used to transform bacteria.
2.12 Mutant screening
2.12.1 Growth complementation assays
2.12.1.1 Thymidylate synthase
1 to 5pl mutagenized DNA was used to transform a 
suitable E.coli thyA strain. Transformants were picked, 
using sterile tooth picks, and patched onto M9 plates, and 
M9 plates supplemented with thymine (50pg/ml) or TdR 
(lOOpg/ml) and incubated at 37°C overnight. Appropriate 
clones were used to set up overnight cultures. Mini-prep 
DNA was prepared and used to retransform a suitable E.coli 
thyA strain. The phenotype was confirmed by streaking for 
single colonies on minimal plates and minimal plates 
supplemented with TdR and incubating them overnight at 
37°C. Thy+ clones were sequenced directly. Thy~ clones 
were analysed by restriction enzyme analysis prior to DNA 
sequencing. In both cases the entire TS coding region was 
sequenced for each clone.
2.12.1.2 Thymidine kinase
1 to 5pl mutagenised pAD507 DNA was used to transform 
E.coli C600tdk cells. Transformants were patched onto M9 
plates supplemented with trimethoprim (lOpg/ml), TdR 
(100pg/ml), and AdR (lOOpg/ml) (MTTA plates) and M9 plates
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supplemented with Amp. Clones growing on both types of 
plates have TK activity whilst clones that grew only on 
minimal plates were predicted to lack TK activity. Mini- 
prep DNA from both types of clone was prepared and used to 
transform fresh E.coli C600tdk cells. The phenotypes were 
reaffirmed and the relevant portion of the TK gene 
sequenced.
2.12.2 Drug resistance screening protocols
2.12.2.1 Method 1
A lOOpL aliquot of E.coli ^2 913, transformed with 
mutagenized DNA, was used to inoculate 3ml LB-Amp and 
incubated overnight at 37°C. A second lOOpl aliquot was 
spread onto LB-Amp plates, and incubated overnight at 37'C. 
Transformants were replica plated onto M9 plates 
supplemented with 7 . 5pM FU (FU7.5 plates) and incubated for 
16 to 40h at 37°C. lOOpl of the overnight culture was 
spread onto FU7.5 plates and incubated for a further 16 to 
40h. Single colonies growing on either plate were streaked 
onto fresh FU7.5 plates, with E.coli GL271 streaked as a 
negative control, and incubated as before. The TS gene of 
clones growing on these plates was sequenced.
2.12.2.2 Method 2
E.coli MC1061thy.4 was transformed with mutagenized and 
wt DNA. Colonies were replica plated from LB-Amp plates 
onto M9 pi at.es supplemented with 4 . OpM FUdR (FUdR4 plates) 
ann incubated as described above. Single colonies were 
streaked onto fresh FUdR4 plates and incubated for a 
further 16 to 40h. Mini-prep DN4 was extracted from clones 
growing on these plates and used to transform fresh E.coli 
MCI 061 thyA. Transformants were replica plated as above. 
Clones that did not grow were discarded. Clones that did 
grow (i.e. showing plasmid linked drug resistance) were 
streaked on fresh FUdR4 plates and incubated for 16 to 
40 h. The TS gene of clones growing on these plates was 
sequenced.
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2.12.2.3 Method 3
Mutagenized DNA was used to transform the E.coli strain 
S0928 thyA. 3ml LB-Amp, was inoculated with lOOpl 
transformed cells and incubated, with vigorous shaking, at 
37°C overnight. 100 to 200pl overnight culture was spread 
onto FUdR5, 10 or 20 plates and incubated at 37*C for 16 to 
40h. Single colonies were streaked onto FUdRl, 2 or 5
Pi ates and incubated as before. Mini-prep DNA was made 
from clones that yielded single colonies on FUdR plates,
and used to transform fresh E.coli S0928thyA cells.
Transformants were streaked onto FUdRl, 2 or 5 plates and
incubated as before. The coding region of the TS gene of
clones growing on these plates was completely sequenced. 
By way of variation, bacteria were grown overnight in 
minimal media (liquid or solid) at all stages immediately 
prior to growth in the presence of FUdR.
2.12.2.4 Method 4
Mutagenized DNA was transformed into E.coli S0928thyA 
harbouring the VZV TK expressing plasmid, pCBTK3, and 
treated essentially as described in method 3 except that 
the overnight growth steps prior to growth in the presence 
of drug were always performed. 5-ethvnyl- 2 ’-deoxyuridine 
(FYUdR) was used at 1 , 5 and lOpM for initial screening and
0.5, 1 and 2 ] i M when colonies were streaked for single
colonies on fresh plates. FUdR was used as in method 3.
2.12.2.5 Method 5
Screening was performed as in method 4, but after the 
initial overnight growth step in M9 media, the bacteria 
were grown in minimal media, supplemented with either FUdR
or EYUdR, through several growth cycles prior to the
initial plating out onto minimal media plates containing 
the drugs. Screening was continued as for method 4.
2.12.3 Slot blot hybridization
Up to 72 overnight cultures, including control cultures, 
were set up. Slot blot hybridization was performed using a
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micro-sample filtration manifold kit (SRC 072/0 Minifold 
II; Schleicher and Schuell). Two gel blotting papers 
(Schleicher and Schuell) and a piece of GeneScreen Plus™  
membrane (DuPont) were soaked in hybridization buffer (20mM 
Tris-Cl pH7.5, 3xSSC, 5xDHB, 0.5% SDS, 20pg/ml denatured 
salmon testes DNA; Maniatis et al . , 1982) for 5 to lOmin.
The kit was completely assembled and connected to a vacuum 
pump. lOOpl overnight culture was loaded into each of the 
72 wells and the vacuum continued for 5mins after the last 
well was loaded. The membrane was removed from the kit and 
washed in 0.5M NaOH for 5 min. After a second wash in 1 .0M 
Tris-Cl pH7.5 for 2 min, a final wash in 0.5M Tris-Cl, 1 .5M 
NaCl for 5 to lOmin was performed. The membrane was placed 
in a polythene bag filled with 20 to 30ml hybridization 
buffer and heat sealed. Prehybridization was performed 
at 65°C for 2h. After prehybridization, the membrane was 
transferred to a 50ml Falcon tube containing 20ml 
hyridization buffer. 20pl 32P labelled oligonucleotide 
(see Section 2.10.3) was added and hybridization performed 
at room temperature for 2h with continuous rotation. The 
membrane was washed with fixSSC at room temperature, placed 
in a polythene bag and heat sealed before overnight 
exposure to Kodak S film 100. If the desired clone could 
not be differentiated from control clones, a series of 
washes at increasing temperatures (usually in increments 
of 5°C) were performed until the desired clones were 
identified.
2.13 Mutant Characterisation
2.13. DNA sequencing
2.13.1.1 Sequencing solutions
USB sequencing solutions:
Labelling mix: 1.5pM dCTP, 1.5pM dGTP, 1.5pM dTTP
Termination mix: A contained 8pM ddATP
C contained 8pM ddCTP
G contained 8pM ddGTP
T contained 8pM ddTTP
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All four termination mixes also included 80pMdATP, 
80pMdCTP, 80pM dGTP, 80pM dTTP, 50mM NaCl.
Pharmacia sequencing solutions:
Labelling mix: 2.0pM dCTP, 2 . OpM dGTP, 2 . OpM dTTP
Termination mix: A contained 15pM ddATP
C contained 15pM ddCTP
G contained 15pM ddGTP
T contained 15pM ddTTP
All four termination mixes also included 150pMdATP, 
150pMdCTP, 150pM dGTP, 150pM dTTP, 50mM NaCl, 40mM Tris-Cl 
pH7.5, lOmM MgCl2 .
Common solutions:
Annealing buffer (5xTM): 0.1M Tris-Cl p H 8 .0, 0.1M MgCl2 . 
Stop solution: 95% deionized formamide, 20mM EDTA
pH7.5, 0.05% xylene cyanol FF,
0.05% bromophenol blue.
Wacker solution (■'5ml): 25pl Wacker silane GF38,
1 50pl 10% acetic acid, 5ml EtOH.
2.13.1.2 Sequencing reactions
DNA dideoxy-sequencing was performed according to the 
method of Sanger et a], (1977) using either modified T7 DNA
polymerase (Sequenase, Tabor and Richardson, 1987) or 
unmodified T7 DNA polymerase. Sequencing was performed 
essentially as described by the manufacturers, with minor 
modifications. 5 to lOng of oligonucleotide were annealed 
to 0.5 to 1.Opg denatured plasmid template (see Section 
2.8.5) or ssDNA (see Section 2.8.4) in lOpl lxTM at 37'C 
for 30min. The labelling reaction was initiated by 
addition of lpl 0.1M D T T , 2pl labelling mix, 2pl [a-35S] or 
0.5pl [a-3 2pj dATP and 3U Sequenase were added to the
annealing mix and incubated at room temperature for 5min. 
Alternatively 5pl Sequetide and 3U Sequenase were added to 
the annealing mix and processed in an identical manner. 
For each sequencing reaction four wells of a 96 microtitre 
Plate were labelled G, A, T and C. 2.5pl of the
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corresponding dideoxy-termination mix was added to the 
wells. 3.5pl labelling reaction was transferred to the 
side wall of each well and the plate covered with a 
titertek plate sealer (77-400-05 Flow Laboratories Ltd.) 
prior to a brief spin to 1 , 500rpm in an International 
Equipment Company Centra-4X centrifuge to mix the 
components. After incubation at 37°C for 5 to 30min, 4pl 
stop solution was added to each well. Samples were boiled 
for 2 to 3 min in a water bath. 2 to 3yl was loaded onto a 
sequencing ge] (see below). When unmodified T7 DNA 
polymerase was used, the reactions were performed as above, 
except that the solutions decribed by the manufacturer were 
employed.
2.13.1.3 Polyacrylamide gel electrophoresis
Sequencing reactions were was resolved on a 6.0% 
acrylamide, 7.7M urea, 0.5 to 2.5x TBE gradient gel (Hong, 
1987). Prior to use, both plates were washed with 100% 
EtOH. If the gel was to be transferred to 3MM paper (see 
below), both plates were coated with Repelcote™, then 
washed once with 100% EtOH, before the gel was poured. 
When the gel was to be oven dried, the front plate was 
treated as above, but the second plate was coated with ~ 5mL 
of Wacker solution, then washed five times with 100% EtOH, 
before the gel was poured. Electrophoresis was performed 
in lxTRE at. BOW. For normal length runs the BPB was used 
as a marker to terminate electrophoresis. In longer runs, 
XCFF was used as a marker to terminate electrophoresis. 
The sequencing gel was either transferred to 3MM paper and 
dried on a vacuum gel drier for "90 min. Alternatively, it 
was soaked in 10% acetic acid for 30 min before drying onto 
the back plate in an oven at 140°C for 60 to 90 min. The 
gel was exposed to Kodak S 100 film for 16 to 72h at room 
temperature with an intensifying screen.
2.13.2 TS extracts
2.13.2.1 Extract preparation
100ml LB supplemented with TdR (50pg/ml), was inoculated
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with 3ml overnight culture and incubated at 37*C, with 
vigorous shaking, until OD6oo "0.6. 1ml cells were removed 
and stored on ice for a phenotype check (see below). The 
remaining cells were pelleted in a Sorvall GS3 rotor at 
7,000rpm for 5min at 4 eC. The supernatant was discarded 
and the pellet resuspended in 10ml ice-cold TES (50mM Tris- 
Cl pH7.4, 5mM EDTA, 50mM NaCl). The suspension was 
transferred to a 15mL Falcon tube and the cells repelleted 
at 3,000 rpm for 10 min at 4 * C in a Beckman GPR benchtop 
centrifuge. The supernatant was discarded, the pellet 
volume estimated, frozen and thawed once, and resuspended 
in 2 vol sonication buffer (50mM Tris-Cl pH7.5, lOmM DTT, 
0.1% Triton X-100). The sample was sonicated in a Dawe 
sonicator with micro-soniprobe for three 10s periods at 
~150W on ice with 30s cooling between each period. The 
sonicate was transfered to a 1.5mL eppendorf tube and 
centrifuged in a Sorvall SS34 rotor, with suitable 
adaptors, at 10,000 rpm for 10 min at 4*C. The supernatant 
was recovered by aspiration and snap-frozen in a dry- 
ice/ethanol bath before storage at -70*C. For the 
phenotype check, the cells were streaked for single 
colonies on an LB plate supplemented with TdR and incubated 
at 376C overnight. Single colonies were patched onto LB- 
TdR-Amp, M9-TdR and M9 plates and incubated at 37*C 
overnight.
2.13.2.2 Protein concentration determination
Protein concentrations were determined by the method of 
Bradford (1976) using the Bio-Rad protein assay kit. lOpl 
diluted extract, protein standard or H2O was mixed with 
990pl Bio-Rad dye reagent (filtered through Whatman No.l 
paper before use) and after 5 to lOmin at room temperature, 
absorbance measured at 595nm. Each extract or protein 
standard was assayed in duplicate. BSA was used as a 
Protein standard. A standard curve was made using 
concentrations of 0, 0.01, 0.02, 0.05, 0.1, 0.2 and
0.4mg/ml. Protein extracts were usually diluted 1:5 with 
H2O to give readings that could be readily determined from
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the standard curve. Alternative dilutions were used when 
necessary.
2 . 1 3 . 3  TS assays
2 . 1 3 . 3 . 1  Tritium release assay
This assay follows the release of radioactivity from 
5-f3H]dUMP to the solvent. Unreacted substrate is absorbed 
to charcoal, removed by centrifugation and the 
radioactivity in the supernatant determined (Roberts, 
1966). TS extract was mixed with 20pl 2xassay mix (128mM 
NaF, 260mM Tris-Cl pH7.5, 64mM sucrose, 0 . 3 % ( w / v  ) BSA,
0.25mM D T T , 38mM HCHO and 0.2mM tetrahydrofolate), 0.4pCi 
5-[3H]dUMP and H20 in a total volume of 40pl and incubated 
at 30°C for 15min. The reaction was terminated by addition 
of 15pl 33% T C A , 5pl 5mg/ml dUMP and 180jil charcoal 
suspension (2% charcoal in 0.1M H20. The sample was 
vortexed for 10s. After centrifugation for 2min, 500pl 
supernatant was removed and added to 3ml scintillation 
fluid (Ecoscint A) prior to liquid scintillation counting 
in a Beckman LS5000CE scintillation counter. A total 
counts control was included by using 5pL sonication buffer 
instead of extract and adding 940pL H20 instead of charcoal 
suspension. A measure of backgound counts was included by 
replacing extract with 5pL sonication buffer and this was 
subtracted f roin all experimental values. Assays were 
performed in duplicate on two or more independant extracts 
for each clone. The amount of extract used was adjusted so 
that less than 30% of the total counts are released. This 
ensures that assays are in the linear region of the 
reaction curve.
The amount of dTMP generated is directly equivalent to 
the amount of [3 H ] released during the assay. The amount 
°f 5-[3H]dUMP added to the reaction in pmol can be 
calculated from its specific activity. The total counts 
represents the equivalent amount of product (dTMP).
1. e
pmol dTMP produced = Sample CPM x pmol 5-[3H]dUMP added
Total CPM •
Fig. 2.1. Debromination assay.
Denomination assay reaction traces. Chart speed was 120s/cm, 
recorder range was 1.0. The reactions contain, in order from top to 
bottom of the figure: 5jil %2913 extract (12mg/ml); zero extract; 0.5, 
FO, 2.0, 3.0, 4.0, 5.0|xl x2913/pAD768 extract (12mg/ml). Note that the 
reaction rapidly becomes non-linear at higher extract concentrations.
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Fig. 2.2 Debromination assay.
The linearity of the debromination assay is shown on this graph of intial 
rate of absorbance change against amount of extract. Data points are 
taken from Fig. 2.1.
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From the protein concentration, the specific activity of 
TS in the crude extracts can be expressed in terms of pmol 
dTMP produced per pg protein per minute.
2.13.3.2 Debromination assay
This assay follows the reduction in absorbance at 285nm 
caused by release of bromine from 5-BrdUMP (Garret et al., 
1979). It represents the first stage of the TS reaction, 
and as such does not require the presence of the folate co- 
factor. The reaction buffer was 200mM N-methylmorpholine 
hydrochloride pH7.4, 25mM MgCl2 , ImM EDTA, 75mM B-ME 
prepared at 2x strength and stored at 4°C. Reactions were 
run in Hellma quartz microcells containing 250pL 2x buffer, 
5pl 4mM 5-BrdUMP (40pM final concentration), 1 to 5pl of 
crude extract and H20 in a final volume of 500pl. 
Absorbance change was monitored using a Cecil CE595 double 
beam spectrophotometer (zeroed on the cuvettes before 
adding extract) and displayed on a chart recorder. 
Reactions were run for 15 to 20min at room temperature 
(usually 25 to 30 °C), and an extract containing WT VZV TS 
was included in each run. The linearity of the assay under 
these conditions was first confirmed. Fig. 2.1 shows 
traces from reactions with increasing amounts of active 
extract. Fig. 2.2 shows that the initial rates of 
absorbance change are proportional to the amount of extract 
added. To compare extracts initial rates were calculated 
and expressed as mOD/min/ug protein.
2.13.4 Characterization 
TS variants
To characterize variants 
colonies on solid M9 media, 
evidence of drug resistance 
devised. The variants were 
S0928 thyA/pCBTK3 and 
medium at 3 7°C. 
same medium, 
the cells
of potential FUdR resistant
could not form single 
which otherwise showed 
following assay was 
in the E.coli strain 
10ml of M9-Amp-Cm 
200ml of the 
at 37°C until 
0.4). At this
that 
but 
, the 
expressed 
grown overnight in 
This was used to inoculate 
The new culture was incubated 
reached mid-log phase (A600 =
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point, the culture was divided equally between two flasks, 
and FUdR added to a final concentration of 50 or lOOpM (see 
Section 3.1). The growth of the bacteria was monitored at 
30min intervals, with OD6oo readings taken at each time 
point. The final growth curves are the results of two 
independent experiments (see Figs. 3.8 and 3.9).
2.13.5 TK extracts
lml overnight culture was pelleted by a 15s spin in' a 
mini-centrifuge. The supernatant was discarded and the 
cells resuspended in lOOpl TK lysis buffer (20mM Tris-Cl 
pH7.5, 2mM MgCl2 , lOmM NaCl, 6. 5mM I3-ME, 0.5% Nonidet 
P 40). 5pL lysozyme (lOmg/ml) was added and the cells 
incubated on ice for lOmin. Three cycles of freeze 
/thawing (-70*C, 5min / 37°C, 5min) were performed. The 
lysed cells were centrifuged for 5rain and the supernatant, 
which represented the TK extract removed and stored at 
-70°C. Protein concentrations were determined as above.
2.13.6 TK assays
10pl TK extract was mixed with 40pl TK assay mix (20mM 
sodium phosphate pH6.0, ImM MgCl2 , 0.25mM ATP, 166pl/ml
[methy]-3H ]TdR and incubated at 37°C for 60min. 10pl TK 
stop solution (lOmM EDTA, 2mM TdR) was added and the 
solution boiled for 3min before cooling on ice for 3min. 
After a 3min spin, 50yl supernatant was spotted onto a 
folded DE81 disc (Whatman) and allowed to dry at RT for 2 
to 3min. The discs were washed three times, lOmin each 
time, in 4mM ammonium formate, lOpM TdR at 37*C. After two 
Imin washes in 100% ethanol, the discs were dried between 
two pieces of filter paper. The discs were placed in 3ml 
scintillation fluid and counted in a liquid scintillation 
counter as above. Assays were performed with 3 discs per 
extract, and two independant extracts were made for each 
clone.
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2.14 Computing and Molecular Modelling
All DNA and protein sequence analysis was performed 
using the Sequence Analysis Software Package of the 
Genetics Computer Group of the University of Wisconsin run 
on the VAX/VMS computer in the Institute of Virology, 
University of Glasgow.
The computer generated graphics of the VZV TS structures 
were constructed using the UCSD Molecular Modelling System 
of run on the Silicon Graphics IRIS computer in the 
Department of Chemistry, University of Glasgow. The 
modelling was performed as described (see Sections 3.1 to 
3.3). Photographs were taken directly from the computer 
screen at 50% brightness, on Kodacolour Gold 100 (daylight) 
film, with exposures of 1/30, 1/15 and l/8s at f2.
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3. RESULTS AND DISCUSSION
The Results and Discussion chapter is divided into four 
sections. The first three detail studies of VZV T S , whilst 
the final section deals with VZV TK. The studies on TS 
commence with a description of the development of protocols 
to isolate drug resistant variants of T S , continue with a 
section on the molecular modelling of a number of variants 
that have a Thy- phenotype, and is completed by site- 
directed mutagenesis studies of two key structural regions 
of the enzyme. The work on TK includes site-directed 
mutagenesis and describes the identification of the 
potential evolutionary source of the herpesvirus TKs.
3.1 Drug resistance studies
The aim of the drug resistance studies was to isolate 
a mutant variant (or variants) of TS that was resistant to 
the effects of various inhibitory drugs. The definition of 
drug (or inhibitor) resistance in this case is that such a 
variant should be able to catalyse the reductive 
methyl at ion of deoxyuridyl ate to form thymidylate as normal 
in the presence of a concentration of the active form of 
the inhibitor that prevents the wild type enzyme from 
catalysing this reaction. The isolation and characteris­
ation of such a mutant would reveal information about the 
role that various amino acids play in catalysis. This 
information may enhance the understanding of the mechanisms 
of drug resistance observed during the treatment of various 
cancers where TS inhibitors are widely used (see Section 
1.12). Finally, it may be useful in evaluating the role of 
TS in VZV infections and establish the use of TS as a 
target enzyme for antiviral chemotherapy.
Neither of the two reports of FU resistance in tumours, 
where a lesion in the TS locus has been demonstrated, have 
described the amino acid changes in the protein that are 
responsible for drug resistance (Heidelberger et al., 
1960a,b; Jastreboff et a l ., 1983). The scarcity of the
Mutagen Screening
protocol
No. of drugR 
clones isolated
No. of drugR
clones
sequenced
Ethyl methanesulphonate 1 12 12
Hydroxylamine 1 2 2
Hydroxylamine 2 2 2
Sodium bisulphite 2 0 0
mutD 2 14 _j 7
Table 3.1. Initial Drug Resistance Screening Results.
Number of drug resistant clones isolated and sequenced from initial 
experiments.
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reports, only two in thirty years of FU use as a drug 
(Heidelberger, 1957), suggests that only a limited number
of mutations in the TS gene may give rise to resistance. 
The isolation of a resistant variant of VZV TS by in vitro 
studies would thus require both highly efficient and 
efficacious mutagenesis and selection procedures.
In order to isolate drug resistant variants, it was 
decided to study VZV TS in an E.coli expression system 
which had previously been shown to express active enzyme 
(Thompson et a l ., 1987). The aim was to generate a library 
of TS variants by a suitable random mutagenesis protocol 
which could be screened for drug resistance. The amino 
acid substitutions responsible for the drug resistant 
phenotype would then be determined by DNA sequencing, and 
the enzyme studied in more detail to establish the 
mechanism of resistance.
The results presented in this section describe the 
selection and optimization of suitable mutagenesis 
protocols and the refinement of a genetic selection system. 
We then go on to describe the use of these methods to 
screen a large number of clones for a drug resistant 
variant of VZV T S .
3.1.1 Initial experiments
Four methods of random mutagenesis were studied for 
application to wide scale screening for drug resistant 
variants of VZV T S . Several drug resistant clones were 
isolated from DNA randomly mutagenized by methods
(EMS, HA  ^ and the E.coli mutD strain
CB158; see Sections 2.11.1 and 2.11.2). The results of
these initial experiments are summarized in Table 3.1. The 
nature of screening protocols 1 and 2 (in that they were
preliminary methods) meant that an accurate number of the 
clones screened could not be readily determined. From 
approximately 1,000 clones generated by each mutagenesis 
protocol, screening resulted in the isolation of 30 drug
resistant variants. Twenty-one of these drug resistant
clones were analysed by DNA sequencing and no nucleotide
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changes were discovered in the TS gene of any isolate.
To assess the efficiency of the mutagenesis protocols, 
200 clones generated from each mutagenesis method were 
assayed for growth complementation. 137 clones generated 
by bisulphite mutagenesis had a Thy- phenotype. When 19 of 
these clones were analysed by EcoRl restriction enzyme 
digestion, 18 had different digestion patterns to that of 
the WT TS plasmid. This suggested that bisulphite was 
inducing excessive damage to the DNA rather than inducing 
point mutations. The TS gene of the single clone that had 
the same digest pattern was sequenced with oligos 3 to 7 
and found to have no nucleotide changes. None of the other
methods produced clones with a Thy" phenotype.
These results suggested that the mutagenesis protocols 
were inefficient as shown by the fact that so few Thy-
clones were isolated, and that those that were isolated had
no nucleotide changes in the TS gene. The drug screening 
methods were not suitable as judged by the isolation of a 
high number of 'false positive’ clones, clones that were 
drug resistant, but had no nucleotide changes in the TS 
gene suggesting the presence of mutations at other loci.
On the basis of these experiments, two new methods of 
random mutagenesis were employed, together with a radically 
different method of screening for drug resistant clones.
These new methods were first evaluated for efficiency and 
eff icacy, and subsequently employed to screen large numbers 
of clones.
3.1.2 New drug screening protocols
To overcome the isolation of the high number of false 
pos i t ives clones obtained when screening for TS variants 
resistant to F U , the following protocols were adopted. 
They were devised to allow the use of FUdR, and the drug 
EYUdR (see Section 2.12.2).
3 .1. 2.1 The use of FUdR rather than FU
Our analysis of the pathways for nucleotide metabolism 
in E.coli, together with previous studies in this area (see
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Fig. 3.1. Nucleotide Metabolism.
The pathways of E.coli nucleotide metabolism relevant to the drug 
screening protocols. The structural and biochemical similarity of uracil 
and FU means that most pathways for their metabolism are the same (see 
text for details).
The following abbreviations are used for the various nucleotides described in this 
schem e: U - uracil; UR, UMP, UDP and UTP - uridine and its mono-, di- and 
triphosphate derivatives. UdR, dUMP, dUDP and dUTP - deoxyuridine and its mono-, 
di- and triphosphate derivatives. dTMP, dTDP and dTTP - the mono-, di- and 
triphosphate derivatives of thymidine. The following abbreviations are used for the 
genes of various proteins: uraA , nupC , nupG  and tsx  - genes for proteins involved in 
nucleobase and nucleoside uptake, udp  - uridine phosphorylase; deoA  - thymidine 
phosphorylase; upp - uracil phosphoribosyl transferase; udk - uridine kinase; tdk -
thymidine kinase; tmk - thymidylate kinase; thyA - thymidylate synthase; nrd  - ribo­
nucleotide reductase; dut - dUTPase; ndk - nucleoside diphosphate kinase.
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Section 1.12), suggested that the use of FU was not 
suitable for the isolation of drug resistant variants of 
T S , and may contribute to the isolation of false positive 
clones. This is due to the fact that FU can kill bacterial 
cells in a number of ways (see Section 1.13.2). To inhibit 
T S , FU must be converted to FdUMP. As FU metabolism 
closely parallels that of uracil (Neuhard & Nyg- 
aard, 1987; O ’Donovan & Neuhard, 1970 ), FU would not be
expected to be converted to FUdR, an immediate precursor of 
FdUMP, to a great extent. This means that FdUMP is 
predominantly formed via the action of ribonucleotide 
reductase (see Fig. 3.1. and Section 1.13.2). Mutational 
events that affect any of the enzymes in this activation 
pathway would prevent the formation of FdUMP, and could 
result in the isolation of false positive clones.
FU can also be incorporated into RNA, which can result 
in cell death (see Section 1.13.2). If the incorporation 
of FU into RNA is the major cause of cell death, then it 
would be impossible to isolate a drug resistant variant of 
TS, as the enzyme is not the main target for the drug. In 
addition, FU can kill certain strains of E.coli by the 
inhibition of normal cell wall synthesis (see Section
1.13.2). This would also prevent the isolation of a drug 
resistant variant of T S , For these reasons, it was decided 
to use FUdR, as opposed to F U , for subsequent experiments.
3.1.2.2 A thyA derivative of E.coli strain S0928
Once inside the cell, FUdR can be phosphorylated to form 
FdUMP, in a reaction catalysed by TK, or degraded to form 
FU, by the action of thymidine and/or uridine phosphorylase 
(see Fig. 3.1). Obviously the use of an E.coli strain that 
could catalyse the breakdown of FUdR to form F U , would 
create the same problems as using FU directly. For this 
reason, an E.coli strain was sought that could not catalyse 
this reaction.
The ideal strain would have deletion mutations in the 
genes deoA and udp, which encode thymidine phosphorylase 
(TdRPase) and uridine phosphorylase (UdRPase) respectively
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(see Fig. 3.1). Such a strain was not available, however 
the E.coli strain S0928 was a more than adequate replace­
ment. This strain has the deoA gene deleted and is also 
deficient in UdRPase activity (Valentin-Hansen et al. , 
1978 ). The lack of these enzyme activities, and the fact 
that the metabolism of FU and uracil are very similar in 
E.coli, means that this strain cannot catalyse the 
formation of FU from FUdR (see Fig. 3.1; Neuhard & Nygaard, 
1987).
As the breakdown of FUdR to FU is prevented in E.coli 
S0928, FUdR can only kill the cells by the inhibition of TS 
and concomitant induction of thymineless death (see Section
1.13.2). In this case, FUdR would be converted to FdUMP in
a single step; the phosphorylation of FUdR being catalysed
/
by TK. Such a strain could then only become resistant to 
FUdR in one of two ways. The first, and the desired 
option, would be due to mutations in the TS gene. The 
second would be due to mutations in the TK gene that would 
result in inefficient phosphorylation of FUdR.
The E.coli strain S0928 also lacks uracilphosphoribosyl 
transferase activity (Valentin-Hansen, et al . , 1978). If
the cells regained UdRPase activity as the result of a 
spontaneous mutation, this gives the added advantage of 
preventing the formation of FUMP from FU, and the 
subsequent incorporation of FU into RNA (see Fig. 3.1 and 
Sect ion 3.1.2.1 ) .
To allow the VZV TS to be the target of drugs used in 
the drug screening protocols (rather than the E.coli T S ) , a 
thyA variant of the E.coli strain S0928 was selected as 
described (see Section 2.7.2).
The new screening protocols facilitated an accurate 
measure of the number of clones that were being screened 
(see Section 2.12.2.3). The E.coli strain S092SthyA 
transformed with either pAD403 or pAD768 was used to 
establish the concentration of FUdR to use for drug 
screening protocol 3. 2.5jiM FUdR was found to inhibit 
single colony formation of cells expressing VZV TS encoded 
by the plamid pAD403, whereas a concentration of 4.OpM FUdR
112
was required when VZV TS was encoded by the plasmid pAD768. 
lO.OpM TFT (trifluorothymidine) was found to inhibit single 
colony formation of cells expressing VZV TS encoded by the 
plamid pAD403.
3.1.2.3 Co-expression of VZV TK in S0928thyA
The strategy of co-expressing VZV TK on a multi-copy 
plasmid in the same cells as VZV TS was chosen to reduce 
the possibility of false positive clones arising due to 
mutation of the E.coli tdk gene and to ensure that nucleo­
side phosphorylation would mimic the situation in VZV 
infected cells.
The active VZV TK gene was subcloned from the plasmid 
pVZVTK+5 (see Section 3.4.1) into the plasmid pCB105 to 
form pCBTK3. pCB105 contains the chloramphenicol acetyl 
transferase gene and can be selected for by using 
chloramphenicol. This vector is also compatible with the 
pBR322-based TS expression vectors and they can therefore 
stably co-exist in the same cell (Sherratt & Boyd, 1986). 
pCBTK3 was used to transform S0928thyA and selected for 
using chloramphenicol.
The transformed cells, referred to as S0928 £hy.4/pCBTK3 , 
were then transformed with pAD768 and selected for by using 
chloramphenicol and ampicillin. These transformants were 
referred to as S0928 thy.4/pCBTK3/pAD768 and were used to 
estabiish the concentration of FUdR and EYUdR to use for 
drug screening protocols 4 and 5. An FUdR concentration 
of 4pM was sufficient to inhibit growth (irrespective of 
the presence of pCBTK3), whereas the concentration of EYUdR 
required to inhibit the formation of single colonies on 
solid media was 0.5pM. In the absence of pCBTK3, the 
concentration required to inhibit the growth is greater 
than 10pM. This confirms the need for the co-expression of 
VZV TK to phosphorylate this compound. This observation 
also suggested that E.coli TK differed in its substrate 
specificity to the herpesvirus T K s , and may resemble the 
cellular TKs in this respect (see Section 3.4.2). Recent 
sequence information pertaining to the E.coli TK gene has
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strengthened this argument (Bockamp et al . , 1990; Black &
Hruby, 1991; R. Thompson, J. E. Scott & P. T. Harrison, 
unpublished data).
3.1.2.4 Drug evaluation
The initial studies to isolate a drug resistant variant 
employed FUdR. As this compound is a close structural 
analogue of dUMP (see Section 1.14.1), and so few instances 
of FUdR resistance have been reported, it was decided to 
screen for a drug resistant variant with an additional TS 
inhibitor, TFT.
During the course of these studies, we gained access to 
several compounds that have been shown to inhibit the 
growth of VZV (see Section 1.4.3). These compounds were 
evaluated as potential TS inhibitors. This was ach i^ved by 
determining the concentration of each drug to prevent 
single colony formation of S0928 fch.y4/pCBTK3/pAD768. BVdU, 
ACV and AraA, all recognised as non-TS inhibitors, allowed 
single colony formation at lOpM and were not tested 
further. PYaraU and EYaraU, also known non-TS inhibitors 
did not inhibit growth at any of the concentrations tested. 
PYUdR, a weak TS inhibitor allowed growth at 20pM and was 
not tested further, however, EYUdR, a potent TS inhibitor, 
prevented single colony formation at 0.5pM. On this basis, 
EYUdR was selected as a replacement for TFT in the search 
for a drug resistant variant of VZV T S .
3.1.3 New mutagenesis protocols
Two new methods were employed for random mutagenesis, 
both requiring the use of vectors producing ssDNA (Geider, 
1986) and the mutant enrichment procedure of Kiinkel 
(Kiinkel, 1985; Kiinkel et al., 1987 ). The first method
involves mi sincorporation mutagenesis (Lehtovaara et al . , 
1988; Holm et a l ., 1990; Shiraishi & Shimura, 1988), whilst 
the other method is based on 'spiked* oligonucleotide 
mutagenesis (McNeil & Smith, 1985; Ner et al, % 1988).
Before use in screening for drug resistant clones, the 
efficiency of both methods was evaluated and optimized.
1 2 3 4
origm->
helper->
phage
ssDNA->
<-ongin
<-helper
phage
<-ssDNA
Fig. 3.2 ssDNA
This figure shows the effects of recloning of the VZV TS gene in the opposite 
orientation. Lane 1 shows helper phage DNA (top) and ssDNA (bottom) 
generated from the vector pAD113. Lanes 2, 3, and 4 shows helper phage 
DNA (top) and ssDNA (bottom) generated from the vectors pAD401, pAD403 
and pAD404. pAD403 was used regularly for the production of ssDNA.
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3 .1 .3 .1 ssDNA and plasmid constructs
Previous attempts to clone VZV TS into M13 vectors have 
resulted in instability problems (R. Thompson, personal 
communication). To counter this, we decided to clone VZV 
TS into various plasmid vectors that contain the
bacteriophage fl origin of replication (Geider, 1986; Mead 
et a l ., 1986).
TS was subcloned from pGL271 into pBS+ to construct the 
plasmid pAD113. The region of ssDNA containing the TS gene 
could be sequenced using oligos 3 to 7 because of the 
orientation of the TS gene, relative to the fl origin of
replication. However, ssDNA produced from this clone had a 
very low ratio of ssDNA to helper phage.
The low levels of ssDNA and high background of helper 
phage were thought to be causing problems with the 
synthesis of the second strand during mutagenesis (see 
below). In an attempt to improve the levels of ssDNA, and 
increase the ratio of ssDNA to helper phage, a variety of 
experiments were performed based on the observations of 
other groups (Geider, 1986; Mead et al., 1986; Russel et 
al., 1986; Vieira & Messing, 1987). These experiments 
included the propagation of pAD113 in different strains of 
E.coli, use of different helper phage, superinfection with 
helper phage at different stages of growth and the use of 
different multiplicities of infection. None of these 
methods increased the yields of ssDNA, or improved the
ratio of ssDNA to helper phage.
TS was cloned into the vector pGEM3Zf+ in the same
relative orientation to the fl origin of replication as 
pADl13 to construct the plasmid pAD203, but the yields and 
ratio of ssDNA to helper phage were still low. The use of
a strong termination signal downstream of the coding region
has previously been shown to facilitate the cloning and
expression of various foreign genes in E.coli (Gentz et 
al., 1981). To see if the termination signal could improve 
yields of ssDNA, the transcriptional termination sequences 
of the rrnB operon (Gentz et al . , 1981; Brosius et al. ,
1981; Amann & Brosius, 1985) were cloned downstream of the
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TS gene to form the clone pAD301 . No improvements in the 
yield of ssDNA or the ratio of ssDNA to helper phage were 
observed.
The construction of the plasmid pAD403, by subcloning 
the TS gene from pAD113 into pBS-, in the opposite 
orientation to the fl origin of replication relative to 
pAD113, gave a dramatic increase in the ratio of ssDNA to 
helper phage. With pADl13 the ratio was approximately 1:5 
compared to 3:1 for ssDNA production from pAD403 (see
Fig. 3.2). Careful analysis revealed that two point 
mutations (A-48G:; A-47T; numbering such that the A of the
ATG codon of the initiating Met of TS is +1) had arisen in 
the -10 region of the promoter region linked to the TS gene 
during the construction of pAD403. These changes were 
corrected by site-directed mutagenesis using oligo 68, and 
the new clone was designated pAD768. The ratio and yields 
of ssDNA from pAD768 was identical to that observed for
pAP4 03.
3.1.3.2 Strand selection procedure
The strand selection procedure for mutant enrichment 
(Kiinkel, 1 985; Kiinkel et al., 1987) was used for both
random and site directed mutagenesis. The method uses an
ssDNA template that contains a number of uracil residues in 
place of thymine (U-ssDNA; Kiinkel, 1985). U-ssDNA is 
produced in an E.coli dut ung strain. Such strains lack
the enzymes dUTPase and uracil N-glycosylase. The lack of
dlJTPase activity leads to raised levels of dUTP (see Fig. 
3.1) and results in increased incorporation of uracil into 
DNA in place of thymine. The lack of uracil N-glycosylase, 
which normally removes uracil from DNA, means that the 
uracil is stably incorporated. The U-ssDNA molecule can 
then be used as a normal template for the in vitro
mutagenesis reactions as the coding potential of uracil is 
the same as that of thymine (Shlomai & Kornberg, 1978).
The completely double stranded molecule, the product of the 
in vitro mutagenesis reaction, has a parental strand that 
contains both uracil and thymine residues, whilst the newly
Primer
VZV TS
Gene
pAD 7 6 8
DNA Polymerase, + dCTP 
dGTP, dTTP in excess; 
dATP at a Limiting 
Concentrat ion
Removal of Free Nucleotides
Misincorporation of 3 dNTPs 
by Reverse Transcriptase
Elongation with 4 dNTPs, 
DNA Polymerase and Ligase
Population of Mutants with T/C, T/G or T/T Mismatches
Fig. 3.3. Misincorporation Mutagenesis.
The principle of misincorporation mutagenesis is shown for an elongation 
reaction where dATP is the limiting nucleotide. See text for details.
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synthesized mutant strand contains only thymine residues. 
When wild type E.coli cells (i.e. Ung+ ) are transformed 
with this DNA, there is a strong in vivo biological 
selection against the replication of the parental template 
strand (Kiinkel et al . , 1987) that results in the production 
of predominantly mutant dsDNA molecules. The high 
efficiency of mutant production (typically >50%) allows the 
screening of site-directed mutants by DNA sequencing or the 
generation of highly mutated DNA libraries by random 
mutagenes i s .
The highest levels of U-ssDNA was obtained from vectors 
in E.coli BW313 cells (compared to E.coli RZ1032 and 
CJ236). The strand selection efficiency was confirmed in 
that ssDNA (normal thymine containing) was capable of 
transforming both E.coli BW313 (Ung~) and JM109 (Ung* ),
whereas U-ssDNA could transform E.coli BW313, but not 
JM109.
3.1.4 Misincorporation mutagenesis
The principle of misincorporation mutagenesis is 
illustrated in Fig. 3.3 (Lehtovaara et al. , 1988; Holm et
al. , 1990). A phosphorylated oligonucleotide is annealed
upstream of the regi'on of the gene targeted for 
mutagenesis. A so-called limited elongation reaction is 
performed with three dNTPs in excess and the fourth at a 
limiting concentration. This generates all possible 
3 ’-ends of the elongated primer over the desired target 
region. Four separate reactions are performed for each 
primer, each of which generates a population of molecules 
terminating just before a given type of base, due to 
limiting amounts of nucleotides (these four populations are 
analogous to those synthesized in dideoxy-sequencing, 
except that the next base to be incorporated is known and 
the 3 ’-terminii can be further elongated in the following 
misincorporation reaction).
Point mutations are introduced to the four molecular 
populations by enzymatic misincorporation of the three 
mismatching nucleotides under conditions where proof-
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reading does not occur. This reaction can be catalysed 
with reverse transcriptase (Lehtovaara et al., 1988) or
with the Klenow fragment of DNA polymerase I if a-thio 
dNTPs are used (Shiraishi & Shimura, 1988). The final 
stage is the complete synthesis of the second strand of the 
molecule.
3.1.4.1 Use of the Klenow fragment of DNA polymerase I
Oligo 56 was used as the primer to initiate the complete 
misincorporation mutagenesis reaction, using a-thio dATP as 
the limiting nucleotide, the Klenow fragment of DNA poly­
merase I to catalyse the misincorporation step and U-ssDNA 
made from pAD403 as described. DNA generated from this 
experiment was used to transform E.coli XL-1thyA cells, and 
the transformants screened by the TS growth complementation 
assay. Of 434 transformants analysed, only 13 non­
complementing mutants were isolated. Analysis by EcoRl 
restriction enzyme digestion revealed that only five had an 
identical restriction digest pattern to that of pAD403. 
The TS gene of these clones was sequenced using oligos 59 
to 62, but only two clones contained nucleotide changes in 
1 he TS gene. One clone had a single nucleotide change 
(C305T) that corresponded to the substitution of Serl02 by 
Leu (S102I), whilst a second clone had several changes; the 
A516G nucleotide substitution caused no amino acid 
changes, whilst the insertion of three C residues between 
nucleotides 1496 and 1497 resulted in two amino acid 
changes. Aspl74 was replaced by Ala (D174A), and an 
additional amino acid, His, was inserted between amino 
acids 174 and 175 (174H175).
Despite the isolation of two T h y  mutants with 
nucleotide changes in the TS gene, the efficiency of 
mutagenesis (estimated by the number of mutations in the TS 
coding region that resulted in a T h y  phenotype) was only 
0.46% (2/434). This suggests that the true mutagenesis
efficiency (the number of clones containing mutations in 
the TS gene irrespective of phenotype) is also very low.
Clone Nucleotide
Changes
Codon
Changes
Amino Acid 
Changes
Phenotype
A T536A GTA to GAA V179E Thy-
B T565C TTT to CTT F189L Thy
F T559G TGT to GTT C187G Thy-
M T589A
T592C
TCC to ACC 
TGC to CGC
S197T
C198R
Thy-
N No Changes No Changes No Changes Thy+
0 T627A CTT to CTA L209 Silent Thy+
P T468A ATT to ATG 1156 Silent Thy+
Q T627G CTT to CTG L209 Silent Thy+
R T573A GTT to GTA V191 Silent Thy+
Table 3.2. TS Mutants.
Nucleotide, amino acid and codon changes of mutant clones, and their 
phenotypes. The nucleotide change T536A indicates that T536 was 
substituted by A. The effect of the nucleotide substitution on the codon 
are shown in bold. The amino acid change V179E indicates that V179 
was replaced by E.
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3.1.4.2 Use of reverse transcriptase
As a consequence of the results shown above, it was 
decided to use U-ssDNA generated from the plasmids pAD403 
and pAD768 as a template for mutagenesis and reverse 
transcriptase to catalyse the misincorporation reaction.
Misincorporation mutagenesis was performed using U-ssDNA 
made from pAD403, oligo 56 as the primer and dATP as the 
limiting nucleotide. Mutagenised DNA was used to transform 
E.coli S0928thyA and the transformants were screened by the 
TS growth complementation assay. Of 150 clones screened, 
20 (13.33%) had a T h y  phenotype. The TS gene of three of 
these clones (A, B and F) was sequenced using oligos 59 to 
62. The nucleotide changes and corresponding amino acid 
substitutions are shown in Table 3.2. In addition, a 
further six clones (M to R), were selected at random from 
the transformants, prior to phenotypic screening, and 
sequenced. The phenotypes of these clones, the nucleotide 
changes they possess and the corresponding amino acid 
substitutions are also shown in Table 3.2. The mutations 
described these clones are in accordance with the
predicted pattern of misincorporation and are randomly 
distributed throughout the region of the TS gene targeted 
by oligo 5 6.
To further assess the efficiency of mutagenesis, a 
reaction was performed using U-ssDNA made from pAD768,
oligos 59, 60 and 62 and dATP as the limiting nucleotide as
described. Mutagenised DNA was used to transform 
E.coli S0928thyA and of 260 transformants assayed by the TS 
growth complementation assay, 35 (13.46%) had a T h y
phenotype. Analysis of 12 of these clones by FcoRI 
restriction enzvm^ digestion revealed that all 12 had a 
pattern identical to that of pAD768.
In summary, the use of reverse transcriptase for the
misincorporation mutagenesis protocol has been shown to be 
superior to the Klenow fragment of DNA polymerase I. A 
high level of transformation was established with DNA 
generated by this method with a misincorporation reaction 
initiated from oligos 56 and 59 to 62. The efficiency of
-35 
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Fig. 3.4. Regions of VZV TS Covered by Spiked Oligos.
The regions of the VZV TS gene target by the spiked oligos and the 
relationship of these areas to the amino acid sequence and the various 
elements of predicted secondary structure of VZV TS targeted by spiked 
oligo mutagenesis. The oligo sequences are indicated in bold and areas 
of overlap by bold italics. They are also underscored by commas 
0 or •) with areas of overlap indicated by vertical lines (I). The various 
elements of secondary structure are also shown. The ribosomal binding 
site (RBS) and -35 and -10 boxes of the promoter are also indicated^
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mutagenesis can be estimated to be at least 50%, that is at 
least every other clone generated will be expected to have 
a single nucleotide substitution, a level necessary for the 
wide scale screening for a drug resistant variant of VZV 
T S . Moreover, the wide and random spread of the mutants 
demonstrates the efficacy of this method. A more detailed 
discussion of the mutagenesis efficiency is given in 
Secti on 3 . 1 . 6.3 ) .
3.1.5 Spiked oligonucleotide Mutagenesis
Most methods of random mutagenesis, including the 
misincorporation method described above, can be susceptible 
to mutagenic 'hot spots’, that is the clustering of 
mutations in certain regions of the gene, whilst other 
regions may be left unmutated (McPherson, 1991). The 
method of ‘spiked’ oligonucleotide mutagenesis avoids such 
hot spots and is probably the most truly random mutagenesis 
protocol available (Blacklow & Knowles, 1991). The 
procedure is essentially the same as with site-directed 
mutagenesis in that oligos are used to generate nucleotide 
changes, and the template DNA is prepared, and selected 
against, in exactly the same way. However, the oligo­
nucleotides have been synthesized by a protocol that gives 
a defined probability of incorporating one of the three 
'wrong’ nucleotide bases at each position along the oligo. 
This is achieved by spiking each phosphoramidite mix with a 
known concent rat ion of the other three mixes (Ner et al. , 
1988; McNeil & Smith, 1985).
11 oligos (R01 to Rll) were synthesized using nucleotide 
mixes spiked with 1.33% of the other three nucleotide mixes 
(see Section 3.1.7.1). The oligos were designed to cover 
most of the elements of secondary structure of VZV TS (see 
Fig. 3.4) and introduce an average of two nucleotide 
changes. The rationale of introducing two nucleotide 
changes per oligo is two-fold. First, it serves to 
increase the variation at individual codons. When one base 
of the codon is1 changed, an average of 5.7 (of the 19) 
other amino acids can be encoded (and these alterations
Oligo Nucleotide
Changes
Codon
Changes
Amino Acid 
Changes
Phenotype
R01 A121C ATC to CTC I41L Thy-
R02 T162G AAT to AAG N54K T h y
R04 A288G ATA to ATG I96M T h y
R07 A546G
T549G
C562A
CCA to CCG 
TGT to TGG 
CAG to AAG
P182Silent
C183W
Q188K
T h y
Table 3.3. Spiked Oligo Mutagenesis.
Nucleotide, amino acid and codon changes of mutant clones, and their 
phenotypes. The nucleotide change A121C indicates that A 121 was 
substituted by C. The affect of the nucleotide substitution on the codon 
are shown in bold. The amino acid change 141L indicates that 141 was 
replaced by L.
tend to be conservative), but when two bases are changed, 
the average number of other amino acids that can be 
accessed rises sharply to an average of 15.7 (Hermes et 
al. , 1990). Secondly it allows the potential for a number
of double amino acid variants to be synthesized. A 
detailed discussion of the factors controlling the number 
of changes is given in Section 3.1.7.1.
Prior to use in conjunction with the drug screening 
protocols, the level of mutagenesis efficiency of this 
method had to be established. Oligos R01 through Rll, and 
U-ssDNA made from pAD403 were used as described. 
Mutagenized DNA was used to transform E.coli S0928thyA. Of 
80 transformants assayed by the TS growth complementation
assa y . 14 (17.5%) had a T h y ph<=>notype. Three of the Thy+
cion es were selected at random and the region of the TS
gene corresponding to the oli go used to introduce mu tations
was sequenced. Two had no det ectable nucleot i de changes
whi 1s t the clone generated f rom o.ligo R1 1 had a single
si 1 ent nucleotide change (A702T]) , wh i ch did not change the
G 1 y re sidue at position 234.
Ana lysis of the phenoty pe of a further 99 clones
r e v ea 1ed that 2 5 (25.25%) had a Thj phenotype The
d i s t ibut ion of clones with a T h y Ph enotype was spread
equa 1 1y amongst the 11 oligos •
To see if the T h y  phenotypes were the result of 
mutations in the TS gene or an incomplete filling-in 
reaction, eight clones were analysed by EcoRI restriction 
enzyme digestion. Five shared an identical restriction 
pattern to that of pAP403. The TS gene of four of these 
was sequenced using oligos 59 to 62. All four clones 
contained point mutations in a region that corresponded to 
the oligo used to generate that particular clone in the 
initial mutagenesis reaction (Table 3.3). Refinements to 
the mutagenesis protocol, that included the use gene 32 
protein and U-ssDNA generated from pAD768 as a template for 
spiked oligo mutagenesis alleviated the problems of an 
incomplete filling-in reaction.
In summary, these results have demonstrated the efficacy
Clone Source Growth on FUdR2 
plates
Growth on TFT 10 
plates
G56 FUdR2 plate single colonies* single colonies* (2)
G56 TFT 10 plate N.T. single colonies* <3>
T56 TFT10 plate N.T. no growth
pAD403 FUdR2 plate poor growth* (4) N.T.
pAD403 TFT10 plate 1N.T. poor growth* <5>
pAD403 M9 plate no growth no growth
Table 3.4. Initial characterization of drug  resistan t clones.
Ability of various clones generated by misincorporation mutagenesis to 
grow in the presence of various inhibitors. An asterisk (*) represents that 
the clone was processed further, with numbers in parentheses representing 
the subsequent clone number. Poor growth indicates that single colonies 
were not formed, but some growth was observed. N.T. indicates not 
tested.
Clone Growth on FUdR plates 
2.0uM 0.4uM
Growth on TFT plates 
lO.OuM 2.0pM
G56-1 poor growth single colonies poor growth single colonies
G56-2 poor growth single colonies poor growth single colonies
G56-3 poor growth single colonies poor growth single colonies
T56-4 no growth no growth no growth no growth
T56-5 no growth no growth no growth no growth
jdAD403 no growth no growth no growth no growth
Table 3.5. F u rth e r characterization  of drug resistan t clones.
Growth of various drug resistant clones after retransformation of E.coli 
S 0 9 2 8thyA cells on solid media in the presence of various inhibitors. 
Poor growth indicates that single colonies were not formed, although some 
growth was observed.
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and efficiency of mutagenesis (>50%) of this method. As 
with the misincorporation mutagenesis method, the distrib­
ution of the mutations is random, with both nucleotide 
transitions and transversions observed. The isolation of a 
mutant with three changes further demonstrates the efficacy 
of this method.
3.1.6 Screening clones for drug resistance generated 
by misincorporation mutagenesis
The new methods of mutagenesis have been shown to be 
highly efficient and reliable. The aim now was to assess 
their worth in conjunction with the new drug screening 
protocols.
3.1.6.1 Success of drug selection scheme
The new selection scheme was shown to be successful by 
the isolation of a plasmid linked drug resistant clone with 
a single nucleotide change in the bacterial promoter 
region. 1,400 clones generated by misincorporation 
mutagenesis (using U-ssDNA made from pAD403 and oligo 56 as 
described) were screened for resistance to FUdR and TFT by 
method 3. When spread onto FUdR2 and TFT10 plates, clones 
derived from the reaction where dGTP was the limiting 
nucleotide for the elongation reaction (G56), grew as a 
lawn, whereas all other clones and a pAD403 control culture 
failed to g r o w  or grew to a significantly lesser extent 
than G56. EYUdR was not available during the initial 
experiments. Bacteria taken from this lawn were streaked 
for single colonies on FUdR2 and TFT10 plates (Table 3.4). 
Five clones (indicated with an asterisk*) were tested for a 
plasmid linked drug resistant phenotype, but only the three 
clones derived from the G56 reaction showed plasmid linked 
drug resistance (see Table 3.5). The TS gene of one of 
these clones (G56-1) was sequenced using oligos 59 to 62. 
Complete sequencing of the TS coding region revealed no 
nucleotide changes. Analysis of the upstream sequences 
revealed a single nucleotide change, A to C at position -53 
(numbering is such that +1 is A of the ATG methionine
Sequence of -10 region of pAD403 TCGTATGTTG
Sequence of -10 region of DrugR G56-3 clone TAGTAJTGTTG
Fig. 3.5. P rom oter changes.
Comparison of the sequences at and surrounding the -10 region of the 
bacterial promoter of pAD403 and the drug resistant clone G56-3. 
Nucleotide substitution is shown in bold. -10 region is underlined. Note 
that pAD403 contains a promoter mutation. The consensus sequence for 
the -10 region is TATAAT.
Nco INco I
VZV TS 
gene
VZV TS 
gene
G56-3 
Drug R
pAD4 03 
Drug S X h o  I■Xho I
TS TS
BB BB
Drug Resistant Drug Sensitive
Fig. 3.6. D rug resistance clones.
Confirmation that the drug resistance is caused by mutations in the 
promoter region rather than in the TS coding region. The Ncol site 
spans the initiating ATG codon of the TS coding sequence. BB indicates 
the vector backbone.
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initiation codon), immediately upstream of the -10 region 
of the bacterial promoter as shown in Fig. 3.5.
To confirm that the drug resistance was linked to the 
nucleotide change in the bacterial promoter, two constructs 
were made. pAD403 and the drug resistant G56-3 clone were 
digested with NcoI and XhoI. This digest generates two 
DNA fragments from each plasmid, a TS containing fragment, 
the initiating ATG codon being part of the Ncol restriction 
site, and a vector backbone fragment. The four fragments 
were isolated. The TS containing fragments of pAD403 and 
G56-3 were ligated to the reciprocal backbone fragment (see 
Fig. 3.6). The resulting DNA was used to transform the 
E.coli strain S0928th.v.4 and the transformants assayed for 
drug resistance. The constructs made from the G56-3 
backbone and WT TS fragment formed single colonies on 
FUdRO. 4 plates. The constructs made from the wild type 
backbone and the G56-3 TS fragment failed to form single 
colonies when streaked onto FUdRO.4 plates. This confirms 
that the drug resistance was linked to a mutation outside 
of the TS coding region. This is most likely the 
identified mutation in the bacterial promoter (see Fig. 
3.5), but the possibility of additional mutations that
affect plasmid copy number cannot be ruled out.
In addition, these results showed that bacteria that 
could grow as a bacterial lawn at 2. OpM FUdR could only
form single colonies at 0.4jiM FUdR, whilst the same clones 
that could grow as a lawn at lOpM TFT could only form
single colonies at 2.OpM TFT. This observation lead to a 
minor alteration of the drug screening protocols (Methods 4 
and 5; see Section 2.12.2). The WT pAD4 03 clone and two 
clones derived from the T56 reaction (where dTTP was the 
limiting nucleotide), could not form single colonies at 
these drug concentrations.
3 .1 .6.2 Wide scale screening using methods 4 and 5
At this point the mutations in the promoter of pAD4Q3 
were identified and subsequently corrected to make the 
vector pAD768 (see Section 3.1.3.1). For all the
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subsequent experiments, U-ssDNA was made from pAD768. 
Misincorporation mutagenesis was performed using the five 
oligos, 56, and 59 to 62, as described. Approximately 
10,000 clones were screened against both FUdR and EYUdR 
from D\A libraries generated from each oligo by either 
method -1 or 5, and the following resistant clones were 
i solated.
Clones generated from oligo 56 where dGTP was the 
limiting nucleotide (G56 clones) grew as a lawn in the
presence of lOpM EYUdR, compared to virtually no growth of 
pAD768 on the same plates. Bacteria from both plates were 
streaked for single colonies on EYUdRO.5, 1, 2, 5 and 10
plates. Bacteria from the G56 reaction formed single 
colonies at concentrations of up to lOpM EYUdR, whilst the 
wild type pAP768 clone failed to form single colonies above 
a concentration of 0.5pM EYUdR.
As a continuation of drug screening method 4, DNA was 
isolated from both clones to see if drug resistance was 
plasmid linked. The G 56 clone retained its resistance to 
EYUdR whilst the wild type pAD768 clone retained
sensitivity to this drug. Both remained sensitive to FUdR. 
Thij TS geri'-1 of the G56 derived isolate was sequenced with 
oligos 59 to 62 but revealed no nucleotide changes. In 
addition, no sequence changes were seen in the upstream 
promoter region of this clone.
In addition to the G56 EYUdRR clone, transformants 
derived from the misincorportion mutagenesis reaction using 
oligo 60 with dCTP (060 clones) or dTTP (T60 clones) and 
the pAD768 control each formed approximately 10 single 
colonies on EYUdRlO plates. When the C 6 0 , T60 and pAD768
resistant clones were tested for chloramphenicol
resistance, the majority were sensitive. This strongly
suggests that loss of the plasmid pCBTK3 was the cause of
drug resistance. By way of contrast, the G56 EYUdRR clone 
was resistant to both ampicillin and chloramphenicol, 
resistance to the latter drug showing that the plasmid 
expressing the VZV TK was present and that resistance to 
EYUdR was not due to loss of this plasmid. The isolation
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of chloramphenicol sensitive mutants led to the inclusion 
of this antibiotic in all further experiments that used the 
drug screening protocols.
3.1.6.3 Summary and statistical analysis
Screening of approximately 10,000 clones for each oligo 
resulted in the isolation of only a single EYUdR resistant 
clone. This clone had no changes in the VZV TS coding 
region or known promoter elements. Moreover, the cells 
expressing this clone had a copy of the pCKTK3 plasmid, 
suggesting the expression of VZV T K , which should ensure 
the phosphorylation of EYUdR. The mechanism of drug 
resistance in this clone remains unresolved, but could 
involve mutations in the origin of replication that control 
plasmid copy number. A plasmid with an increased copy 
number would be expected to over-express TS in much the 
same way as MTX resistant strains of L.casei (see Section
1.14.2). However, since it did not contain mutations in 
the TS gene, it was not processed further.
This method of mutagenesis can generate all the possible 
single nucleotide changes over a given target area 
(Lehtovaara et al., 1988; Holm et al.> 1990). To estimate
the number of clones that need to be screened in order to 
give a high level of confidence (>99%) of covering all 
possible point mutations, both the mutagenesis efficiency 
and efficacy must be determined.
The mutagenesis protocol is highly efficacious with 
mutants distibuted randomly across the target area, and 
sequencing studies suggesting an efficiency of ‘83% (a 
mutant in 5 out of 6 clones; see Table 3.2 - clones M 
through R ).
If the mutagenesis efficiency is 100%, then the number 
of clones that will need to be screened to give a high 
degree of confidence of identifying all possible single 
nucleotide changes is given by the following equation 
(Hutchinson et al., 1986).
N = [ ln(1-p1 / 8 )/ln(1-1/s)] + s/2 (Equation 1)
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Where p = Degree of confidence (0.99)
N = Number of clones to be screened 
s = Number of possible single nucleotide changes
Since each oligo (56 and 59 to 62) can be expected to 
mutagenize approximately 250 nucleotides (Lehtovaara et 
al., 1988; Holm et al ., 1990), then for any of 3 nucleotide 
replacements at each position this gives a value for s of 
750. This means that 8,785 clones must be screened in 
order to give a 99% level of confidence for evaluating all 
the possible single nucleotide substitutions. Exper­
imentally, at least 10,000 clones were analysed in each 
case. A mutagenesis efficiency of 83% reduces this figure 
to 8,300 clones. By equation (2) (Hutchinson et al. , 
1986), this gives a 98.1% degree of confidence that all the 
single nucleotide subtitutions were seen.
p = [1-et1n( 1 " 1 I s >(N " 3 / 2 >1 ]s (Equation 2)
If the mutagenesis efficiency was as low as 66%, 
corresponding to 6,667 mutant clones being screened, this 
still results in an acceptable degree of confidence (84.4%) 
of screening all the possible single point mutations.
In summary, this data suggests that all the possible 
single nucleotide substitutions were made in the VZV TS 
gene, and when screened for resistance to FUdR or EYUdR, 
none of these changes conferred a drug resistant phenotype.
3 . 1 . 7  Screening clones generated by spiked oligo 
mutagenesis
5,500 clones (500 clones per oligo), generated from 
U-ssDNA made from pAD768 and using all 11 spiked oligos, 
were screened by method 4 for resistance to EYUdR. Clones 
derived from oligo R02 grew significantly better than 
PAD768 and clones derived from the other oligos on EYUdRlO 
plates. When streaked on to FUdR20 and EYUdRlO plates, the 
oligo R02 derived clones formed single colonies whereas 
PAD768 and clones derived from the other oligos did not.
Clone FUdR EYUdR
5nM lOpM 20pM lpM 2pM 4juM
R01 + - N.T. + - N.T.
R02 + - N.T. + - N.T.
R03 + - N.T. + - N.T.
R05 + - N.T. + - N.T.
R06 + + + + - -
R07 + + + + - -
R08 + - - + + +
pAD768 + - N.T. + - N.T.
Table 3.6. Drug Resistant Variants.
Initial characterization of clones derived from spiked oligo mutagenesis. 
The growth of clones R01 to R03, and R05 to R08 in liquid M9 medium, 
supplemented with various concentrations of FUdR and EYUdR. 
+ indicates growth; - indicates no growth; N.T. indicates not tested.
Clone Solid Medium 
FUdR EYUdR 
(3pM) (0.5 |iM)
Liquid Medium 
FUdR EYUdR 
(20uM) (4pM)
R06 single colonies (1> single colonies <2> growth growth
R07 single colonies no growth growth growth
R08 single colonies (4) single colonies growth growth
pAD768 no growth no growth no growth no growth
Table 3.7. Further characterisation.
Clones isolated from screening DNA generated from spiked oligo 
mutagenesis. Growth clones R06 to R08 in solid and liquid M9 medium, 
supplemented with various concentrations of FUdR and EYUdR. 
Numbers in parentheses indicate clones processed further (see text for 
details).
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The drug resistant R02 derived clone formed single colonies 
when streaked onto LB-Amp/Cm, confirming the presence of 
pCBTK3. However, further analysis of this clone 
demonstrated that it did not have a plasmid linked 
phenotype, and this clone was not processed further.
A further 11,000 clones (1,000 clones per oligo), 
generated from U-ssDNA made from pAD768 were screened by 
method 4 for resistance to both FUdR and EYUdR. All were 
sensitive. Another 3,500 clones (500 clones per oligo), 
generated from U-ssDNA made from pAD768 and using the doped 
oligos R01 to R03 and R05 to R08 were screened by screening 
method 5 for resistance to both FUdR and EYUdR. All the 
cultures grew in the presence of FUdR (5pM) or EYUdR (lpM) 
(see Table 3.6). When sub-cultured into fresh drug 
containing medium, cultures derived from pAD768 and oligos 
R01 to R03 and R05, failed to grow in the presence of FUdR 
(IOjjM) or EYUdR (2pM) . Cultures derived from oligos R06 
and R07 grew in the presence of FUdR (lOpM) but failed to 
grow in media containing EYUdR (2pM), whilst the culture
derived from oligo R8 grew in the presence of EYUdR (29*4^^ 
Table 3.6). When drug screening method 5 was continued, 
clones R06, R07 and R08 formed single colonies in the
presence of the two drugs and grew in liquid culture at 
higher drug concentrations as shown in Table 3.7.
Mini-prep DNA was made from the five drug resistant 
clones that grew as single colonies (see Table 3.7) and 
digested with FcoRI. The restriction pattern of the TS
expressing plasmid was the same as the wild type pAD768 
plasmid. The restriction pattern of the plasmid pCBTK3 of 
the drug resistant clones 1 and 2 (numbering as in 
Table 3.7) were identical to that of pCBTK3 from drug 
sensitive control cells and purified plasmid, whilst the 
restriction pattern of clones 3 to 5 were different. When 
DNA of all these clones was used to retransform E.coli
S0928thyA/ pCBTK3, transformants containing DNA from clones 
3 to 5 were sensitive to both FUdR and EYUdR, whilst
transformants containing DNA from clones 1 and 2 were 
resistant to FUdR and EYUdR. These two plasmid linked drug
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resistant clones (1 and 2) grew in the presence of
ampicillin and chloramphenicol, confirming the presence of 
the pCBTK3 plasmid. The TS gene of these two resistant 
clones was sequenced using oligos 59 to 62 but no 
nucleotide changes were detected.
3. 1.7.1 Statistical analysis
This method of mutagenesis can generate any number of
point mutations within the given target region, depending 
upon the number of changes in the oligo. Before discussing 
the results in more detail a statistical analysis of this 
method of mutagenesis will be described.
To calculate the degree to which the oligos should be
spiked (a) to give the desired number of changes (c) for an
oligo of a defined length (n), the following equation is 
used (Ker et al., 1988; McNeil & Smith, 1985).
a = c/n (Equation 3)
Where o = Fraction to which each oligo mix should be
spiked with the other three phosphoramidite
n = Length of oligo ---------------------~ “
mixes
c = Desired number of changes
The value for o was calculated for n = 51 (the average 
length of the 11 spiked oligos) and c = 2. This gives a 
value for a of 0.04. On this basis, the ol i gonucl eot ide 
synthesis mixes were spiked as follows. 0.04 vols of a 
fresh vial of each mix were removed, and replaced by 0.013 
vols of the other 3 mixes. The four vials, each contained 
96% of the original precursor and 1.33% of the other three 
nucleotide precursors. The oligonucleotides were then 
synthesized as normal (the spiking of the oligonucleotides 
mixes and subsequent synthesis of the oligos was kindly 
performed by John McLauchlan).
From the binomial distribution, the probability of the 
number of changes in each oligo can be calculated by the 
following equation (Hermes et al., 1990).
42-mer
c s N P N*
1 126 1,248 0.32 4,696
2 7,749 108,910 0.27 485,986
3 309,960 5,500,269 0.15 44,178,871
4 9,066,330 191,566,940 0.06 3,846,725,606
57-mer
c s N P N*
1 171 1,746 0.23 9,149
2 14,364 210,752 0.27 940,439
3 790,020 14,758,887 0.21 84,675,200
4 31,995,810 717,669,530 0.12 7,205,517,374
Table 3.8. Statistical analysis of spiked oligo mutagenesis.
The values of s, N, P and N* for a 42-mer and 57-mer for different 
values of c.
c = Number of base changes per oligo.
s = Number of different mutations per oligo (see Equation 5).
N = Number of clones to be screened to give a 99% degree of
confidence of analysing all possible clones.
P = Expected fraction of clones containing c changes
(calculated for c = 2).
N* = Number of clones to be screened (N) multiplied by 1/P 
multiplied by 1/E, where E = mutagenesis efficiency 
(see text for details).
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P< c , n , a ) = [n!/(n-c)! c!] [a]c [l-a]n_c (Equation 4)
As this method of mutagenesis can introduce more than 
one change, the number of different mutations (s), each
oligo can generate can be calculated by the following 
equation, derived from equation 4 (Hermes et a l ., 1990).
s = [n!/(n-c)! c!] [3]c (Equation 5)
From Equation 1, the value of N, the number of clones 
that must be screened to give a 99% degree of confidence of 
analysing all possible variants, can be determined. 
However, this figure must be corrected to account for the 
mutagenesis efficiency (E; ~83% in our experiments), and
the fraction of the clones that contain c changes (P) as
shown in the legend to Table 3.8. The values of P, N and 
N* for two representative oligos are shown in Table 3.8.
3 . 1 . 7.2 Summary
A number of diug resistant clones were isolated although 
none had mutations in the VZV TS gene. In several 
instances, the plasmid encoding the VZV TK was found to 
h a v e  undergone some kind of rearrangement such that it 
could no longer express an active form of T K . This would 
account for the resistant phenotype observed. For the two 
clones where the TK encoding plasmid appeared normal by 
FroRI restriction enzyme analysis, other mechanisms of 
resistance must be considered. The VZV TK gene may contain 
mutations that inactivate the enzyme and account for the 
drug resistant phenotype. However, as the gene is
expressed on a mi/lticopy plasmid, every copy would be
required to harbour this mutation, thus making this option 
unlikely. Mutations that alter the copy number of the TS 
expressing plasmid are also possible.
At this point it seemed that the drug selection scheme 
was likely to reveal high numbers of drug resistant clones 
that had mutations in the VZV TK gene rather than the VZV 
TS gene. Furthermore, our statistical analysis performed
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for this method of mutagenesis had shown that an 
inordinately large number of clones would have to be 
screened to ensure that all possible mutations were tested.
Clearly these values were not ach ved, the typical 
number of clones being screened was approximately 2,000. 
For a 42-mer this only gives a 4.7% degree of confidence of 
screening all the possible 1 base substitution mutants 
(<<1.0% for a 57-mer). Similar calculations were performed 
for the number of clones required to detect all the two, 
three and four base substitutions (Table 3.8). Screening 
for all the three and four base changes was clearly 
prohibitive. An extension of the screening procedures to 
encompass all the two base substitution mutants was also 
discounted for the following reasons. The screening of 
clones generated by misincorporation mutagenesis has 
already shown that a single base substitution is unlikely 
to confer drug resistance to VZV TS (see Section 3.1.6). 
To screen all of the clones necessary to cover all the 
permutations of two substitutions would require of the 
order of 10,000,000 clones to give a 99% chance of covering 
all the possible mutants, which in itself is a 
considerable, though feasible, task.
However, problems were emerging with the drug resistance 
screen, namely the continued isolation of false positive 
clones. In addition, the screening of this number of 
clones would still only give access to an average of ~15.7 
other amino acids at each position (Hermes et al. , 1990).
Although it is possible that a single amino acid change is 
responsible for the drug resistant phenotype of TS 
previously reported (see Section 1.14.1), there is no 
guarantee that a single amino acid replacement would confer 
resistance to VZV T S . In addition, there is no certainty 
that the equivalent mutation in TS from two different 
sources would have the same effect on activity (see Section 
3.4.1). Together, these arguments lead to the termination 
of this part of the project.
k
G A T C G A T C
Fig. 3.7. Sequencing gel.
This figure shows a portion from a representative sequencing gel. The 
four tracks on the left are of the wild type VZV TS gene (pAD768) and 
the four tracks on the right are ffom the Y21H variant of VZV TS. The 
tracks were loaded G, A, T, C. Both clones were sequenced with oligo 
62. The nucleotide substitution, A61G is indicated in bold . The 
sequence shown corresponds to the non-coding strand of the gene.
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3.1.8 Site-directed mutagensis studies
The failure of the random mutagenesis studies to isolate 
a variant of VZV TS that is resistant to FdUMP suggests 
that only a very limited number of mutations, if any, may 
give rise to a drug resistant enzyme. Indeed, only one 
instance of a variant of TS that showed decreased affinity 
for FdUMP, but retained catalytic activity has been 
reported (Jastreboff et al ., 1983; see Section 1.14.1). In 
this case, the amino acid changes responsible for the 
decrease in affinity were not determined.
A second report has shown that the TS expressed in a
human cell line resistant to FUdR contains a single amino 
acid substitution, Y33H (Barbour et al . , 1990). These
authors reported that the variant enzyme has decreased 
affinity for FdUMP, but did not show conclusively that it 
retains catalytic activity (see Section 1.14.1). However, 
as this variant constitutes the only known amino acid 
substitution that may confer FdUMP resistantce to T S , it 
was decided to make the same amino acid substitution at the 
equivalent residue of VZV7 T S . By way of a control, and to 
see if the human variant retains catalytic activity as 
suggested (Barbour et al. , 1990), the same mutation was
introduced into human T S .
3 .1 .8 . 1 Mutant construction and enzyme activities
Both mutants were constructed by site-directed
mutagenesis. Tyrosine 21 of VZV TS (the equivalent of Y33 
of human TS; see Fig 1.6) was replaced by histidine in 
pAD768 using oligo 70 to create the mutant Y21H. Tyrosine 
33 of human TS was replaced by histidine in pAD876 using 
oligo 72 to create the mutant Y33H. The TS gene of Y21H 
was sequenced with oligos 3 to 7 and revealed no nucleotide 
changes apart from those introduced by site-directed 
mutagenesis (see Fig. 3.7). The region of the TS gene of 
Y33H that could be sequenced by oligo 74 revealed no 
nucleotide changes apart from those introduced by site-
directed mutagenesis. The enzymes were expressed in the 
E.coli thyA strain ^ 2 9 1 3 .  The TS activities measured by
Expressed
enzyme
Tritium release assay 
pmols dTMP/min/ug
% WT
VZV WT 105.8 ± 10.9 100.0
VZV Y21H 5.7 ± 1.3 5.3
Human WT 28.8 ± 2.7 100.0
Human Y33H 11.0 ± 2 .7 38.2
Table 3.9. TS assays.
TS activity of the VZV and human wild type and variant enzymes 
measured by the tritium release assay. All enzymes were expressed in 
E.coli %2913. Activities are given as mean ± standard error of the mean.
Expressed
Enzyme
Growth in M9 medium
Patch Single Colonies Liquid Culture
VZV WT + + +
VZV Y21H + - +
Human WT + + +
Human Y33H + * +
Table 3.10. Growth complementation assays.
The growth complementation of E.coli %2913 expressing the TS variants 
is shown for single colonies from LB-Amp-TdR plates which were 
patched or streaked on to solid M9 medium, or used to inoculate liquid 
M9 medium. + indicates growth; - indicates no growth.
Expressed
Enzyme
FUdR concentration (uM)
1.0 5 .0 10.0
VZV WT + + +
VZV Y21H + - -
Human WT + - -
Human Y33H + +/- -
Table 3.11. Assay of drug resistance.
The growth of E.coli S0928 J/ryA/pCBTK3 expressing the TS variants i 
liquid minimal medium supplemented with various concentrations of FUdI 
+ represents growth; +/- represents poor growth; - represents no growth.
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Fig. 3.8 Characterization of Y33H.
Effect of 50p,M FUdR on the growth of E.coli  S0928 thy A cells 
expressing the wild type and Y33H variant of human TS. Arrows 
indicate the addition of FUdR to a final concentration of 50|iM.
oo
vo
Q
O
1.4
1.0
0.8
0.6
0.4
0.2
0.0
765432
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■  Human TS (+FUdR) 
O Y33H 
•  Y33H (+FUdR)
Time (hours)
Fig. 3.9. Characterization of Y33H.
Effect of IOOjiM FUdR on the growth of E.coli  S0928 thy A cells 
expressing the wild type and Y33H variant of human TS. Arrows 
indicate the addition of FUdR to a final concentration of IOOjiM.
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the tritium release assay are shown in Table 3.9. The 
mutants were also scored by the TS growth complementation 
assay (see Table 3.10). The inability of the two mutants 
to form single colonies on M9 medium resulted in the use of 
alternative methods to assess the drug resistance of these 
clones.
The mutant and wild type clones were expressed in 
S0928 thy/4/pCBTK3 (see Section 3.1) and scored for the 
ability to grow in liquid M9 medium supplemented with FUdR 
(see Table 3.11). The VZV mutant Y21H is clearly not drug 
resistant in that at the lowest concentration that the 
mutant does not grow, the wild type still grows. However, 
cells expressing the human mutant Y33H grow poorly in the 
presence of 5pM FUdR compared with cells expressing the 
wild type enzyme that do not grow at all.
To further characterize the apparent drug resistance 
shown by the human variant Y33H, the affect of adding FUdR 
at the mid-log stage of growth of S0928fchjM/pCBTK3 
expressing the wild type human TS and the Y33H variant was 
analysed (see Section 2.13.4 and Figs. 3.8 and 3.9). Both 
the human wild type TS and Y33H variant grew at similar 
rates, although the mutant takes longer to commence 
exponential growth. 50pM FUdR has an almost identical 
inhibitory effect on both wild type human TS and the Y33H 
variant. When lOOpM FUdR is added, cells expressing the 
Y33H mutant do not reach the same final cell density as 
cells expressing the wild type enzyme. Moreover, cell 
lysis is clearly visible in the cultures of cells express­
ing the Y33H variant in the presence of lOOpM FUdR. This
is
suggests that the Y33H enzyme^slightly more susceptible to 
the effects of FUdR than the wild type human TS.
3.1.8.2 Molecular modelling
The Y21H mutant was modelled on the VZV TS structure to 
investigate why the histidine substitution leads to the 20- 
fold drop in enzyme activity. In the wild type enzyke 
structure, the aromatic ring of the Y21 side chain is very 
tightly packed against the side chains of M207, V211 and
Fig. 3.10. Y21H
The wild type enzyme is shown on the left with the mutant on the right. 
Amino acid 21 is shown in green. The red arrows illustrate that rotation 
about the Ca-Cp bond and Cp-CY bond of the H21 side chain has been 
performed. Residues M207, V211 and P212 that form the bend between 
p-strand iii and the J-helix are shown at the top of the picture. Several 
other neighbouring amino acids are also shown.
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P212 that form the bend between B-strand iii and the
J-helix, and also against the side chains of E18, L22, V25, 
L62 and Q256 (Fig. 3.10). All of these residues are very 
highly conserved in all the known TS sequences (see 
Fig 1.6). In addition, the hydroxyl group of the Y21 side 
chain points in the direction of the side chain of M297, 
however, the role of this hydroxyl group, if any, is not 
clear from the model. No potential H-bonds are apparent, 
and it would seem to be the presence of the bulky aromatic
ring of the side chain of Y21, rather than its hydroxyl
group that is the conserved feature.
When a histidine residue is modelled at this position of 
VZV TS, the major disruption is the loss of hydrophobic 
contacts to the junction between B-strand iii and the
J-helix. In addition, the distance between the delta 
carbon of M297 and the side chain of amino acid 21 
increases from 5.6 to 7.7 Angstroms.
The introduction of a charged residue and the creation 
of a large gap (and possibly the loss of a hydroxyl group) 
in a buried region of the protein in which movement is 
essential for catalysis, may explain why this mutant loses 
activity. Exactly why the human variant retains catalytic 
activity is not apparent from the VZV model. It should 
however be noted that the N-terminus of the human TS is 12 
amino acids longer than the VZV T S , and as the residue 
being studied here (Y21) is close to the N-terminus, the 
conformation that these residues adopt may account, at 
least in part, for the observed phenotypic differences.
3 .1 . 8.3 Summary
Tyrosine 21 (Y33 in human T S ) is almost totally
conserved in all TS sequences reported to date, the single 
exception being replacement by phenylalanine in L .lactis 
(see Fig 1.6). Such a substitution (Tyr to P h e ) is 
generally accepted as a vative substitution that would
be expected to have little effect on the overall structure 
of a protein (Taylor, 1986; Bordo & Argos, 1991; Rennell et 
al., 1991; John Overington, personal communication).
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However, the more disruptive Tyr to His substitution would 
be expected to have a greater affect on enzyme activity.
The mutant Y21H of VZV TS clearly does not have a drug 
resistant phenotype. This mutant should have been detected 
during the misincorporation mutagenesis procedure, as it 
requires only a single point mutation to change Y21 
(codon TAT) to H21 (codon CAT). By way of contrast, the 
Y33H variant of human TS differs from the VZV Y21H enzyme 
in that it retains significant catalytic activity 
(Table 3.9). This mutation has been proposed as the major 
determinant of the FUdR resistant phenotype of a human 
colorectal tumour cell line (Barbour et al., 1990), and the 
data presented here go some way to supporting this claim. 
The Y33H variant enzyme has detectable TS activity, but the 
assays used here gave conflicting results concerning the 
drug resistant character of this mutant.
The observation that the same mutation in TS from 
different sources can have different affects on enzyme
activity, is not unusual (see Section 1.11), and is most 
probably the result of local differences in accomodation of 
the amino acids side chains (see Sections 1.9, 3.2 and
3.3). Purification of both the VZV and human TS mutants, 
and detailed kinetic analysis could lead to a better 
understanding of these differences.
3.2 Mutants created by random mutagenesis
During the assessment of the efficiency of the random
mutagenesis protocols, a number of clones were identified 
that failed to complement the growth of an E.coli thyA 
strain. The aim of this section is to exploit the
availability of the VZV TS models, in an attempt to 
determine why the mutations disrupt enzyme activity. In
addition the comparison of the activities of some of these 
mutants with that of the wild type enzyme establishes a 
link between in vivo complementation and enzyme activity.
Expressed
enzyme
Tritium release assay 
pm ol/m in/ttg
% WT
WT 105.8 ± 10.9 100.0
S102L 0.9 ± 0.3 0.9
C187G <0.05 <0.05
F189L 4.9 ± 0.5 4.7
Table 3.12. TS assays.
Tritium release assay of three of the mutants isolated by random 
mutagenesis. Activities are given as the mean ± standard error of the 
mean. All variants were derivatives of pAD768 expressed in the E.coli 
strain %2913.
Clone Solvent
accessib ility
I41L buried
N54K buried
I96M buried
S102L buried
D174A/174H175 buried
V179E accessible
C183W/Q188K accessible
C187G buried
F189L buried
S197T/C198R buried
Table 3.13. Mutants of VZV TS.
The amino acid changes in the mutants isolated during the random 
mutagenesis protocols and the solvent accessibilty of their side chains in 
the wild type enzyme. 174H175 represents the insertion of histidine 
between residues 174 and 175.
Fig. 3.11. I41L
The model of the wild type VZV TS is shown at the top of this figure and 
the mutant is shown at the bottom. Residue 41 is highlighted in green in 
both cases. Van der Waals radii are shown for I/L41, Y246 and L247. 
The backbone carbonyl groups of several residues are highlighted in red. 
The most striking feature is the gap created between Y246 and L247.
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3.2.1 Mutant enzyae activities
The activity of three of the mutant enzymes in the 
tritium release assay are shown in Table 3.12. These 
results suggest that a specific activity of between 1% and 
5% of the wild type level in crude extracts results in a 
T h y  phenotype. This value is slightly higher than the 
values obtained in more detailed studies of L.casei TS 
(-1%; Climie et al. , 1990) and E.coli TS (0.97% to 1.25%;
Michaels et a l ., 1990).
3.2.2 Modelling Studies
The interpretation of the phenotype of these mutants 
has been facilitated by the availability of the models of 
VZV TS generated by Celia Schiffer and Robert Stroud 
(personal communication) based on the E.coli TS structures 
determined by the same group (Perry et al ., 1990; Finer-
Moore et al.y 1990; Montfort et al ., 1990). A full list of 
the mutants studied is given in Table 3.13. The 
classification of the residues in relation to their state 
of solvent accessibility is also shown.
Several different classes of possible explanation for 
loss of activity are suggested in the following sections. 
These include steric clashes with other amino acid side- 
chains and the polypeptide backbone, creation of gaps in 
the structure which may lead to instability, or the 
stabilization of an unfavouable structure, and disruption 
of possible H-bonds. In each particular case, the enzyme 
is thought to be incapable of accomodating these changes, 
without invoking structural abberations that ultimately 
lead to loss of activity. A brief description is given for 
each mutant, and in several cases this is illustrated with 
representations of the enzymes tertiary structure.
3.2.2.1 I41L
Isoleucine 41 packs neatly into a cleft created by the 
hydrophobic side-chains of Y246 and L247 to form part of a 
flat hydrophobic surface, which is at right angles to the 
orientation of the backbone carbonyl groups of T39 and
Fig. 3.12. N54K
The wild type enzyme is shown at the top and the mutant is shown at the 
bottom. Residue 54 is shown in green with van der Waals radii. The 0§ 
of the side chain of N54 is labelled. Potential H-bonds between the side 
chain of N54 and side chain of R56 and backbone carbonyl group of 
T233 are represented with a dashed yellow line, the distance shown in A. 
As H atoms are not shown, the length of the H-bonds are increased by
-1.2A.
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M299, and the carboxyl group of the C-terminal residue 
(Fig. 3.H). When a leucine residue is modelled in place of 
isoleucine, its side-chain projects out of this plane and 
leaves a gap in the cleft of Y246 and L247 (see Fig. 3.11). 
This gap may lead to the incorrect formation of this region 
of the protein which could disrupt the orientation of the 
surrounding residues.
A comparison with other TS sequences at the position 
equivalent to VZV 41 shows that only threonine and valine 
are found in this position (except for phage 03T and 
L.lactis, which have an alanine at this position). Both of 
these amino acids, like isoleucine, have a branched 
B-carbon, one arm of which contains a lone methyl group. 
Both valine and threonine can be modelled in this position, 
easily filling the cleft between Y247 and L248, without 
disrupting the planar hydrophobic surface that is 
interupted by the side chain of leucine. This confirms the 
need for the presence of a methyl group in the cleft 
between these residues, and its absence due to the 
substitution by leucine is probably the major factor that 
contributes to enzyme inactivation. This observation 
strongly suggests that the backbone carbonyl groups of T39 
and M299, and the carboxyl group of the C-terminal residue 
may play some role in catalysis or substrate binding. 
Interestingly, the side-chain hydroxyl group of threonine 
points in exactly the same direction as the other three 
carbonyl/carboxvlate groups, augmenting the possiblity of 
H-bond interactions involving these groups.
3.2.2.2 N54K
Asparagine 54 resides at the carboxy end of B-strand i 
and is naturally seen substituted only by serine and 
aspartate in the known TS sequences. Analysis of the VZV 
TS model reveals that the N54 side chain may form hydrogen 
bonds with the side chains of T233, R56 and N57 (see Fig. 
3.12). Substitution of N54 with lysine would prevent 
hydrogen bond formation. In addition, a lysine side chain 
would clash sterically with the side chain of R56 and the
Fig. 3.13. I96M
The wild type enzyme is shown at the top and the mutant is shown at the 
bottom. Residue 96 is depicted in green and van der Waals radii are 
shown for A71.
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resulting juxtaposition of two positive charges would also 
be destabilizing. The protein is probably unable to 
accomodate this amino acid substitution without disrupting 
the structure of 13-strand i which is essential for dimer 
formation and movement against other elements of secondary 
structure during catalysis.
3.2.2.3 I96M
Isoleucine 96 is a highly conserved residue substituted 
only in TS from phage T4 and L ,'lactis. This residue forms 
part of a conserved loop between helices C and D, forming 
close contacts with other residues in this loop. 
Substitution by methionine would cause a steric clash with 
the side-chain of alanine 71 in helix B (see Fig. 3.13). 
If a glycine residue is modelled at position 71, the 
methionine subtitution no longer clashes j sterically. 
Interestingly, a glycine is found at the equivalent 
position in all other eukaryotic TS sequences, suggesting 
that the equivalent lie to Met substitution may be 
tolerated in TS from other sources. Further analysis of 
the VZV TS model reveals that the substitution of 196 with 
other hydrophobic amino acids could result in an inactive 
enyzme. A valine residue at position 96 would leave an 
unfavourable gap, whereas leucine at this position would 
create the same steric problems as methionine. These 
observations may partly explain the conserved nature of 
this residue.
3.2.2.4 S 1 0 2 L
The side chain of S102 sits in a pocket created by the 
residues G101, S103, K104 and D118 and is within hydrogen- 
bonding distance with the side-chain amino group of K104. 
This amino acid is highly conserved in the eukaryotic TS 
sequences, substituted only in Plasmodium spp. by 
threonine. Indeed, a threonine residue can be modelled at 
this position of VZV T S , preserving the potential to from a 
H-bond with K104, thus it seems likely that such a contact 
is made in all eukaryotic TSs. A I C u o h ^  residue
Fig. 3.14. D174A/174H175
Only the wild type enzyme is shown in this case as the mutant could not 
be accurately modelled. Residues D174 and 1175 are coloured in green. 
The closely packed neighbouring residues are shown with their van der 
Waals radii, commencing with W170 at the top of the figure, and 
continuing toward the C-terminus in a clockwise direction.
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modelled at this position not only interferes sterically 
with Q117 and D118, but removes the possibility of a H-bond 
with K104, due to the loss of the side-chain hydroxyl 
group. Unfortunately, this region of VZV TS differs in 
sequence, and presumably structure, from prokaryotic TSs, 
and these differences may affect the accuracy of the 
corresponding region of the VZV model (as it is based on 
the E.coli structure). For this reason, no representation 
of this mutant is shown here and, the affects of the amino 
acid substitution must be interpreted with additional 
caution.
3.2.2.5 D174A/174H175
The two residues at this position (D174 and 1175) are 
located in helix I and conform to the consensus sequences 
(D/E/A) (I/V/L/F) respectively (see Fig. 1.6). Our
analysis of this region reveals that residues W170 through 
K173 which form a very highly conserved loop that joins 
B-strand v and helix I, form a surface perfectly 
complementary to residues D174 and 1175 (see Fig. 3.14). 
It also illustrates beautifully how three highly conserved 
(P172, P176, P181) and one invariant proline residue (P182) 
'wrap’ themselves around these two residues forming a 
compact buried region of the protein. The D174A mutation 
is not that disruptive per se, as shown by modelling. 
However, the insertion of a histidine residue cannot be 
modelled in this region without gross disruption of the 
surrounding structure. It is therefore likely that the 
disruption of the precise packing of residues in this 
region is the cause of enzyme inactivation. It should be 
recalled that P182 immediately precedes the active site 
C183 residue.
Fig. 3.15. V179E
The wild type enzyme is shown at the top and the mutant is shown at the 
bottom. Amino acid 179 is shown in green with van der Waals radii. 
The steric clash of the glutamate side chain of the mutant with the 
backbone carbonyl group of Y 100 is clearly seen.
Fig. 3.16. C187G
The wild type enzyme is shown on the left and the mutant is on the right. 
Residue 187 is depicted in green. Residues from p-strands iii, iv and v 
are shown, as is W97, with van der Waals radii shown for all residues.
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3.2.2.6 V179E
This residue lies at the end of helix I, and is re­
placed in other TS sequences by the amino acids alanine and 
glycine which in itself suggests the requirement for a 
small amino acid at this position (see Fig. 1.6). V179
fits snugly into a small pocket created by Y100, L119,
1122 and L180 (see Fig. 3.15). The side chain of E179 can­
not fill this pocket and clashes with the backbone of Y100 
from helix D. Although one arm of the valine side chain 
points towards the solvent, modelling of the glutamate side 
chain such that it is exposed to the solvent, could only be 
ach \eved by unacceptable distortion of its side chain.
3.2.2.7 C183W/Q188K
The two substitutions in this mutant were not modelled 
as the lack of the active site cysteine residue alone is 
almost certainly the cause of the loss of enzyme activity 
(see Section 1.11).
3.2.2.8 C187G
This residue lies in the middle of 13-strand iv and its 
side-chain points into the core of the TS monomer, clearly 
suggesting that it has no interactions with the second 
subunit of the dimer. It is not a well conserved residue, 
although in eukaryote TS sequences, only amino acids with 
small side-chains are found at this position (see 
Fig. 1.6). C187 is packed against the side chains of
residues C198, V200 and Y218, and is also close to F189
(see Fig. 3.16). Substitution by glycine creates a gap 
that could lead to inefficient hydrophobic packing in this 
region, which could ultimately result in enzyme 
inactivation.
The factors that affect structural accomodation have 
recently been quantified (see Section 1.9; Lim & Sauer, 
1991; Perry et al . , 1990). One of the observed rules
governing accomodation is that, in general, for a reduction 
of three or more heavy atom equivalents (carbon, nitrogen, 
oxygen or sulphur), a second site or covariant mutation is
Fig. 3.17. F189L
The wild type enzyme is shown on the left and the mutant is shown on the 
right. Residue 189 is shown in green with van der Waals radii. L196 
and SI97 are also shown with van der Waals radii. The red arrow 
indicates that rotation about the Cp-CY bond of the LI89 side chain was 
performed. A prominent gap is seen in the F189L mutant that is 
normally filled by the side chain of FI 89 in the wild type enzyme.
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required. In this case, only two heavy atom equivalents 
have been lost, but this may still be sufficient to cause 
the need for a second site mutation.
Two additional observations add weight to this proposal. 
Firstly, a glycine residue is seen at this position in 
C.fasiculata TS suggesting that the presence of a glycine 
alone is not disruptive to the 13-strand per se. Secondly, 
the gap created in this substitution in VZV T S , may well be 
accomodated in C.fasiculata TS. A detailed analysis of the 
VZV TS model suggests that residue 200 may be covariant 
with residue 187. Indeed, when V200 is replaced with 
leucine (seen at the equivalent position of C.fasiculata 
T S ) the leucine side chain can fill the gap created by the 
original C187G substitution.
3.2.2.9 F189L
The aromatic side-chain of F189 falls neatly into a 
pocket created by residues L196, S197 and C198 from
13-strand iv, and L221, T222 and V225 from the J-helix
(Fig. 3.1). Modelling reveals that a Leu residue cannot 
fill this pocket, which presumably is important for the 
correct packing of the core residues. Such a view 
correlates with the observation from a detailed analysis of 
the core packing of the lambda repressor, that a decrease 
in the hydrophobic core of greater than two methylene group 
equivalents causes disruption of the core and results in 
loss of protein function (Lim & Sauer, 1989; 1991). F189
is invariant, save for phage 03T where it is replaced by 
tryptophan. Tryptophan was modelled such that its aromatic 
side-chain fitted into this pocket of the VZV T S , but this 
resulted in a steric clash with one arm of the side-chain 
of V152. Interestingly, the equivalent residue is Leu in 
phage 03T, which, when modelled at position 152 of VZV TS 
(with tryptophan substituted for phenylalanine at position 
189), facilitates the accomodation of W189. This suggests 
that these two residues may be an example of a covariant 
pair (see Section 1.6).
These results suggest that the positioning of a large
Fig. 3.18. S197T/C198R
The wild type structure is shown on the left and the mutant on the right. 
Residues 197 and 198 are coloured in green and shown with their van der 
Waals radii. F47’ from the second subunit is coloured in yellow. The Id- 
bond between the side chain hydroxyl group of S/T197 to the backbone 
NH of G234 is shown by the dashed yellow line, and the distance depicted 
in A. As H atoms are not shown on the model, the length of the H-bonds 
is increased by -1 .2A.
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side chain in the groove created by residues 196 to 198 may 
be essential for the correct folding or stability of this 
region. This analysis may explain why the substitution of 
phenylalanine by leucine, often considered a conserved 
change (Bordo & Argos, 1991; Taylor, 1986; John Overington, 
personal communication), in this case leads to enzyme 
inactivation.
3.2.2.10 S197T/C198R
These two residues are completely conserved in all 
eukaryotic TS sequences reported to date. Indeed the tight 
packing of their side chains in the interior of the 
protein, surrounded by highly conserved residues, provides 
some reason for the high degree of conservation. Replace­
ment of S197 with threonine preserves a H-bond from the 
backbone amino group of G234 to the serine/threonine side 
chain hydroxyl group, but the additional methyl group of 
T197 clashes with the side chain of F47’ and the backbone 
carbonyl group of D235 (see Fig. 3.18). The more 
disruptive C198R substitution results in a major steric 
clash with the invariant Y218 residue. Together these 
steric clashes probably account for the observed enzyme 
inactivation.
3.2.3 Summary
These analyses show the combined power of modelling, 
phylogenetic comparisons and random mutagenesis studies. 
They provide arguments as to why some residues are highly 
conserved, suggest a variety of ways in which substitutions 
lead to inactivation and describe possible amino acid 
changes that could be made to probe the way in which TS can 
accomodate mutations.
Many of the mutants are inferred to lead to inactivation 
due to steric clashes or the creation of gaps in core 
regions of the protein. Steric clashes must be overcome in 
order to form a stable protein structure. In some cases, 
the protein may be unable to accomodate these clashes 
producing an unstable enzyme unable to catalyse the normal
VZV
43 i 54
1........... 1
DRTGiGTlSlFG.mqarYnLrne.FP
HVS DRTGtGTlSiFG.tqsrFsLene.FP
HVA DRTGvGTlSvFG.mqsrYsLekd.FP
Human DRTGtGTlSvFG.mqarYsLrde.FP
Mouse DRTGtGTlSvFG.mqarYsLrde.FP
C.albicans DRTGtGTkSlFappqlrFdLsndtFP
P .carinii DRTGtGTlSvpapsplkFsLrnktFP
S.cerevisiae DRTGtGT1S 1FappqIrFsLrddtFP
C.fasciculata DRTGvGTiSlFG.aqm.FslrdnqLP
L.amazonensis DRTGvGTlSlFG.aqmrFsLrdnrLP
L.major DRTGvGTiSlFG.aqmrFsLrdnrLP
L.tropica DRTGvGTiSlFG.aqmrFsLrdnrLP
P.chabaudi DRTGvGvlSkFG.ymmkFnLsey.FP
P.falciparum DRTGvGvlSkFG.yimkFdLsqy.FP
E.coli DRTGtGTlSiFG.hqmrFnLqdg.FP
B . subtilis DRTGtGTiStFG.yqmrFnLreg.FP
L. lactis DgqmanskyvtG.s fvtYdLqkgeFP
L.casei DRThtGTySiFG.hqmrFdLskg.FP
Tn4003 DRThtGTiSkFG.hqlrFdLtkg.FP
Phage T4 DRTGtGTialFG.sklrWdLtkg.FP
Phage phi3T DgTpahTlSvms.kqmrFdnse..vP
Fig. 3.19. Alignment of p-strand i sequences.
The alignment of the residues in and around p-strand i of the 21 known 
TS sequences. Residues shown in capitals are conserved in at least 17 of 
the sequences. C.albicans, P.carinii and S.cerevisiae are the three yeast 
sequences referred to in the text. For the full legend, see Fig. 1.6.
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reaction. Alternatively, the required repacking may lead 
to the re-orientation of residues that play a critical role 
in catalysis. In cases where the amino acid substitution 
appears to cause no steric clashes or readily detectable 
disruption to the final structure, the phenotype may 
reflect disruption of the folding pathway (Rennell et al. , 
1991) .
3.3 Studies of key structural regions of TS
Two regions of TS were chosen for analysis by site- 
directed mutagenesis. The first was a buried region, 
13-strand i, whilst the second, the carboxy-terminal tail, 
lies on the surface of the protein.
3.3.1 fi-Strand i
13-strand i has several important roles to play in the 
function of TS (Matthews et al., 1989, 1990b; Finer-Moore
et a l ., 1990). However the amino acid sequences show some
degree of redundancy in TS from different organisms (see 
Fig. 3.19)* To investigate these differences, several 
mutants were constructed in this region of VZV T S , and 
their effects on enzyme activty determined.
3.3.1.1 Mutant construction and enzyme activities
All of the mutants were constructed by site-directed 
mutagenesis. Glycine 48 was replaced by alanine in pAD403 
using oligo 57 to create the mutant G48A. The mutant 
G48A/48P49/M49P was constructed using oligo 58, whilst 
oligo 67 was used for mutant 58T59. Mutant G48A/48P49/ 
M49P/58T59 was constructed using oligo 67 and template DNA 
made from pAD403 containing -the G48A/48P49/M49P mutations. 
All four mutants complemented the growth of the E.coli 
strain ^2913. The mutants were initially identified by 
slot blot hybridization or by direct DNA sequencing. The 
TS gene of each mutant was completely sequenced with oligos 
3 to 7 and revealed no nucleotide changes apart from those 
introduced by site-directed mutagenesis. The TS coding
Expressed enzyme Tritium release assay 
pm ol/m in/jig
% WT
pAD768 (WT) 105.8 ± 10.9 100.0
G48A 50.8 ±7.1 48.0
G48A/48P49/M49P 32.6 ±3 .3 30.8
58T59 73.2 ± 3 .7 69.2
G48A/48P49/M49P/58T59 80.4 ± 3.4 76.0
Table 3.14. TS assays.
Tritium release assays of the wild type VZV TS and variants with 
mutations in p-strand i. Activities are given as mean ± standard error of 
the mean. All variants were derivatives of pAD768 expressed in the 
E.coli strain %2913.
Codon Amino acid Codon Amino acid Codon Amino acid
CGA Arg AAA Lys AGC Ser
GGA Gly ACA Thr AGG Arg
TGA Stop ATA lie AGT Ser
Table 3.15. Possible revertants of G48R.
The nine codons shown above represent all the possible revertants of the 
mutant G48R using ethyl methanesulphonate.
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sequence of each mutant was excised from pAD403 and 
transferred to the pAD768, as this plasmid has the wild 
type -10 region of the bacterial promoter sequence (see 
Section 3.1.3.2). Enzyme activities were determined in 
crude extracts made from E.coli 9^2913 cells, and the 
results are shown in Table 3.14.
3.3.1.2 Predicted role of G31 in E.coli TS
13-strand i moves against (3-strand ii during the 
formation of the ternary complex and is one of the three 
(3-strands that play host to the so-called (3-kink of the 
sheet (Matthews et a l ., 1989, 1990b; Finer-Moore et a l .,
1990). A feature of this (3-kink is the hydrogen bonding 
network that starts from the. side chain of an arginine 
residue (R52’) in (3-strand i of the second subunit, 
traverses (3-strands i, ii and iii of the first subunit and 
ends at the backbone carbonyl group of the active site 
cysteine residue (C183), resulting in the correct 
orientation of the side chain for catalysis (Matthews et 
al. , 1989; see Fig. 3.20). When this structure was first
described for E,coli T S , Matthews and co-workers (1989) 
proposed that two highly conserved glycine residues, G31 
(G48 in VZV) in (3-strand i and G204 (G241) in (3-strand ii 
must always be found at these positions because the 
observed dihedral angles are only allowed for glycine 
(Ramachandran & Sasisekharan, 1968). A mutant of VZV TS,
G48R/M49I had previously been identified that failed to 
complement the growth of the E.coli strain 2913 (R.
Thompson and J. E. Scott, personal communication). In 
experiments using EMS to induce revertants that regained 
the ability to complement the growth of the E.coli thyA 
strain, only enzymes with glycine at residue 48 were found. 
This shows that the M49I change in itself had little effect 
on activity, as measured by the TS growth complementation 
assay.
The G48R mutation was due to a change in the codon from 
GGA to AGA. Single mutations, induced by EMS, could change 
this to several alternate codons, resulting in substitution
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of a variety of amino acids, but not alanine (see Table 
3.15). Of 40 independent complementing revertants 
isolated, all had a glycine at position 48 (R. Thompson and 
J. E. Scott, personal communication) suggesting that a 
residue with a side chain equivalent in size or larger than 
that of serine cannot be tolerated at this position.
The phylogenetic comparison immediately suggests that 
there may not be an absolute requirement for glycine at 
this position as alanine is found in the yeast TS sequences 
and a serine residue is seen in the bacteriophage 03T at 
the equivalent position (see Fig. 3.19).
3.3.1.3 A glycine residue at position 48 is not 
absolutely essential for VZV TS activity
On the basis of these observations, it was decided to 
substitute G48 of VZV TS with alanine. This mutant (G48A) 
had approximately half the enzyme activity in the tritium 
release assay compared to the wild-type enzyme (see 
Table 3.14). This demonstrates that a glycine residue at 
this position is not absolutely essential for enzyme 
activity. This is in contrast to the proposal of Matthews 
and co-workers (1989). The model of VZV TS cannot 
accomodate an alanine residue at this position due to 
steric clashes (data not shown). This suggests that the 
mutant form of TS undergoes some conformational changes at 
this position to accomodate the methyl side chain of 
alanine. The changes in the structure that allow this 
accomodation cannot presently be modelled from the crystal 
structure of E.coli TS or the model of VZV TS due to the 
lack of access to suitable modelling software. In 
addition, more recent work by Matthews group (Michaels et 
al. , 1990) has shown that substitution of G204 (G241) of
E.coli TS with alanine or serine (but none of 10 other 
amino acids) produces active enzyme, showing that the 
glycine in /3-strand ii is similarly not absolutely 
required.
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3.3.1.4 The additional residue in 6-strand i of yeast TS 
and a VZV TS mutant is accomodated by a 6-bulge
The yeast sequences contain an additional amino acid 
immediately adjacent to the glycine in 6-strand i (see Fig. 
3.17). As mentioned previously, 6-strand i is the only 
buried element of secondary structure that has a variable 
number of amino acids (Hardy et al. , 1987; see F3
1.6 ). The presence of this additional residue may be
linked with the replacement of glycine by alanine in this 
region of the yeast TS enzymes. To investigate this 
possibility, the mutant G48A/48P49/M49P was constructed. 
This mutant may serve as a reasonable ‘mimic’ of the yeast 
6-strand i sequence. It bears the closest resemblance to 
the S.cerevisiae sequence, differing by three conserved 
amino acids (A51L, Y53F and N54S) out of the 13 that make 
up 6-strand i (see Fig. 3.19). The activity of this mutant 
(30% of the wild type enzyme) clearly demonstrates that the 
VZV enzyme can tolerate this additional amino acid (see 
Table 3.14).
From the structural information available for TS from 
L.casei and E.coli it seems unusual that 6-strand i could 
tolerate an additional amino acid, as this would be 
expected to interfere with the movement and precise 
orientation of this element of secondary structure. 
However, yeast TSs have naturally accomodated an additional 
residue in the centre of 6-strand i, and we have shown that 
VZV TS can tolerate an extra residue at this position.
Recent experiments by various workers have shown that 
several other proteins are capable of accomodating amino 
acid insertions. Sondek and Shortle (1990) have shown that 
when glycine or alanine residues were inserted at 20 
randomly selected sites in staphylococcal nuclease, insert­
ions only at five sites totally inactivated the enzyme, 
whilst the majority of insertions reduced activity by 
approximately two-fold. Many of these tolerated insertions 
fell within a-helices or 6-strands. Other groups have 
recorded similar results with other proteins (Barany, 1985, 
1987; Tanese & Goff, 1988). The resulting rearrangements
Fig. 3.20. p-kink of VZV TS model.
This figure shows the hydrogen bonding network of the p-sheet of TS, 
with residues from p-strands i, ii and iii running horizontally across the 
figure. The residue shown in red is R52' from the second subunit. G48 
and G241 are shown in green. Hydrogen bonds are represented by 
yellow dashed lines. The active site residue, Cl 83, is also shown and the 
sulphur atom indicated by the letter S.
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that are made to accomodate these changes have not yet been 
described. It should be noted for these proteins, the 
amino acid insertions are tolerated in elements of 
secondary structure that are not significantly buried. 
This is in contrast to the insertion of an extra amino acid 
in B-strand i of T S , an element of secondary structure 
which is buried in the core of the protein.
Initially, it was not clear how an additional residue 
could be accomodated in this region of the enzyme (see Fig. 
3.20), however, several observations, described below, are 
consistent with the formation of a B-bulge (Richardson et 
al . , 1978). The insertion of an extra residue to B-strand 
i of VZV TS should not disrupt the H-bond interactions 
between the side chain of R 5 2 ’ from the second subunit to 
the backbone carbonyl groups of residues 47 and 48 of the 
first (nor the reciprocal interactions between R52 and 47* 
and 4 8 ’) as the residue is inserted into B-strand i of both 
subunits.
B-strand i should still be able to move during catalysis 
if its general structure is maintained, which seems likely 
for the following reasons. If one half of the strand were
to undergo a register shift, caused by the insertion of an
extra residue, then the side chains of residues pointing 
into the core would be reorientated to point into the dimer 
interface and vice-versa. This would require extensive 
repacking to accomodate at least five residues, which in 
itself is unlikely. Moreover, if this was the way in which 
the yeast enzymes have evolved to accomodate this 
insertion, then extensive sequence changes would be 
expected in the regions that pack against the B-strand i 
residues; such sequence changes are not apparent (see 
Fig. 3.19).
Taken together, these observations, and experimental 
data, suggest that some local accomodation of the
additional proline residue takes place. This is most
likely achieved by the formation of a B-bulge, a structure 
with which proline residues are often associated 
(Richardson et al ., 1978; see Fig. 3.21). Several other
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Fig. 3.21. A classic p-bulge.
A classic p-bulge in anti-parallel p-sheet. Small triangles represent side 
chains below the sheet, and larger triangles represent side chains above it 
(taken from Richardson & Richardson, 1989). Residue number 1 would 
represent G48 and residue number 2 would be the additional proline 
seen in the p-bulge of the VZV TS mutant G48P/48P49/M49P. 
X represents G241 of P-strand ii.
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features of 8-bulges are consistent with this proposal. 
8-bulges are common in anti-parallel 8-sheets (but rare in 
parallel 8-sheets); B-strands i and ii of TS are anti- 
parallel. 8-bulges are usually located between a close 
pair of interstrand H-bonds rather than a wide pair; in TS 
the presence of the 8-kink would mean that the 8-bulge 
would occur between two intermediary spaced H-bonds. 
8-bulges do not induce a register shift of the 8-strand, an 
observation compatible with the argument that such • a 
conformational change is highly unlikely. In general, 
8-bulges are considered the ideal way to accomodate 
insertions, especially when located at the end or edge of a 
8-sheet (Richardson et a l . , 1978), as is the case for
8-strand i in TS.
The conformation of a 8-bulge requires that the single 
residue on the opposite strand adopts a similar dihedral 
angles to those observed for the polyproline conformation 
(near phi= -60°, psi= 140*). The glycine residue situated 
at this position in 8-strand ii of TS could readily adopt 
this conformation (Ramachandran & Sasisekharan, 1968).
3.3.1.5 Identification of a covariant insertion 
adjacent to the 8-bulge in 8-strand i
Immediately adjacent to the carboxy-end of 8-strand i, 
an additional amino acid is seen in both yeast (threonine) 
and Leishmania spp. (arginine) TS sequences. To determine 
whether this insertion is linked to the additional residue 
in the 8-strand i, two mutants were constructed . The first 
mutant, containing a threonine between residues 58 and 59 
(58T59), reduces activity to approximately 70% of wild type 
TS when measured by the tritium release assay (see 
Table 3.14). This suggests that the extra amino acid can 
be accomodated by VZV TS. This region is part of a surface 
loop between 8-strand i and helix B so the presence of an 
additional hydrophilic amino acids, such as threonine or 
arginine (which are often found on the surface of proteins) 
could possibly be expected not to be too disruptive.
Recently, the consequences of the addition of extra
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residues has been quantitated in a study of single amino 
acid insertion mutagenesis of staphylococcal nuclease 
(Sondek & Shortle, 1990). They found that 11 out of 11 
glycine and/or alanine insertions at seven different sites 
in four different surface loops only reduced enzyme 
activity by two- to five-fold, suggesting that loop regions 
in general are tolerant to amino acid insertions.
An additional mutant containing the above insertion, 
together with the B-strand i mutations (G48A/48P49/M49P/ 
58T59), has approximately 2.5 times the
activity of the G48A/48P49/M49P mutant, and slightly more 
than the 58T59 mutant (see Table 3.14). This data suggests 
that the two positions are covariant, that is, both may 
contribute towards the stable accomodation of the other.
3 . 3.1.6 Summary
These experiments have shown that a glycine residue at 
position 48 is not absolutely essential for enzyme 
activity. Also, the additional residue found in B-strand i 
of yeast TS sequences can be accomodated in VZV T S . The 
construction of this latter mutant can be thought of as a 
crude example of the recruitment of an element of secondary 
structure from one enzyme to the backbone of a second. 
Alternatively, it can be viewed as an illustration of the 
plastic response of the VZV enzyme to insertions in this 
region. The suggestion that the additional residue in the 
loop region is covariant with the B-strand i insertion 
supports this notion.
3.3.2 Carboxy-terminus
The removal of the C-terminal residue of L.casei TS by 
carboxypeptidase has been shown to inactivate the enzyme 
(Aull et a l ., 1974). The creation of the equivalent
L.casei mutant by site-directed mutagenesis has confirmed 
that the C-terminal residue is essential for catalysis 
(Climie et al., 1990). This has been presumed to be due to 
the disruption of H-bonds between the C-terminal carboxyl 
group and the side chains of W85, R23 and T24, and to the
Expressed
enzyme
Tritium  
release assay 
pm ol/m in/|ig
% WT Debrom ination
assay
m O D /m in/|ig
% WT
pAD768
(WT)
105.9 ± 10.9 100.0 0.19 ±0.01 100.0
L301A 3.5 ± 0.6 3.3 0.16 ±0.02 84.2
E298P 6.0 ± 0.8 5.7 0.22 ± 0.07 115.8
E298P/
L301A
6.3 ± 0.8 6.0 0.24 ± 0.03 126.3
A300E/
L301A
1.5 ± 0 .3 1.4 0.13 ±0.01 68.4
Table 3.16. TS assays.
TS assays (tritium release and denomination) for the wild type VZV TS 
and variants with mutations in the C-terminal region. Activities are given 
as means ± standard error of the mean. All variants were derivatives of 
pAD768 expressed in the E.coli strain %2913.
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PABA ring of the cofactor (Montfort et al . , 1990; Finer-
Moore et al. , 1990; Matthews et al . , 1990b; see Section
1.8). To investigate the nature of these interactions in 
VZV T S , a number of mutants were constructed in this 
region. All of the mutants were designed before the VZV TS 
model became available.
3.3.2.1 Mutant construction and enzyme activities
All of the mutants were constructed by site-directed 
mutagenesis. The C-terminal leucine residue was replaced 
by a stop codon in pAD403 using oligo AR1 to form L301A, 
whilst A300E/L301A. was constructed using oligo 69. Mutant 
E298P was made in pAD403 using oligo A R 2 , whilst the mutant 
E298P/L301A. was made using the same oligo, but using 
template DNA made from pAD403 containing the L301A 
mutation. The mutants were initially identified by DNA 
sequencing. The TS gene of each mutant was completely 
sequenced with oligos 3 to 7 and revealed no nucleotide 
changes apart from those introduced by site-directed 
mutagenesis. The TS coding sequence of each mutant was 
excised from pAD403 and transferred to pAD768, prior to the 
determination of enzyme activities in crude extracts made 
from E.coli %  291 3 cells.
The L.casei TS C-terminal deletion mutant was originally 
shown to be inactive by the tritium release assay (Aull et 
al. , 1974 ). However, the same mutant has been shown to
have essentially wild-type debromination activity (Dan 
Santi , personal communication). This suggests that the 
C-terminal interactions are independent of the first stage 
of the covalent binding of dUMP, and the activation of the 
C5-H (or C5-Br) bond. For this reason, the activities of 
all of the mutants were measured by both the tritium 
release and debromination assays (Table 3.16).
3.3.2.2 The C-terminal interactions of L.casei and 
E.coli TS are essentially identical
The lack of a crystal structure for the ternary complex 
of L.casei TS has meant that interpretation of mutagenesis
VZV K296MEMAL301
L.casei K311APVAV316
E.coli K259APVAI264
Fig. 3.22. C-terminal sequences.
Sequence alignment of the six C-terminal six amino acids of TS 
VZV, L.casei and E.coli.
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data from L.casei TS must be performed on the basis of the 
equivalent complex of E.coli T S . The use of the E.coli 
structure to describe the interactions at the C-terminus of 
L.casei TS is valid due to the extensive structural 
homology observed between the L.casei and E.coli native TS 
structures (Perry et al., 1990). The only sequence 
difference in the region of interest lies in the C-terminal 
amino acid of L.casei (V316) and E.coli (1264). This 
difference (in molecular terms, a single methyl group) is 
probably of little significance since the replacement of 
V316 by several hydrophobic residues (i.e. A/V/L/M), has no 
deleterious effect on activity, suggesting that this amino 
acid difference is of little consequence when comparing the 
structural and functional equivalence of this region of 
these two enzymes (Climie et al., 1990). For the purposes 
of the following discussion, all the interactions described 
for L.casei T S , are based on the E.coli TS structure.
3.3.2.3 The C-terminal interactions of VZV and L.casei 
TS are significantly different
To assess the role of the C-terminal residue in the VZV 
TS catalysed reaction, the mutant L301A was constructed. 
The debromination activity of this mutant is essentially 
the same as the wild type enzyme, suggesting that the 
C-terminal tail does not play a significant role in the 
initial stages of catalysis. However, when TS activity was 
measured by the tritium release assay, this mutant was 
active, albeit 30-fold lower than WT (see Table 3.16). 
This is at least 30-fold higher than the activity of the 
L.casei V316 mutant (Aull et al., 1974), suggesting both 
structural and functional differences between this region 
of TS. These differences could lie in the C-terminal tail, 
a region with which the C-terminal tail interacts or a 
combination of both.
It was decided to investigate the differences in the 
C-terminal tail. A comparison of the final six amino acids 
of VZV TS with those of L.casei and E.coli TS shows four 
amino substitutions (see Fig. 3.22). The most significant
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appears to be the glutamate in VZV TS (E298) which is 
replaced by proline in L.casei TS (P313) and E.coli (P263). 
To investigate the role that E298 plays in the conformation 
of VZV TS, two mutants were constructed. The mutant E298P 
was made as a mimic of the L.casei and E.coli C-terminal 
tail structures. This mutant shows a 15- to 20-fold 
decrease in tritium release activity compared to the wild 
type enzyme, but has essentially wild type debromination 
activity. The second mutant, E298P/L301&, was constructed 
as a mimic of the L.casei 1316 mutant. The E298P/L301/i 
mutant also shows a 15- to 20-fold decrease in tritium 
release activity, and a slight increase in debromination 
activity.
Clearly, the activity of these mutants suggests that 
neither serves as accurate mimics of the L.casei TS 
C-terminal tail. Moreover, it suggests that the structural 
differences between VZV and L.casei TS that account for the 
observed differences in activity of their respective 
C-terminal deletion mutants, do not reside solely in the 
C-terminal tail.
3.3.2.4 Comparison of the C-terminal interactions of VZV 
and L.casei TS at a molecular level
As the results presented above have shown, the 
C-terminal interactions in VZV TS are different from those 
found in L.casei T S . The availablity of the VZV TS models 
and the E.coli TS crystal structures has allowed us to 
perform a detailed analysis of the putative interactions 
made between the C-terminal tail of VZV TS and the rest of 
the protein, and the C-terminal tail of E.coli TS and the
CD
rest of the protein. The aim of this section is^describe 
the identification of the molecular basis of the structural 
and functional differences observed between VZV and 
E.coli/L.casei T S .
The interactions at the C-terminus of the TS ternary 
complex from L.casei include four H-bonds. These are 
formed between the carboxylate group of the C-terminal 
amino acid and the side chains of residues R23, T24 and
Fig. 3.23. C-terminal interactions of VZV TS.
This figure shows the interactions that occur at the C-terminus of VZV 
TS, with the wild type enzyme is shown at the top and the mutant L301A 
shown at the bottom. Residues E298 to L301 (A300 in the mutant) are 
coloured in green with van der Waals radii shown for M299, A300 and 
L301. The carboxylate group of the C-terminal residue is not shown. 
R38 and T39 are shown in white, with H-bonds shown in yellow. 
Residues 199 and Y100 are shown in white with van der Waals radii.
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W85, and also to the PABA ring of the cofactor (Matthews et 
al . , 1990b; Finer-Moore et al . , 1990; Monfort et al.,
1990). Our comparison of the model of the VZV TS ternary 
complex and the TS ternary complex from L.casei reveals 
that the H-bonds formed between the carboxylate group of 
the C-terminal amino acid and the side chains of residues 
R38 and T39 (the equivalent amino acids of R23 and T24 in 
L.casei T S ) are virtually identical in both enzymes. The 
H-bonds to the para-aminobenzoicacid ring of the cofactor 
cannot be modelled by us at present (due to the lack of 
access to suitable computer software), but the high degree 
of similarity between the L.casei structure and VZV model 
around the immediate area to which the cofactor binds 
suggests they will be essentially the same.
However, a H-bond equivalent to the one between the
C-terminal residue of L.casei TS and W85, is not found in 
the VZV TS model. This is because the residue equivalent 
to W85 from L.casei TS is Y100 in VZV T S . The hydroxyl 
group of Y100 (VZV) can act as both a H-bond donor and
acceptor. However, we could not position the side chain of 
Y100 such that its hydroxyl group was in a position to form 
a H-bond with the carboxylate group of the C-terminal amino 
acid of VZV T S , without significant disruption to the rest 
of the protein structure.
On this basis, we predict that a different set of 
interactions will occur. In VZV TS the side chains of M299 
and L301 pack tightly against the side chain of 199 and
Y100 forming a strong hydrophobic interaction in the 
ternary complex. In L.casei TS these interactions appear 
to be much less significant. This is due, in part, to the 
smaller size of the V314 side chain of the residue V314 in 
L.casei compared to the larger M299 side chain in VZV TS. 
This suggests that the VZV enzyme is stabilized more by the 
hydrophobic contacts across the face of TS, between the 
C-terminus and the D-helix, than the predominantly H-bond
contacts observed in L.casei (see Fig. 3.23).
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3.3.2.5 Differences in activity of the L.casei and VZV 
TS C-terminal deletion Mutants explained in 
■olecular terms
Our findings may well explain why removal of the 
C-terminal residue from L.casei TS completely abolishes TS 
activity (when measured by the tritium release assay), but 
the VZV TS mutant L301A retains 3 to 4% activity compared 
to the wild type enzyme. In the mutant form of both 
enzymes, weak H-bonds can still be made from the 
carboxylate group of the newly exposed C-terminal residue 
(A315 in L.casei, A300 in VZV) to R23 and T24 (R38 and T39 
in VZV) and possibly to the para-aminobenzoic acid ring of 
the cofactor. This suggests that the difference in 
activity is independent of these interactions.
In the L.casei TS mutant 1316 , the carboxylate group of 
A315 can no longer form a H-bond to W85 as the distance is 
too great. As this is the only major observed difference 
between the wild type and mutant L.casei T S , it would 
suggest that this H-bond interaction may greatly contribute 
to the stabilization of the ternary complex. This also 
suggests that its subsequent disruption may be the major 
factor leading to enzyme inactivation.
VZV TS however, does not form such a H-bond, so the 
removal of the C-terminal residue (L301) might be expected 
to invoke a different response. Indeed, we have shown this 
to be the case, in that the L301 mutant of VZV TS is not 
totally devoid of TS activity as determined by the tritium 
release assay (see Table 3.16). This may be interpreted as 
a decrease in, but by no means an abolition of, the 
hydrophobic contacts between the C-terminal tail and 
residue Y100 located in the D-helix.
An alternative hypothesis must also be considered. 
Although the hydroxyl group of Y100 cannot be modelled in 
an orientation conducive to H-bond formation in the wild 
type structure, in the L301A mutant, the side chain of Y100 
may be able to reposition itself to form a H-bond with the 
newly exposed carboxyl group, and could stabilize the 
enzyme.
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3.3.2.6 The C-terainal interactions in VZV TS are unique
That the interactions found in VZV TS differ greatly 
from those found in L.casei and E.coli TS begs the 
question, "What interactions take place in other TSs?". 
The answer may not be simply that TS from prokaryotic 
sources rely on a H-bond whilst TS from eukaryotic sources 
rely on hydrophobic interactions. Indeed, VZV TS appears 
to be unique in this respect. A comparison of all the TS 
sequences at the position equivalent to Y100 reveals the 
presence of asparagine in phage T4 TS and all the 
eukaryotic TSs, whilst tryptophan is found at this position 
in TS from all other organisms. Our examination of the 
structure of E.coli TS has shown that replacement of W83
(W85 in L.casei) with Asn allows the formation of a H-bond 
to the carboxylate group of the C-terminal residue, similar 
in length to that in wild type E.coli T S , with little
disruption to the surrounding structure. This suggests 
that a H-bond could be formed in all other TS enzymes.
We have also found that the replacement of W83 with Asn 
in E.coli TS results in the formation of a gap in this
region. However, in all the TS sequences where Asn is 
found at this position, Met is seen at the antipenultimate 
position in the sequence (see Fig. 1.6). Modelling shows 
that the side chain of this residue can fill this gap, 
suggesting these positions may be covariant (see 
Section 1.9).
The activities of the mutants E298P and E298P/L301&. may 
be explained in terms of this observation. The mutant
E298P has approximately 6% of the wild type level of TS 
activity when measured by the tritium release assay, but 
essentially wild type levels when measured by the de­
bromination assay. This in itself suggests that the 
C-terminal interactions are different from other enzymes, 
as TS from HVA and 77j4003 has a Pro residue at this 
position (see Fig. 1.6).
The presence of a Pro residue at this position may make 
the C-terminal tail curve further in towards the active 
site due to the restrictions in the conformations that a
Fig. 3.24. A300E/L301A
Residues E298 to E300 are coloured in green, with van der Waals radii 
shown for E300. The red arrows represent rotations about the N-Ca, 
Ca-Cp and Cy-C§ bonds of E300 to position the Oe atoms of the E300 side 
chain in an eqivalent position to those of the true carboxylate side chain 
of L301 in the wild type enzyme (see Fig. 3.22 for comparison). 
Residues R38 to 141 and 199 and Y100 are shown in white. Van der 
Waals radii on 141 illustrate the steric clash with the main chain 
carboxylate group of E300.
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Pro residue can adopt. In VZV TS, the Pro residue could 
re-position the side chain of M299 such that it protrudes 
into the active site, and may result in steric clashes with 
the para-aminobenzoic acid ring of the cofactor. This 
could account for the loss of tritium release activity. 
This should not disrupt the dUMP binding site, and would 
therefore account for the wild type levels of debromination 
activity (see Table 3.16). In TS from other sources where 
a Pro residue is found at this position, such as HVA, the 
side chain of M288 (M299 in VZV T S ) may be accomodated in 
the space adjacent to the side chain of N89 (Y100).
An alternative explanation could be that the real 
structure of VZV TS is slightly different from the model 
structure. The M299 side chain may lie further out into 
the solvent, away from the side chain of Y100. When the 
Glu residue at position 298 is substituted by Pro, this 
could re-position the Met side chain close to that of Y100 
which would cause steric clashes in the active site. In 
the E298P/L301 mutant, the Pro residue could re-position 
the side chain of M299 as before. This would explain the 
similar levels of tritium release activity. In addition, 
the increased debromination activity could reflect greater 
access to the dUMP binding site.
3.3.2.7 TS activity and modelling of the mutant 
A300E/L301&
This mutant was constructed to see if the side chain 
carboxylate group of A300E could replace the carboxylate 
group of the true C-terminus. The low tritium release 
activity of this mutant (see Table 3.16) suggests that side 
chain of E300 cannot mimic the C-terminal carboxylate 
group. In addition, the decreased debromination activity 
also suggests disruption in this region.
The availability of the VZV TS model has permitted this 
mutant to be studied in more detail. The side chain of 
A300E can be positioned such that the its 0« atoms lie in 
the same position as those of the carboxylate group of L301 
in the wild type VZV enzyme (see Fig. 3.24). However, when
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placed in this position, a steric clash occurs between the 
(new) C-terminal carboxylate group of E300 and the side 
chain of 141. The replacement of 141 with a Gly residue 
could alleviate the steric clash between these two groups. 
The construction and characterization of this mutant 
(I41L/A300E/L301&) could be instructive in determining the 
relative contribution of the hydrophobic and H-bond inter­
actions in the C-terminal region of VZV T S . Similar 
changes could also be introduced into L.casei T S , to 
further investigate the nature of the interactions that 
occur between the C-terminus and the rest of the enzyme.
3.3.2.8 Summary
These results have shown that the C-terminal inter­
actions of VZV TS are different form those found in L.casei 
T S , and possibly all other known TS enzymes. We have also 
revealed several examples of covariant accomodation. Many 
of these observations are directly open to test by several 
simple mutagenesis experiments on TS from various sources. 
More importantly, the human TS structure (which has been 
determined, but not yet published; Bob Stroud and Celia 
Schiffer, personal communication), will provide an 
immediate test of the hypothesis that the C-terminal 
interactions in VZV TS are unique. The ultimate test, the 
determination of the crystal structure of the VZV ternary 
complex, and some of the mutant enzymes, is a currently in 
progress (R. Thompson, personal communication).
3.4 Thymidine Kinase
TK catalyses the formation of thymidylate by the 
phosphorylation of thymidine using ATP as the phosphate 
donor. The VZV TK gene was of interest for the drug 
selection protocols used during for the selection of VZV TS 
variants (see Section 3.1). The gene has been the subject 
of a mutagenesis experiment, which has lead to the 
identification of a previously undetected conserved region 
of the herpesvirus TKs. During the course of these
SITE 1 SITE 2 SITE 3 SIT:. 4
........ ...... ... ...
HSV-1 NH2 -50- rVYIDGphGmCKTtttq1L -13- KPMtYW -7 0- 1i fDRHPiaalIcYPaary -38-
HSV-2 NH2 -50- rVYIDGphGvGKTttsaqL -14- EPMtYW -7 0- lvfDRHPiaslIcYPaary -38-
VZV NH2 -13- rIYLDOayGiGKTtaaeef -15- EPLsYW -72- mlsDRHPiast icFP; ~ . r y -38-
MHV n h 2 -11- rVYLDGphGvGRSttaeaL -15- EPMaYW -7 5- 1 wDRHava smvc Y P : 3 r f - 3 8 -
PRV NH2 -04- r I YLDGayGtGICSt ta rvM -09- EPMaYW -66- wfDRHPvaalvcFP'. ji I - 3 6 -
FHV NH2 -21- rIYIDGayGiGKSltakyL -15- BPMlYVf -69- 1 i i DRHP1 aslvcFP'. ary -38-
EHV-1 NH2 -26- rIYLDOvyGiGKSttgrvM -14- EPMaYW -69- w f  DRHPvasavcFPaa r y -38-
EHV-4 NH2 -26- rIYLDOvyGiCKSttgrvM -14- EPMaYW -69- lvfDRHPvastvcFPaary -38-
BHV-1 n h 2 -11- rlYLDOahGlGKTttgraL -14- EPMaYW -79- 1vfDRHPvaac1cYPf a ry -38-
BHV-2 NH2 -05- rVYVDC^hGl GKT taa s r L -11- EPMsYW -70- 1i fDRHPtas11cYP1 a ry -38-
I LTV NH2 -30- ILYVDOpfOvGKTvtaktL -14- EPMqaK -74- f 1 vDRHPlaaclcFPvaq-y -38-
MDV NH2 -20- rVYLDOsmCiGKTsm1neL -14- EPMkYW -67- 1iIDRHPisatvcFP iarh -39-
HVT n h 2 -11- rVYLDOpfOiGKTs iInaM -14- EPMkYW -67- lmlDRHPvaa iIcFPit ry -39-
EBV NH2-285- sLFLEOapGvOKTtmlnhL -12- BPMrYK -66- ilhDRHllsaswFPlml 1 -37-
HVS NH2-210- fIFLEOsiOvCKTt11ksM -13- EPIaYW -63- vmf DRHP1 satwFPynh f -37-
CCV NH2 -17- vfcVEOn iOcGKSt1vkaL -13- EPVdqW -40- dimERsPmsatrvFcavng -43-
1 dCK NH2 -22- klsIEOniaaCKStfvniM -11- EPVarW -71- vysDRyifasn.1 Yeseem -40-
HSV-1
HSV-2
VZV
MHV
PRV
FHV
EHV-1
EHV-4
BHV-1
BHV-2
I LTV
MDV
HVT
EBV
HVS
CCV
dCK
SITE 5 
* * * * * * *
RlakRqRpGE -56- 
RlarRqRpGE -55- 
RvskRaRpGE -58- 
RlraRaRpGE -61- 
RlraRaRaGE -59- 
RlrgRsRtGE -59- 
RlrtRaRiGE -59- 
RlrtRaRiGE -59- 
RlaaRaRpGD -61- 
RlvaRgppGE -53- 
RiiqRgRpGE -61- 
RlssRnRtGE -65- 
RicsRdRpGE -66- 
RlkkRgRkhE -61- 
RvkkRnRkeE -61- 
RmrrRdRtGE -61- 
RiylRgRneE -63-
SITE 6
♦ * * * ♦ ♦  ♦
phigdTLFt 1 f rape 1 lapnGdlyn . vf awa ldvLak . r Lrp!6h7f i Ldydqsp .age - 4 0 - COOH 
pr iedTLFal f rvpel lapnGdlyh. ifawvldvLad.rLlpMnLfvLdydqsp.vgc -39- COOH 
pgiedTLFavlklpelegefGnilp.lwawgmetLsn.csrsMspIvLs1eqtp.qha -3 6- COOH 
pgladTLFaalkvpef IdarCypra .ahavtIdiLan . r I raLr'.-'yt-Ldl tgpp . c-ac -52- COOH 
pe lqdTLFgaykape ledr rGrple . vhawamdaLva . kLl pLrVst. vd 1 gpspr.vc -3 5- COOH 
sdlcdTLFsvfkarelsdqnGdlId.mhawvldgLme.tLqnLqIf t Ln1egtp.dec -32- COOH 
pelsdTLFamfktpellddrGvile.vhawaldaLml.kLrnLsYfcadisgtpr.qc -37- COOH 
pelgdTLFa1fktqellddrGvile.vhawaldaLml.kLrnLnYfsadlsgtpr.qc -37- COOH 
pa 1rdTLFaa1kcrelypggGag1pavhawaIdaLag.rLaaLeV fvLdvsaap.dac - 4 6 - COOH 
pgghnTLLalihga..gatrGcaam..tswtIdlLad.rLrsMnMftwt.tarprslc -23- COOH 
psidqTLFailafdq.qnvhGerlktvlsfwqkLat .vLknLcI IyLpahg1tpeac -37- COOH 
vslhhTLLa i fkrrelcaedGslst.thawilwgLlm.kLrr, 1nVer f n itglsttkc -37- COOH 
mpldrTLLa i f krkelcsenGel It. qyswi lwgLl t . k.Lht I r.'.'e 1 f d l sgmsrr e -c  - 4 4 - COOH 
klyknSIFsvlkeviqpf radavl levcla f t rtLay lqf v l'.'dLsef qdd 1 pgewte - 34 - COOH 
dmlksSIFntwiemtkahrdsctlmeclIt f ckeLekvqLihVnY'spf tdd i pelwas - 31 - COOH 
COOH 
COOH
Fig. 3.25. Comparison of the herpesvirus TK sequences. 
Alignment of the amino acid sequences of six conserved sites in 15 higher 
vertebrate herpesvirus TKs and comparison with CCV TK and human 
dCK. BOLD UPPER CASE letters are shown for the 15 TKs when all 
15 amino acids are identical at that position. UPPER CASE letters are 
shown for the 15 TKs when at least 13 have the same amino acid at that 
position, and when at least 14 TKs possess a residue in one of the 
following groups: (I/L/M/V) (D/E) (S/T) (F/Y) (F/L) (K/R). Upper case 
letters are shown for CCV TK and dCK when residues are identical to, or 
in the same group as, upper case residues in the 15 TKs. The six 
conserved sites proposed by Balasubramanian et al., (1990) are indicated. 
Dots represent spacing characters introduced to produce the alignment. 
The abbreviations used are as shown in the abbreviations lists. The 
references to the sequences can be found in Harrison et al. (1991).
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studies, the evolutionary source of the herpesvirus TKs was 
also established (Harrison et al. , 1991).
3.4.1 Site-directed Mutagenesis of VZV TK
The TK gene of the Dumas strain of VZV has previously 
been cloned and expressed at high levels in the E.coli 
strain C600tdk, however, no detectable TK activty was found 
in crude extracts of these cells (McKee et al ., 1990). Our 
comparison the amino acid sequence of TK from the Dumas 
strain (Davison & Scott, 1986) with the TK gene of several 
other VZV strains, revealed a single amino acid 
substitution (corresponding to a single nucleotide change) 
with serine (T C A ) at position 288 in place of leucine (T T A ) 
(Sawyer et al., 1988; Mittal & Field, 1989). Leucine is
highly conserved at this position, being replaced only by 
isoleucine in MHV (see Fig. 3.25). This suggested that the 
amino acid difference at this position of the TK gene of 
the Dumas strain was the cause of the observed lack of TK 
activity. On this basis, it was decided to replace the 
serine residue at positon 288 with leucine by site-directed 
mutagenesis.
3.4. 1.1 Mutant construction and enzyme activities
The TK gene of the Dumas strain of VZV was subcloned 
from the vector pTM9 into pBS+ and pBS- to Create the 
plasmids pAD507 and pAD601 respectively. The yields of 
ssDNA and ratio of ssDNA to helper phage were high for both 
vectors. Site-directed mutagenesis was used to create the 
mutant S288L using oligo 52 and U-ssDNA made from the 
vector pAD507, with DNA transformed into the E.coli strain 
C600 tdk.
Transformants were screened by the TK growth complement­
ation assay and approximately 30% grew. Of six complement­
ing clones that were sequenced with oligo 53, all contained 
a single nucleotide substitution (T863C) corresponding to 
the replacement of S288 with leucine.
One of these clones, S288LTK+5 was used to re-transform 
E.coli C600tdk cells and evaluated for growth complement-
Source of extract
Specific Activity 
(pmol dTMP/jig protein
Extract 1 Extract 2
C600tdk 0.009±0.0 0.010±0.0005
C600fcM/pAD507 0.011±0.0005 0.010±0.001
C600rd£/pVZVTK+5 1.583+0.049 0.382+0.012
Table 3.17. TK assays.
The TK activities of two independent extracts of a mutant and potential 
wild type variant of VZV TK. The variants were expressed in E.coli 
C600tdk. Activities are given as the mean ± the standard error of the 
mean.
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ation ability. This clone gave complementation, in 
contrast to pBS+ and pAD507 which repeatedly failed to 
complement the growth of this strain. Enzyme activities 
were determined for the S288LTK+5 and pAD507 clones and 
compared to the cells only activity as shown in Table 3.17.
3 . 4.1.2 Summary
Substantial TK activty is seen in both extracts of the 
S288LTK+5 clone compared to the cells alone, and the Dumas 
derived clone. Although the second extract has approxim­
ately four-fold less activity than the first, the TK 
activity is still significantly greater than the background 
levels.
The active TK gene of S288LTK+5 was subcloned into the 
vector pCB105 to create the plasmid pCBTK3. This plasmid, 
was used in the drug screening protocols (see Section 3.1).
The genetic selection described in Section 2.12.1.2, was 
based on the enrichment procedure used for the isolation of 
E.coli thyA mutants. In the presence of trimethoprim 
E.coli cells fail to grow due to the inhibition of de novo 
thymidylate synthesis (see Section 1.13.2). However, in 
the presence of exogenous thymidine, E.coli cells express­
ing an active form of TK should be able to catalyse the 
formation of thymidylate from thymidine, thus overcoming 
the toxic effects of trimethoprim. Bacteria that fail to 
express an active form of TK are unable to utilise 
exogenous thymidine and thus do not grow. The data suggest 
that this selection scheme was completely successful.
The role of L288 in VZV TK is unknown, but this amino 
acid lies within a region that contains a number of highly 
conserved hydrophobic residues. A recently published model 
of the HSV-1 TK structure places this hydrophobic region in 
close proximity to the active site of the enzyme (Folkers 
et al., 1991), although the function of this region remains 
unknown.
3.4.2 Evolution of the herpesvirus thymidine kinase
Herpesviruses encode a variety of enzymes that catalyse
source Mr
(kDa)
subunit
composition
phosphate
donors
natural
substrates
alternative
substrates
herpesvirus
TKs
25-60 dimer ATP
CTP
TdR, (CdR), 
(dTMP)
ACV,
araA
mammalian
TKs
25-27 tetramer ATP TdR -
poxvirus
TKs
20-21 tetramer ATP TdR -
E.coli & 
T4 TK
22-23 trimer/
tetramer
ATP TdR -
mammalian
TmpKs
24-25 - ATP dTMP -
poxvirus
TmpKs
25-26 - ATP dTMP -
dCK 31 dimer ATP
GTP
CdR, AdR, 
GdR
ddC, araC
Table 3. 18. Properties of TK.
The properties of TKs and similar enzymes from various sources (see 
text for details and references).
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reactions involved in nucleotide metabolism, including 
thymidine kinase (see Section 1.2.3). Many of these 
enzymes show significant amino acid homology to their 
cellular counterparts, suggesting the^ i were captured by an 
ancestral herpesvirus at some point during evolution. 
However, the herpesvirus TK is clearly not related to its 
cellular counterpart, and its evolutionary source has so 
far remained obscure.
3 . 4 . 2 .1 Herpesvirus TKs are genetically and biochemic­
ally distinct from their cellular counterparts
The sequences of the TK gene of at least 15 different 
herpesviruses have been reported to date, making it, in 
sequence terms at least, the most studied herpesviral gene. 
Indeed, the wealth of information provided by these 
sequences has prompted the construction of several 
evolutionary trees for the Herpesviridae (Gentry et al. ,
1988) and lead to much speculation on the acquisition of 
this gene (Gentry et al ., 1983; Robertson & Whalley, 1988).
In addition to these phylogenetic studies, several 
groups have found highly conserved amino acids (Robertson & 
Whalley, 1988; Honess et al., 1989), which have recently
been grouped into six conserved 'sites’ (Balasubramaniam et 
al., 1990). The functions of these sites have been
reviewed in detail elsewhere (Balasubramaniam et al., 1990; 
Harrison et al., 1991). Several comparisons between the
sequences of cellular TKs and those of herpesvirus TKs have 
strongly suggested that they have no relationship, apart 
from a region common to many different classes of ATP 
binding proteins (Saraste et al., 1990). This is in marked 
contrast to the poxviruses which encode TKs that share a 
clear amino acid similarity with cellular TKs, and have 
very similar substrate specificities and physical
properties. Indeed, these conserved features have led to 
the proposal that poxvirus TKs evolved from the cell 
cytosolic TKs (Kwoh & Engler, 1984; Boyle et al., 1987 and 
references therein).
This lack of amino acid similarity also extends to a
159
lack of common biochemical features which are summarized in 
Table 3.18. Unlike cellular TKs, the herpesvirus TKs can 
utilize a broad range of substrates in addition to 
thymidine. Many herpesvirus TKs can phosphorylate 
deoxycytidine and a number of nucleoside analogues 
including acyclovir (ACV) and ( E)-5-(2-bromovinyl)-2 * - 
deoxyuridine (BVdU; Fyfe et al., 1978; Cheng et al ., 1981; 
Larder et al. , 1983). Moreover, several herpesvirus TKs
also possess thymidylate kinase activity (Chen et al. , 
1979). These combined activities play a crucial role in 
the activation of certain nucleoside analogues (Fyfe, 1981; 
reviewed in Larder & Darby, 1984).
In addition to their broad substrate specificity, 
herpesvirus TKs, like mitochondrial TKs (and in contrast to 
cytosolic TKs), can use CTP as well as ATP as a phosphate 
donor (Kit, 1985; Kit et al., 1974). However, the herpes­
virus (and cell cytosolic) TKs are not inhibited by dCTP, 
which differentiates them from the mitochondrial TKs which 
are inhibited by dCTP (Kit, 1975; Kit et al. , 1974). To
the best of our knowledge, no mitochondrial TK sequences 
have been reported to date.
The herpesvirus TKs also differ in their subunit 
composition, being homodimeric enzymes, whereas the cell 
cytosolic enzymes consist of four identical subunits (Kit, 
1985; Kit et al . , 1974). The subunit composition of the
mitochondrial enzymes has not been reported (Kit, 1985). 
Thus, on the basis of these genetic and biochemical 
differences, the herpesvirus TKs form a distinct group 
whose evolutionary source remains obscure.
When reporting the sequence of EHV-1 TK, Roberston and 
Whalley (1988) suggested that herpesvirus TKs may have 
originated from the cellular thymidylate kinase (TmpK) gene 
on the basis of local sequence homology at both the ATP- 
binding and proposed nucleotide-binding regions (Darby et 
al., 1986). Indeed, the homology at both sites is 
reasonably high (although homology at the ATP-binding site 
is not necessarily indicative of homology between TK and 
TmpK). Moreover, several herpesvirus TKs possess TmpK
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activity. However, the homology at other regions of the 
protein is very low, and the fact that the physical and 
biochemical properties of TmpK bear little resemblance to 
those of herpesvirus TKs suggests that TmpK may not be the 
true evolutionary source of the herpesvirus TKs.
3.4.2.2 Channel catfish virus TK: the most divergent 
herpesvirus TK sequence known?
The herpesvirus TK sequences reported to date are 
encoded by viruses that infect mammals or birds, however 
information has recently become available on the TK of 
channel catfish virus (CCV). This enzyme can be disting­
uished from cWmx\e\ caVfisV\ TK and, in contrast to other 
herpesvirus TKs, cannot use CTP as a phosphate donor. The 
gene encoding it has been located to within 3kb by marker 
rescue of a TK deficient CCV mutant (L. A. Hanson, R. L. 
Thune & K. G. Kousoulas, personal communication). The DNA 
sequence of the complete CCV genome has recently been 
determined (Davison, 1992) and shows that the 3kb region 
including the TK gene contains three complete ORFs. One of 
these was found to contain the amino acid sequence, 
GNTGCGKS, which perfectly matches the consensus sequence 
GXXGXGK(S/T) for the ATP-binding region of a TK enzyme 
(Saraste et al ., 1990). Computer analysis using standard
GCG homology search programs (FASTA and GAP), revealed no 
strong homology with either the herpesvirus, poxvirus or 
cell cytosolic TKs, suggesting it may represent a novel 
form of TK (Andrew J. Davison, personal communication).
However, by close inspection of the CCV TK sequence, we 
have been able to show that it bears significant sequence 
similarity to five of the six conserved sites recently 
described for herpesvirus TKs (Balasubramaniam et a l ., 
1990; Harrison et a l ., 1991; see Fig. 3.25). This analysis 
was performed using the GCG manual alignment program, 
LINEUP. Several herpesvirus TK sequences were aligned 
using this program, based on a previous alignment for 
herpesvirus TKs (Balasubramaniam et al,, 1990). The CCV TK 
sequence was then aligned using the highly conserved amino
SI T E  1
Human dCK matpp k r s c p s  f sassegt r i k k i s 1EGNI a a G K S T F V n i L k q l c e d w  . . e W p
- i m  i 1111*1 1 II
52
CCV TK . . m a l r e g p t p a r  f lpeg 1 vf cVEGN I g c G K S T L V k a L m e r v a g s g v n W e  
SITE 2
49
Human dCK E P V a r W c N v q s t q d e f e e l t m s q k N G g N v L q M m Y e k P e r w s f t F Q t y a c l S r I r a 107
C C V  TK
111 1 1 II 1 I - 1 1 M  1
E P V d q W v N ...................h N G k N y L e L s Y t d P t g y a v p F Q n l v f d S y V n v
SITE 3 SITE 4 
* * * * * *
89
Human dCK Q l a s l n g k l k d a e k P v l f f e r s v y s D R y i  f a s n  . l Y e s e c ..... mneTewt iyq
i i - i - 1
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C C V  TK
1 l - I - '
Q ...........r l q n P .........d i m E R s p m s a t  rvFca v n g s r g v i p a T a l p g m a
S I T E  5 
*******
128
Human dCK d w h D w m n n q f g q s l e L d g l i Y L q a t P E t C L h R i y l R g R n e E q G I p L E Y L e k L H y K  
: : - 1 1 II I 1 1 : 1 1 1 1 -* 1 : I 1 1 1 : 
argEavmrt iat r p v F . . V y Y L e l p P E e C L r R m r r R d R t g E a G V g L D Y L r l L H e R
211
C C V  TK 181
Human dCK h E s W L l h r t l k T n f D y l q e V p i l t l d v n E D f k D k y E s L v e k v k e F l s t L ......
t i l  . i i . i - i i  - t
260
C C V  TK
i l l  - i l - t - I I - - i
y E a W L .......S s a E dverVd. - a s r s r E E i v D r i E i L c r r h p r L r a p L t r k s q l 228
Fig. 3.26. Comparison of human dCK and CCV TK.
Alignment of entire human dCK and CCV TK sequences. Vertical bars 
(I) indicate identical amino acid residues and colons (:) indicate similar 
residues. Residues are numbered on the right. Dots represent spacing 
characters introduced to produce the alignment. Upper case letters are 
used as described in the legend to Fig. 3.25.
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acids in the other herpesvirus TK sequences as a reference 
for the alignment of the residues in the CCV TK sequence. 
This method of alignment is similar to those described by 
Argos and co-workers (1991). Similar analysis could not 
detect any sequence similarity to the cell cytosolic or 
poxvirus TKs (data not shown). This strongly suggests that 
the CCV TK is clearly related to herpesvirus TKs. However, 
the lower degree of sequence similarity, the lack of one of 
the six conserved sites due to the shorter length (by 73 to 
105 amino acids), and the inability to use CTP as an 
alternate phosphate donor suggest that it is also the most 
divergent herpesvirus TK studied to date (Harrison et al., 
1991 ) .
3.4.2.3 Evolutionary source of herpesvirus TK is the 
cellular deoxycytidine kinase
During the course of our analysis of the proposed CCV TK 
gene, the sequence of the human deoxycytidine kinase (dCK) 
was reported by Chottiner and co-workers (1991). An 
earlier report of the sequence of the human dCK gene (Huang 
et al. , 1989), has since been discounted as the predicted
protein product is approximately twice the size of the 
purified dCK (Chottiner et al., 1991). Moreover, Huang and 
co-workers have recently concluded that the gene they 
sequenced represents the human counterpart of the murine 
ERp72 (luminal endoplasmic reticulum protein; Mazzarella et 
al. , 1989; Huang et a l . , 1991). As several herpesvirus TKs 
have been shown to possess dCK activity, we decided to 
compare the amino acid sequence of herpesvirus TKs with 
that of human dCK. Somewhat suprisingly, amino acid 
homology was detected at five of the six conserved sites 
mentioned, by comparing the human dCK sequence to the 
herpesvirus TK sequences by the method described above. 
However, a comparison between the amino acid sequences of 
dCK and CCV T K , revealed a much higher degree of amino acid 
similarity. 52 amino acids are identical from a common 
core of 213 amino acids, and a further 22 amino acids 
represent conserved changes (see Fig. 3.25). Again many of
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these amino acids can be assigned to five of the six sites 
found in the other herpesvirus TKs. In addition to the 
homology to these sites, the spacing between sites is also 
well conserved, strengthening the argument for an 
evolutionary relationship.
Several of the physical and enzymatic features of dCK 
are also similar to the herpesvirus TKs. Human dCK, like 
the herpesvirus TKs is a homodimeric enzyme with a broad 
substrate specificity which includes purine nucleosides and 
several cytidine analogues. In addition, both CTP and GTP, 
as well as ATP, can act as phosphate donors (Chottiner et 
al., 1991).
Although it is conceivable that the situation has arisen 
by convergent evolution, on the basis of the strong 
sequence, physical and enzymatic similarities shown between 
the human dCK and herpesvirus TKs, it is highly likely that 
the higher and lower vertebrate TKs have evolved from a 
captured cellular dCK gene. In developing the ability to 
phosphorylate thymidine, the enzyme specified by the 
captured gene in most cases has retained the ability to 
phosphorylate deoxycytidine, thus the proposed origin of 
herpesvirus TKs is consistent with their distinctive 
biochemical properties (Harrison et al. , 1991).
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4. FINAL DISCUSSION
4.1 Drug resistance studies
The Discussion outlines the original aims and contrasts 
them with our findings. It also describes some future 
avenues for research.
4.1.1 Original aims and rationale
The original aim of these studies was to isolate and 
characterize a variant of VZV TS that could catalyse the 
normal formation of dTMP in the presence a concentration of 
the drugs FdUMP or EYdUMP that prevents the wild type 
enzyme from catalysing this reaction. This was attempted 
by the mutagenesis of VZV TS in vitro, in combination with 
a suitable screening protocol.
Our initial studies were constrained by the lack of 
information. Previous work in this field had given no 
indication as to which amino acid substitut ions might give 
rise to a drug resistant variant (Jastreboff et al. , 1983;
Heidelberger et al ., 1960a,b). In addition, the structural 
data pertaining to TS was limited to the crystal structure 
of the native enzyme from L.casei at 3.0 Angstroms 
resolution (Hardy et al., 1987). Although molecular
modelling had allowed the identification of a few putative 
contacts between the protein and ligands, the majority were 
not known at this point (Hardy et al., 1987).
On this basis, it was decided that a site-directed 
mutagenesis approach would be too restrictive and a random 
mutagenesis approach was adopted. Also, as many amino 
acids, from several different regions of the protein, were 
predicted to line the active site cavity of TS (Hardy et 
al., 1987), it was decided to mutagenize the complete gene, 
rather than to target the mutagenesis to a few selected 
regions.
4.1.2 A drug resistant variant of VZV TS requires more 
than one nucleotide substitution
In screening a library of all the possible variants of
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the VZV TS gene that contain a single nucleotide substitut­
ion, we failed to isolate a variant of VZV TS that was 
resistant to FUdR or EYUdR. This suggests that more than 
one nucleotide change may be necessary to yield a drug 
resistant variant.
This observation is in contrast to those relating to the 
genetic basis of drug resistance in other herpesvirus 
encoded enzymes. For herpesvirus TK, several variants of 
both HSV and VZV have been isolated where the enzyme shows 
wild type levels of TK activity but reduced drug kinase 
activity (Lacey et al., 1991; Larder et a l., 1983). In
addition, a single nucleotide change, which results in the 
same amino acid substitution in the DNA polymerase of both 
HSV-1 (N815S) and VZV (N779S), has been shown to confer 
resistance to ACV (Gaillard et al., 1990; Matthews et al ., 
1989b) .
However, not all instances of drug resistance are the 
result of a single nucleotide change, as is seen in HIV. 
Some of the most potent inhibitors of HIV reverse 
transcriptase (R T ) include the nucleoside analogues 
3 *-azidothymidine (AZT) and dideoxyinosine (ddl) (St. Clair 
et al ., 1991). Studies of AZT and ddl resistance by Larder 
and co-workers ( 1989; 1991; St. Clair et al. , 1991), have
shown that more than one nucleotide substitution is 
necessary before HIV aquires a drug resistant phenotype. 
In fact a critical step in acquiring an AZT r^s*s tant 
character may be the occurrence of a double nucleotide
mutation (ACC to TTC or ACC to TAC) that gives rise to the 
T215F or T215Y changes, thought to be essential for AZT
resistance (Larder et a l ., 1989). This then allows other
mutations to increase the levels of drug resistance (Larder 
et a l ., 1989; 1991; St. Clair et al., 1991).
4.1.3 Possiblities for future studies
We have shown that more than one nucleotide substitution 
in the VZV TS gene is necessary to give rise to a drug
resistant variant. We have also shown that the use of the 
same protocols to screen a library of all the possible
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variants of the VZV TS gene that contain two nucleotide 
substitutions would approach the limits of feasibility, and 
that screening for variants with three and four nucleotide 
substitutions would dramatically exceed these limits. This 
poses two questions. What would be the value of the 
characterization of a drug resistant TS, and what would 
be the best approach to isolate such a variant?
The isolation and characterization of a drug resistant 
variant could increase our understanding of the mechanism 
of the binding of various inhibitors, and reveal the role 
that different amino acids play in the recognition and/or 
binding of drug to T S . This suggests that the isolation of 
a drug resistant variant should be pursued.
Several recent findings should assist in this process. 
The determination of the structure of the native enzyme and 
ternary complex of E.coli TS at high resolution, has lead 
to the identification of the amino acids in contact with 
the natural substrate, dUMP, and the TS inhibitor, FdUMP, 
together with a more thorough understanding of the 
conformational changes associated with catalysis. Such 
information could be used to identify smaller regions of 
the enzyme that could be targeted for random mutagenesis. 
This would dramatically reduce the number of clones that 
would have to be screened.
Because of the unpredictable effects of site-directed 
mutagenesis, the structural similarity between dUMP and 
FdUMP, and the fact that differences exist between VZV and 
E.coli TS, an attempt to design a drug resistant variant de 
novo, using the VZV TS model, would probably be too 
ambitious at this stage. However, the determination of the 
crystal structure of VZV TS is in progress (R. Thompson, 
personal communication). In addition, it may be easier to 
exploit the structural differences between drug EYdUMP and 
dUMP. EYdUMP has an ethynyl group at C5 compared to the 
hydrogen at C5 of dUMP. By molecular modelling, the 
conformation of the 5-ethynyl group of EYdUMP could be 
determined. If for example, the 5-ethynyl group lies close 
to an amino acid with a small side chain, then the sub­
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stitution with an amino acid with a large side chain may 
decrease the affinity of TS for EYdUMP. If this amino acid 
substitution did not affect enzyme activity, it would 
confer drug resistance to T S . These ideas may be explored 
in the future, as the effects of amino acid substitutions 
become better understood, and protein design skills 
improve.
4.2 VZV TS as a possible target for antiviral
chemotherapy: identification of an exploitable 
difference for rational drug design
During the course of these studies, we have identified a 
region of VZV TS that differs structurally in TS from other 
sources, possibly including human TS (see Section 3.3.2.6). 
The structural difference between VZV TS and TS from other 
sources resides in the interactions of the C-terminal tail. 
As this part of the enzyme is involved in catalysis, 
specifically in interactions with the cofactor, it opens 
the possibility for the rationale design of differential TS 
inhibitor. Such an inhibitor of TS is one which inhibits 
TS from one source with a much greater potency than that 
from a second source.
If these structural differences between the human and 
VZV TS are confirmed, the exploitation of them could lead 
to the development of novel anti-varicella drugs. To this 
end, the crystal structure of human TS has been determined, 
although not yet published (Schiffer et al., 1991; Robert
Stroud, personal communication). The folate analogue, 
pteroyl-hexaglutamate, inhibits TS from bacteriophage T2 
with a 100-fold greater potency than TS from E.coli (Maley 
et al , 1979c) suggesting that it may be possible to achieve 
similar discrimination between human and VZV TS.
On the basis of the fact that the differential inhibitor 
of E.coli and bacteriophage T2 TS was a folate analogue 
(Maley et a l ., 1979c), it could be expected that a suitable 
differential inhibitor of VZV and human TS would also be a 
folate analogue. Indeed, several folate analogues are
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currently being evaluated for their ability to inhibit the 
purified VZV and human enzymes, and the growth of VZV in 
tissue culture (R. Thompson and M. J. Hutchinson, personal 
communication).
4.3 Plastic and covariant accomodation: the ability
of proteins to tolerate amino acid substitutions
Plastic and covariant accomodation have been briefly 
discussed in Section 1.9. This section will outline some 
of the background that led towards a better understanding 
of these phenomena and show how our findings are consonant 
with, and enhance, this understanding.
4.3.1 Globins, lac and lambda repressors, and 
T4 lysozyme
Many of the currently held ideas pertaining to the 
ability of a protein to tolerate amino acid substitutions 
emanate from the studies by Perutz and colleagues on the 
relationship between haemoglobin amino acid sequences and 
the known 3-D structures (Perutz et al . , 1965; Perutz &
Lehman, 1968). They noted that, in general, residues which 
lie at the surface of the protein can have either polar, 
non-polar or charged amino acids, and can be freely 
interchanged with a variety of other amino acids without a 
deleterious affect on the structure and function, except 
where the amino acids are in direct contact with ligand. 
However, buried residues, which almost invariably have non­
polar side chains, are considerably more sensitive to 
replacement, with polar or charged residues not being found 
as naturally occurring substitutions. In addition, they 
found that substitutions that affect subunit contacts can 
also be disruptive. Subsequent studies by several groups 
have reaffirmed these observations for other protein 
families including the cytochromes, serine proteases and 
lysozymes (Dickerson, 1971; Hampsev et al ., 1988; Bashford
et al., 1987; Lesk & Chothia, 1980; Chothia & Lesk, 1987).
With the advent of recombinant DNA technology, the
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experimental evaluation of these theories was opened up, 
led by the pioneering work of Miller and colleagues (Miller 
et al. , 1979; Miller & Schmeissner, 1979; Miller, 1979).
They utilized different E.coli suppressor strains to 
incorporate a variety of amino acids at defined nonsense 
codons of the E.coli lac repressor. This technique is very 
powerful as it allows a single mutation in the gene (i.e. 
the nonsense codon) to generate many different amino acid 
substitutions in the protein. The more suppressor strains 
that become available, the more powerful the technique.
In these early studies, they described the suppression 
of a large number of nonsense mutations of the E.coli lac 
repressor and found that of 323 amino acid substitutions 
analysed (at 90 different positions), 187 (58%) were found 
to be phenotypically "silent” , that is, they result in 
proteins that are not measurably altered in their activity 
compared to the wild type protein.
A breakdown of these results revealed that 43 out of 53 
(81%) polar residues could be freely replaced by any of a 
selection of the amino acids Ser, Gin, Tyr, Leu, Lys and in 
some cases Trp, without seriously affecting the activity of 
the protein. By way of contrast, of 32 non-polar residues 
tested, 20 (63%) could be replaced only by non-polar
residues or not at all without disrupting function, whereas 
the other 12 (37%) could be freely substituted with the
amino acids experimentally available.
In an impressive extension of these studies, Kleina and 
Miller (1991) have studied close to 1,600 amino acid 
replacements (nearly one quarter of all the possible single 
amino acid replacements possible!). They showed that the 
DNA binding domain of the repressor, involving the 
N-terminal 59 amino acids is extremely sensitive to amino 
acid substitutions with 70% of the resultant proteins being 
inactive, confirming the observation that residues in 
contact with the ligand will be refractory to substitution 
(Perutz et al ., 1965). However, the remaining 301 amino
acids are tolerant to substitution, with only 30% of 
substitutions leading to an inactive phenotype. The long
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awQvted determination of the crystal structure of the 
E.coli lac repressor will dramatically improve the 
interpretation of this data.
An even more remarkable study was performed by Rennell 
and co-workers (1991), where they described the phenotypic 
characterisation of 2015 of the 3097 possible single amino 
acid replacements of phage T4 lysozyme (almost two-thirds 
of all the possible single amino acid replacements 
possible!). The availability of the 3-D structure of the 
enzyme allowed the effects of the amino acid substitutions 
to be interpreted. They showed that over half (55%) of the 
residues could be replaced by up to 13 different amino 
acids with no serious deleterious affect to enzyme 
activity. When this data was correlated with the solvent 
access cbility of the amino acids, it was shown that the 
buried residues were, in general, more sensitive to amino 
acid replacement than solvent exposed residues. Notable 
exceptions to this were two residues thought to participate 
in catalysis (Hardy & Poteete, 1991).
The studies of Sauer and co-workers (Lim & Sauer, 1991, 
1989; Bowie et al. , 1990), has lead to a quantification of 
some of the factors determining a proteins tolerance to 
amino acid replacement. They have used a combination of 
novel mutagenesis techniques to investigate the molecular 
basis of the factors that dictate a proteins ability to 
tolerate amino acid substitutions. Their studies have 
focused on the hydrophobic core of the bacteriophage lambda 
repressor. Three interacting residues in the hydrophobic 
core of the N-terminal domain of the lambda repressor were 
randomized combinatorially. The randomization was 
restricted to the five amino acids V a l , Leu, lie, Met and 
P he, thereby generating a sterically diverse set of core 
sequences composed solely of hydrophobic residues. Of 78 
of the 125 possible amino acid combinations that were 
generated during this study, 56 (72%) retained some degree 
of activity (Lim &. Sauer, 1991).
Their results strongly suggest that "repacking” can 
occur for certain combinations of side-chains, but not all.
Fig. 4.1. M utants of VZV TS.
Representation of the distribution of the mutants made to VZV TS. The 
figure depicts a monomer of the VZV TS model with the N- and C- 
terminal residues illustrated. Site-directed mutants are shown in yellow 
and G48 is shown in green. Mutants introduced by random mutagenesis 
are shown in red.
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Also, they suggest that packing interactions do not appear 
to play a major role in specifying the basic conformation 
that the protein will adopt. However, packing interactions 
do appear to play an important role in specifying the 
precise structure, stability and ligand binding properties 
of the protein (Lim & Sauer, 1991), a process of fine 
tuning. In more general terms, these results suggest that 
the basic structural information "encoded” by these 
residues appears to reside largely in their hydrophobic 
character, that is, the majority of sequences that simply 
maintain hydrophobicity at core positions are able to adopt 
the overall lambda repressor fold and maintain moderate 
stability. These results were interpreted by the authors 
as implying that the basic structural features of a protein 
can be predicted from relatively simple, degenerate 
sequence patterns (Lim & Sauer, 1991).
In summary, the results of these various groups and 
those described elsewhere (Perry et al ., 1990; Bone et al ., 
1989; see Section 1.9), have lead to the establishment of 
the concepts of plastic and covariant accomodation,
qualities of proteins that allow them to tolerate amino 
acid substitutions that have occurred during the course of 
evolution, or have been introduced artificially.
4.3.2 Relationship of our studies of VZV TS to 
previous studies in other proteins
We have discovered novel examples of both plastic and 
covariant accomodation in VZV TS that have not previously
been reported for TS from other sources. We have shown
that VZV TS can tolerate amino acid substitutions, (G48A, 
M49P), insertions (48P49, 58T59) and even a deletion
(L301A). These mutations are distibuted throughout various 
regions of the protein (see Fig. 4.1). With the 
availability of the model of VZV T S , we have been able to 
predict the manner in which these changes may have been 
accomodated (see Sections 3.1 and 3.3).
Another important finding has been the identification of 
several amino acid substitutions that inactivate VZV TS.
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Many of the substitutions occur at residues that have 
hydrophobic side chains and are buried in the protein, and 
would not be expected to tolerate replacement by residues 
that are not non-polar. Indeed, this is the case for 
several of the mutants (V179E; S197T/C198R; see
Section 3.2). More interesting are those substitutions 
that involve the replacement of core hydrophobic residues 
with other hydrophobic side residues. These include the 
mutants I41L, I96M and F189L (see Section 3.2). The local 
environment of each of these residues and the reasons why 
the substitution cannot be tolerated is described in detail 
in Section 3.2. In each case, the repacking of adjacent 
amino acid side chains is not possible for steric reasons, 
or due to the formation of energetically unfavourable gaps. 
Indeed, these findings substantiate the findings by other 
workers. Several of the mutants of the lambda repressor
characterized by Sauer and co-workers have also been 
proposed as incapable of repacking due to local constraints 
(Lim & Sauer, 1989, 1991; Bowie et al., 1990).
An additional example serves to illustrate the concept 
of covariant accomodation. The mutant C187G of VZV TS is 
inactive and cannot be accomodated locally due to the
formation of an unfavourable gap in the protein core as
described in Section 3.2. However, a Gly residue is found
at the equivalent position in TS from C .fasiculata. This 
suggests that a Gly at this position is not disruptive to 
the enzymes function per se, and that the amino acid side 
chains of residues in the immediate vicinity of the Gly 
residue can fill the gap in TS from C . fasciculate, but not 
in TS from VZV.
In summary, these observations show that VZV TS, like 
several other proteins possesses inherent structural 
plasticity. Our studies, and those of others (Climie et 
al., 1990; Michaels et al. , 1990), have revealed that
highly conserved residues are not always resistant to 
substitution. The limits of plasticity are illustrated by 
the fact that even less well conserved residues cannot be 
freely substituted.
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4.4 Conservation of the TS primary structure
The unusually high degree of primary structure 
conservation of TS from various sources has been pointed 
out in several reports in recent years (Hardy et al., 1987; 
Perry et al., 1990). The aim of this section is to extend 
these observations, and to offer some reasons for this 
level of conservation.
4.4.1 The primary structure of TS is highly conserved
TS has one of the most highly conserved primary 
structures, with 21 different sequences reported from 
organisms as diverse as bacteriophage through to man (see 
Section 1.5). From a core of " 250 residues, 27 (11%) are 
completely conserved (see Fig. 1.6). Such a high degree of 
conservation is higher than for most other enzymes and 
similar to that found for cytochrome c (Perry et al., 1990; 
Dickerson, 1971). In contrast to T S , cytochromes are small 
proteins (104 to 112 amino acids) and their conserved 
functional component per unit volume is high. In addition, 
much of the surface of cytochrome c is involved in 
interaction with its oxidase and reductase, both factors 
contributing to the conservation of the primary structure 
(Perry et a l ., 1990; Dickerson, 1971).
It is also instructive to compare the degree of amino 
acid sequence conservation of TS with that of DHFR,
especially considering the intimate relationship of these 
two enzymes (see Section 1.5) and the fact that they 
probably evolved at around the same time. DHFR has only 8
residues from a core of "170 residues (5%) that are
completely conserved (Lagosky et al. , 1987). The DHFR
sequences are from the same range of organisms as those 
studied for T S . A recently published archaebacterial DHFR 
sequence shows a high degree of of similarity to the other 
DHFR sequences and contains all eight of the completely
conserved residues (Zusman et al.t 1989). Thus, TS has 
more than twice as many completely conserved residues in 
the ‘core* region when compared to DHFR.
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4.4.2 Why is the primary structure of TS so highly 
conserved?
Dickerson (1971) stated that, "The rate of evolution of 
a protein is the rate of occurrence of mutations in the 
genome modified by the probability that a random change in 
the amino acid sequence will be tolerated in a functioning 
protein” . This suggests that the conservation of an amino 
acid indicates structural and/or functional significance. 
This therefore implies that the highly conserved residues 
in TS are essential for, or have a significant role to play 
in, the correct functioning of the enzyme.
Structural studies of TS have to a certain extent 
confirmed this hypothesis. Many of the highly conserved 
residues are in direct contact with the substrate and 
cofactor molecules. Other highly conserved residues 
comprise the dimer interface of the protein, whilst some 
appear to be essential for the correct formation of other 
portions of the protein. In addition, the complexity of 
the conformational changes that occur during catalysis, 
namely the concerted movement of individual elements of 
secondary structure against each other, may account for the 
high degree of amino acid conservation.
Although TS does exhibit a very high level of amino acid 
conservation, two intriguing observations are worthy of 
comment. Many of the completely conserved residues can 
individually be freely replaced by a variety of other amino 
acids without inactivating the enzyme (see Climie et al . , 
1990; Michaels et al ., 1990). Perhaps even more intriguing
is the observation Op the high degree of divergence between 
the sequence of TS from L.lactis and the TS sequences of 
other organisms. The L.lactis TS sequence can be 
considered the result of an elegant ’natural* mutagenesis 
experiment that has shown that a large number of conserved 
amino acids can be substituted en masse without 
inactivating the enzyme.
It would be illuminating to determine the structure of 
L.lactis TS and compare it with the structure of TS from 
other organisms to see how these amino acid differences
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have been accomodated. A complementary approach would be 
to introduce a combination of the amino acid substitutions 
found in L.lactis TS, into TS from an alternate source. 
Together, these approaches may reveal much about the 
ability of TS to tolerate amino acid substitutions.
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APPENDIX 
A reappraisal of the thyl gene product of 
Dictyostelium discoideum 
Introduction
The isolation of the thyl gene of the cellular slime 
mould Dictyostelium discoideum has recently been reported 
(Dynes & Firtel, 1989). The experiments involve the growth 
complementation of the Dictyostelium strain HPS400, a 
thymidine auxotroph which lacks TS activity, using a
partial Dictyostelium genomic library. The complementing 
gene encodes a 1.2 kb mRNA molecule and the authors were 
unable to show any homology of the derived protein product 
to TS or to any other protein sequence (Dynes & Firtel, 
1989). The isolated gene, thyl is either the wild type
copy of the gene mutated in HSP400 that confers the 
requirement for TdR or a suppressor of that mutation. 
However, since the molecular defect of the original
mutation is not known, it is not possible to formally 
distinguish between these two possibilities. However, the 
publication of the L.lactis TS sequence (Ross et a l . , 
1990a) prompted us to re-examine the sequence of the 
D.discoideum thyl gene product.
Results
The D.discoideum thyl gene product sequence, the
L.lactis, phage 03T and T4 TS sequences (Kenny et al . , 
1985), and the phage T4 dCMP hydroxymethylase sequence were 
manually aligned using the GCG program LINEUP (see Section 
3.4.2). Of the 27 invariant amino acids from a core of 
‘ 250 amino acids in TS (see Section 1.5.4), the
D.discoideum thyl gene product sequence has 15 of these 
residues at equivalent positions. Of a further 20 highly 
conserved residues in the core region, the D.discoideum 
thyl gene product has an amino acid of similar properties 
(Taylor, 1986) in the equivalent position (see Fig. A.l).
The most notable disruptions to elements of predicted
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secondary structure are the lack of the N-terminal portion 
of helices H and I, the loss of 13-strand iii and the 
shortening of the C-terminus. In addition, the region of 
the D.discoideum thyl gene product that aligns with the 
sequence of the highly hydrophobic J-helix of TS contains a 
high proportion of acidic residues. The most significant 
difference between the TS and D.discoideum thyl sequences, 
is the lack of a cysteine residue at the N-terminus of 
13-strand iv that could serve as a catalytic residue.
Discussion
The original report by Dynes and Firtel (1989) makes no 
definitive claims as to the function of the Thyl gene 
product. However, at least two models can be envisaged.
1 Transactivator Theory
If D.discoideum TS gene expression is regulated by 
transactivation, then a mutation that results in a 
defective transactivating protein will result in a T h y  
phenotype (TdR auxotroph; no TS activity). If this is the 
genetic basis for the T h y  phenotype of the Dictyostelium 
HSP400 strain, then introduction of the wild type gene that 
encodes the transactivating protein would complement the 
T h y  phenotype. In this model, introduction of the wild 
type gene for D.discoideum TS would not necessarily result 
in complementation as the gene would still be under the 
control of the same promoter that requires an active trans- 
activator for gene expression.
However, the concept of a transactivator protein that 
regulates only the expression of the TS gene seems unlikely 
due to precedents set in other eukaryotic organisms. In 
mouse and human systems, viWere TS gene expression has been 
studied, the levels of TS are co-regulated with several 
other enzymes involved in DNA precursor synthesis (see 
Section 1.5.). It is reasonable to assume that the 
expression of these enzymes is therefore regulated by a 
similar protein (or series of proteins) and that a defect 
in this protein(s) would affect the expression of many
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other genes. Since the lesion in the Dictyostelium HSP400 
strain seems to affect only TS (Dynes & Firtel, 1989; 
Podgorski & Deering, 1984), this would seem to discount 
this theory. Further evidence that the mutation results 
solely in a defect in TS comes from the report that the 
mouse TS gene, expressed under the control of the 
Dictyostelium actin promoter, can complement the thyl 
lesion of the Dictyostelium HSP400 strain (Chang et a l .,
1989).
2 TS Complementation Theory
The most straightforward model that would explain the 
observations of Dynes & Firtel (1989), is that the thyl 
gene encodes the enzyme thymidylate synthase. Indeed, from 
our main argument against the transactivation theory, this 
seems more likely. However, the stumbling block with this 
argument is the degree to which the thyl gene product 
sequence has diverged from other TS sequences. As origin­
ally reported, the authors could find no sequence homology 
to TS from a variety of sources (Dynes & Firtel, 1989), 
however, our sequence comparisons have shown, there is 
evidence of homology between TS and the thyl gene product 
of D.discoideum. Obviously the degree of homology is not 
as high as seen between TS from most of the sources 
reported to date (see Fig. A.l). However, the publication 
of the L.lactis TS sequence (Ross et al. , 1990a), changed
our, and others (Matthews et al. , 1989a), dogmatic way of
thinking towards what constitutes an active TS sequence.
Prior to the publication of the L.lactis sequence, a 
comparison of 17 diferrent TS sequences, from a very 
diverse range of organisms, revealed a total of 46 
invariant residues from a core of " 250 amino acids (see 
Section 1.5.3). However, when the L.lactis TS sequence was 
included in this comparison, the number of invariant 
residues dropped dramatically to 27 invariant residues. 
Additional amino acids are found in at least 5 sites, 
including the insertion of an extra residue in the 
predicted helix I, and the first two amino acids of the
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predicted helix H are missing (see Fig. A.l). These 
observations, coupled with the extensive mutagenesis data 
available for TS (see Section 1.11) and the inherent 
structural plasticity of this enzyme (see Section 1.9), 
suggest that requirement for many of the highly conserved 
residues is not absolute. Thus the low degree of 
similarity between the thyl gene product of D.discoideum 
and other TSs is not a strong reason to dismiss this gene 
as encoding a functional T S .
Nevertheless, the lack of a potential active site 
cysteine residue, the amino acid that forms a covalent 
adduct with dUMP during the normal course of the TS 
catalysed reaction (see Section 1.6), is cause for concern. 
The absence of a serine residue, that can also act as the 
active site residue in E.coli TS (Dev et al., 1988;
Michaels et al. , 1990), adds to this problem. To explore
this concern, we examined the structure/function relation­
ship of several enzymes that have a catalytic mechanism 
similar to T S . These include dUMP and dCMP hydroxymethyl- 
ases, and certain RNA and DNA modifying enzymes (Gu & 
Santi, 1991; Santi & Hardy, 1987; Wu & Santi, 1987).
The first group of enzymes, which includes dUMP and dCMP 
hydroxymethylase, more closely resemble TS in that they 
utilize N5 ,N10CH2FH4 as a cofactor (Santi & Danenberg, 
1984) and act upon an isolated nucleotide rather than one 
located in DNA or RNA. Only one sequence of either of 
these two enzymes from any source has been reported, namely 
that of the phage T4 dCMP hydroxymethylase (Lamm et al ., 
1987). Comparison of this sequence with that of T4 TS 
reveals a significant degree of homology and aligns the 
conserved Pro-Cys of T4 TS with the amino acid doublet Met- 
Cys (Lamm et al., 1987). Furthermore, mutagenesis data has 
shown that the invariant Pro of this doublet can be 
replaced by Met (and various other amino acids) in E.coli 
TS without a serious affect on enzyme activity (Climie et 
al. , 1990). The amino acid pair Pro-Ser also lies within
close proximity to the Met-Cys pair, however, if the 
Pro-Ser pair is aligned with the Pro-Cys pair of T S , then
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there is disruption of several elements of secondary 
structure.
The DNA[cytosine-5]methyltransferases use S-adenosyl- 
methionine as a methyl donor, in place of N5 ,N10-methylene- 
tetrahydrofolate (Wu & Santi, 1987), and bear no sequence 
similarity to TS (even by the method described in 
Section 3.4.ii), save for the amino acid doublet Pro-Cys 
(K1imasauskas et al., 1989). The Cys residue of this pair
is thought to act as the active site amino acid that forms 
a covalent adduct with the 5-position of cytosine (Wu & 
Santi, 1987).
The RNA modifying enzymes, of which the E.coli tRNA- 
(m5U54)methyltransferase is the best characterized, also 
use S-adenosyl methionine as a co-factor (Gu & Santi, 1991; 
Santi & Hardy, 1987). The same authors have predicted that 
this enzyme will use a cysteine residue in an analogous 
manner to that found in TS (Gu & Santi, 1991; Santi & 
Hardy, 1987), but, somewhat surprisingly, our analysis of 
the amino acid sequence (Gustafsson et al., 1991) of this
enzyme reveals no Pro-Cys amino acid doublet, although the 
sequence Pro-Ser was found. Several other cysteine and 
serine residues are found within this protein, but too few 
sequences of this enzyme have been reported to define a 
conserved catalytic residue.
Summary
In summary, the above considerations suggest that the 
amino acid sequence of a protein that is capable of 
catalysing the de novo synthesis of dTMP may not need to be 
as rigidly conserved as was first apparent. The only 
universal feature of enzymes catalysing a methyltransferase 
reaction appears to be the presence of an active site 
cysteine residue, that serves as a nucleophile. That the 
Thyl gene product of D .discoideum lacks an appropriately 
positioned cysteine residue is the major stumbling block to 
promoting it as an enzyme with TS activity.
It is reasonable to assume that the phage T4 dCMP 
hydroxymethylase has a similar tertiary fold to that of TS
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due to the similarity of the catalytic mechanism and the 
observed level of amino acid homology (Sander & Schneider, 
1991). Indeed, an interesting finding emerged during these 
alignments which supports this idea. The conserved Asn 
residue found in the J helix of all TS sequences (including 
the D.discoideum thyl gene product; see Fig A.l) is 
replaced by Asp in dCMP hydroxymethylase. The Asn side 
chain in TS makes H-bond contacts to the C-4 carbonyl 
oxygen atom and N-5 hydrogen of the pyrimidine ring of dUMP 
(Matthews et al., 1990a; Finer-Moore et al.> 1990). As
dCMP (the substrate for dCMP hydroxymethylase) has an amino 
group at C-5 of the pyrimidine ring, in contrast to the 
carbonyl group found at C-5 of dUMP, it is not unreasonable
to suppose that the Asp side chain could form H-bonds to
dCMP in a similar way to those between Asn and dUMP. These 
questions will be resolved when structural studies of T4 
dCMP hydroxymethylase, which are currently in progress 
(Thylen & Mathews, 1989), are completed.
How the tertiary fold of the thyl gene product of
D.discoideum compares to that of TS is a matter for debate 
only after more information is available as to the function 
of the thyl gene product. One approach would be to clone 
the thyl gene under the control of a bacterial promoter, 
and determine if it has the ability to complement the
E.coli thyA strain 2913, and/or to see if it has
detectable TS activity by the conventional TS assays. If 
such activity is confirmed, then the thyl gene represents 
by far the most divergent TS sequence reported to date, and 
challenges many of the currently held ideas on the nature 
of the TS catalysed reaction and the structure/function 
relationships of the enzyme.
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Evolution of herpesvirus thymidine kinases from cellular 
deoxycytidine kinase
Patrick T. Harrison, Russell Thompson and Andrew J. Davison*
M RC Virology Unit and Department o f Virology, Institute o f Virology, University o f  Glasgow, Church Street, 
Glasgow G i l  5JR, U.K.
The thym idine kinases encoded by herpesviruses o f 
higher vertebrates form  a d istinct group and are 
unrelated  to the thym idine kinases (TKs) o f o ther 
organism s. T heir evolutionary source has not been 
identified, but our analysis has revealed a clear 
relationship  with a sequence o f hum an deoxycytidine 
kinase (dCK) published recently. W e report the
sequence o f the putative TK o f channel catfish virus, a 
herpesvirus o f a lower vertebrate, and show th a t it is 
also related to dCK. W e propose, therefore, th a t the 
TK s o f herpesviruses o f higher and lower vertebrates 
have evolved, e ither independently or successively, 
from  a cellular dCK.
Thym idine kinase (TK ; EC 2 .7 .1 .2 1 ) catalyses the 
form ation of thymidylate by the phosphorylation of 
thym idine using A TP as the phosphate donor. Herpes­
virus TK s differ from cell cytosolic TK s in both their 
substrate specificity and the phosphate donors that they 
can utilize. Herpesvirus and certain m itochondrial TKs 
have the ability to use CTP as an alternative phosphate 
donor, but differ in their sensitivity to dC T P inhibition 
and physical properties (K it, 1985; K it et al., 1974).
Unlike cellular TK s, herpesvirus TK s can utilize a 
broad range of substrates in addition to thym idine, 
including deoxycytidine, a capability which is essential 
for the recognition of several antiviral nucleoside 
analogues, such as acyclovir and C£)-5-(2-bromovinyl)-2'- 
deoxyuridine (BVdU; Fyfe et al., 1978; Cheng et al., 
1981; Larder et al., 1983). Moreover, most herpesvirus 
TK s are also able to phosphorylate thym idylate (Chen et 
al., 1979), which has a crucial role in the activation of 
certain nucleoside analogues. For example, herpes 
simplex virus type 1 (HSV-1) and varicella-zoster virus 
(VZV), which are sensitive to BVdU, express TK s that 
phosphorylate this compound to both the mono- and 
diphosphate forms, whereas HSV-2, which is resistant to 
BVdU, expresses a TK that can catalyse production of 
the m onophosphate form only (Fyfe, 1981). Most 
nucleoside analogues are active in the nucleoside 
triphosphate form, which inhibits virus replication by 
interacting with D N A  polymerase and presumably is 
formed by the action of a cellular kinase (reviewed in 
Larder & Darby, 1984).
Poxviruses encode TK s with substrate specificities 
and physical properties similar to those of cell cytosolic
TK s (Kit, 1985; K it et al., 1974), and these features, as 
well as clear am ino acid sequence similarity, have led to 
the proposal that poxvirus TK s evolved from cell 
cytosolic TK s (Kwoh & Engler, 1984; Boyle et al., 1987 
and references therein). However, there is no apparent 
similarity between the sequences of herpesvirus and cell 
cytosolic TKs, with the exception of a single m otif 
common to many enzymes that bind A TP (W alker et al., 
1982; Gentry, 1985), and cellular TK is a tetram er 
whereas herpesvirus TK s are dimers. To our knowledge, 
no sequence data are available for m itochondrial TKs. 
Thus, on the basis of sequence, physical and enzymic 
properties, herpesvirus TK s form a distinct group, the 
evolutionary source of which is obscure.
Com parisons between herpesvirus TK  sequences have 
revealed several highly conserved am ino acid residues 
(Robertson & Whalley, 1988; Honess eta l., 1989), which 
have been grouped into six ‘sites’ (Balasubram aniam  et 
al., 1990). The locations of the sites in the 15 published 
herpesvirus TK sequences are shown in Fig. 1. The 
herpesvirus TK  sequences reported to date are encoded 
by viruses that infect mam m als or birds, but inform ation 
has recently become available on the TK  of channel 
catfish virus (CCV). This enzyme has been characterized 
biochemically and the gene encoding it has been located 
on the genome to within 3 kbp by m arker rescue of a TK  
deficient CCV m utant (L. A. Hanson, R. L. Thune & 
K. G. Kousoulas, personal communication). CCV TK 
can be distinguished biochemically from the channel 
catfish cellular TK  and, in contrast to other herpesvirus 
TK s, cannot use CTP as a phosphate donor. CCV D N A  
has been completely sequenced (A. J. Davison, unpub-
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Site 1 Site 2
HSVl N H ?
HSV2 NH p 
VZV NH j 
MHV N H 2 
PRV NH j 
FHV NH p 
EHV1 N H 2 
EHV4 N H 2 
BHV1 N H 2 
BHV2 N H 2 
ILTV N H 2 
MDV N H 2 
HVT NH 2
EBV N H 2 -285- sLFLEGapGvGKTtmlnhL -12- EPMrYW -69-
HVS N H 2 -210- fIFLEGsiGvGKTtllksM -13- EPIaYW -66-
CCV N H 2 -17- vfcVEGniGcGKStlvkaL -13- EPVdqW -43-
dCK N H 2 -22- klsIEGniaaGKStfvniL -11- EPVarW -74-
Site 3 Site 4 Site 5 Site 6* * * * * * ******* ******
HSVl DRHPIaalLCYP -42- RLakRqRpGE -58- igdTLF -87- COOH
HSV2 DRHPIaslLCYP -42- RLarRqRpGE -57- iedTLF -86- COOH
VZV DRHPIastICFP -42- RVskRaRpGE -60- iedTLF -83- COOH
MHV DRHaVasmVCYP -42- RLraRaRpGE -63- ladTLF -99- COOH
PRV DRHPVaatVCFP -42- RLraRaRaGE -61- lqdTLF -82- COOH
FHV DRHPLaslVCFP -42- RLrgRsRtGE -61- IedTLF -79- COOH
EHV1 DRHPVasaVCFP -42- RLrtRaRiGE -61- lsdTLF -84- COOH
EHV4 DRHPVastVCFP -42- RLrtRaRiGE -61- IgdTLF -84- COOH
BHV1 DRHPVaacLCYP -42- RLaaRaRpGD -63- lrdTLF -94- COOH
BHV2 DRHPtaslLCYP -42- RLvaRgppGE -55- ghnTLL -67- COOH
ILTV DRHPLaacLCFP -42- RIiqRgRpGE -63- idqTLF -85- COOH
MDV DRHPIsatVCFP -43- RLssRnRtGE -67- lhhTLL -85- COOH
HVT DRHPVaaiLCFP -43- RIcsRdRpGE -68- IdrTLL -91- COOH
EBV DRHlLsasVvFP -41- RLkkRgRkhE -63- yknSIF -84- COOH
HVS DRHPLsatVvFP -41- RVkkRnRkeE -63- IksSIF -81- COOH
CCV ERsPMsatrvFc -46- RMrrRdRtGE -62- COOH
dCK DRyifasn.lYe -44- RIyiRgRneE -63- COOH
Fig. 1. Alignment of the amino acid sequences of six conserved sites in 
15 higher vertebrate herpesvirus TKs, and comparison with CCV TK 
and human dCK. MHV, marmoset herpesvirus; PRV, pseudorabies 
virus; FHV, feline herpes virus; EHVI and -4, equine herpesvirus 
types 1 and 4; BHV1 and -2, bovine herpesvirus types 1 and 2; ILTV, 
infectious laryngotracheitis virus; MDV, Marek’s disease virus; HVT, 
turkey herpesvirus; EBV, Epstein-Barr virus; HVS, herpesvirus 
saimirii. The TK sequences are from Balasubramaniam et al. (1990) 
with the exception of EHV-4, Nicolson et al. (1990); BHV-2, Sheppard 
& May (1989); ILTV, Griffin & Boursnell (1990). The BHV-1 sequence 
used by Balasubramaniam et al. (1990) is replaced by that of Smith et al. 
(1990). The HVT sequence used in this analysis and in that of 
Balasubramaniam et al. (1990) differs from the original sequence 
published by Martin et al. (1989) by the replacement of the two amino 
acids at the carboxy terminus with 42 amino acids, resulting from the 
insertion of a G residue between nucleotides 1532 and 1533 in the 
original D N A  sequence. The considerable similarity between the C- 
terminal extension and the TK of the closely related M D V  suggests that 
there was an error in the original sequence. The human dCK sequence 
is from Chottiner et al. (1991). The sequences were aligned using 
programs GAP, LINEUP and PRETTY (Sequence Analysis Software 
Package, Genetics Computer Group, University of Wisconsin). Upper 
case letters indicate identical residues in at least 13 of the TK 
sequences, or a residue in one of the groups (I/L/M/V) (D/E) (S/T) 
(F/Y) (F/L) (K/R) in at least 14 sequences. Upper case letters are shown 
for CCV TK and dCK when residues are identical to, or in the same 
group as, those residues in the other TKs. The six conserved sites 
proposed by Balasubramaniam et al. (1990) are indicated. Dots 
represent characters introduced to produce the alignment.
lished data) showing that the 3 kbp region including the 
TK  gene contains three com plete open reading frames 
which are predicted to encode proteins, one of which is
-50- rVYIDGphGmGKTtttqlL -13- EPMtYW -73-
-50- rVYIDGphGvGKTttsaqL -14- EPMtYW -73-
-13- rIYLDGayGiGKTtaaeef -15- EPLsYW -75-
-11- rVYLDGphGvGKSttaeaL -15- EPMaYW -78-
-04- rlYLDGayGtGKSttarvM -09- EPMaYW -69-
-21- rIYIDGayGiGKSltakyL -15- EPM1YW -72-
-26- rIYLDGvyGiGKSttgrvM -14- EPMaYW -72-
-26- rIYLDGvyGiGKSttgrvM -14- EPMaYW -72-
-11- rIYLDGahGlGKTttgraL -14- EPMaYW -82-
-05- rVYVDGphGlGKTtaasrL -11- EPMsYW -73-
-30- 1LYVDGp fGvGKTvt a kt L -14- EPMqaW -77-
-20- rVYLDGsmGiGKTsmlnel -14- EPMkYW -70-
-11- rVYLDGpfGiGKTsilnaM -14- EPMkYW -70-
M A L R E G P T P A R F L P E G L V F C  20 
ATGGCGCTCAGGGAAGGTCCCACACCCGCCAGGTTTCTCCCCGAAGGGCTAGTGTTCTGT 8 844
V E G N  I G C G K S T L V K A L M E R V  40 
GTCGAGGGTAACATAGGATGCGGGAAGAGCACCCTGGTAAAAGCTCTGATGGAGCGCGTG 8 904
A G S G V N V V E E P V D Q W V N H N G  60 
GCGGGGTCCGGGGTCAACGTGGTCGAAGAGCCGGTAGATCAGTGGGTGAATCACAATGGG 8964
K N Y L E L S Y T D P T G Y A V P F Q N  80 
AAGAACTATCTCGAACTGTCGTACACGGATCCCACGGGGTACGCCGTCCCGTTTCAGAAC 902 4
L V F D S Y V N V Q R L Q N P D I M E R  100 
CTGGTGTTCGACAGTTACGTGAACGTGCAGCGCCTGCAGAATCCCGACATCATGGAGCGC 9084
S P M S A T R V F C A V N G S R G V I P  120 
TCCCCGATGAGCGCGACCCGGGTCTTTTGCGCGGTCAACGGGAGCCGCGGGGTCATCCCC 914 4
A T A L P G M A A R G E A V M R T  I A T 140 
GCGACCGCGCTCCCGGGGATGGCGGCGAGGGGGGAGGCCGTGATGCGAACCATCGCCACC 9204
R P V F V Y L E L P P E E C L R R M R R  160 
CGTCCCGTCTTCGTGTACCTGGAGCTACCCCCCGAGGAGTGTCTGCGCAGGATGCGTCGT 92 64
R D R T G E A G V G L D Y L R L L H E R  180 
CGGGACAGGACCGGGGAGGCGGGCGTGGGGCTGGACTACCTGCGTCTCCTCCACGAAAGA 932 4
Y E A W L S S A E D V E R V D A S R S R  200 
TACGAGGCGTGGCTATCCTCCGCGGAGGACGTGGAGCGCGTGGACGCGTCCCGCTCCCGA 9384
E E I V D R V I E I L C R R H P R L R A  220 
GAGGAGATTGTCGATCGCGTGATAGAGATACTGTGCCGCCGCCACCCACGACTCCGCGCC 94 44
P L T R K S Q L -  228
CCCCTAACACGAAAAAGTCAGTTATAA 9471
Fig. 2. Nucleotide and predicted amino acid sequences of the putative 
CCV TK. Nucleotides are numbered with respect to the complete CCV 
D N A  sequence. Residues in the amino acid sequence are also 
numbered.
related to other herpesvirus TK s (Fig. 1). The nucleotide 
and predicted am ino acid sequences o f the putative CCV 
TK  are shown in Fig. 2. The herpesvirus T K s are related 
in four or five of the six conserved sites to the hum an 
deoxycytidine kinase (dCK) sequence reported recently 
(Chottiner et al., 1991) (Fig. 1). H um an dC K , like 
herpesvirus TK s, is a dim eric enzyme with a broad 
substrate specificity, including purine nucleosides and 
several cytidine analogues. Both C TP and G T P, as well 
as ATP, can act as phosphate donors.
Site 1 is the proposed A TP-binding m otif o f higher 
vertebrate herpesvirus TK s and has the consensus 
sequence (D /E)G X X G X G K (T/S) (G entry, 1985); CCV 
T K  site 1 is identical to this consensus sequence and the 
dC K  sequence differs only by a single substitution 
(alanine for the second glycine). Replacem ent of this 
glycine by valine in HSV-1 TK  results in inactivation of 
the enzyme (Liu & Summers, 1988), although a strict 
requirem ent for this am ino acid is not observed in other 
A TP-binding proteins (reviewed in Saraste et al., 1990). 
Therefore it seems likely th a t dC K  site 1 is part of a 
functional A TP-binding motif.
Site 2 in the higher vertebrate herpesvirus TK s has the 
consensus sequence EP(M /L/I)X Y W  (B alasubram an­
iam et al., 1990). In ILTV T K , an alanine replaces the 
tyrosine (Griffin & Boursnell, 1990), and th a t o f CCV 
possesses a glutam ine at this position and a valine at the 
third position, at which the consensus sequence contains 
other small hydrophobic am ino acids. As small hydro- 
phobic residues are often considered to be sim ilar for the 
purpose of denoting am ino acid conservation (Taylor, 
1986; Bordo & Argos, 1991), the consensus sequence
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could be modified to EP(M /L/I/V ) XXW , which is 
identical to the site 2 sequence of dCK . The distance 
between sites 1 and 2 of CCV TK  and dC K  is similar to 
that between those of the other herpesvirus TKs.
The region containing sites 3 and 4 has been proposed 
to have a role in thym idine recognition (Darby et al., 
1986). The triplet D R H  is conserved at site 3 of all 
herpesvirus TK s described. Indeed, it was its similarity 
to a D R Y  sequence in yeast thymidylate kinase (Tm pK) 
tha t was used, in part, by Robertson & Whalley (1988) to 
suggest an evolutionary relationship between this en­
zyme and herpesvirus TKs. In site 3 of CCV TK, 
glutam ate replaces aspartate and serine replaces histi­
d ine; in site 4, the conserved proline is replaced by 
cysteine. Despite a lower level of similarity between 
higher vertebrate herpesvirus and CCV TK  sites 3 and 4, 
the CCV enzyme does appear to be related to herpesvirus 
TK s in this region, most notably to that of HVS. dC K  
has D RY  in place of the D R H  m otif in site 3 but lacks 
convincing similarity in site 4. Nevertheless, the sim ilar­
ity between dC K  and herpesvirus TK s at sites 3 and 4 is 
greater than tha t between yeast Tm pK  and herpesvirus 
TK s (Robertson & W halley, 1988), and that between 
herpesvirus TK s and the sequences reported recently for 
vaccinia virus (Smith et al., 1989) and hum an Tm pK s (Su 
& Sclafani, 1991). We could detect no correlation 
between the ability of the enzyme to phosphorylate 
substrates other than thym idine and the am ino acid 
sequence o f this region. The distance between sites 2 and 
3 of dC K  is sim ilar between those of higher vertebrate 
herpesvirus TK s, but that between those of CCV TK  is 
significantly shorter.
A rginine-rich site 5 is similar to a region of porcine 
adenylate kinase that is thought to be involved in 
phosphoryl group binding (Dreusike et al., 1988; 
Balasubram aniam  etal., 1990). Three conserved arginine 
residues are present in all herpesvirus TK s reported 
previously with the exception of BHV-2, which has a 
proline in place of the th ird  arginine, and there is also a 
well-conserved G E m otif; CCV TK  contains the 
arginines and the G E motif. dC K  also possesses the three 
arginines and the glutam ate, but the glycine is replaced 
by a glutam ate. The distance between sites 4 and 5 of 
CCV TK  and dC K  is marginally greater than between 
those of the other herpesvirus TKs.
CCV TK  and dC K  are similar in length and, unlike 
other herpesvirus TK s, show similarity outside the five 
conserved sites, particularly in the regions between sites 
2 and 3, and surrounding site 5 (Fig. 3). They are 
significantly shorter than higher vertebrate herpesvirus 
TK s, and lack site 6 and at least one other residue of 
functional im portance (Darby et al., 1986).
The sequence alignm ents discussed in this paper 
dem onstrate significant similarity between dC K  and
Site 1 
* * * * * * *
CCV TK malregptparfIpeglvfcVEGnigcGKStlvkaLm 37
: : I I I I I I I I : I I
dCK matppkrscpsfsassegtrikkisIEGniaaGKStfvniLk 42
Site 2
CCV TK ervagsgvnvveEPVdqWvn................. hngknyl 64
M I N I !  I I I I
dCK qlcedw. . ewpEPVarWcnvqstqdefeeltmsqknggnvl 82
CCV TK elsytdptgyavpfQnlvfdsyvnvq.......... rlqnP.. 95
I I I  II I : I I
dCK qmmyekperwsftfQtyaclsrlraqlaslngklkdaekPvl 124
Site 3 S ite  4
CCV TK  dimERspMsatrvFcavngsrgvipatalpgmaarge 132
: I : I : I :
dCK ffersvysDRyifasn.lYesec mnetewtiyqdwhd 160
S ite  5 
* * * * * * *
CCV TK avmrtiatrpvf...VyleLppeEclrRMrrRdRtGEagvgl 171 
: : I I M i l l :  I I  I I : I
dCK wmnnqfgqsleldgilylqatpetclhRIylRgRneEqgipl 202
CCV TK dylrllheryeawl...... ssaedvervd..asrsreeivd 205
: I I I I : I I I : : : I I : I
dCK eyleklhykheswllhrtlktnfdylqevpiltldvnedfkd 244
CCV TK rvieilcrrhprlrapltrksql 228
dCK kyeslvekvkeflstl 260
Fig. 3. Alignment of the entire human dCK and CCV TK sequences. 
Vertical bars indicate identical amino acid residues and colons indicate 
similar residues. Dots represent characters introduced to produce the 
alignment. Upper case letters are used as described in the legend to 
Fig. 1.
herpesvirus TKs. Although it is conceivable that this 
situation has arisen by convergent evolution, we consider 
that the data strongly suggest that higher or lower 
vertebrate herpesvirus TK s have evolved from a cap­
tured cellular dCK  gene. In developing the ability to 
phosphorylate thym idine, the enzyme specified by the 
captured gene in most cases has retained the ability to 
phosphorylate deoxycytidine. Thus, the proposed origin 
of herpesvirus TK s is consistent with their distinct 
biochemical properties.
P. T. Harrison was the recipient of a C.A.S.E. research studentship 
from the Science and Engineering Research Council, and the 
Wellcome Research Laboratories.
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. . . gVKyWgewgigd...................................................... gtiGqrYGatvKkYn
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